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Abstract 
 
 
Package leaflets (PL) belong to the complex communication system related to the 
minimization and prevention of pharmaceutical risk. Their legal nature is not 
exhausted by safety regulation though: as a privileged form of product instruction, 
they are also subject to liability regulation with a consequent reallocation of damage 
responsibility through risk disclosure. After illustrating the articulation of 
pharmaceutical risk through risk prevention norms (residual risk, development risk), 
the thesis goes on with a discussion of the PL role within the therapeutic decision as 
a complementary vehicle to doctor’s information. It results that the liability 
framework in which both information channels are embedded determines a 
communication model, which far from promoting a shared decision process, 
radicalizes the two-step communication structure typical of the informed consent 
model inherited by surgery judicature.  
The second part investigates PL information as a source of knowledge updating 
through the methodological tools provided by Bayesian decision theory.  
Finally, an empirical study conducted over a sample of 55 drug consumers 
investigates the impact of PL information on drug risk perception and its perceived 
value to therapeutic decision.   
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 Introduction  
 
 
 
 
 
 
 
Pharmaceutical products are at the centre of vivacious debates, and the importance 
of transparent, timely and comprehensive information is acknowledged by the 
society at large as an indispensable means of risk prevention and consumers’ 
protection. 
The relevance of timely information for an effective risk management has 
particularly come to light in the occasion of sadly famous pharmaceutical scandals 
such as the Contergan tragedy in Germany, up to the recent Vioxx case in the U.S.
1
  
Precisely as a consequence of the Contergan scandal, in Europe, and particularly in 
Germany, a detailed regulation of pharmaceutical risk management and information 
has been developed and continues to absorb legal theorists and policy makers in the 
complex task of conciliating the widest possible accessibility to health technology 
innovations with the requirement of safety.
2
 
Debates about pharmaceutical products focus on one and the same concern: Health 
as an individual and societal good, which drugs contribute to promote and threaten at 
the same time. 
The need for preventing damaging events has led to a strict regulation of the 
pharmaceutical market. Pharmaceutical risk communication is at the core of this 
regulatory activity and aims at protecting health and life as constitutional goods 
regarding both the individual and the society, but also the right to an autonomous 
therapeutic choice by patients with regards to the benefits and risks associated with 
any pharmaceutical product. 
                                                 
1
 For a recent discussion see: Gaßner, Reich-Malter, 2006: 147 ff. 
2
 European directives on pharmaceuticals have been issued since 1965 with the council directive 
65/65/EEC (Official Journal 22, 9.2. 1965, p. 369/65, amended through directives 66/454/EEC, 
75/319/EEC, 83/570/EEC, 87/21/EEC, 89/341/EEC, 92/27/EEC, 93/39/EEC); following to the first 
directive other council directives with related amendments have been issued: 75/318/EEC (amended 
through 83/570/EEC, 87/19/EEC, 89/341/EEC, 91/507/EEC, 93/39/EEC, 1999/82/EC and 1999/83/EC – 
commission directives); 75/319/EEC (amended through 78/420/EEC, 83/570/EEC, 89/341/EEC, 
92/27/EEC, 93/39/EEC, 2000/38/EC – commission directive); both directives can be considered as the 
legislator’s answer to the Contergan catastrophe; finally directives 89/342/EEC, 89/343/EEC, 89/381/EEC, 
92/25/EEC, 92/26/EEC, 92/27/EEC, 92/28/EEC, 92/73/EEC, the most recent commission directive 
assembles all preceding ones in a single text: 2001/83/EC (amended through 2002/98/EC, 2003/63/EC, 
2004/24/EC, and 2004/27/EC).  
The German legislation has evolved from a mere danger avoidance to a risk prevention system through the 
German Medicines Act issued in 1976 (Gesetz über den Verkehr mit Arzneimitteln: Arzneimittelgesetz – 
AMG). This law has evolved in accordance to European legislation and in the attempt to meet the safety 
requirements deriving from the continuously evolving pharmaceutical field. Amendments to AMG 1976 
have been issued in 1983 (1
st
 amendment), 1986 (2
nd
), 1988 (3
rd
), 1990 (4
th
 and 5
th
), 1996 (6
th
), 1998 (7
th
 
and 8
th
), 1999 (9
th
), 2000 (10
th
), 2002 (11
th
), 2004 (14
th
), 2005 (13
th
, 14
th
, 15
th
).  
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As a special support of such sort of information, the drug package leaflet has been 
object of thorough legal regulation, which has been amended and refined through the 
time by the legislator.
3
   
In despite of these efforts, the package leaflet is still object of harsh criticism and is 
blamed by health professionals of hindering compliance and failing to provide a 
valid information support for therapeutic decision.
 4
 Moreover, in Germany, recent 
court decisions concerning damage compensation for information faults have 
delivered contradictory judgments in relation to package leaflet information:  
- A much discussed sentence of the LG Dortmund (6. 10. 1999)
5
 has emphasized the 
patient’s responsibility in taking notice of the risks reported by the package leaflet as 
a basis for his own risk/benefit evaluation and consequent therapeutic decision.  
- In contrast to this sentence, other decisions,
6
 have pointed at the inadequacy of this 
information support alone – and generally of standardized forms of risk disclosure 
(brochures, pre-drafted formularies) – as a sufficient source of therapeutic 
information for the lay consumer: in these sentences, doctor’s personal and tailored 
communication is considered a necessary condition for consent to be valid, and 
cannot be substituted by PL information. 
 
The legal debate concerns the distribution of risk responsibility among patient, 
doctor, and pharmaceutical firm in relation to the delivered information. 
In fact, differently than in the U.S, where no legal value is assigned to 
pharmaceutical product instruction, and the theory of “learned intermediary” 
imposes information duties only on the doctor, PL information has in Germany, a 
                                                 
3
 In particular, the European guideline 92/27/EEC recommends the insertion of product instructions in the 
drug package specifically addressing the patient. The 92/27/CEE directive (31. 3. 1992) represents a 
milestone in the development of pharmaceutical labeling. It provides a detailed list of information contents 
that the PL text must cover (particularly at point 3 of art. 7 and in art. 8) and invites to a closer connection 
with the layman medical background (the notion of “health literacy” is explicitly mentioned).  
In 1998  “A Guideline on the readability of the Label and Package Leaflet of Medicinal Products for 
Human Use” has been emanated as a valid companion to an enhanced patient information quality. The 
document presents a set of examples and provides a guideline for testing PL readability. The 1992 directive 
with related guideline have been officially implemented in the German legislation in 2002, through the 
recommendations for the configuration of package leaflet, and translated in legal norms through the 14
th
 
amendment to AMG.  More recently, § 61 I of the modified European directive 2001/83/EC prescribes the 
introduction of a comprehensibility test for patient leaflets as part of the documentation for drug approval. 
This requirement has been implemented in the German Law through § 22 VII, 2 AMG in the 14
th
 AMG-
amendment, which declares: “Der zuständigen Bundesbehörde sind bei Arzneimitteln, die zur Anwendung 
bei Menschen bestimmt sind, außerdem die Ergebnisse von Bewertungen der Packungsbeilage vorzulegen, 
die in Zusammenarbeit mit Patienten-Zielgruppen durchgeführt wurden.” 
4
 See among others Aumiller, 1978, 1982; Degner, 1982, Karpa, 1991, Kepplinger 1990, 1991, Nickolaus, 
1991; Nöthlich, 1991; Wenzel, 1985; Winckelmann, 1983; Wolff, 1982; Zink, 1985; Zylka, 1986. Until 
recently the BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte – the German Federal Office for 
Drugs and Medical Products – has organized a seminar for investigating the state of the art as for PLs 
readability and patient friendliness. 
http://www.bfarm.de/cln_042/nn_599148/DE/BfArM/Publikationen/Praesentationen/060215-Dialog.html 
Bonn, 15.3.2006.    
5
 LG Dortmund, MedR 2000, 332. 
6
 BGH, 14. 3. 2006 (NJW 2006: 2108); BGH 15. 3. 2005, NJW 2005, 1716 (1718); BGH 15. 2. 2000 (NJW 
2000, 1784). 
 17 
specific binding force for the drug consumer, which is nevertheless difficult to 
define precisely because of the information duties also imposed on the doctor.  
 
The issues tackled by this thesis are therefore the following: 
1) Specify the legal nature of package leaflets on the basis of available juridical 
sources (statutory law and case law) within the German regulatory system and 
with respect to prescription drugs; 
2) Evaluate whether the PL informative-communicative structure allows the patient 
to accomplish the task(s) established at legal level. 
 
The adoption of these themes in the perspective of communication sciences has been 
determined by the persuasion that only the integration of the communicative and 
legal perspectives would lead to the solution of the legal dilemmas raised by PL 
information.  
In fact, the state of the art on the topic presents contributions from the health 
communication, from the linguistics, and from the legal literature, each of which 
brings some autonomous advancement in the investigation, whose progress  
nevertheless seems to be compromised by their reciprocal isolation. This for the 
following reasons:  
- The legal literature cannot claim to exhaustively deal with the complexity of 
factors involved in the question of drug-consumer information (health risk 
perception, health information processing, lay decision autonomy) without involving 
the expertise of related disciplines.  
- Linguistic literature cannot clearly grasp the textual typology of the package leaflet 
– and therefore analyze its congruity to the communicative functions established by 
the law – without being aware of its contextual functions within the health system. 
- Finally, both legal and linguistic literature cannot disregard the insights on lay risk 
perception and health information seeking behavior gained by psychosociological 
approaches in the health sciences. 
 
The methodological tool used to integrate the legal and communicative perspectives 
has been offered by speech act theory. This has helped define the communicative 
functions of PL information within the German legal system by analyzing its 
contribution in the determination of the stakeholders’ responsibilites (in speech act 
terms: commitment manipulation).  
 
The analysis of the legal sources brings to the conclusion that PL information has a 
twofold function: 
1) consumer safety protection; 
2) warranty of the consumer’s right to self-determination and autonomous decision 
(in analogy to the institute of informed consent for the doctor-to-patient 
interaction), with consequent reallocation of risk responsibility. 
These two legal tasks translate into two communicative functions:  
1) risk warning (recommend a behavior which possibly averts so called “avoidable 
risk”); 
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2) risk declaration and consequent disclaiming function (for risk which are 
considered unavoidably associated to drug consumptions: “residual risk”)7. 
 
The evaluative part of the study examines the legitimacy of considering PL 
information has a legally binding source of information for the drug consumer.  
 
The evaluation is carried out at two distinct levels: a theoretical and an empirical 
one.  
The theoretical evaluation departs from the achievements obtained by linguistic 
studies. In these studies PL information is blamed to make the reader insecure, and 
major sources of uncertainty are identified in incomprehensibility, technical 
language and general reader-unfriendliness. 
However, the linguistic approach fails to consider the epistemological uncertainty 
bound to any decision which is made on the basis of inconclusive knowledge. This is 
that sort of uncertainty which traces back to insufficient knowledge about the state of 
affairs related to the decision and the possible outcomes, and which is not removed 
through reader-friendliness and enhanced comprehensibility.  
In order to analyze this aspect of the lay therapeutic decision and the role of PL 
information within it, a Bayesian approach has been adopted in order to establish the 
specific epistemic contribution brought by PL information with respect to its legal-
communicative functions.  
This methodological choice is justified by the fact that Bayesian theory is the 
privileged discipline in order to account for decision making under uncertainty.  
 
In fact all main components of Bayesian theory (the theory of knowledge updating 
through probabilistic induction – Bayesian theorem – the theory of decision 
optimization through maximization of the expected utility; and the theory of 
information value) are relevant to our research.  
In this specific framework, this approach has provided the instruments for analyzing 
PL information: 
-  as a basis for knowledge updating (probability of side effects occurrence) for a 
risk/benefit assessment about the drug;  
-  as a support for decision optimization based on the expected reward of taking the 
drug vs. not taking it;  
- finally, its perceived value as a function of its expected contribution to decision 
optimization. 
 
At an empirical level, a quantitative and a qualitative study have been conducted in 
order to assess how real drug consumers make use of their information in the 
therapeutic context.  
 
The thesis is subdivided in three parts:  
                                                 
7
 See later on in the presentation of the single chapters for the distinction between 
avoidable/intolerable/unacceptable risk and unavoidable/tolerable/acceptable (“residual”) risk.  
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I. The first part is devoted to the description of pharmaceutical law in Germany 
with a focus on the regulation of information exchange among the different 
stakeholders;  
II. The second part is devoted to the normative analysis of PL information within 
the context of lay therapeutic choice.  
III. The third part presents some empirical findings derived from a quantitative 
study and a qualitative research conducted with a sample of subjects that were 
under therapy at the time of the survey. The purpose of this part is to give a 
deeper insight on the way drug consumer process PL information and use it in 
the therapy context.  
 
 
 
Part I 
Pharmaceutical regulation 
 
The first part of the study is devoted to the pharmaceutical regulation in Germany.  
Special attention is devoted to norms addressing information exchange among the 
different stakeholders. 
 
 
Chapter 1 
 
An introductory chapter is devoted to pharmaceutical risk management and the 
distinction between avoidable and unavoidable (residual) risk.  
A risk can be avoidable in two senses:  
- either because it can be averted by taking adequate precautions,  
- or because the risk is unacceptable along risk/benefit considerations.  
In this second sense, the underlying principle is that risks are tolerable insofar as 
they are not avoidable for achieving a certain therapeutic purpose. Residual risk in 
general is the risk which cannot be excluded with absolute safety, but which can be 
regarded as enough improbable or insignificant to be considered legally acceptable 
in the face of the benefit offered by the risk source.  
In a comparative setting, acceptable is the risk associated with a benefit source 
which is inferior to the risks associated with other sources bringing about the same 
benefit,
8
 and is proportionate to the associated benefit. 
After distinguishing between the different notions of risk within the pharmaceutical 
field (juridical, statistical-epidemiological, medical, personal risk), the chapter 
illustrates the risk management and communication system in the pharmaceutical 
setting. Interestingly, the legal notion of residual risk helps draw important 
distinctions about the role of communication in the field of health risk. 
Risk communication to the concerned parties (doctors and consumers) and, when 
needed, to the public at large, can either serve as a warning to reduce risk and 
                                                 
8
 Räpple, 1991: 110. Scheu, 2003: 713. 
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instruct about adequate use as to prevent avoidable risk, and/or as an instrument for 
allowing the autonomous decision about the residual risk.
9
 
This double purpose is reflected in the liability regimes regulating both doctor’s and 
pharmaceutical product information.  
 
 
Chapter 2 
 
Chapter 2 deals with liability regulation concerning pharmaceutical product 
instruction and presents the two main liability regimes: tort and strict liability. Strict 
liability is related to unacceptable risks exceeding the legally established tolerability 
threshold, and gives rise to compensation independently of product instruction faults. 
Tort liability is related to product faultiness in design, manufacturing or related 
instructions. A drug which has no construction or manufacturing flaws can still give 
rise to compensation duties for damages caused by faulty instructions. PL 
information therefore acquires a fundamental importance in liability litigations 
concerning residual risk.  
 
 
Chapter 3 
 
Chapter 3 deals with doctor’s risk disclosure duties towards the patient. This is 
subjected to contract and tort liability and is divided into two broad categories: 
“Sicherungsaufklärung” (safety information) and “Selbstbestimmungsaufklärung” 
(information for self-determination)
10
 in according to the distinction between 
avoidable and unavoidable risk associated to the therapy/intervention.  
Safety information is aimed at preventing avoidable damage by instructing the 
patient as to a correct and safe therapeutic behavior (dosage, duration eventual 
precautions).
 11
 In the post-therapy phase, this can translate into information about 
the necessary measures for preventing complications and eventually insistence in the 
danger represented by non-compliance.
12
  
Information for self-determination aims to make the patient knowledgeable of the 
residual risk connected to the therapy, and which must be taken into account because 
it is not ascribable to medical error.  
Information for self-determination is a necessary condition for consent to be valid as 
established by the institute of informed consent which regulates doctor-patient 
interaction. In addition to information about the residual risk, this concerns also the 
expected benefit, probability of therapeutic success and in general any relevant data 
for an informed consent to the proposed therapy (economic costs, relevant 
alternatives). 
The institute of informed consent is relatively recent and has begun to find its way in 
the U.S. legal system in the ‘50ies as a consequence of a new interpretation of 
                                                 
9
 Hart, 1998b: 182. 
10
 See also Francke, Hart, 1999: 55 ff. 
11
 BGH 22.1.1960 (VersR 60, 417-19). See also Krudop-Scholz, 2005: 70. 
12
 Francke, Hart, 1999: 49. 
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individual liberties and autonomy brought about by a new right-orientation (civil 
rights and consumer rights).
13
  However, in Germany, the development of case law  
around the concept of “informierte Einwilligung” (German version of informed 
consent) dates back to 1894 with a court decision establishing that a doctor that 
commits a bodily injury with no permission of the patient acts tortuously because he 
violates the bodily integrity and health.
14
 
Lacking a specific regulation on the matter, judges facing the task of determining 
compensation duties for the doctor have subsumed the medical intervention under 
823.1 BGB which states that: “A person who intentionally or by his negligence, 
unlawfully causes death or injury or impairment of the health, freedom, property is 
bound to compensate him for damages arising therefrom”,15 where compensation is 
linked to the qualification of the medical intervention as “Körper- und 
Gesundheitsverletzung” (bodily and health injury - tort liability).  
In this context, consent serves the purpose of legitimizing the doctor’s intervention 
and safeguarding him from liability charges: “The tortuousness, and thereby the 
responsibility of the doctor according to 823.1 BGB is excluded only if – and to the 
extent that – the patient or his legal representative has consented to the lesion”.16  
In order for consent to be valid however, it must be given in observance of the right 
to autonomy and self-determination
17
, and therefore must be preceded by adequate 
information about the intervention itself and consequent health implications.  
As a consequence, the information delivered within the context of informed consent 
is a legal tool aimed at the distribution of the responsibility concerning the residual 
risk associated with a therapy or a medical intervention. Two critical aspects are 
questioned in the legal debate in this respect:  
- on one side the institute of informed consent is considered an inadequate ground 
for the regulation of the doctor-patient relationship, because it equates the 
doctor’s action to that of a knifer (“Messerstecher”),  
- but on the other side it is also criticized because it reduces the doctor-patient 
communication to a risk disclaimer. 
                                                 
13
 Faden, Ruth. R, Beauchamp Tom L., A History and Theory of Informed Consent, (New York: Oxford 
University Press, 1986), pp. 23-143.  
14
 Reichsgericht 31.5.1894, Strafs. Bd. 25, nr. 127: 375: “Ein Arzt der vorsätzlich für Heilzwecke eine 
Körperverletzung verübe, ohne sein Recht heirzu aus einem bestehenden Vertragsverhältnisse oder einer 
präsumtiven Zustimmung, dem vermuteten Auftrage hierfür legitimierter Personen, herleiten zu können, 
handelt überhaupt unberechtigt, also rechtswidrig”.  
15
 English translation from: Dietl, C.E., E. Lorenz, Dictionary of Legal, Commercial and Political Terms 
(2005). § 823 I BGB: “Wer vorsätzlich oder fahrlässig das Leben, den Körper, die Gesundheit, die Freiheit, 
das Eigentum, oder sonstiges Recht eines anderen widerrechtlich verletzt, ist dem anderen zum Ersatz des 
daraus entstehende Schadens verpflichtet”. The German formulation differentiates from other European 
equivalents in that it restricts the general clause to a specific list of goods protected by the constitution (s. 
Wagner, 2004:1473) and than extends the obligation to compensate to other goods only indirectly in the 
second paragraph through reference to specific laws (see later on).   
16
 “Die Widerrechtlichkeit und damit die Haftbarkeit des Arztes aus 823 [I BGB] ist nur ausgeschlossen, 
wenn und insoweit der Kranke oder sein gesetzlicher Vertreter in die Verletzung eingewilligt hat”: 
Reichsgericht 14.3.1911, Juristische Wochenschrift, 1911: 450.  
17 
Which follows from article § 1 I GG: „Die Würde des Menschen ist unantastbar. Sie zu achten und zu 
schützen ist Verpflichtung aller staatlichen Gewalt.“; and § 2 I GG: „Jeder hat das Recht auf die freie 
Entfaltung seiner Persönlichkeit, soweit er nicht die Rechte anderer verletzt und nicht gegen die 
verfassungsmäßige Ordnung oder das Sittengesetz verstößt“. 
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This debate has only recently found a solution with the disentanglement of 
indemnity for information failures from 823.1 BGB through the 2
nd
 Amendment 
Law for Damage compensation.
18
 In fact, through this law, compensation for moral 
damages (under which the violation of the right to self-determination falls) is also 
granted within contract liability. It has been observed that by allowing the claim for 
moral damages also for contract breaches, the legislator intends to steer the future 
medical liability law into its natural setting, namely breach of contract (rather than 
tort law)
19
. 
Indeed, differently than in tort liability, within contract liability, the damage derived 
from the lack of self-determination information consists in the lost chance to decide 
upon one’s own health, independently of eventual material damages.  Therefore 
information for self-determination ceases to be a risk disclaimer and rather responds 
to the need of enabling the patient’s autonomous choice within a counseling activity: 
risk information is only part of the more general duty of fostering a shared decision 
making.  
This analysis constitutes the basis for examining the legal status of PL information 
within the institute of informed consent and for evaluating PL information within 
this institute. 
 
 
Chapter 4  
 
Chapter 4 is devoted to analyze the legal nature of PL information within its 
interplay with doctor’s information. From the analysis of statutory and case law it  
results, that in addition to the traditional safety function ascribed by safety regulation 
to product instruction (warning), PL information also plays an autonomous role 
within the institute of informed consent; precisely that of informing of all possible 
residual risks associated with the therapy, besides the risks which must be disclosed 
by the doctor according to the information duties established by judicature.  
As a second step, fundamental objections are presented against the PL as an 
adequate source of information for the patient consent on legal grounds.  
 
 
Part II 
Normative analysis of PL information 
 
The second part of the thesis is devoted to evaluate the adequacy of PL information 
to accomplish the legal functions established by the law and identified in the first 
part. 
                                                 
18
 II Schadensersatzänderungsgesetz, 2SchadÄndG: 25.7.2002 BGBl I S 2674. 
19
 „An die Einbeziehung des Schmerzensgeldanspruchs in die Rechtsfolgen vertraglicher Haftung hat der 
Gesetzgeber die Erwartung geknüpft, dass die ihrer Rechtsnatur nach vertragliche Arzthaftung künftig 
nicht mehr mithilfe des Deliktsrechts abgewickelt ist“. Ibid, citing the BT-Drucks. 14/7752: 15 (my 
emphasis). 
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Chapter 5 is devoted to the linguistic analyses of package leaflets, whereas chapter 6 
presents a Bayesian analysis of PL information as a source of risk/benefit prognosis 
for the therapeutic decision.  
 
 
Chapter 5 
 
Linguistic research
20
 has analyzed PL texts as a token of expert-to-lay 
communication and has identified major sources of uncertainty induced by PL 
information in semantic and pragmatic factors such as ambiguity, vagueness, 
technical vocabulary and information overload.  
However, the distinction between avoidable and unavoidable risk helps distinguish a 
further and more fundamental cause of uncertainty beyond textual content and 
design: the uncertainty typically affecting any decision under imperfect knowledge.  
In fact the information about side effects (residual risk) results in prognostic 
uncertainty: this sort of uncertainty is inherent to the risk itself and does not simply 
result from background knowledge asymmetries due to expert-to-lay 
communication.  
What is lacking therefore is the investigation of the contribution brought by PL 
information to the consumer’s informed consent as a source of information within 
the specific decisional context inherent to lay therapeutic choice. 
 
 
Chapter 6 
 
This chapter undertakes the task of answering the following questions: 
1. What requirements the legislator establishes for consent to be qualified as 
informed; 
2. Whether PL information fulfils these requirements.  
As for the first point, the requirements are derived by the right which the institute of 
informed consent should honor, i.e. the right to self-determination: Information prior 
to consent should enable the patient to make an autonomous choice and therefore 
provide him with relevant data about the intervention/therapy and the risks and 
benefits involved. In order to allow a risk/benefit prognosis also probabilistic data 
about the healing effect and potential damage should be given.    
The criterion of including probabilities as relevant information for choice mirrors the 
procedure developed in the framework of probabilistic decision making: Bayesian 
decision theory.
21
  
                                                 
20
 Analyses range from text typology (Bock 1994; Dontscheva 1990; Ehlich 1994; Ehlich/Noack/Scheiter 
1994; Eckkrammer 1995, 1998, 1999, 2002, 2002b; Fickermann 1994; Grosse/Mentrup 1982; Hoffmann et 
al. 1998, 1999; Langer 1995; Mohn 1991; Nickl 2001; Werner/Heyne 1989) to lexicography (Mentrup 
1982, 1988), and pragma-linguistics (Hensel 1989; Hoffamnn, 1983; Saile 1984; Schuldt, 1992, 1998, 
Völzing, 1976, Zacharias, 1986).  
21
 With the caveat that in the frame of informed consent – at least within the tort liability setting – the 
decision is understood as a yes/no option rather than a choice among several alternatives. 
The decision-maker needs to be made aware of the risks and benefits of the proposed intervention mainly. 
A duty to inform about alternatives is triggered only insofar they are attached with a significantly different 
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Bayesian theory results from the development of three distinct but interconnected 
fields of research devised in order to describe (and optimize) the management of 
decisions under uncertainty:  
1) the theory of decision optimization through maximization of the expected utility; 
2) the theory of knowledge updating through probabilistic induction; 
3) the theory of expected value of information as a function of the expected reward 
in terms of contribution to decision optimization. 
“Uncertainty” means in this framework an epistemic state of less than perfect 
knowledge about the actual state of affairs, which is modeled by a probability 
distribution/function over a state partition.
22
  
The Bayesian approach to informed consent seems to underlie also the regulation of 
PL risk disclosure, as can be evinced from article 13.1 of the 1994 BfArM 
recommendations for PL information, which suggests to give frequency of side 
effects whenever possible, in order to ease the risk estimation of the patient.
23
  
Thus, PL information is precisely thought of by the legislator as a source of 
probabilistic information for an autonomous decision, with related shouldering of 
residual risk. 
In order to analyze the role of PL information in this setting, it has been considered its 
role as a contributor to epistemic accuracy within the therapeutic choice. The 
introduction of a Bayesian model for health choices accounting for the presence of 
genuine uncertainty (Andersson and Littkens, 2002) has allowed us to identify and 
distinguish relevant parameters in relation to the role of information in health 
decisions.  
The model is constituted by a two-components function. The first component is a 
traditional expected utility function (where utilities are weighted by probability 
assignments); the second is a generalized expected utility where health statuses 
(utilities) are surrounded by uncertainty and cannot be assigned firm probabilities: 
 
U(a) = γ(a) ∙∑s π s (a) u(h
s
, a) + (1- γ(a)) ∙ u0(a).
24
  
 
Along this model, consent has been defined to be informed to the extent that it 
approaches a decision under risk (known probabilities), i.e. to the extent that the 
decision maker can assign a probability measure to each health status in a ranking 
from the most favorable to the worst – being health statuses nothing else then 
quantities of quality adjusted healthy days – and that he knows whether the act of 
                                                                                                                                                 
risk/benefit profile.
 
See chapter 3 § 4 for the distinction between contract vs. tort liability approach to 
informed consent.  
22
 A decision under uncertainty differentiates from a decision under risk such as that of games of chance, 
where probabilities are objectively determined by the stochastic mechanisms underlying the game (1/6 
probability for any die face in a throw, 1/52 of a Queen of hearts, etc.). However terminology slightly 
varies in the literature, especially objections are moved against the misleading use of the word “risk”: 
Gärdenfors, Sahlin, 1988: 5. Andersson and Littkens, 2002, which provide the model presented below 
speak of conventional risk for uncertainty with known probabilities, in the sense that the individual is 
sufficiently confident to assign a specific probability measure to the events under consideration, and of 
“genuine uncertainty” for a situation approaching ignorance, i.e. where the decision maker has a very vague 
of no idea about the probabilities which should be assigned to the relevant events.  
23
 See original excerpt in chapter 4 § 4.2, footnote: 35. 
24
 Andersson and Littkens (2002): 42.  
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taking the drug (a) shifts the probabilistic distribution towards stochastic dominance 
with respect to the act of not taking the drug.  
This means that the weight factor associated to the first component of the utility 
function (which assigns a probability measure to each health status) tends to 1 (γ→1).  
Against the framework of this model, PL information seems to provide the drug 
consumer with data whose personal relevance, and therefore prognostic value for the 
individual, is difficult to assess.  
There are in fact no legitimate epistemic grounds for directly assuming this statistical 
frequency as a prognostic judgment about the probability that a single user might be 
concerned by the side effect. 
In order for it to ground the prognostic assessment, PL information should be 
integrated with other parameters such as personal susceptibility given 
dosage/duration.  
Given that side effects must however be taken into account by the drug user in 
accordance to the responsibility shouldered within informed consent, these data are 
bound to contribute to the weight factor assigned to the uncertainty component of the 
utility function.  
Furthermore the probabilistic assessment should be combined with the perceived 
importance of the eventual damage (subjective disutility), the evaluation of which is 
most of the times hindered by the lay incompetence to appraise the magnitude and 
health implications of the risks mentioned in the PL. 
This means that consent on the basis of PL information rather approaches a decision 
under ignorance than one under risk: as a prognostic device, PL information 
fundamentally asks more questions than it answers. 
Given that the legislator implies that consent is given with knowledge of the 
probabilities of risks and benefits, PL information cannot be considered adequate for 
consent.  
As for the safety function which PL information should also accomplish, so the 
contribution of PL information in this respect does meet minimal requirements, in 
that the drug consumer can actually profit from it in order to use the product correctly 
and safely. In this respect, also information about residual risk (side effects) 
accomplishes a safety function in that it might help the consumer identify eventual 
unexpected symptoms as side effects, whenever they are already listed in the text. 
Side-effect information can be validly used for diagnostic rather than for prognostic 
assessments.  
The legislator should account for this asymmetry and regulate liability based on 
information consequently: the consumer should not be considered committable to 
residual risk on the basis of PL information, but instead it should be emphasized his 
contributory negligence whenever safety aspects of PL information are not 
sufficiently taken into account by him.  
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Part III 
Empirical findings 
 
The third part presents a quantitative and a qualitative research on PL use. The final 
chapter integrates the results obtained in the empirical studies in a unitary model of 
health risk information processing. 
Chapter 7 presents the results of an exploratory survey on the effect of PL 
information on the risk/benefit assessment of concrete drug users.  
Chapter 8 investigates lay strategies for PL information selection and risk/benefit 
assessment through the material provided by a “think aloud experiment”.  
Chapter 9 integrates Bayesian categories of analysis with bounded rationality 
theories in order to construct an integrated model of health risk information 
processing.  
 
 
Chapter 7  
 
Chapter 7 presents the data emerging from a survey based on a questionnaire 
administered to 55 drug consumers in the university campus. In order to investigate 
the impact of PL information, a sort of “paired comparisons test” has been devised. 
Questions related to the risk/benefit estimation and decision confidence were asked 
before and after reading the PL accompanying the drug.  
The information impact was measured by the difference between risk/benefit 
assessment before and after reading the PL. 
No significant change in the risk/benefit impact has been registered from the pre PL 
to the post PL phase. Contrary to commonly held opinions – but in line with recent 
studies – not all participants seem to get frightened by PL reading.  
This apparently contradicts the perceived increased level of knowledge after reading 
the PL, which is the only statistically significant change among all assessments before 
and after the PL.  
The data fundamentally hints at a gap between the perceived information value of 
package leaflets, and their concrete contribution to an autonomous choice. 
Furthermore the findings neither confirm nor disconfirm the supposedly uncertainty 
inducing effect generally attributed to PL information, instead they suggest that 
rather than being influenced by a vague prognostic uncertainty about all possible 
risks, the confidence in the therapeutic choice is mostly affected by the emergence of 
specific topics of concern.  
The fact that no overall increased risk perception can be associated to PL reading, and 
that nonetheless the presence of specific topic of concerns is indeed associated with 
different risk and benefit perception patterns can be interpreted as a sign of no spill-
over effect: participants do not take seriously any item of risk information contained 
in the PL, but only specific items.  
The main result deriving from this study is however the gap between increased 
perceived level of information and  
1. insignificant PL impact on benefit and risk assessments; 
2. absolute no impact on the decision. 
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Considering the generally positive evaluation of PL information and the increased 
perceived level of information after PL reading, these data support the hypothesis that 
the therapeutic decision concerning prescription drugs is quite insensitive to PL 
information. 
 
 
Chapter 8 
 
The qualitative study (chapter 8) enjoys the technique of the “think aloud” 
experiment. Participants have been asked to answer the questionnaire and read the 
PL in the presence of the analyst. Comments and answers to open questions give 
important insights as to the way drug consumers cope with the perceived 
unmanageability of PL information.  
A contrasting feeling towards the package leaflet can be observed, which is 
explained through the phenomenon of “relevance paradox”: each item of PL 
information is perceived as potentially relevant for the drug consumer; but the 
probability that all of them jointly concern him is extremely low. This leads the 
single user to consider the text as constitutively over-informative.  
PL information seems to raise more questions than it answers. Generally people 
perceive it as highly important, but are not in the position to adequately select 
personally relevant information. This might lead to the overload sensation accounted 
for through the notion of “relevance paradox”. Common heuristics to bypass these 
shortcomings are reappraisal, counterfactual neglect, idiosyncratic causal models, 
and uncertainty neglect.  
As a result, PL information is not processed in its entirety and is selected through the 
most diverse filters.  
A key for the selection of relevant information is constituted by the information 
provided by the doctor’s consultation: PL information which can be connected to 
what the doctor has already communicated is considered relevant; any 
incomprehensible data are considered to be addressed at the expert, and are therefore 
neglected. A space of uncertainty opens for risk information which has not been 
previously addressed by the doctor and is comprehensible: in this case uncertainty 
arises as to its possible occurrence.  
The analysis allows to spot the institutional context in which the PL communication 
is embedded as the framework providing the pragmatic clues, through which PL 
information processing is at all possible. Without the cues provided by the doctor’s 
information, the reader would find himself in front of an amount of unmanageable 
information, which only becomes intelligible through the knowledge previously 
acquired in the consultation. 
Therefore, any information with no relationship to any item of knowledge in one’s 
own database is perceived as irrelevant and dismissed as such.  Paradoxically one 
might say here, that information that sounds “new” at this stage of post-consultation, 
will be considered irrelevant. 
This raises some doubts as to the legitimacy of PL information as a basis for a the 
consumer’s informed consent. 
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Rather then being a basis for an evaluation of the treatment choice, the PL is 
conceived as a modular reference text to be consulted at the beginning for 
precautionary reasons, and then during the therapy in order to identify eventual side 
effects.  
 
 
Chapter 9  
 
Chapter 9 posits the therapeutic decision as the teleological determinant for the 
information processing. Thereby, the therapeutic decision, which is established by the 
legislator as the communicative purpose of the PL text, suggests the theoretical 
framework within which the behavior concerning PL information processing can be 
investigated, namely: decision theory. 
The theoretical structure is provided by the Bayesian theory of expected information 
value. This frame is integrated with the insights gained by cognitive approaches to 
information processing (“Bounded rationality” theory), and emotional accounts of 
health risk information processing. 
The added value brought about by this integrated model is that it accounts for the 
accuracy level of PL information processing and impact by tracing them back to the 
decision sensitivity to the information at hand.  
In particular, recurrent phenomena observed in the empirical literature – reappraisal, 
cognitive dissonance, information avoidance – are integrated in a comprehensive 
model including the structural factors which determine the expected value of 
information to decision, and the perceived capacity to deal with this information (self-
efficacy).  
The integrated Bayesian-cognitive model implies for instance that whenever no 
alternative is at sight, the cost of acquiring further information is considered 
worthless. Also when information is perceived as useful, but too demanding in terms 
of information design in relation to one’s own processing capacities it tends to be 
neglected. 
 
 
Chapter 10 
 
The conclusive chapter summarizes the research results and proposes some 
suggestions for the legislator and for the text designer. 
In particular it is proposed that the legislator clearly discriminates between the safety 
and the self-determination components of PL information as it is already 
distinguished in the regulation of doctor’s information.   
A possible consequence of this distinction could be the partial disentanglement of 
PL risk disclosure from risk responsibility allocation.  
Patient’s responsibility should be therefore articulated as follows:  
 The patient’s contributory liability for damages caused by non-compliance to 
safety instructions should be maintained. Indeed along the analysis proposed in 
the thesis, this sort of information can be validly used by drug consumers for 
averting or minimizing risk.   
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 Instead PL information cannot be considered adequate for consent to be valid. 
Therefore it cannot offload the pharmaceutical firm from the responsibility 
related to residual drug risk, whenever the doctor cannot be considered liable for 
it. As a consequence strict liability of pharmaceutical firms should be extended 
to damages which are beyond the residual risk level, but which are nevertheless 
relevant for the damaged person.     
These claims can be also supported by the consideration that damage liability is 
only a monetary compensation for injuries which touch high valued goods such as 
psychophysical wellbeing.  
More generally, with an explicit separation of the safety and self-determination 
aspects related to PL information, patient’s contributory negligence in safety issues 
could be more clearly emphasized and contribute to balance the distribution of 
responsibilities around drug consumption.  
 
 
 
 
 
Although the research regards German pharmaceutical regulation, the thesis is 
written in English (American spelling) in order to make the results available to the 
widest possible audience.  
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PART I 
 
Pharmaceutical information and the law 
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1 Product safety  
 
 
 
 
 
 
 
 
 
 
1. The Janus-character of pharmaceutical products: sources of uncertainty and 
risk communication 
 
The development of medicine and pharmacology after World War II has 
significantly contributed to a new attitude towards health and illness. Nowadays the 
multiplicity and sophistication of medical technologies has reached such a level that 
a specific term has been coined in order to describe this process:  medicalization of 
the society.
25
 
 
However, after a first phase of unlimited trust in the progress of medical sciences 
and pharmaceutical research in particular, a phase of disenchantment has followed as 
a consequence of shocking events which had deep direct and indirect impact on 
public awareness about pharmaceutical products.
26
 These tragedies contributed to 
enhance efforts about possible ways to minimize the risk connected to drug use 
without renouncing to its benefits.
27
  
 
Medicine and pharmacology show indeed a double identity: they both offer a kind of 
service to which anyone would gladly renounce for two reasons: the first and most 
obvious is that normally you would prefer not to need this service; the second is that 
the benefit of a therapy is always accompanied by a certain risk. Drugs have a Janus 
character as healing promise and poison at the same time.
28
 Debates about 
                                                 
25
 Zola, I. 1972; Camper, 1996; Domenighetti, 2005: 221 ff. ascribes the “surmédicalization de la vie” to 
three major factors: 1) the higher uncertainty in job market, with consequent stress and higher morbidity in 
the population; 2) the decrease of risk parameters levels such as cholesterol or hypertension so as to 
increase pharmaceutical market (so called disease mongering), and the overuse of diagnostics; 3) finally, 
population aging in western societies. The most worrying aspect of this state of affairs is represented by the 
limited economic resources in face of a potentially unlimited demand.  
26
 See the case of a tranquilizer Contergan (Thalomid) in Germany: 2800 physically and/or mentally 
handicapped newborns from mothers using the drug during their pregnancy (1957-1961). More recently: 
Lipobay©, Vioxx©, and Bextra ©.  
27
 For a detailed report about the last forty years of drug regulation in Germany and Europe see Sheu, 2003. 
28
 Hart, 2005: 204. 
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pharmaceutical products focus on one and the same principle: Health as an 
individual and societal good, which drugs contribute both to promote and to 
endanger. 
The need for preventing damaging events has led to a strict regulation of the 
pharmaceutical market. This has increasingly enriched the list of responsible care 
duties for dangerous entities
29
, and enlarged the intervention powers of the authority 
in charge.
30
  
These measures though do not constitute an absolute guarantee of safety: however 
carefully designed and manufactured, pharmaceutical products can produce 
unpredictable reactions in the different organ systems. The awareness of this residual 
risk has led the legislator to regulate pharmaceutical safety through a risk prevention 
and management system.  
Risk communication assumes in this context diverse functions in face of the 
uncertainties deriving from pharmaceutical products.  
These uncertainties are of various natures and can be briefly described as follows: 
 
1. Epistemological uncertainty about any specific product: because drug reactions 
are idiosyncratic and depend on several epidemiological and genetic factors, 
knowledge about the effects of any drug grows with the number of its users. This 
means that even many years after approval, it is still an “experimental product”31, the 
information about which is neither exhaustive nor conclusive.  
To face this kind of uncertainty, the legislator has predisposed a risk surveillance 
and management system, with the aim to prevent and reduce risk to the minimum. 
Risk communication among experts and to the public (top-down) proves to be a 
fundamental alarming tool. Warning failures and risk miscommunication should be 
all the more stigmatized. 
 
2. Ontological uncertainty affecting pharmaceuticals in general: differently than in 
the case of other products, where the damage is generally to be traced to product 
faults, in the case of drugs, health injuries can also be the result of the organic 
reaction to the drug components. Risk is inherent to pharmaceuticals even if no 
design or production defect affects them.  
Against this type of uncertainty a risk tolerance threshold is established above which 
the drug is considered unsafe. It is a pragmatic answer to an unsolvable dilemma.  
 
3. Metrical-methodological uncertainty: it concerns the risk/benefit assessment and 
evaluation themselves. Pharmaceutical risk and benefit are umbrella concepts, whose 
several dimensions are difficult to operationalize, and therefore to measure and 
compare.  
                                                 
29
 Generally also accompanied by deontology codes of self-regulation from the side of the industry (Scheu, 
2003: 59-60). See in the pharmaceutical field the BPI-Kodex (Bundesverband der Pharmazeutischen 
Industrie).  
30
 For a historical contextualization of this evolution see Scheu, 2003. A fundamental reference to the 
evolution of risk regulation is Di Fabio, 1994. 
31
 Drugs are products under constant testing („Arzneimittel sind Produkte in Dauererprobung“) declared the 
Health Minister Dr. Focke in the ministerial statement for the provision of the drug act ’76. Scheu, 2003: 
701. 
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Shortcomings of medical sciences in quantifying these dimensions might be 
compensated by a deeper understanding of the health implications related to the 
therapeutic choice according to the perspective of the most concerned parties 
(bottom-up communication).  
 
4. The fourth type of uncertainty is ethical and is related to the risk tolerance 
threshold established through the risk/benefit assessment. This determines the level 
of socially accepted risk and it represents a compromise among the different 
stakeholders: also here communication among authority, pharmaceutical enterprises, 
the health professional and the public plays a decisive role. Risk communication 
among stakeholders should build the basis upon which risk acceptability is 
established.  
At this level, communication is an indispensable tool for guaranteeing decision 
autonomy through adequate risk information and allow a personal risk/benefit 
evaluation (both for the doctor and for the end-user). It is within this framework that 
the nature of risk information to the patient through the package leaflets needs to be 
investigated. 
 
In addition to these different sources of uncertainty, several concepts of risk 
intertwine and overlap in the pharmaceutical field:
32
 
1. the legal articulation of the concept of risk in a rich dogmatic for  
1a. safety regulation  
1b. and the distribution of damage liability. 
2. the statistical-mathematical notion of risk as analyzed through probabilistic 
models for the prognosis of drug effects; 
3. the statistical-epidemiological survey of drug risks on a population; 
4. the medical prognosis of risks for a specific risk group or individual; 
5. the lay perception of risk and risk acceptance at societal level; 
6. the lay perception of risk and risk acceptance at individual level. 
 
These different conceptions are strictly interconnected. The legislator is continuously 
challenged to subsume under legal categories aspects of technology and scientific 
development which are difficult to control. 
 
Risk communication plays two distinct roles in this setting. As for point 1a – safety 
regulation – risk communication among pharmaceutical/medical experts and 
administrators serves the purpose of helping experts coordinate their efforts for 
monitoring and reducing risk (in the sense 2-4), establishing acceptable risk 
thresholds (where legal norms are legitimized by scientific documentation) by 
eventually involving psychosociological dimensions (5 and 6). Moreover, 
transparent and timely communication is an essential tool for drug risk management. 
Within liability regulation (1b), risk communication among different stakeholders 
equates to a distribution of responsibility as for the consequences brought about by 
health technologies.  
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 See also Preuss, S. 1996: 68.  
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The PL has emerged as a vehicle for risk communication to the end-user within 
safety regulation (risk avoidance/minimization), but has increasingly acquired 
liability relevance (distribution of risk responsibility). Moreover, it is embedded in a 
wide risk communication framework, where the risk information delivered by the 
doctor should constitute the principle channel for therapeutic communication. It is 
precisely in this framework that point 4 (medical tailored risk prognosis) and 6 
(individual perception of risk) can come to collide because of the interference of PL 
information, and eventually lead to non-compliance.  
 
The aim of this chapter is to illustrate drug safety regulation and the role of 
communication measures at each of the uncertainty levels mentioned above. The 
following chapters will investigate the function of risk communication as a 
distributor of risk liability. 
 
 
2. Safety regulation in Germany 
 
Safety regulation has evolved through the specification of the professional duties of 
the pharmaceutical firm and of the intervention powers and duties of the responsible 
authority.  
Specific professional duties concerning pharmaceutical enterprises were first 
articulated in the court decision following the Contergan trial.
33
  It is thanks to this 
sentence that a general consumer protection and risk disclosure duty concerning the 
pharmaceutical firm have been established and concretized.  
The first and foremost duty mentioned in the judgment is the obvious task of 
thoroughly investigating a chemical entity prior to marketing through 
pharmacological and clinical studies.  
The general protection duty towards the consumer also determines the safety 
practices required after authorization. A sufficient protection for the consumer is not 
guaranteed when a pharmaceutical firm takes countermeasures against side-effects 
after they have been proven.
34
 Because a positive proof of damage causality requires 
time, and a large epidemiological base – and can also never be definitively assessed 
– a scientific proof of causality cannot be a valid criterion for determining the 
threshold of safety countermeasures.  
Neither is a scientifically founded suspicion is an adequate condition for requiring 
safety measures. Before a risk suspicion can be founded scientifically, enough time 
may pass as to produce damage in some consumer. During this vacillation time, the 
risk has to be undertaken by the pharmaceutical firm. This translates into the 
implementation of adequate measures to reduce the risk (labeling changes, 
suspension of the product distribution, product retirement). 
The risk linked to causal uncertainty falls primarily upon the producer and results in 
an obligation to adopt adequate actions, whenever the protection of the consumer 
requires it.  
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 LG Aachen, 18. 12. 1970 – 4 KMs 1/68, 15 – 115/67. JZ 507 (521). 
34
 LG Aachen, 18. 12. 1970, JZ 515. 
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Moreover, for the principle of inverse proportionality, and from the high importance 
of the goods at stake (health and possibly life) even very low probable suspicions ask 
for timely countermeasures.
35
 General criteria for determining the opportunity and 
entity of safety actions are provided: 
 
1. severity of the suspected health damages: the more dangerous the drug is 
supposed to be, the earlier and prompter must the firm react to risk news concerning 
the product; 
2. the nature of the damages: irreversible damages require quicker reactions than 
transitory disturances; 
3. side effects frequency: the higher the frequency of risk data, the lower the 
suspicion needs to be in order to require safety countermeasures from the firm; 
4. therapeutic importance: the higher the interests of patient in the availability of 
the drug, the higher can the risks be, that are taken into account in order to allow the 
drug to stay in the market. Therapeutic importance is determined by the lack of 
alternatives and the severity of the illness. 
As for the question about which concrete measures shall be adopted, the answer 
changes from case to case, but depends fundamentally on the course of action, which 
allows the best possible protection of the consumer.  
So, for instance, the further investigation of the causal connection between drug and 
damage does not have a direct impact on the protection of health, but rather serves to 
absolve the product from eventual imputations. More pertinent measures instead 
involve the adoption of communication actions towards the health professional and 
the end-user, the introduction of the prescription requirement, and possibly the 
retirement of the product from the market.
36
  
 
The justification for the adoption of this safety regime can be summarized in the 
following points:
37
 
1. pharmaceuticals are a special kind of product. No drug is void of side-effects, 
some of which can be identified only years after introduction into the market; 
2. the causal assessment of side-effects as it is performed through clinical studies is 
not always feasible and sometimes also illegal and unethical, when the side effect 
under investigation is severe and irreversible, and the experiments require a re-
exposition to the drug; 
Consequently, the level of professional care required is characterized by high strong 
requirements. Any identifiable danger source must be defused as long as the 
possibility of damage is identified.  
Furthermore, the threshold level for the adoption of safety measures is lowered to the 
level of well-founded suspicion, and depends on the gravity of the risk (the higher 
the supposed risk, the lower need to be the suspicion in order to require for 
countermeasures). 
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The Contergan decision has not only greatly contributed to the definition of the 
principles underlying professional duties related to the production and distribution of 
pharmaceuticals, but also – and more importantly judicially– to the shift of risk 
regulation from a mere danger avoidance towards a risk prevention system. This has 
resulted from the introduction of lower thresholds for the adoption of safety 
measures as those established by traditional causal requirements typical of classical 
safety regulation (police law): well-founded suspicion rather than causal connection 
between possible damage and danger source.  
The introduction of this principle in the definition of professional duties for 
pharmaceutical firms has been mirrored by corresponding intervention powers 
granted to the responsible authority through the articulation of a specific law for 
pharmaceuticals.  
 
 
2.1 State duties towards health as a constitutional good  
 
Health is a good constitutionally protected in all western countries. It is also 
recognized that this good concerns not only the individual but also the society as a 
whole.
38
 Indeed the protection of the individual health is intertwined with the 
safeguarding and promotion of public health.  
The democratization of western societies honors this right through the principle of 
equal access to health services for everybody, and has led to the institution of 
national health institutions aimed at providing healthcare for all citizens on the basis 
of quality, efficacy, economical rationality, and satisfaction of patients as well as 
health professional.
39
 
 
The German constitution grounds the state duty to protect the citizen from health 
impairment and lethal agents through Art 2 II GG
40
 in connection with Art 1 I GG.  
Art 2 II GG establishes the right of the individual to inviolability of life, bodily 
integrity and freedom.
41
 Art 1 I GG obliges the state to actively protect human 
dignity.
42
 This implicates, that the protection of the goods mentioned in Art 2 II GG 
should translate not only in the prohibition to violate them, but also in the active 
protection from third party infringements.
43
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41
 § 2 II GG: “ (1) Jeder hat das Recht auf die freie Entfaltung seiner Persönlichkeit, soweit er nicht die 
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In diese Rechte darf nur auf Grund eines Gesetzes eingegriffen werden”. 
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aller staatlichen Gewalt. (2) Das Deutsche Volk bekennt sich darum zu unverletzlichen und 
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und Rechtsprechung als unmittelbar geltendes Recht.” 
43
 Scheu, 2003: 724. 
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In the case of pharmaceuticals however, the state’s duty to protect the individual 
from third parties is also triggered by the citizens’ domain-inexpertise and 
subsequent incapacity to protect himself from drug related risks.
44
 In fact, the very 
protection of Art 2 II GG through drug selection prior to approval would constitute a 
violation of another constitutionally protected good, namely, the freedom of 
(therapeutic) choice (Art 2 I GG).
45
 However, because of the enormous amount of 
information and data which this choice would presuppose you cannot de facto speak 
of a freedom of choice for the consumer.
 46
  Neither consumers’ nor doctors would 
be able to make a rational decision among all possible pharmaceutical products, if 
these entered the market without any prior selection. Therefore they would not 
concretely exercise the right itself: it is precisely this impossibility on principle for 
the interested party that constitutes the basis for the authority subsidiarity.
47
 
Safety protection is a task that legislator, administrative authority, and case law 
(court decisions) jointly accomplish. 
 
 
2.2 The German medicines act 
 
Safety is legally defined as the absence (absolute safety) or at least the improbability 
(relative safety) of future offences to goods protected by the law.
48
 The aim of  
police law is precisely to prevent the offence of such goods by averting damages. 
Therefore safety law is inherently preventive.
49
 To the two legal concepts of 
“danger” (Gefahr) and “risk” (Risiko) correspond to different levels of intervention 
powers from the state.  
 
Danger refers to the probable concrete possibility of the occurrence of a not 
irrelevant damage:
 50
 for instance a fire in a forest. Danger avoidance measures aim 
at preventing the danger emerging at all.
51
  
The authority has the right to intervene in the measure that the damage probability is 
high and its gravity is severe. The rule for danger avoidance intervention is the 
classic formula of inverted proportionality: the greater the eventual damage, the 
lower the probability of occurrence needs to be for allowing authority intervention.
52
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 Scheu, 2003: 71. 
52
 The concept of probability as a legitimating factor for state intervention was originally defined by mere 
possibility of occurring. With the complex evolution of modern society into a risk society, it has become a 
relational factor dependent on the damage dimensions. Di Fabio, 1993: 110.“Der Begriff der 
Wahrscheinlichkeit entwickelte sich bereits in der allgemeinen Dogmatik des Gefahrbegriffs von einer 
 40 
 
Risk refers to the awareness of an abstract possibility of a hypothetical damage with 
no concrete menace of occurrence: for instance adverse drug reactions.
53
  
Risk prevention measures presuppose the establishment of a tolerable risk threshold 
level over which intervention is demanded.
54
 It is the establishment of this risk 
threshold that decides when and if countermeasures are to be taken.
55
 The formula of 
inverted proportionality does not refer to the concrete possibility of occurrence but to 
the abstract statistical incidence.  
Neither does any casual connection need to be established between the eventual 
damage and the risk source: the only plausibility of the link between the two suffices 
for authorizing risk reduction measures. Given the high value of constitutional goods 
such as life and health, even low probabilities of connection are sufficient for 
intervention.
56
 With the principle of risk prevention (Risikovorsorgeprinzip) the 
possibility of damage is taken into account, for which a causal link with the 
hypothesized source can neither be established nor denied.
57
 
Eventual damage should not only be concretely averted, but also anticipated through 
continuous monitoring of sources of danger. 
 
Increasing risk awareness in the society and the consequent lowering of thresholds 
for legitimate intervention has led to the evolution of safety regulation from mere 
danger avoidance to risk prevention.
58
  
Both intervention conditions for danger avoidance and risk prevention makes 
reference to the probability concept. In the first case though, this is simply applied to 
the damage and its objective possibility of occurrence; while in the second, it is an 
epistemological judgment about the hypothesis that the danger source is the real 
cause for the possible damage under consideration.  
 
With the German Medicines Act 1976 (henceforth AMG: Arzneimittelgesetz), also 
pharmaceutical safety regulation has evolved from mere danger avoidance 
(Gefahrenabwehr) to a risk prevention system (Risikovorsorge).
59
 This has resulted 
both from the evolution of the probability concept for legitimizing intervention – the 
principle of well-founded suspicion
 60
 instead of the causality requirement – and also 
                                                                                                                                                 
überwiegenden Möglichkeit zu einer wertungsabhängigen Risikoeinschätzung. Je größer der befürchtete 
Schaden desto geringer die Anforderungen an den verlangten Wahrscheinlichkeitsgrad”.   
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55
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60
 Wolz, 1988: 1, 5. 
 41 
from the integration of scientific criteria in the determination of the intervention 
threshold.
61
  
 
The first law regarding pharmaceuticals dated back to 1961 and did not impose any 
authorization procedure, but just required a formal registration for any 
pharmaceutical introduced into the market. It was still a norm of danger avoidance:  
- according to the legislator, it should be a duty of the state to regulate the 
production of pharmaceuticals so as to completely prevent health damages to the 
population;
62
 
- the intervention criterion in case of danger required a causality assessment. 
This causality requirement of AMG ’61 (Arzneimittelgesetz: AMG) had the effect of 
thwarting the prohibition norm, given the methodological difficulties associated with 
causal assessment in medicine.
63
  
On the wave of public bewilderment after the tragic pharmaceutical scandals, the 
legislator recognized that drugs are no ordinary products, and that the production of 
pharmaceuticals is a public task.
64
 This led to a complete new version of the law as a 
risk prevention and consumer protection norm, issued in 1976.
 65
  
 
The AMG is part of a system of regulation, which guarantees the safety of 
pharmaceutical products. The other laws covering this health sector comprise the 
norms related to drug circulation (especially pharmacy law), civil and criminal 
liability (of the pharmaceutical company and of the state), norms related to 
information and advertising of pharmaceuticals, the regulation of doctors’ 
professional duties and liability, and public insurance legislation.
66
  
It was emanated in its actual form in 1976 and is the result of the political debate 
followed to the thalidomide tragedy (Contergan) and of the implementation of the 
European directives 75/318/EEC and 75/319/EEC, themselves following from this 
pharmaceutical catastrophe.
67
  
The law incorporates the professional duties imposed on a pharmaceutical firm, as 
they had been delineated by the Contergan court decision.
68
 
The explicit purpose of the law for pharmaceuticals is the safety of drugs 
administered to the public through the establishment of criteria for the efficacy, 
quality and safety (“Unbedenklichkeit”) evaluation of candidate drugs.69 It warrants 
for safety through drug approval, surveillance and liability norms.  
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 § 1 AMG: „Es ist der Zweck dieses Gesetzes, im Interesse einer ordnungsgemäßen 
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 42 
Risk prevention is promoted by AMG through a strict regulation of competences, the 
establishment of quality and safety requirements, the institution of a surveillance 
system, and finally through norms regulating risk disclosure when this cannot be 
avoided. 
 
Competent federal authorities are the Federal Institute for Medicines and Medical 
Devices for drugs in general (BfArM: Bundesinstitut für Arzneimittel und 
Medizinprodukte) and the PEI (Paul Ehrlich Institut) for blood products, sera, 
allergens, vaccines, and pharmaceutical products derived from tissues, bone marrow, 
genetic and cell pharmaceuticals. The federal office for consumer protection and 
food safety (BVL: Bundesamt für Verbraucherschutz und Lebensmittelsicherheit) is 
responsible for drugs  for veterinary use (§ 77). 
All decisions concerning pharmaceutical approval – approval grant, withdrawal, 
revocation or suspension – belong to the administrative authority (§ 25). Primary 
task of the administrative authority is therefore to take care of the safety of 
pharmaceuticals present in the market. This translates in an administrative activity 
which is grounded in scientific data provided by the different stakeholders 
(pharmaceutical companies, doctors, independent research) and in cooperation with 
other safety agencies at European and international level (EMEA, WHO).
70
  
Approval through the administrative authority however does not diminish the 
company’s civil and criminal liability for torts or crimes.71 
 
The competent authority is also liable for taking adequate measures as to remove 
breaches against pharmaceutical regulation or prevent future violations (§ 69 I) – 
coherently with other warning and safety measures
72
 – to the extent that their activity 
is required by the obligation to protect health from danger coming from the drug. In 
particular they have the authority to prohibit the circulation of a pharmaceutical, or 
to order  recall and confiscate it when approval or registration is not available or has 
been suspended (§ 69 I 1); the active ingredient does not comply to quality standards 
(§ 69 I 2); when benefit is wanting (§ 69 I 3); or there is a well founded suspicion 
that the risk exceeds the tolerable threshold as established by medical science (§ 69 I 
4). 
 
Risk prevention is managed through two control systems: drug approval (Verbot mit 
Erlaubnisvorbehalt: “default” prohibition with reserve of permission) and the post-
marketing control.  
Liability norms also constitute an indirect incentive to safety beyond their principal 
compensatory aim. 
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 § 25 X: “Die Zulassung lässt die zivil- und strafrechtliche Verantwortlichkeit des pharmazeutischen 
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 Binding of approval to the enforcement of particular warnings (§ 28 I, II); or to the prescription of further 
pharmacological and toxicological research (§ 28 III); causes for approval withdrawal, recall, suspension (§ 
30); approval prolongation refusal because of causes for withdrawal, recall or suspension (§ 31 IV). 
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In general, AMG interferes in the pharmaceutical market through legal instruments 
of different categories:
73
 
- The norms for the authorization of administrative acts and ordinances constitute 
the general regulative aspect of the law. These norms are part of the state’s 
obligation to danger avoidance and risk prevention; 
- The repressive norms of criminal law and against breaches of administrative 
rules (§§ 95 ff.) represent the second regulation level, through which transgressions 
of ordinances or prohibitions are subject to penal sanctions; 
- Finally, civil liability norms (§§ 84 ff.) ground the legal basis for damage 
compensation duties from the pharmaceutical firm towards the user. 
 
The law is divided in several sections and subsections. I present a succinct inventory 
with special attention to norms related to risk communication. 
Section 1. Purpose of the law and terminological definitions (§§ 1-4 AMG). 
Section 2. Requirements for drug approval and circulation. It comprises criteria for 
the establishment of the tolerated risk threshold and the prohibition of circulation for 
drugs, whose risk exceeds this threshold (§ 5); competent authority (§ 6); fraud 
prohibition (§ 8); responsible agent for drug circulation: pharmaceutical entrepreneur 
(§ 9); product labeling (§§ 10: package labeling; 11: patient package leaflet; 11a: 
information leaflet for the doctor; 12: authority powers concerning warning 
enforcement). 
Section 3. Drug production requirements (§§ 13-20). 
Section 4. Drug approval: approval duty (§ 21); application documents (§§ 22-24); 
clauses of approval refusal and approval decision process (§ 25-27); special 
conditions for approval linked to information duties (§ 28, 29); approval withdrawal, 
revocation, suspension (§ 30) approval extinction and prolongation (§ 31); other 
competencies of the administrative authority regarding approval (§§ 32-37), among 
which information of administrative acts to the public (§ 34). 
Section 5. Drug registration (§§ 38-39): it concerns homeopathic drugs and herbal 
products for which no approval process is required. 
Section 6. Good clinical practice (§§ 40-42): protection of test persons within 
clinical studies prior to approval. 
Section 7. Pharmaceutical distribution (§§ 43-53): authorized agents for the 
distribution and administration of pharmaceutical products, prescription duty, and 
exceptions to the requirement of pharmacy sale. 
Section 8. Production quality controls (§§ 54-55). 
Section 9. Special norms for veterinary drugs (§§ 59-61). 
Section 10. Drug risk monitoring, survey and evaluation (§§ 62-63): risk 
management coordination duty of the competent authority, cooperation with other 
competent institutions at European (EMEA) and international level (WHO), and 
authority to inform the public about measures which are intended to be undertaken 
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(§ 62);
74
 § 63 “Stufenplan” – risk management plan comprising disclosure duties of 
the pharmaceutical firm (§ 63b). 
Section 11. Authority inspection and general notification duties towards and among 
authorities; intervention powers of the competent authority (§§ 64-69): inspection 
process (§ 64); sample drawing (§ 65); cooperation duties by inspection activities (§ 
66); general duty to give notice about pharmaceutical product development, 
manufacturing, clinical testing, storage, packaging, marketing, or commercialization 
in general (§ 67); centralized system of information gathering in the DIMDI data 
bank (Deutsches Institut für Medizinische Dokumentation und Information – 
German Institute for Medical Documentation and Information) (§ 67a); 
communication duties among competent authorities at state, federal, and European 
Commission level (§ 68).  
Section 12. Special norms for Federal Armed Forces, Federal Police, riot police, 
civil protection (§§ 70-71). 
Section 13. Import and export regulation (§§ 72-73). 
Section 14. Responsible appointee for pharmaceutical information and medical 
representative (§§ 74-76): the high importance of continuously updated and correct 
information for drug safety is underlined by the norm concerning the appointment 
within the pharmaceutical enterprise of a person in charge of information quality and 
correctness.
75
 This delegate is personally responsible for the information 
accompanying the product and must have an adequate medical/pharmaceutical 
university degree and a minimum experience of two years in the field.  
Furthermore medical representatives are appointed as mediators between the 
pharmaceutical company and the health professional. The task of medical 
representatives is to provide the health professional with detailed scientific 
information about the product and to inform the employer in written form of any 
communication received by the health professional (§ 76). 
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 § 62 AMG: „Die zuständige Bundesoberbehörde hat zur Verhütung einer unmittelbaren oder mittelbaren 
Gefährdung der Gesundheit von Mensch oder Tier die bei der Anwendung von Arzneimitteln auftretenden 
Risiken, insbesondere Nebenwirkungen, Wechselwirkungen mit anderen Mitteln, Verfälschungen sowie 
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den Dienststellen der Weltgesundheitsorganisation, der Europäischen Arzneimittel-Agentur, den 
Arzneimittelbehörden anderer Länder, den Gesundheits- und Veterinärbehörden der Bundesländer, den 
Arzneimittelkommissionen der Kammern der Heilberufe, nationalen Pharmakovigilanzzentren sowie mit 
anderen Stellen zusammen, die bei der Durchführung ihrer Aufgaben Arzneimittelrisiken erfassen. Die 
zuständige Bundesoberbehörde kann die Öffentlichkeit über Arzneimittelrisiken und beabsichtigte 
Maßnahmen informieren“ (My emphasis).  
75
 § 74a AMG: “Informationsbeauftragter. (1) Wer als pharmazeutischer Unternehmer Fertigarzneimittel, 
die Arzneimittel im Sinne des § 2 Abs. 1 oder Abs. 2 Nr. 1 sind, in den Verkehr bringt, hat eine Person mit 
der erforderlichen Sachkenntnis und der zur Ausübung ihrer Tätigkeit erforderlichen Zuverlässigkeit zu 
beauftragen, die Aufgabe der wissenschaftlichen Information über die Arzneimittel verantwortlich 
wahrzunehmen (Informationsbeauftragter). Der Informationsbeauftragte ist insbesondere dafür 
verantwortlich, dass das Verbot des § 8 Abs. 1 Nr. 2 beachtet wird und die Kennzeichnung, die 
Packungsbeilage, die Fachinformation und die Werbung mit dem Inhalt der Zulassung oder der 
Registrierung oder, sofern das Arzneimittel von der Zulassung oder Registrierung freigestellt ist, mit den 
Inhalten der Verordnungen über die Freistellung von der Zulassung oder von der Registrierung nach § 36 
oder § 39 Abs. 3 übereinstimmen.”  
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15. Competent federal authorities (§ 77); conflict of interests (§ 77); federal 
authority competence for veterinary drugs prices (§ 78) special authorizations in 
emergency cases (§ 79); authorization for procedure regulation in emergency cases 
(§ 80); AMG relationship to norms concerning atomic energy, animal protection, 
and psychotropic drugs (§ 81); general administrative prescriptions (§ 82); 
implementation of European Community Directives (§ 83). 
16. Civil liability for pharmaceutical damage (§§ 84-94). 
17. Criminal liability for non compliance to pharmaceutical regulation (§§ 95-98). 
18. Law amendments and transition prescriptions. 
 
AMG norms regulate information duties and authorizations among the different 
stakeholders. Information regulation concerns risk disclosure duties from 
pharmaceutical company towards the authority and the public: the patient package 
leaflet is the main vehicle of direct communication to the user and its configuration 
is strictly regulated by AMG. Furthermore AMG establishes authorization powers 
assigned to the competent authority: these comprise not only approval of product 
information but also enforcement of special warnings when deemed necessary for 
health protection. After approval, risk management procedures determine 
“information vehicles and channels”.76  
The following chart represents the information pyramid as it is shaped by AMG 
regulation: 
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Figure 1: Pharmaceutical information regulation through German Medicines Act 
(Arzenimittelgesetz: AMG). 
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 AMG § 63: “In dem Stufenplan können ferner Informationsmittel und –wege bestimmt werden”. 
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AMG regulates communication channels between: authority and the public, 
authority and the pharmaceutical firm; pharmaceutical firm and single user/health 
professional.  
- Authority towards the public: 
§ 34 I: The competent authority must notify any change in the approval status in the 
Federal Gazette. Furthermore they must make information regarding the granting of 
approval, the evaluation of pharmacological experiments results and clinical tests 
publicly available (§ 34 Ia). Also free access to approval decisions must be 
guaranteed (§ 34 Ib). In general any administrative act which concerns more than 50 
people may be publicly notified by the authority (§ 34 II). 
In case of approval recall, the competent authority can also publicly notify the 
administrative act (§ 69 IV). 
- Authority towards pharmaceutical firm:  
§ 12 I: the federal authority has prescriptive powers over labelling, package and 
specialist information, and can order that the quantity of specialist information be 
expanded with further data;  they are furthermore entitled to prescribe that product 
information be transmitted through additional means other than package labelling 
and leaflet; and to enforce special warnings for specific drug groups. 
§ 28: the federal authority is entitled to bind approval to special conditions, among 
others the imposition of specific information duties as for the correct product 
preservation and risk prevention. 
Any modification in the information accompanying the product must be granted by 
the authority prior to execution (§ 29 II a) 
- Pharmaceutical firm towards authority:  
§ 22: the documentation for approval application is strictly standardized and 
comprizes reports of chemical, (micro-) biological experiments, clinical trials, and 
pharmacological tests; package leaflet and summary of product characteristics as 
well as expert opinion as to the evaluation of quality control methods and test results 
(§ 24). Approval is to be granted on the basis of the documentation and expert 
opinion provided for approval application (§ 25 V)
77
 and following a hearing from 
the approval commission (§ 25 VI).
78
  
§ 29: the pharmaceutical sponsor is obliged to disclose any change in the 
information and documentation for approval. A disclosure duty also concerns any 
new data which might influence the drug risk/benefit assessment.  
Within the drug risk management process (stages plan – “Stufenplan”), the 
pharmaceutical company is obliged to promptly refer any severe or not expected 
adverse event, and to provide the authority with periodical reports (§ 63b). 
- Pharmaceutical firm towards user:  
                                                 
77§ 25 V AMG: “Die Zulassung ist auf Grund der Prüfung der eingereichten Unterlagen und auf der 
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 § 25 VI AMG: “Vor der Entscheidung über die Zulassung eines Arzneimittels, das der 
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die Gegensachverständigen. Weicht die Bundesoberbehörde bei der Entscheidung über den Antrag von 
dem Ergebnis der Anhörung ab, so hat sie die Gründe für die abweichende Entscheidung darzulegen”. 
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§ 8: protection norm against fraud (false labelling, indication of therapeutic effects 
which do not correspond to reality, declaration of certain benefit or of no side-
effects);  
§ 10: package labelling,  
§ 11: package leaflet (PL). 
- Pharmaceutical firm towards health professional  
§ 11a: summary of product characteristics (SPC). 
 
The regulation of information from health professional towards pharmaceutical firm 
or authority and vice-versa is outside the competence field of AMG. However the 
spontaneous surveillance system heavily relies on physicians’ contribution to drug 
monitoring, and explicitly obliges the pharmaceutical company to notify any 
suspicious risk reported by health professional (§ 63b II 2a). Moreover doctors are 
must report adverse event cases by the Medical Association Code (§ 6 MBOÄ 
1997).
79
   
 
AMG deals with risk communication as an instrument of agreement about risk 
acceptability, as a tool for risk prevention and management, and finally, as a support 
for the safeguard of decisional autonomy. 
Thorough investigation has already been devoted to the nature of administrative 
(communication) actions within the framework of police law and safety regulation.
80
 
Little attention has been devoted instead to the qualification of product information 
for the patient in the form of package leaflets (PLs).  
The official qualification of this form of information as product instruction for safe 
use does not exhaust its function. Beyond safety concerns, the presence of detailed 
information about residual risk, which is per definition unavoidable, cannot but be 
interpreted as a form of communication for an informed therapeutic decision, in 
analogy to information duties regulating doctor-patient relationship.  
In this respect information about avoidable risk (instruction about adequate use, 
dosage and duration, contraindications, drug interferences, overdosage) and residual 
risk (side-effects associated with the drug) require and allow different responses 
from the reader: the former type of risk information demands the reader to comply to 
the instructions provided so as to avoid any undesired effects (safety aspect), in the 
latter case instead, no countermeasure can be taken in order to prevent side-effects to 
occur – apart from interrupting the therapy and informing the doctor, when reactions 
have already occurred. The only purpose of warning the reader about them, can only 
be to allow the user decide whether to undergo the risk listed in the PL or not, by 
putting him into notice (autonomy aspect). 
  
                                                 
79
 Information in the pharmaceutical field is also regulated by the Drug Advertising Act 
(Heilmittelwerbungsgesetz: HWG) and indirectly by liability norms related to product instruction. I will not 
indulge on the former law, as it is marginal to the investigation of package leaflet. Instead I will deal with 
liability regulation extensively in chapters 2 to 4.  
80
 See a. o. Egert, Osimani forthcoming; Hart et al. 1998; Hart 1998a; Pitschas 1998; Domeyer 1998; 
Sickmüller 1998; Deutsch, 1997; Di Fabio, 1993, 1994; Damm, Hart, 1993; Brandt, 1993; Paschke, 1993. 
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The present dissertation aims to analyze the role of PLs within the legal framework 
in which they are embedded, and than to investigate the extent to which its epistemic 
contribution is adequate for accomplishing the task it is supposed to fulfill. 
 
 
2.3 Pharmaceutical product safety 
 
Safety norms for pharmaceuticals regulate residual risk and development risk by 
establishing: 
- principles and procedures for assessing the residual risk thresholds according to 
which a product can be allowed/forbidden to circulate in the market;
 81
 
- principles and procedures for intervention and risk prevention measures (well 
founded suspicion of unacceptable risk and risk management). 
A central norm of AMG in this respect is § 5.
82
 This is a prohibition norm that 
stipulates circulation prohibition for unsafe drugs and provides the related definition: 
according to § 5 II, unsafe drugs are such that on the basis of available scientific 
data, there is the well-founded suspicion that, by adequate use, they produce damage, 
which is beyond the threshold tolerated by medical sciences.
83
  
This definition is articulated in four main components: 
1. The degree of association between risk and danger source needed for 
intervention (“well-founded suspicion”); 
2. the tolerance threshold (residual risk); 
3. unsteadiness of approval status as a result of continuous drug profile updating 
(development risk); 
4. and the reference to medical sciences as the perspective through which the 
tolerance threshold shall be drawn.  
 
 
2.3.1 Intervention principle: well founded suspicion 
 
The general recognition of the limited and fragmentary causal knowledge affecting 
especially chemical and pharmaceutical technologies has contributed to the 
awareness that criteria for the management of not-knowledge are needed.
84
 The 
                                                 
81
 The requirement of approval is prescribed by § 21 I AMG. The decision of approval is regulated 
according to § 25 with reference to § 5. The authority can reject an application for approval, only in case 
one of the conditions mentioned in paragraphs § 25 Abs. 2 or 3 AMG are not met. These conditions refer 
to therapeutic efficacy, (§ 25 II S. 1 Nr. 4 AMG), and adverse reactions (§ 25 II S. 1 Nr. 5 AMG) in that 
the risk tolerance for each treatment is decided upon its indication and therapeutic effect.  
82
 Authority for intervention is linked to this norm throughout the law: § 25 II S 1. Nr. 5 (approval) in 
connection with § 28 (special conditions), § 30 (approval withdrawal, revocation, suspension), and § 69 I S. 
2 Nr. 4 (risk management interventions). Hart, 1998b: 168.  
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 § 5 II: “ Bedenklich sind Arzneimittel, bei denen nach dem jeweiligen Stand der wissenschaftlichen 
Erkenntnisse der begründete Verdacht besteht, dass sie bei bestimmungsgemäßem Gebrauch schädliche 
Wirkungen haben, die über ein nach den Erkenntnissen der medizinischen Wissenschaft vertretbares Maß 
hinausgehen”. 
84
 Enquete-Kommissions-Bericht “Schutz des Menschen und der Umwelt”: BT-DrS. 12/8260, cited in 
Scheu, 2003: 72. In addition to inherent epistemological limits, Scheu also mentions the objective 
information insufficiency regarding the risk profile of chemical products in general. For most of the 
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“well-founded suspicion on the basis of available scientific data” substitutes the 
adequacy condition required in AMG ’61 as for the degree of association needed for 
intervention. The term suspicion is defined as hypothesis of causal connection.
85
 As 
already mentioned, this terminological modification is the reflection of a new 
understanding of the risk represented by drugs as unavoidably unsafe products
86
, for 
which the requirement of causal assessment is too demanding and therefore not 
adequate for timely measures to risk emergencies.  
Given that the causal nexus can be seldom proven, waiting for the establishment of a 
causal connection before intervening would most times lead to late intervention and 
irreparable damage. Therefore “softer” epistemological concepts such as frequency 
of association serve the purpose of providing a reference tool for risk decisions.  
The legal notion of suspicion is less demanding than that of cause, and in the case of 
pharmaceuticals, it begins as soon as a doctor assesses an association between a side 
effect and a drug.
87
 However, the modifier “well founded” puts limits to the 
looseness of this requirement: the suspicion must be founded on concrete facts and 
cannot be justified by simple hypothetical speculations.
88
 The facts supporting the 
suspicion do not necessarily need to be concrete cases of damage: also the 
acquisition of new substantial theoretical knowledge can ground risk suspicion, 
especially when there is little or no experience with the drug, which could refute the 
theory.
89
 
The concept of suspicion has precisely been devised in order to regulate cases of 
decisions under uncertainty, where a resolution is administratively required and 
cannot be put off even in the absence of perfect knowledge.
90
 In case of doubts about 
product toxicity the legislator is allowed and supposed to protect the user by 
undertaking adequate measures (from alerting measures to product retirement from 
the market).
91
 
 
The risk prevention principle (Risikovorsorgeprinzip) applies whenever, as a 
consequence of scientific uncertainty, there is no positive knowledge about the 
threatening hazard.
92
  
Epistemological limits spread out of the complexity of the systems involved (human 
organ and/or environment) and of the fragmentary and progressive nature of science. 
This structural uncertainty demands a flexible intervention rule: differently than in 
for danger avoidance, risk prevention applies the principle of proportionality not to 
                                                                                                                                                 
chemical products on the market, fundamental data about chemical behavior and environmental 
consequences of their use are simply not available (Scheu, 203: 80).  
85
 Scheu, 2003: 113. 
86
 Scheu, 2003: 692. 
87
 Di Fabio 1993: 125. The establishment of well founded suspicion in the single case is however more 
complex and an eventual solution seems to be far from being reached without the united efforts of medical 
and legal experts. See § 4.2 on causal assessment. 
88
 Di Fabio, 1993:  125. 
89
 See Di Fabio, 1993: 126-127. 
90
 Di Fabio, 1993: 113. 
91
 „Der Schwebezustand einer unsicheren Bewertung soll nicht vom Patienten getragen werden, der unter 
Umständen irreversible Gesundheitsschäden erleiden kann“: Hielscher, Zulassung von Phytopharmaka, 
pharmaR 1984, 1, 3, f cited in Hart, 1998b: 175. 
92
 Dettling, 2005: 165. 
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the probability of occurrence, but to the value of the threatened good. The higher the 
good at stake, the lower needs to be the probability of causal link to allow for 
intervention. In case of high value goods, the mere possibility suffices for 
intervention.  
In the case of uncertainty about damage causes with reference to high value goods 
(health, life), the principle of “In dubio pro securitate” should apply: the hypothesis 
of damaging effects should be taken as true as long as no counterevidence refutes 
it.
93
 
 
The intervention threshold is not only decided upon the acquisition of new data. Also 
new theoretical insights might contribute to deeper pharmacological understanding 
and favor or contradict established knowledge about the therapeutic effect of a 
specific substance.
94
  
The mention of “the state of the art of actual research” (“jeweiligen Stand der  
wissenschaftlichen Erkenntnisse”) as a criterion for deciding drug approvability, 
recall and suspension, introduces in the legal formulation a second factor of 
contingency in risk decisions about pharmaceutical products.
95
  By means of this 
formulation, the legislator integrates a dynamic factor in risk regulation and 
synchronizes safety decisions to scientific developments.
96
  
On the other hand, the integration of scientific paradigms in the evaluation of the 
intervention threshold corresponds to the standardization needs in the field of risk 
regulation. This has also required an effort towards the systematization of risk 
knowledge and the gradual reduction of ad hoc considerations about single cases.
97
  
The conformity to scientific standards for risk decisions is inevitably characterized 
by the controversies typical of scientific development.
 98
 In order to account for this 
fact, the legislator uses the plural form: “wissenschaftliche Erkenntnisse” (scientific 
knowledges) and thereby allows any well-founded suspicion coming from any 
current of knowledge to require the adoption of adequate countermeasures. The 
norm is to be interpreted by conforming to the principle of “in dubio pro 
securitate”:99 where the vagueness of the term “well founded suspicion” is to be 
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 Scheu, 2003: 75-78. 
94
 See Di Fabio, 1993: 126-127; Räpple, 1991: 90-91. 
95
 “Da sich unser Wissen um Risiken permanent verändert, ist jede Bewertung und jede auf ihr basierte 
Entscheidung unbeständig”: Hart, 1998: 141.  
96
 Räpple, 1991: 95.  
97
 See Di Fabio, 1993: 111. The traditional basis for police law judgments about danger sources refers to 
daily experience as a criterion for assessing the probability that damage occurs: this probability refers to the 
eventuality that no countermeasure is taken in order to contrast the natural course of the events. The 
criterion of daily experience however, is inadequate to deal with technological danger sources and has been 
substituted in these fields by the requirements of “technical standard” and/or “state of the art”. The AMG is 
one of these specific legislation sectors (see also: Räpple, 1991: 93).  
98
 Räpple, 1991: 95-96; Kriele, 1976, 355(356); Scheu, 2003: 103. 
99
 In the conditions for approval though, the legislator adds to the formulation for benefit proof the 
expression: “jeweils gesicherten Stand wissenschaftlicher Erkenntnisse” (‘established state of the art’: § 25 
Abs. 2 Nr. 4 AMG). Procedures to establish efficacy must submit to stricter requirements than criteria for 
establishing the risk tolerance threshold: See Räpple, 1991: 95-97. 
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solved by resorting to the interpretation that adheres with the highest fidelity to the 
spirit and the purpose of the legislation.
100
 
 
 
2.3.2 Tolerance threshold and residual risk 
 
The risk tolerance threshold is the pragmatic answer to ontological uncertainty – 
risky and beneficial nature of the drug at the same time. The function of § 5 AMG is 
in fact to prohibit the circulation of drugs not exclusively on the basis of their risk 
profile, but rather on the combined evaluation of its beneficial and harmful effects.
 
101
  
Given the ambiguous character of pharmaceuticals and the consequent impossibility 
of absolute safety, the evaluation of drugs cannot result in a distinction between 
harmfulness and innocuousness but rather between an acceptable (“zumutbar”) and 
an unacceptable (“unzumutbar”) risk.102 This is a relational judgment and is done by 
relating the drug risks to its expected benefit and evaluating them in a 
comprehensive fashion. The upshot of this evaluation is the classification of the drug 
as relatively safe or not (“unbedenklich” vs. “bedenklich”) and of the related risks as 
tolerable or not tolerable (“vertretbar” vs. “unvertretbar”). The evaluation of 
benefit/risk assessment therefore is the instrument for the acceptability judgment 
about its damaging effects.
103
  
The principle underlying this evaluation refers to the consideration that risks are 
tolerable to the extent that they are not avoidable for achieving a certain therapeutic 
purpose. Acceptable is solely the minimal risk compensated by a comparable 
benefit.
104
 The tolerance threshold refers to this comparison and determines the line 
above which a drug is declared as “bedenklich” (unsafe).105  
 
The state’s duty to protect and promote constitutional goods such as life and health 
finds insurmountable limits in the unavoidably unsafe nature of drug products.
106
 
Residual risk in general is the risk which cannot be excluded with absolute safety, 
but which can be regarded as improbable (or insignificant) enough to be considered 
legally irrelevant. In the case of pharmaceuticals, this is the risk which is to be taken 
into account in general, independently from concrete signs of damage suspicion. 
107
 
This has led to the development of criteria for establishing an acceptable level of risk 
in face of the benefit promised by the health technology, so called residual risk.  
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 Scheu, 2003: 766. 
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 „Funktion des § 5 AMG soll und kann es dabei nicht sein, jedem mit Risiken behafteten Arzneimittel 
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 Räpple, 1991: 50-57. 
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 Wolz, 1988: 83. 
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This threshold is established through a risk/benefit evaluation, which decides how 
much risk is to be accepted in the face of how much benefit. It is a relational 
judgment which determines the legal relevance of a danger and the threshold under 
which damage caused by endangering sources should be tolerated by the damaged 
party.  
 
2.3.3 Development risk   
 
The combination of the evaluation method based on the risk/benefit assessment
108
 
with the particular epistemological framework in which drug risks and benefits are 
learned, i.e. only progressively, makes the approval status unsteady and revocable. 
Contrary to other fields of safety regulation, in which damage thresholds are 
generally established in absolute terms, the tolerance threshold for pharmaceuticals 
varies from product to product and follows the knowledge acquisition related to it.  
Moreover, differently than from other danger sources (e.g. nuclear power station), 
where the source of uncertainty is to be traced back to defects caused by human error 
or technological failures, the danger coming from pharmaceuticals need not consist 
of a product fault. Health damages are rather the byproduct of an unintended 
interaction of the chemical entity with the body (drug kinetics and dynamics)
109
, 
which is not completely foreseeable.  
A fundamental concept in this framework is the notion of “Development risk” 
(design risk). This is the residual risk linked to the epistemological uncertainty 
affecting drug also after approval: a risk which, notwithstanding compliance with 
the highest safety standards can go undetected for long time after admission into the 
market.
110
 For this type of risk no guarantee of absolute avoidance can be provided 
even under the best possible preventive measures.
111
  
As a consequence, the approval status is unsteady and provisory. New data about the 
drug coming from the market may change its risk profile and require corresponding 
measures.  
 
 
2.3.4 Medical criteria for risk acceptability  
 
The reference to medical knowledge as a basis for deciding the tolerability threshold 
(“damaging effects that exceed the tolerance threshold according to medical 
knowledge”) is critical point which is object of debate in the legal literature and 
concerns the criteria for risk acceptability.  
                                                 
108
 The concept of “Unbedenklichkeit” establishes an inextricable connection between the benefit of a 
drug and its danger: “Im Gegensatz zum sonstigen (technischen) Sicherheitsrecht, in dem meist (absolute) 
Schädlichkeitsgrenzen festgelegt werden, stellt der Unbedenklichkeitsbegriff eine Beziehung zwischen 
dem Nutzen eines Arzneimittels, in der arzneimittelrechtlichen Terminologie der Wirksamkeit, und seiner 
Schädlichkeit her” Hart, 2004: 467. 
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 Drug kinetics refers to the way the chemical entity is transformed when interacting with the body; drug 
dynamics refers on the contrary on the action of the chemical entity on the body. 
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 Scheu, 2003: 683. 
111
 Dettling, 2005: 164, footnote 18. 
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Medical sciences can and must offer the preliminary knowledge upon which a 
risk/benefit evaluation takes place. But their task and competence ends precisely 
with the description of the risk/benefit situation. Whether the benefit of relieving 
head-ache justifies the risk of 1: 10
6
 agrunolacytosis (changing of blood spectrum) is 
not a question that can be answered by means of natural sciences: this decision is 
rather a normative evaluation.
 112
   
Medical sciences determine the risk/benefit assessment providing the data for 
decision, but cannot constitute themselves the criteria underlying this decision. The 
question arises however as to what reference criteria should guide the risk/benefit 
evaluation and related decision of risk acceptability. The criterion of social 
consensus proposed by Fülgraff seems to encounter several difficulties, because 
preference values differ from user to user and from group to group, and therefore a 
social consensus is difficult to find. 
113
 Also the reference to the most concerned 
party and the rule of “hypothetical consent” proposed by Wolz cannot be of any 
help, for the same reasons. 
114
 
Hart speaks of a normative consensus in the sense that the decision about risk 
acceptability is reached through a communication process among the different 
experts and stakeholders.
115
 In this sense “residual risk” is the risk that a society 
accepts to undergo in exchange for the benefits expected from the danger source. 
 
 
3. Quality, efficacy and safety standards  
 
Drug approval and circulation in the market is determined by quality, efficacy, and 
safety criteria. The evaluation of these criteria is not only based on scientific 
standards, but requires the integration of sociological and psychological factors in 
the experience of illness and risk. This is because the benefit related to a therapy 
cannot only be measured quantitatively on the basis of organic modifications, but is 
rather a psychological dimension related to well-being and quality of life 
improvement as it is experienced by the patient. The same is valid for the evaluation 
of pharmaceutical risk. 
 
The basis for this evaluation however is a (semi-)quantitative assessment of the 
objective benefits and risks related to the drug.  
From a strictly pharmaceutical perspective, quality refers to the chemical structure, 
its pureness, and other chemical, physical, and biological characteristics.
116
  
Efficacy refers to the statistical significance of its therapeutic effect on the basis of 
the data coming from clinical studies.   
As for safety, it has already been mentioned that absolute risk-freeness cannot 
possibly be obtained in the case of drugs. The legislator refers to a relational concept 
of safety, namely “being unobjectionable” (“Unbedenklichkeit”). A drug is declared 
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 Räpple, 1991: 114-117; Fülgraff, 1980 “Arzneimittelgesetz” in Pharm Ind (42), 581 ff. 
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 See Wolz, 1988: 102. 
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 Hart, 1998b:186. See also Besch, 2000: 61. 
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 Wolz, 1988: 51. 
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“unobjectionable” (“safe”) when its beneficial effects exceed the risk associated with 
it. As a consequence a certain amount of risk is taken into account by the legislator 
and by the risk analyst in connection to the illness risk and the therapy impact. The 
risk threshold that the society decides to accept for each drug determines its presence 
in the market. This is normally established by safety regulations and is embedded in 
a complex system of agencies and stakeholders.  
 
 
3.1 Pharmaceutical benefit 
 
The AMG does not define the notion of benefit. The most commonly cited definition 
of drug benefit traces back to 1978. It is considered also somehow official, because it 
was delivered by the president of the BGA (Bundesgesundheitsamt: National Health 
Office, now BfArM Bundesamt für Arzneimittel und Medizinprodukte) Georges 
Fülgraff. According to his definition, drug efficacy is sum of the intended effects in 
relation to a specific indication.
117
  
A consequence of this construal is that drug evaluation is a relational value 
proportionally dependent to the severity of the illness which is supposed to cure.
 118
 
The higher the risk connected to the illness, the higher will be considered the benefit 
produced by the drug. This is valid also if the drug has only symptomatic effects, 
when the symptoms of a disease deeply impact the quality of life. 
The benefit assessment is related to qualitative and quantitative considerations at the 
same time: qualitative aspects refer to the therapeutic importance and effectiveness, 
as well as to the health consequences on an individual and societal level; quantitative 
aspects are related to the effectiveness probability.
119
 
 
Criteria for judging benefit are: 
 
- Efficacy probability (quantitatively measurable); 
---------------------------------------------------------------- 
- Efficacy degree; 
- Therapeutic importance; 
- Healing;  
- Life expectancy prolongation; 
- Quality of life improvement;   
- Symptoms relief; 
- Transitory or permanent positive effect.120 
 
The efficacy probability is measured by statistical data coming from clinical studies 
(pharmacological data); efficacy degree refers to the extent to which the therapeutic 
purpose is obtained; therapeutic importance is a multi-attribute category which 
involves epidemiological considerations such as the diffusion of the illness in the 
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population, eventual alternative treatments available and their effectiveness, but also 
the doctor’s judgment of the potential impact of the drug; the healing aspect of a 
drug refers to the degree to which it helps remove the illness (causally vs. 
symptomatically; directly vs. indirectly
121
); life expectancy prolongation refers to 
fatal illnesses and the drug contribution in slowing down the course of the illness; 
quality of life improvement is a multi-scale measure based on quality of life 
parameters, symptoms relief refers to the extent to which symptoms are removed or 
alleviated through the therapy; finally, transitory vs. permanent positive effect refers 
to the drug capacity to remove the illness disturbs only temporarily or definitively.  
 
 
3.2 Pharmaceutical risk 
 
Since the early beginnings of pharmacology, it has always been clear that “poisons 
in little doses are the best medicines, and useful medicines in big quantities are 
poisonous”.122 For instance the efficacy of digitalis purpurea against “dropsy”, first 
discovered by the British doctor William Withering (1741-1799) is due to its 
enhancing action on the heart contraction power, with consequent water expulsion 
from the body through the kidney. Its poisonous effect in high doses (delirium, as 
well as heart cramps up to fatal fibrillation) comes therefore from the same 
disturbing effect on the heart rhythmus, which in the right dose can be of beneficial 
therapeutic use for a specific indication.
123
    
 
The so-called “therapeutic range” is one of the criteria to judge the safety spectrum 
of a drug: up to a certain quantity the drug does not produce any effect (either benefit 
or damage). It is only from a certain amount that the substance begins to produce an 
organic reaction, which augments together with higher doses. But from a certain 
quantity side effects also begin to appear until the point is reached where the drug 
produces damages. The difference between the minimal therapeutic dose and the 
damage threshold is called therapeutic range. The therapeutic range of different 
chemical entities can vary greatly. The digitalis purpurea, for instance, has a very 
limited range: already by double or triple dose, it produces relevant damage to 
healthy patients. On the contrary, acetyl-salicylic acid begins to produce side effects 
at five to ten times the normal dose, and can be fatal if the dose reaches 30 to 60 
times the normal dose.
124
   
 
The definition of beneficial and harmful effects is not only dependent on the dose, 
but it is also related to the unpredictability of its impact on the organic system: 
sometimes unintended effects can result from drug intake, which are eventually 
considered beneficial for specific disturbances. Therefore unintended effects are not 
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harmful per se. For instance, the lowering of blood sugar level that accompanies an 
antibacterial therapy with sulfonamides is considered an unintended effect, which 
can also be harmful in individual cases; however it is a beneficial property in the 
therapy of diabetes.
125
 
 
Moreover, adverse drug reactions greatly depend from the specific organic and 
genetic constitution of any single user, so that also a minimal dose can produce side 
effects (and possibly no benefit). Furthermore in case of pregnancy, the effects of the 
chemical entity may not be noticed by the mother, but may be of severe 
consequences for the baby.
126
  
 
If the benefit of a drug can be defined by the sum of intended side effects, then the 
amount of risk connected to a drug is measured by severity and probability of its 
unintended harmful side effects.  
 
The WHO definition of ADR is: “A response to a drug which is noxious and 
unintended, and which occurs at doses normally used for the prophylaxis, diagnosis, 
or therapy of a disease, or for the modification of physiological functions”.127 This 
definition excludes adverse events caused by erroneous dosage, administration or 
prescription, which are called Adverse Drug Events (ADE), and is independent from 
the mechanisms which produce an ADR. These can be of various nature: 
1. pharmacological-toxicological reactions and interactions; 
2. reactions depending on the drug mechanisms; 
3. pseudo-allergic reactions; 
4. allergic reactions depending from the individual immune system: 
- anaphylactic shocks; 
- grippe-like syndromes; 
- damages to the immune system.128 
 
1. In the first case the drug components – or a byproduct of the metabolic reaction – 
lead to a damaging result on a specific organ. The time and dosage associations help 
identify the drug as a probable cause.  
 
2. In the second case, the same beneficial function for a specific mechanism 
produces harmful effects on another organ system. An example is the inhibiting 
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effects on prostaglandins production induced by anti-rheumatic drugs. This 
inhibiting effect favors the anti-infectious action, but at the same time damages the 
stomach mucous membrane, where prostaglandins protect the mucosa from self-
absorption. The link between unintended and intended effects is direct and follows 
from the same mechanism.  
 
3. By pseudo-allergic reactions the drug components affect directly the regulating 
processes which influence the immune-system. Also here the causal attribution is 
eased by direct proportionality to dosage and by the time association. 
 
4. Real allergic reactions though are neither dosage dependent nor timely associated 
with drug intake. Apart from anaphylactic reactions, which take place soon after the 
drug has been ingested, grippe-alike reactions or damages of the immune system 
through pharmaceutical components are very difficult to recognize as such.
129
 This is 
due to the lack of any time or dosage association, and to the similarity of the 
symptom to warning signs for an illness (sometimes the same which is being 
treated!).  Allergic reactions are very deceptive and therefore often lethal.  
 
The definition of risk traditionally provided by safety regulations is derived from a 
multiplication of the two dimensions of damage severity degree and probability of 
occurrence,
130
 where the damage is any injury caused to goods protected by the 
law.
131
 In analogy to the benefit assessment, a quantitative measure (occurrence 
probability) should weight a qualitative factor made up of several dimensions 
(severity degree). The evaluation of risk related to a drug in the risk/benefit 
assessment prior to market approval is made along the following categories:  
 
- Frequency (risk probability: quantitative measurable); 
----------------------------------------------------------------------------- 
- Severity, intensity, extension, duration (risk magnitude); 
- Type and severity of impact on life quality  
- Controllability 
- Reversibility  
- Possibility of recognition   
- Possible countermeasures.132  
 
Similarly to the benefit assessment, the major difficulties lie in the operationalization 
and standardization of these parameters. Generally the hypothetical impact on 
autonomy and work capacity is the standard criterion taken into consideration in 
evaluation algorithms together with the level and range of medical countermeasure 
                                                 
129
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needed to contrast it. For very severe side effects irreversibility of damage up to 
fatality are the extreme points of the scale.  
 
 
3.3 Risk-benefit assessment and evaluation 
 
The condition for market approval is a positive risk/benefit assessment in absolute 
terms (when no other drugs compete with the candidate in the market) as well as 
relative to the pharmaceutical environment (i.e. in relation to treatments already 
present in the market for the same indication).
133 
 
This evaluation is based on a comparative weighting of therapeutic importance and 
efficacy on one side, and of risk severity and frequency on the other side (according 
to the principle of inverse proportion: the higher the risk, the lower the probability of 
its occurrence has to be).
134
 It is a risk-risk evaluation where the health consequences 
of different alternative treatments need to be compared and evaluated in face of the 
illness health implications.
135
  
At any rate for an r/b assessment to be positive, the risk-“sum” associated to the 
product must be inferior to the risk-“sum” associated to the illness, or to the other 
products in relation to the benefit.  
Given the relational value of the benefit in relation to the illness severity, and of the 
relational weight of the risk in relation to the benefit, the principle underlying 
risk/benefit assessment translates in an optimizing rule, precisely of reciprocal 
optimization.
136
   
When fatal consequences on both side of illness and drug are under consideration, 
then the comparison can be reduced to a numerical difference: 
 
Benefit/risk assessment Case  
negative Illness X is fatal in 10% of the cases.  
Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 6% of them.  
“undecided”  
negative 
Illness X is fatal in 10% of the cases.  
Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 5% of them. 
positive Illness X is fatal in 10% of the cases.  
Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 4 % of them. 
 
 
Relative assessment: 
 
Benefit/risk assessment 
for Z in relation to Y 
Case 
Negative Illness X is fatal in 10% of the cases.  
Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 1 % of them. 
Drug Z cures the illness in 95 % of the subjects but can produce fatal ADR in 4 % of them. 
“undecided”  Illness X is fatal in 10% of the cases.  
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positive Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 1 % of them. 
Drug Z cures the illness in 95 % of the subjects but can produce fatal ADR in 1 % of them. 
positive Illness X is fatal in 10% of the cases.  
Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 1 % of them. 
Drug Y cures the illness in 95 % of the subjects but can produce fatal ADR in 0.9 % of them. 
 
On most occasions though, comparison is made difficult because of the diversity of 
drug effects: these can be limited to inhibiting or symptomatic functions, and the 
illness itself can have other consequences than death if not treated. For these cases 
additional aspects need to be used. However, the epistemological difficulty lies here 
in the parameterization and quantification of these positive and negative health 
factors. Moreover, for each drug there is a different combination of values for the 
several parameters. The table presents a hypothetical comparison between two drugs 
(X; Y) with same indication: 
 
Comparison table between two hypothetical drugs (X, Y) 
 
 
 drug 
Benefit 
parameters  
X Y 
Efficacy degree .9
0 
.9
5 
Therapeutic 
importance 
8 7 
Healing 6 6 
Life expectancy 
prolongation 
9 9 
Life quality 
improvement 
7 8 
Symptoms relief 8 9 
Transitory vs. 
permanent 
positive effect 
p p 
 
  
 drug 
Risk parameters  X Y 
Frequency (risk 
probability) 
.0
1 
.0
1 
Severity, intensity, 
extension, duration 
(risk magnitude) 
8 8 
Type and severity 
of impact on life 
quality  
7 9 
Controllability 2 3 
Reversibility  no no 
Possibility of 
recognition   
2 1 
Possible 
countermeasures 
4 3 
 
 
The evaluation of all parameters in the comparison of different drugs determines a 
complex configuration: for each treatment, the combination of parameter values is 
diverse. The assessment would be easy if only one of the factors considered would 
differ, or when opposing divergences would differ strikingly in quantity: such cases 
are very rare.  
Major difficulties in the risk-benefit assessment and evaluation task can be 
summarized under the following points: 
 
1) The quantification of some factors is especially difficult to establish (e.g. Life 
Quality);  
a. The scientific knowledge upon which the assessment should be made is 
heterogeneous and not rarely controversial;
137
 
b. The preference values associated to these factors may differ from group to 
group of stakeholders with consequent variance of risk acceptance;
138
  
                                                 
137
 Räpple, 1991: 96. 
138
 See Hart, 2005; 2004; 1998; 1998b. 
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c. Risk exposure is also different for each user depending on drug sensitivity; 
2) As a consequence, no standardized operationalisation of these parameters has 
taken place.
139
  
Statistical data about efficacy and risk therefore constitute only a part of the risk-
benefit assessment. The pharmacological data must be further evaluated in the 
perspective of relevant health issues. On the basis of the risk/benefit assessment, 
performed by pharmaceutical and medical experts, a risk/benefit evaluation is 
issued, upon which the authority decides in favor of the drug approval, and other 
safety interventions.
140
 However, even if the two tasks of risk/benefit assessment and 
evaluation should be performed officially by experts and the authority respectively, 
both are strictly intertwined.
141
 It is a communication process which takes place 
among the diverse stakeholders.
142
  
The uncertainties at the assessment level transfer to the evaluation level.
143
 Safety 
(“Unbedenklichkeit”) and benefit remain vague legal terms which need specification 
through the cooperation of different stakeholders (experts, pharmaceutical 
companies, administrative authority) within a procedural and evaluative legal-
scientific/theoretical-practical perspective.
144
  
 
 
3.3.1 Risk exposure 
 
For obvious reasons, the risk benefit assessment and evaluation cannot be tailored to 
each single eventual user. It is rather a general judgment on the basis of the entire 
population of patients considered as a whole.
145
 Some severe risks might therefore 
constitute no barrier to drug approval if their statistical weight is deemed to be 
irrelevant. 
The most striking consequence of the general character of risk/benefit evaluation is 
that some users might be concerned by side effects which are intolerable per se in 
comparison to the indication. This is possible because even if these side effects are 
severe, their low probability incidence acts as a compensatory weight in the 
evaluation of the drug (they are multiplied by a low probability incidence): as a 
consequence, the drug is approved for the market notwithstanding. 
The disappointing corollary is that in individual cases the use of the drug might 
result in damage which is worse than the illness condition. This eventuality cannot 
be avoided in the case of mass products distributed among a heterogeneous 
population.
146
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A crucial factor in this sense is a deeper knowledge of risk groups. If it can be 
established that particular groups are more subject than other to be affected by 
certain side effects, than a special risk/benefit assessment should be made for this 
group, and for the rest of the population. The two assessments could lead to 
precautionary warnings for the more sensitive group, or to exclude this group from 
usage (contraindications).
 147 
But more importantly this could help the doctor assess 
more specifically the kind of risk his patient is exposed to.
148
  
The peculiarity of organic reactions to a drug should indeed lead to a more 
differentiated approach to drug authorization, so that the health of the majority 
would not prevent a particular group to profit from the drug. In fact the risk/benefit 
assessment of a drug might be generally negative, but specifically positive, if a 
special subgroup of users is taken into consideration.
149
 Both safety and efficacy 
would profit from a more refined approach to drug approval. 
 
 
3.3.2 Preference values 
 
The impossibility of finding a mathematical standardization for the comparison of all 
risk and benefit factors is also a consequence of the fact that their assessment and 
evaluation needs to be performed on the basis of preference values. However, in that 
this assessment cannot but be general, personal preferences are necessarily taken into 
account only by means of a compromise. The legislator has granted the medical 
sciences a direct voice in the decision of risk acceptability, less clear is the role of 
doctors’ and end-users preferences in the establishment of the acceptability threshold 
through risk/benefit assessment.
150
 In this respect, the principle should be that of 
“hypothetical consent”: the evaluation of parameters which are not quantifiable is to 
be based on what can be considered reasonable for the most directly concerned party 
(the drug users).
151
 However, the extent to which this principle can be implemented 
is all but established.  
This state of affairs has resulted in the gradual acknowledgment, at least in the legal 
literature, of a decision space in which epidemiological data and their medical 
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interpretation becomes integrated through a communication exchange among the 
different stakeholders.
152
 In this perspective, risk decisions are the result of a 
“normative consensus”, where the level of risk acceptability is determined socially 
and by the different concerned parties.
153
 This decision margin left to social 
instances grounds the base for a political element in drug safety resolutions.
154
  
 
 
3.3.3 Risk policy  
 
The risk policy determines the level of risk acceptability for drug approval. This 
means that on the basis of the same risk and benefit a drug can be approved in a 
system and rejected in another.  
Drug approval decisions are never void of risk: both rejection and approval of a 
certain product bring about potential dangers.
155
 The degree of risk avoidance vs. 
risk proclivity has considerable repercussions on the healing chances for specific 
patients groups. If conditions for marketing approval are too strict, then important 
drugs for specific patient groups may never reach the market because they are 
associated to a level of risk which exceeds the threshold established by the law; if on 
the other hand, they are too liberal, than the users are exposed to a greater risk (in 
terms of side effects magnitude and/or probability).
156
 
The question here is how much risk the authority should and the stakeholders are 
willing to undergo in face of how much benefit.
157
  
The decision of a drug approval (or suspension, or recall) thus draws on different 
competencies and is determined a. o. by the risk acceptance levels of each expert 
group.
158  
In the USA, for instance, the risk policy has been put into discussion over the last 
decennials either because of its supposed inertia and over-caution or because of its 
negligence and carelessness
159
.  
These claims reflect the shaky nature of the drug safety status: a status which can 
legally change after the authority approval, on the basis of risk data coming from the 
circulation in the market but also depending on the level of risk acceptance. 
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3.3.4 Risk acceptance 
 
The political character of drug safety decisions was the object of a debate in 
Germany at the end of the ’70s.160 The two poles of the debate advanced arguments 
pro and contra the legitimacy of the integration of social risk acceptance criteria in 
the acceptability judgment for drug approval and circulation in the market. Hart 
identifies in the work of Di Fabio the consequent development and upshot of this 
debate. Following Di Fabio, terms such as benefit and risk are purposely left vague 
by the legal system.
161
 It is precisely by integrating lay risk perception and the 
different concepts of risk pertaining to different disciplines that risk/benefit 
optimization can improve methodologically.
162
  
Furthermore, other disciplines specialized in the investigation of risk, other than 
medicine, might help optimize the risk/benefit evaluation methodology, in that they 
provide important insights on diverse dimensions of risk. These studies range from 
the empirical work of Paul Slovic and colleagues to the sociological considerations 
of Niklas Luhmann.
163
 
Following socio-psychological research on risk perception, several dimensions can 
be accounted for to explain the level of risk acceptance. Considering these 
dimensions, a divergence in risk acceptance attitudes can be identified between lay 
and expert or decision-makers.
164
  
Dimensions like voluntary exposition, control, expertise are generally linked to risk 
proclivity. Also the membership to an institution/organization and the associated 
sense of responsibility distribution is also connected with proclivity to risk. As a 
consequence, both the authority and pharmaceutical firms – as expert and complex 
institutional/organizational entities with decision making powers – tend to set the 
acceptability threshold lower than a lay decision maker would do. The legal level of 
drug risk acceptance is therefore “structurally” lowered in comparison to the lay 
level of acceptability. This demands a counterforce to balance the risk proclivity of 
administrators and pharmaceutical entrepreneurs.
165
 Actual drug regulation does not 
provide any substantial means for the involvement of the public or target groups in 
drug risk policy and decision making.  
Legal and political arguments speak for the citizen’s involvement in the decision 
processes related to health provision and safety system, as well as to the 
establishment of quality standards and to the organization of the health care system 
in general. The regulation system however lacks the adequate law instruments to 
allow and promote participation.
166
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4. Safety regulation after approval: Risk management and Development risk 
 
Because any drug can be affected by risks which go undetected at time of approval, 
there is the possibility that the drug reveals itself as unsafe (“bedenklich”) when 
already in the marketing phase. This theoretical possibility is captured by the notion 
of development risk and is dealt with by resorting to a risk prevention system.  
Whereas classical danger avoidance is rather reactive and casually prompted by the 
single hazard, the drug risk prevention system is characterized by a systematic 
surveillance and pervasive regulation of all phases of risk management.
167
   
Thanks to harmonization efforts such as the International Conference for 
harmonization (ICH), aimed at standardizing the approval conditions among USA, 
Japan, and Europe,
168
 approval, registration and surveillance of pharmaceuticals 
follow a standardized procedure which is relatively homogeneous across countries, 
and can be broken down into the following phases:  
1) Application for marketing approval: The pharmaceutical firm applies to the 
competent Authority for a New Chemical Entity (generally already patented in this 
phase): data consist mostly of “in vitro” studies and animal trials. 
2) Clinical trials (in three phases): designed to prove efficacy and safety of the new 
chemical entity: first on a delimited number of healthy volunteers (to prove safety), 
then on a greater number of possible patients (to prove efficacy and further confirm 
safety), finally on a large scale – 300 to 1500 trials – (to further confirm both 
variables)
 169
.  
3) Post-market surveillance: At the stage of approval, too little is known about the 
remotest side-effects (those occurring in one out of 10.000 – 20.000 cases). 170 These 
are also the most severe (sometimes with lethal consequences) and most difficult to 
identify because of the complex causal network in which they are embedded.  
The knowledge about a newly approved drug is therefore severely limited. Some 
even speak of population experiments.
171
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In order to face the problem of unexpected adverse reaction, a post-market 
surveillance system is established as a monitoring and alarm device to manage 
pharmaceutical risks. Cases of side-effects are spontaneously communicated and 
periodically collected so as to update the drug profile and take adequate and timely 
countermeasures in case of risk suspicion.   
The double safety control system provided by AMG comprehends therefore not only 
a selection gate prior to approval, but also a risk management system after the 
product has entered the market. This is intended to avoid or reduce the risks arising 
from any lack of information at time of approval (epistemological uncertainty).  
The risk management system is based on a surveillance system (§§ 64-69a) and 
develops in the following phases: 
- drug monitoring and risk data recording (risk information gathering); 
- risk analysis; 
- risk evaluation; 
- risk decision.172 
 
 
 4.1 Drug monitoring 
 
Post-marketing drug monitoring presupposes a system of information exchange.
173
 
The authority in charge for risk data recording and risk management  is according to 
§ 77 AMG the Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM (the 
Paul Ehrlich Institut – PEI for blood products). 
The following chart illustrates the side effect reporting system as it is regulated by § 
29 and § 62 - 64 AMG “Stufenplan”, which prescribe among other 
“Informationsmittel- und wege” (§ 63 AMG).   
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Phoenix (1995)
PSURs (AMG § 63b)
65% 25% 
Berufsordnunug
(§ 6 MBOÄ 1997)
Scientific literature
In vitro studies
Clinical experiments
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Figure 2 Data Source: Karl-Heinz Munter (1998)  and Martin H. Stopp (1998) 
 
According to § 62, the responsible authority should survey and evaluate all risk news 
associated with an approved drug as a safety measure for preventing endangering of 
health and life of humans or animals.  
Of course the principal information duty concerns the pharmaceutical firm: when 
severe or repeated adverse reactions are reported, or interactions with other 
pharmaceuticals occur, or else the drug reveals to be contraindicated for specific 
target groups, the firm must notify this to the authority.  
 
Pharmaceutical firms update drug profiles with periodical reports: Periodic Safety 
Update Reports (PSURs). Since the 14
th
 amendment to AMG
174
 these are regulated 
through § 63b Abs. 5 and take place: 
 Promptly under request;   
 At least every 6 months in the first two years after approval until introduction 
into the market; 
 At least every 6 months in the two years after introduction into the market;  
 Every 12 months after the following two years after approval (3rd and 4th year); 
 In time lapses of 3 years together with the application for approval renewal 
afterwards.
175
 
According to § 29 I the pharmaceutical firm is liable for communicating to the 
authority any suspicion of a “qualified” risk (for instance severe ADR or interference 
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with other drugs) within15 days. Moreover any changes in the documentation related 
to approval decision must be also notified to the authority. 
 
The Medical Commission for Pharmaceuticals (Arzneimittelkommission der 
deutschen Ärzteschaft, AkdÄ) acts as advisory committee in the evaluation of the 
risk/benefit ratio associated with the drug. Moreover it collects all adverse drug 
reaction (ADR) reports coming from physicians in a data-bank (which since 1995 
both AkdÄ and BfArM commonly share).
176
  
Also the end-user acts as monitoring “signaler”: in fact, since AMG ’94, § 11 I 2 nr. 
13 prescribes a specific instruction in the PL so as to invite the drug user to notify to 
the health professional of any adverse reaction not already contained in the PL.
177
  
 
Risk data is continuously analyzed and evaluated according to the course of action 
established by the “stages plan” (§ 63 AMG: Stufenplan), which is structured in 
different procedures at increasing risk degrees:  
1. first level: routine sessions: periodical exchange of information; 
2. second level: observations and reports about the drug manifest the concrete 
possibility of risks (danger degree I); 
3. third level: extraordinary session – well-founded suspicion of health risks 
(danger degree II). 
The upshot of this process is a decision about the risk tolerability. This can be 
changed from tolerable to intolerable if it is judged unacceptable in relation to the 
benefit provided by the product. As a consequence it is declared avoidable, in the 
sense that the decision maker evaluates that the technology in question can be 
substituted by other ones, which show a more favorable risk/benefit balance.  
 
If the risk is severe enough to demand for precaution measures but also limited to a 
specific group, and the drug is important for the community, than risk 
communication can reduce the danger by alerting the more exposed groups.  
If the risk regards the entire community, then warning messages help the single users 
make a personal risk/benefit assessment and decide whether to run the risk or 
suspend the treatment. 
Generally, when a drug is suspected of causing side-effects unknown at time of 
approval, the authority follows a sequence of steps: 
 
a. Analysis of post-market spontaneous reports related to the drugs; 
b. Literature review (and/or in-vitro data review); 
c. Risk assessment of alternatives (taking into account drug history and 
importance to community); 
d. Discussion with the drug manufacturer about the eventuality of providing 
further studies; 
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e. Consultation of a committee of experts (physicians, medicine academics, 
pharmaceutical experts); 
 
If the risk is assessed, then (communication) actions follow:  
f. Change labeling ; 
g. Inform the health providers community; 
h. Inform the public; 
i. Suspend the approval; 
j. Retire the product from the market. 
 
The pharmaceutical firm on their turn is granted the opportunity of taking several 
countermeasures in order to reduce the eventuality of damag: 
- Health providers can be warned of possible interactions or contraindications with 
a “Red Hand Letter” (Rote-Hand Brief) according to § 27 of the BPI Kodex (the 
auto-regulation code of the Federal Association of Pharmaceutical Companies: 
Bundesverband der Pharmazeutischen Industrie).
178
  
- Other spontaneous actions that the firm can adopt are product information 
changing (by authority received: AMG § 29) and, eventually, 
- Spontaneous recall from the market.  
The authority obviously has the right to enforce all actions (AMG § 12; 28; 30). 
This is a peculiarity which can be considered specific to drug risk prevention norms: 
in fact the authority is not only entitled to make drug risk information public, but 
also to enforce warning measures to the responsible firm.
179
  
 
 
4.2 Causal assessment of adverse drug events 
 
A major problem connected to drug monitoring is constituted by the difficulties 
related to the assessment of the side effect association with the drug. In fact the data 
upon which the causal association should be judged are affected by several flaws. 
This is a critical issue for risk management interventions, given that they are 
legitimized by the threshold of well-founded suspicion, which draws the line 
between monitoring and safety measures.  
The assessment of a causal link between a drug and a specific side effect after 
approval can be compared to a signal detection system.
180
 First, single cases of 
suspected association are reported by physicians: at this stage a causal assessment of 
the single case takes place (signal generation). Through the accumulation of 
individual side-effects reports, the signal strengthens up to a point where a position 
about the drug is required. In this phase, interpretation of aggregated data is needed.  
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Contergan court decision (LG Aachen, JZ 1971, 517. See also Räpple, 1991: 121). See Sickmüller, 1998 
for a detailed discussion on the matter. 
179
 Di Fabio, 1993: 119.  
180
 Meyboom et al., 1997: 376 ff. 
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Figure 3: The discovery of an adverse drug effect (source: Meyboom et al. 1997: 376).  
The crucial point in pharmacovigilance is the steep middle part of the curve: this is 
where a weak hypothesis develops into a strong suspicion and should result in 
corresponding safety measures. These range from labeling changes to product 
withdrawal.  
Warning measures include: addition of the detected side effect in the information for 
the doctor (Summary of Product Characteristics, SPC) – and for the patient (PL) – 
inclusion of special recommendations, and restrictions of the indications for use.  
However, it is often the case that regulatory decisions must be made while the 
scientific proof still need further analytical or experimental studies.
181
  
The interpretation of available data takes into account several factors: quantitative 
strength of the association, consistency of the data, exposure-response relationship, 
biological plausibility, pharmacological or pathological mechanism, and possible 
analogies with other drugs.
182
  
The aggregated data interpretation is rooted in the causality assessments of the single 
reports.
183
 However these tend to be qualitatively heterogeneous: some provide 
sufficient documentation to assume a causal relationship; others present instead 
insufficient or inconsistent information, so that the causal link may even be doubtful 
or not assessable at all. Therefore, spontaneous reporting databases contain a mixture 
of signals in various phases of development: probably true and probably false 
associations, and random associations that may have no pharmacological 
meaning.
184
  
In the attempt to decrease heterogeneity and ambiguity of the data, several methods 
for assessing adverse medical events associated with drugs were introduced since the 
early 1980s.
185
 Generally they aim at the standardization of the aetiological 
                                                 
181
 Meyboom et al., 1997: 384. 
182
 Meyboom et al., 1997: 377. 
183
 The causal evaluation of each single reported case is mandatory in many regulations (the German 
regulation prescribes it under § 29.1 AMG). 
184
 Meyboom et al., 1997: 383. See also Hartmann-Besche, 1998: 125. 
185
 Meyboom et al., 1997: 375. 
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procedure through an algorithmic formula.
186
 This consists of a series of questions 
with a numerical score for each answer. The questions regard the time association 
between drug intake and occurred symptom, disappearance of the symptom with 
therapy interruption, and other aspects relevant for causality. According to an 
agreement reached in a meeting in Morges, Switzerland, in 1981, nine points are 
considered to be the most important in causal assessment algorithms:
187
 
 
1
. 
Drug given to prior event? 
2
. 
Reaction at site of application? 
3
. 
Drug/adverse reaction interval compatible with the event? 
4
. 
Adverse reaction immediately follows drug administration and is of acute onset? 
5
. 
Rechallenge positive? (After a repeated exposition to the drug, the AR reappears). 
6
. 
Dechallenge positive? (After interrupting the therapy the AR disappears).  
7
. 
Were concomitant drugs stopped at the same time? 
8
. 
Same adverse reaction to this drug before? 
9
. 
Adverse reaction known with the suspected drug? 
 
The scores result in a cumulative value, which is subsequently translated into a 
ranking category attached to the causality assessment: for instance, ‘unlikely’, 
‘possible’, ‘probable’, and ‘certain’. The resulting outcome is not a quantitative 
measure of the likelihood of causality, but rather a standardization of the uncertainty 
about adverse reaction causation through semi-quantitative categories.
188
   
 
Regardless of minor differences, the national surveillance systems are generally 
based on four fundamental criteria: time association (challenge, dechallenge, 
rechallenge); pharmacology (knowledge of kinetics, dynamics, metabolites, adverse 
effects) characteristic diagnostic features (clinical data and laboratory results); 
alternative explanations. Apart from the first one, the judgment of these criteria 
requires thorough expertise in pharmacology, clinical medicine, and 
epidemiology.
189
  
Particularly, epidemiological information should support one hypothesis rather than 
another by providing frequency data of symptoms associations (base rate). 
                                                 
186
 One of the most widespread is the Naranjo algorithm, but also the Karch and Lasagna operational 
method of assessing ADR is used by several companies. Edwards and Lindquist have created a list of 
quality criteria for causal assessment. Bégeaud et al. have created a method which differentiates among 
different drugs. See Meyboom et al., 1997, and Buckingham Stevens, 1997 for references. 
187
 Meyboom et al., 1997: 377. 
188
 However the impact of any question may vary for different adverse reactions. For example, a “positive 
dechallenge” (prompt recovery after stopping) favors the causation hypothesis, but a negative answer to 
this question can also be the result of an irreversible side effect, and would therefore introduce an element 
of ambiguity in the causal assessment system.  Meyboom et al., 1997: 382. 
189
 Meyboom et al., 1997: 380. 
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Frequency assessment is in fact complicated by the absence of a reliable base rate: 
the lack of appropriate consumption data constitute a significant obstacle to the 
development of an epidemiological analysis. Reference to the turnover produced by 
a pharmaceutical product is not adequate because it does not correspond to 
consumption.
190
 
The collection of such data is one of the reasons of being of pharmacosurveillance 
systems, but their spontaneous method constitutes the strongest hindrance to a 
systematic gathering of epidemiological information. Thus the reporting system 
cannot be considered statistically flawless.  
The risk prevention system is affected by the following sources of uncertainty:  
 
1. The pharmaco-surveillance suffers from “underreporting“.191 This is due to two 
interconnected reasons:  
a. It is fundamentally based on spontaneous reporting (reliability flaw);  
b. Adverse reactions and illness symptoms are often difficult to distinguish not 
only for patients but also for physicians (validity flaw).
 192
  This is due to the 
complex causal networks linked with the presence of suspicious symptoms. 
2. Consequently data are epidemiologic (and therefore statistic-methodologically) 
flawed. 
 
A further critical shortfall of the standardized methods of causality assessment is that 
they do not specify the signal threshold, i.e. a criterion for deciding that there is 
sufficient evidence for a risk management intervention (well founded suspicion). 
Therefore risk decisions are the result of a shared assessment among different 
experts within the pharmaceutical company and beyond.
 193
 This presupposes a 
continuous communication exchange between company and authority. 
 
Notwithstanding the progress made by pharmaceutical safety regulation in Europe 
and USA through the emanation of an articulated legislation and the institution of 
special surveillance agencies, the incidence of drug adverse events is still worrying: 
it results that in the U.S. 35% of the doctors participating in a survey declared to 
have observed ADEs in their relatives (7% of which fatal); in England up to 5600 
hospitalizations per year are due to ADEs for a cost of € 702 Mio; from a study 
made in Erlangen (Germany), it results that 3.5% of the hospitalizations are due to 
ADEs, among which 44% are classified as avoidable. In general the fatality rate of 
                                                 
190 „Nur im Rahmen von klinischen Prüfungen steht fest, wie viele Patienten ein Präparat bei welcher 
Dosierung eingenommen haben“: Räpple, 1991: 109.  
191
 “The main limitations are the difficulty in recognizing previously unknown reactions … and 
underreporting”:  Talbot, Nilsson, 1998: 428. Reasons for underreporting are identified in the following 
factors: daily work overload in the surgery; fear of own errors; fear of further enquiries; ignorance of the 
reporting tracks; no availability of reporting forms: Hartmann-Besche, 1998: 124. The problem of 
underreporting is also mentioned by Di Fabio, 1993: 116; Räpple, 1991: 109; Schönhöfer et al. 1998: 111. 
Meyboom et al. 1997: 383.  
192
 Schönhöfer, P. S., Lelgemann M., von Maxen, A., Wille, H. 1998: 112. Räpple, 1991: 109-110.  
193
 See Buckingham Stephens, 1997 for an empirical survey about the causal assessment methods used by 
different pharmaceutical companies in the U.S. 
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ADEs is superior to road accidents in USA, England, Norway, Denmark, and 
Australia as well.
194
  According to a report publishd in the JAMA a good 121 drugs 
have been retired from the market in the last forty years.
195
 If, according to the 
authors this does not mean a worsening of the safety level in drug approval, still it is 
no good sign of improvement.   
 
A systematic “intensive” monitoring system 196and a risk oriented research197 from 
side of pharmaceutical companies have been advocated from legal theorists and 
concerned parties as well. Both at European and national levels, some progress has 
been made in the management and organization of drug surveillance systems, for 
instance through reliance on hospitals, rather than only practitioners.
198
  
Instead, pharmaceutical research seems to be as much as before oriented towards the 
prevalent investigation of pharmaceutical benefits. This has not only to do with the 
low return of investment brought about by research on pharmaceutical risks – a 
factor that could be steered through tailored economic incentives – but also to do 
with the structural difficulty of research on side effects.
199
 The hypothetical benefit 
is an identifiable object of investigation when analyzing a specific molecule, the 
same is not valid for the scrutiny of potential side-effects, which is virtually infinite 
because it has no definite targets to which it can be referred to.
200
  
 
 
5. Risk communication 
 
A fundamental principle of AMG is the prevention, elimination, reduction, and 
where this is not possible, the declaration of risks.
201
 
Pharmaceutical risk management draws on risk communication at different stages 
and for different purposes. Indeed, risk communication is the key to drug safety.
202
  
Given the existential relevance of goods such as health and (physical as well mental) 
integrity, stronger requirements are demanded of all stakeholders performing 
information tasks than in other fields of public communication.
203
  
                                                 
194
 Source: Grandt et al. 2005: 509. 
195
 Friedman et al., 1999: 1728. 
196
 See for instance Francke, Hart, 1999: 90-91; Schönhöfer et al. 1998: 112 ff.; Hartmann-Besche, 1998: 
124 ff.; Stopp, 1998: 102. Grandt et al. also underline that drug monitoring must not only focus on the 
identification of previously unknown side-effects, but also in the epidemiological task of reliably 
quantifying the incidence of already known ADRs (2005: 511).  
197
 Francke, Hart, 1999: 85. 
198
 The “Bremer Modell” must be mentioned among the pioneers of this approach in Germany: see 
Schönhöfer et al., 1998: 109-120. 
199
 Francke, Hart, 1999: 85-86. 
200
 Francke, Hart, 1999: 86. 
201
 “Tragender Grundsatz des Arzneimittelgesetzes ist die Vermeidung, Eliminierung, Reduzierung und 
erst, wo dies nicht geht, die Deklarierung von Risiken”: VG Berlin (1993) cited in Scheu, 2003: 783. 
202
 Scheu, 2003: 714. 
203“Information ist in aller Regel Bestandteil eines jeden zivil- oder öffentlich-rechtlichen Schuld- bzw. 
Rechtsverhältnisses. Ihre Erbringung wird allerdings normalerweise in Form einer Nebenpflicht geschuldet. 
Anders verhält es sich dagegen in sog. Risikoverhältnissen. In diesen bildet die Information einen 
unverzichtbaren Faktor zur Aufrechterhaltung der Sicherheit der Betroffenen; sie erstarkt wegen dieser 
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Moreover, not only risk communication but also the generation, collection, 
evaluation of risk information is subject to strict requisites: the standard is provided 
by the state of the art of medical sciences. This means that the pharmaceutical firm is 
supposed not only to gather and forward data, but also to get actively involved in 
research (e.g. through literature review) so as to anticipate as early as possible any 
drug damage.
204
  
Risk communication reveals an indispensable tool especially where a risk/benefit 
assessment is highly difficult and controversial. If the therapeutic value of a drug is 
high, the illness severe and no other adequate alternatives are available, so a warning 
against very severe ADR can constitute an alternative measure to product 
retirement.
205
 Warning actions are the default policy in any uncertain situation 
involving risk: 
 
“Informational strategy is often viewed as a stopgap measure until the health implications 
of the hazard are better understood, thus permitting greater flexibility in situations in which 
our knowledge of risks is evolving over time. In situations in which our knowledge about a 
risk is not sufficient to warrant a ban but does provide cause for concern, policy makers 
often adopt labeling as an intermediate course”.206  
 
The following diagram illustrates the communication flux around pharmaceuticals 
besides package leaflets and specialist information (SPC for the doctor).  
The drug consumer receives information from different sources: the pharmaceutical 
firm, the doctor and the mass-media. Each source accomplishes different tasks and 
meets different needs. The PL has a special place among these channels, because it is 
endorsed by the authority (this is why it is colored in blue) and because it is 
explicitly proposed as a necessary complement to the therapy.  
 
Pharmaceuticals: Information sources, Channels, and Targets 
                                                                                                                                                 
Bedeutung zu einer Hauptleistungspflicht in den Rechtsbeziehungen. Das Arzneimittelrecht bildet eines der 
Beispiele für derartige Risikoverhältnisse.” Pitschas, 1998: 222 (my emphasis). 
204
 Hart, 1998b: 181. See also Scheu, 2003: 769-775. 
205
 Hart, 1998b: 177. 
206
 Viscusi, Magat, Huber, 1987: 61 
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Figure 4: Communication flux around pharmaceuticals 
 
The two halves of the diagram represent two fundamental aspects concerning risk 
communication: 
- Risk information exchange between authority and experts in the decision phase. 
In this phase communication aims at increasing the shared knowledge and 
integrating expertise of different fields and backgrounds. It has fundamentally 
epistemological aims. The involvement of different stakeholders does not 
respond to a demand for the largest representation of the public community as a 
legitimization instrument. It is rather the answer to a complex scientific 
administrative decision.
207
  
- Risk communication to the concerned parties and, when needed, to the public at 
large, after a decision about the pharmaceutical product has been reached. At this 
stage of the risk management process, it can either serve as a warning to reduce 
risk and instruct about adequate use as to prevent avoidable risk, and/or as an 
instrument for allowing the autonomous decision about the residual risk.
208
 
 
This second aspect concerns the safety of prescription/use and decision autonomy. 
Prescription safety is proportional to the doctor’s acquaintance with the 
pharmaceutical offer and the risk profiles of the different products in relation to 
relevant risk groups. To the safety of drug prescription belongs thus also a 
continuous updating about the pharmaceutical products.
209
 On the basis of 
specialized information – scientific literature, association bulletins, authority 
newsletters, product information (SPC) – and of medical directives, guidelines and 
recommendations, the doctor should prescribe the pharmaceutical product which 
                                                 
207
 See Di Fabio, 1993: 123. 
208
 Hart, 1998b: 182. 
209
 Francke, Hart, 1999: 86. 
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consents an optimization of the risk/benefit profile in relation to the specific patient. 
This decision has safety and autonomy components at the same time, because it is 
ultimately a comparative decision among different products, about the risk which 
one chooses to undergo in the face of the related benefit. 
 
From the patient’s side therapeutic safety depends from compliance to doctor’s 
instructions (therefore indirectly from his knowledge of safety information) but also 
from a direct involvement in the therapy through control of bodily symptoms and 
parallel consultation of patient information. PL information represents a privileged 
vehicle for detailed information from pharmaceutical firm to end-user. However, in 
that the legal authority validates the product information included in the package, 
they act as trustees of its quality both for its scientific validity and for its correctness. 
 
The function of product information does not exhaust in its risk prevention function 
however. In fact, the presence of information about unavoidable risk means that this 
information is offered to the user in order to let him decide whether to undergo the 
risk or not based on a personal risk/benefit assessment: directly through the PL, 
indirectly through the SPC provided to the practitioner.
210
 
 
Given the legal value attributed by safety and liability norms to PLs, the legal 
function of patient information approaches that of the information provided by the 
doctor in the institute of “informed consent”. As we shall see in the following 
chapters, in the institutional framework of informed consent, risk communication 
acquires a specific meaning, precisely that of a liability disclaimer: in case of 
damage no compensation is guaranteed for residual risk. 
Some legal theorist also advances the hypothesis of constructing a special model of 
informed consent for the pharmaceutical therapy. In this model informed consent 
proceeds in two phases: first, consent to the prescription after receiving doctor’s 
information, and afterwards, consent to drug intake after reading the PL.
211
 
 
Questions arise however as to the capacity for a lay reader to really deal with such a 
great amount of specialized information, and ultimately as to the role it plays in 
compliance problems. In fact, non-expertise in dealing with medical information and 
other psycho-sociological factors (coping styles to bad news, information seeking 
behavior) can represent relevant obstacles for a rational risk/benefit assessment and 
ultimately a real autonomous choice.  
 
 
6. Summary and conclusion 
 
The pharmaceutical product safety is compromised by several sources of 
uncertainty. Safety regulation aims to reduce pharmaceutical risk to the minimum 
while at the same time optimize its benefit. A central tool for this procedure is the 
evaluation of the drug risk/benefit profile in relation to the indication and to the pre-
                                                 
210
 Hart, 1998b: 181. 
211
 Koyuncu, 2006: 343 ff. See chapter 4.  
 76 
existing pharmaceutical environment. Both drug approval and circulation depend on 
a positive risk/benefit evaluation.  
The reference to a risk/benefit profile rather than to absolute safety implicates the 
acknowledgment that no risk-freeness can be guaranteed for the pharmaceutical 
product, which is also defined as “unavoidably unsafe”. 
Safety regulation therefore concentrates on the aversion of all avoidable risks 
(through prevention and reaction norms) and in the (penal and civil) sanction of 
damage.  
Notwithstanding all these efforts a residual risk remains, which constitutes a constant 
danger to private and public health. 
 
Risk communication plays several roles in this framework: 
- Given the complex network of competences and expertise involved in the 
evaluation and surveillance of pharmaceuticals, communication among the 
different stakeholders is an essential tool for coordinating the different 
perspectives and activating the most adequate risk management measures; 
- In cases where the risk dimension merits alarm but is compensated by a high 
benefit – for instance, for specific risk groups – warning measures constitute a 
valid instrument for providing concerned parties with sufficient information to 
control it (when avoidable) or decide not to undergo it (residual risk).   
 
The autonomy element implicated by this perspective is also underlined by liability 
law, whose norms regulate the distribution of residual risk. In this respect risk 
disclosure equates to a discharge of responsibility about risks which are 
uncontrollable. 
As a consequence, the communicative status of PL information is strictly connected 
to its legal status within this risk prevention and liability framework.  
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2 Product liability  
 
 
 
 
 
 
 
 
1. Liability regimes  
 
As illustrated in the first chapter, drug approval is a provisory administrative act 
always subject to revision: also after being authorized for marketing, the 
pharmaceutical product might reveal unexpected damaging properties exceeding its 
beneficial virtues.
212
 The legislator acknowledges this phenomenon by instituting 
special administrative measures for drug safety surveillance after approval.
213
  
In addition to these preventive measures, liability norms for the distribution of 
damage costs build a complementary tool, which should orient the endangering 
entity into the adoption of all possible preventative and reactive measures for 
averting risk.
214
 
Liability in general should build a complement to the safety system through its 
steering effect, and civil liability in particular should secure the economic 
compensation for the health impairment suffered by the consumer.  
 
Liability regimes for pharmaceutical products comprise criminal liability and civil 
liability (tort, strict, and product liability). 
- Criminal liability is independent from damage and comes into effect for the non-
fulfillment of safety norms (§ 95 AMG).  
- Civil liability presupposes damage. Within civil liability, different regimes are 
discriminated in relation to the matters of fact presupposed for compensation.  
 tort liability (“Verschuldenshaftung”), regulated by § 823 BGB. It presupposes 
damage caused by a breach of professional duty; 
 strict liability (“Gefährdungshaftung”), regulated by § 84(1) nr. 1 AMG. It does 
not require breach of professional duty, but that the damage outcome exceeds a 
threshold level established by the law. Strict liability applies when the damage 
was not caused by tort (because it was unknown and therefore unavoidable) but 
it is considered unacceptable. 
 
A risk is considered acceptable (tolerated) to the extent that no alternative way 
exists to obtain the related benefit, i.e. to the extent that it cannot be avoided least by 
                                                 
212
 Besch, 2000: 27, 28.  
213
 Sieger, 1989: 1014. See chapter 1, § 4: Risk management.  
214
 See Wagner, 2004: 1487 ff. Given that the purpose of this work is the investigation of the legal status of 
PLs as a preliminary step for the definition of its communicative function towards the single user, I will 
skip over criminal liability and concentrate on civil liability regulation. 
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renouncing to the beneficial activity of the related damage source.
215
 This is why 
tolerated risk is also called unavoidable or residual: it is the danger taken into 
account by the society/the individual in order to profit from the benefits offered by a 
health technology. It cannot be averted absolutely, but only minimized. Accordingly, 
risks that can be averted without renouncing the beneficial activity are considered 
avoidable and therefore unacceptable.  
In the case of pharmaceuticals, the acceptability judgment regarding the damage 
source is the result of a policy decision made within the regulation provided by 
safety law: a drug may enter/stay in the market until a positive risk/benefit 
evaluation legitimates it (§ 5 AMG).  
The specific norm concerning strict liability for pharmaceutical products is § 84 (1) 
nr. 1 AMG.
216
  
 
Whenever new risk information is acquired, risks which were previously 
unavoidable because undetected should be scrutinized in order to decide if they can 
still be accepted in the face of the provided benefit. Both the authority and the 
pharmaceutical firm are supposed to react accordingly. Risk-management duties 
range from product surveillance to additional warning measures up to product 
retirement. The breach of these duties gives rise to tort liability sanctions.  
Strict liability requires that the damage exceeds the acceptability threshold. It does 
not presuppose a breach of duty, because it covers risks that could have not been 
possibly averted.  
 
Tort liability is independent from the unacceptability of a risk: any damage is 
compensated whenever it is not irrelevant and could have been prevented if 
professional standard duties were adequately met. In this sense avoidable risk is that, 
whose occurrence is imputable to duty violations and thereby presupposes 
intentionality or professional negligence.
217
  
In general, a risk is considered avoidable if the responsible party should have 
knowledge of its possible occurrence and has not taken adequate measures in order 
to avert it. In the pharmaceutical field these are production flaws (pharmaceutical 
firm responsibility), prescription errors (doctor’s responsibility), and consumer 
misuse (patient’s responsibility). 
Judicature related to tort liability has established a series of professional duties, the 
compliance to which presumes the implementation of a risk management system 
related to development risks.
218
  
 
                                                 
215
 See chapter 1 § 2.3.2. 
216
 Other norms regulating strict liability in other technological fields are § 25 ff AtomG (nuclear act) for 
nuclear power stations, and § 32 GenTG (genetic technologies act) for genetic technologies. 
217
 Tort liability applies also when the product is not efficacious: the legal motivation is that through the 
expectations placed in the inefficacious treatment, the consumer is detained from using other drugs present 
in the market, which are instead efficacious (for the causality requirement, the firm is liable only if other 
drugs are really available and efficacious).   
218
 Hart, 1998b: 180. The first and most detailed sentence in this regard is the Contergan decision. See 
chapter 1: 4-5. 
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This chapter and the following illustrate the distribution of responsibilities about 
pharmaceutical risks among the different stakeholders in order to define the legal 
meaning of health risk communication and the communicative role of PL as a 
function of their institutional effects. In particular this chapter is devoted to liability 
regulation concerning the pharmaceutical firm, whereas the next one will be devoted 
to the doctor’s liability regime.  
 
 
1.1 Tort liability  
 
The German liability system related to pharmaceutical damages comprises a general 
product responsibility for the pharmaceutical firm and a particular prescription 
responsibility for the prescribing physician.
219
  
Both the pharmaceutical firm and the doctor must respond for civil liability deriving 
from the violation of legal duties (tort liability). This is regulated by § 823 (1) BGB: 
“A person who intentionally or by his negligence, unlawfully causes death or injury 
or impairment of the health, freedom, property is bound to compensate him for 
damages arising therefrom”.220 According to this norm, compensation conditions for 
tortuous acts presuppose: 
1) the existence of a legal duty; 
2) a breach of the duty (act illegitimacy); 
3) a damage; 
4) causal connection between point 2 and 3. 
 
In general the manufacturer of a product has to undertake all possible measures in 
order to prevent the offence of the consumer regarding any constitutionally protected 
good, where the level of care is determined by the principle of proportionality: 
reasonability (“Zumutbarkeit”) of required measures in relation to the level of 
protection demanded by the protected good.
221
  
In the case of pharmaceutical firms, given the high value of health as a 
constitutionally protected good, safety requirements are accordingly strict.
222
   
 
 
 
 
                                                 
219
 From the perspective of safety warranty, this dual model has been defined as a “safety regulation 
system” (“System des Sicherheitsrechts”): Hart, 2003: 603. Doctor’s liability regulation is extensively 
discussed in chapter 3.  
220
 English translation from: Dietl, C.E., E. Lorenz, Dictionary of Legal, Commercial and Political Terms 
(2005). § 823 I BGB: “Wer vorsätzlich oder fahrlässig das Leben, den Körper, die Gesundheit, die Freiheit, 
das Eigentum, oder sonstiges Recht eines anderen widerrechtlich verletzt, ist dem anderen zum Ersatz des 
daraus entstehende Schadens verpflichtet”. The German formulation differentiates from other European 
equivalents in that it restricts the general clause to a specific list of goods protected by the constitution (s. 
Wagner, 2004:1473) and than extends the obligation to compensate to other goods only indirectly in the 
second paragraph through reference to specific laws (see later on).   
221
 Besch, 2000: 79. 
222
 Besch, 2000: 80. 
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The civil duties concerning a product manufacturer concern the following fields of 
action: 
i. construction (design); 
ii. product manufacturing; 
iii. product instruction; 
iv. product monitoring; 
v. reaction to relevant monitoring data. 
 
i. Construction. The product design must meet adequacy and safety standards in 
relation to the use for which it is marketed. In general, these standards depend 
essentially on the safety expectations of the consumer and on the state of scientific 
and technical knowledge. In the case of pharmaceuticals though, the safety level is 
established through § 5 AMG, and therefore fails to involve the consumer 
expectations. This is a significant divergence from general producer liability and 
constitutes a neglect of individual risk acceptance which parallels the similar 
situation observed in safety regulation.
223
 
Damages which are caused by product defects that are not detectable by following 
the safety standards do not lead to tort liability, because no duty has been breached 
by causing them (this is covered by strict liability).  
 
ii. Product manufacturing. Manufacturing defects are originated by failures in the 
production process.  
Tort liability however, does not cover defects which emerge when the best possible 
adherence to production standards of quality have been adhered to, because there has 
been no breach of duty.  
Following the same line of argument, so called outliers do not lead to tort liability, 
because they do arise even in the best possible compliance to production quality 
standards, therefore they are not the result of a professional duty violation.
224
 
 
iii. Product instruction. A product which is not affected by design or manufacturing 
defects can be considered faulty if not adequately accompanied by relevant warning 
instructions. These should prevent foreseeable misuse and secure that the product is 
used without bringing harm to the users or third persons. In the case of 
pharmaceuticals requirements for warning, instructions have been progressively 
specified on the basis of important court decisions like the Contergan sentence,
225
 
the Estil (BGH 11. 7. 1972)
226
 and the Asthma Spray case (BGH, 24. 1. 1989).
227
  
                                                 
223
 Besch, 2000: 81. See chapter 1, § 3.3.4 and related discussion about the neglect of individual risk 
acceptability in safety regulation.  
224
 This differentiates producer tort liability from the liability cases covered by ProdHaftG (product liability 
law), which also includes outliers.  
225
 LG Aachen, 18. 12. 1970 – 4 KMs 1/68, 15 – 115/67. JZ 507 (521). 
226
 BGH 11. 7. 1972 (VI ZR 194/70, Stuttgart) VersR, 1972: 1075 (1078). 
227
 BGH, 24. 1. 1989 (VI ZR 112/88, Frankfurt am Main) VersR 1989, 399 (401). 
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It emerges that information duties deriving from liability norms do not perfectly 
overlap those prescribed by safety norms. 
228
 Norms such as §§ 10, 11, 11a AMG 
(product labeling, PL and Summary of Product Characteristics) stipulate necessary 
conditions for information compliance to legal standards of safety. The adherence to 
this regulation does not however absolve the pharmaceutical company from tort 
charges, if it can be established that adherence to these norms was not sufficient to 
prevent damage and that the firm could have possibly prevented it by adopting 
additional measures as necessitated by the required level of care.  
Tort liability for product information is equally regulated by § 84 I 2 AMG. The 
explicit condition for liability is failure to comply with the state of the art of medical 
sciences.  
 
iv. Product monitoring. As for the duty to monitor the product in the market, this 
includes the collection of risk data referring to the product as well as to competing 
products placed into the market after approval. In this sense professional duties 
linked to product risk management play an incentive role in the detection of 
development defects. However tort liability does not cover the first case through 
which the development defect is detected, precisely because it was unknown 
before.
229
  
Also here, the professional standard can be measured along § 5 AMG: this prohibits 
the marketing of a product whenever there is a well-founded suspicion that the 
product risk exceeds the benefit. This is the case when other new products which 
enter the market are less risky, or because new adverse reactions emerge that were 
not known at time of approval and are considered unacceptable in relation to the 
benefit or to the risk/benefit balance of other alternatives for the same indication.  
 
v. Reaction to relevant monitoring data. As a consequence of this standard, the 
producer is responsible for undertaking corresponding measures if new data change 
the product risk profile: changes in design or manufacturing procedures, or 
additional warnings, up to product retirement from the market.
230
  
 
Tort liability is not only regulated by § 823 I BGB, but also by § 823 II BGB in 
connection with safety norms. I present § 823 I together with § 823 II BGB for the 
reader’s convenience: 
“ (1) A person who intentionally or by his negligence, unlawfully causes death or 
injury or impairment of the health, freedom, property is bound to compensate him 
for damages arising therefrom. 
 (2) The same obligation concerns the person who transgresses a law protecting the 
good of another. If, according to this law, the transgression is possible also without 
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 If no damage (and therefore no tort) results from violations to safety duties, the pharmaceutical firm is 
nevertheless criminally liable for letting circulate a product which is affected by development risk. 
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incurring in tortuous acts, the obligation to compensate regards only tortuous 
transgressions”.231 
 
In this case liability is not triggered by the violation of a duty, but by the 
transgression of a specific norm. Relevant norms in the case of pharmaceutical 
damages are: § 5 AMG for product safety; §§ 10, § 11, § 11a AMG for product 
information and § 8 I 1 AMG for product efficaciousness. However no relevant 
differences derive from the two regimes.
232
  
 
Tort liability does not cover those damages that can emerge unknowingly from the 
pharmaceutical firm. This potential risk can go undetected for a time sufficient to 
allow drug approval, and, when realized, cannot fall under tort liability: neither 
under § 823 I BGB nor § 823 II BGB. It cannot fall under 823 I BGB because the 
firm has made no illegal act in distributing an approved drug for which no evidence 
of the risk in question was available until the specific case brought it to light. For the 
same reason, no violation of a specific norm can be ascribed to the firm, because the 
damaging product was legitimately circulating in the market until the first damage 
occurred. The firm would violate the relevant safety norm (§ 5 AMG) only by not 
retiring the product or undertaking other appropriate measures soon after becoming 
aware of the risk: yet they can do nothing to prevent the first case of damage 
occurrence related to it.  
Outrageous cases such as the Contergan scandal have made the legislator conscious 
about the inadequacy of tort liability to deal with these types of product faults 
(development risk) and ultimately produced the shift from a mere tort liability 
towards a strict liability regime for pharmaceuticals.  
 
 
1.2 Strict liability  
 
Because of the high meaning of health as a good protected by the constitution, and in 
consideration of the difficulties experienced by courts in dealing with defective 
pharmaceuticals only by the means of tort liability, the legislator has introduced an 
additional form of liability for the pharmaceutical firm in addition to tort liability. 
This should constitute a complement to tort liability in cases where no duty violation 
can be imputed to the firm, but still damages are so relevant that at least an economic 
compensation is demanded.
233
 This has been made possible by introducing the 
notion of “Entwicklungsrisiko” (“development risk”): with this term the legislator 
captures defects which are not imputable to negligence by the producer, but must be 
rather traced back to the epistemic uncertainty inherent to the pharmaceutical 
product as a consequence of the limited knowledge available at the time of approval. 
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Liability for damages not caused intentionally or negligently can be classified as 
strict liability.  
 
Strict liability has been introduced in pharmaceutical regulation together with the 
shift from a “danger avoidance” into a “risk prevention” system, through AMG 
1976.
234
  
The paragraph which refers to strict liability in AMG is § 84 I. It prescribes 
following conditions for compensation:  
The product has been marketed within the norms expressed in AMG, it has caused a 
relevant health damage, it has been used as determined by its purpose, and in 
accordance to related instructions, and: 
1. the damage exceeds in a fashion not tolerable the measure established by 
current medical knowledge; 
2. or the damage could have been foreseen by the producer, and has not been 
communicated in the medical information or in the patient package leaflet.
 235
 
This second paragraph is a norm of tort liability referring to product instruction (see 
§ 2 later in this chapter). 
As can be noted, § 84 I 1 establishes the same condition for damage compensation 
which also determines product illegitimacy: trespass of risk tolerance threshold. This 
means that no compensation is contemplated for damage already taken into account 
in the risk/benefit assessment related to product approval.  
Furthermore, damage whose risk was not contemplated in the risk/benefit 
assessment prior to approval does not give rise to liability compensation, whenever it 
does not exceed the tolerance threshold. This tie between safety and liability 
regulation results in a reduced practical relevance of strict liability. As a preliminary 
step to the presentation of this issue, two important aspects related to strict liability 
are presented in the following two paragraphs.   
 
 
1.2.1 The systematization of § 84 I 1 under strict liability 
 
The legislator explicitly labels § 84 I 1 AMG as strict liability, but there is not 
unanimity around this classification. Some legal theorists adhere to this 
categorization,
236
 whereas others qualify§ 84 I 1 AMG under other sorts of liability.
 
237
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There are in fact some technical difficulties in the straightforward systematization of 
§ 84 I 1 AMG under strict liability. The question can be dealt with by referring to the 
legal principle underlying the transfer of damage costs from the concerned party to 
another one. This principle traces back to Roman law and prescribes that anyone has 
to bear the consequences of damage insofar as there is no reason to ascribe it to 
another. Therefore, compensation rights are linked to liability attribution 
principles.
238 
 
The attribution principle underlying tort liability is the illegitimacy of the act which 
caused the damage; on the contrary strict liability regulates cases where the simple 
fact of causing the damage gives rise to liability even if the act which produced it is 
not illegal: in this case the ascribing principle is the declared dangerousness of the 
activity under consideration.  
Tort liability is a general norm of civil liability. Strict liability instead is regulated in 
specific norms for particular danger sources or dangerous activities (nuclear power 
stations, aircraft services, and genetic technologies a. o.): the risk connected to these 
activities is taken into account in consideration of the related benefit, but the holder 
of the activity must respond for any damage caused by it, even if the activity itself is 
legally accepted. 
Because the intention of § 84 I 1 AMG is precisely to capture those risks which can 
go undetected before approval and therefore unknowingly by the pharmaceutical 
producer until the damage occurs, the consequent responsibility cannot fall under 
tort liability which presupposes intention or at least negligence, and therefore 
knowledge of the defect.  
However also the classification of § 84 I 1 AMG under strict liability is problematic 
in that the legislator does not categorize drugs as dangerous products (which should 
be one of the conditions for subsuming the norm under strict liability),
 239
 which on 
the contrary are submitted to an approval procedure prior to marketing, and are 
admitted to circulate only when declared “safe” (“unbedenklich”).  
Instead § 84 I 1 AMG grounds the liability of pharmaceutical producer not generally 
on the dangerousness of its activity, but on the distribution of concrete defective 
products.
240
 Even if AMG does not explicitly mention defectiveness; still it alludes 
to it by referring to development and production as possible causal factors for the 
damage.
241
  
In this respect, the marketing of a defective product cannot be considered an 
“allowed risk”, but, because the production and distribution of pharmaceuticals in 
general is considered a legitimate activity, § 84 I 1 AMG is also qualified in the 
literature as liability without fault for product defect (objektive Fehlerhaftung).
242
 
 
The theoretical classification of § 84 II 1 AMG under tort or strict liability is rather a 
question of legal status and has no actual repercussion in compensation decisions. 
However the debate around the nature of liability for pharmaceutical development 
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risks deserves further attention, and would certainly profit from an epistemological 
perspective allowing explicitness about the scope and importance of the risk 
shouldered by the drug consumer.  
The liability classification should furthermore do justice to the complexity and 
uncertainty of knowledge acquisition about a pharmaceutical product by the 
producer and the scientific community. Most of all it should take into account the 
general opacity of pharmaceutical products and the degree of awareness about non-
knowledge on the side of the producer.  
 
 
1.2.2 Residual risk  
 
In order to be approved for the market any drug must obtain approval from the 
authority. The criterion is established by the law through § 5 AMG, according to 
which a drug cannot be marketed if there is a well-founded suspicion that it has 
damaging effects which exceed a tolerable measure as established by actual medical 
knowledge.
243
 The tolerance threshold is established through a risk/benefit 
assessment as illustrated in chapter 1 and constitutes the benchmark in case of 
liability resolution. Safety norms and liability regulation are therefore connected.
244
  
The general consequence of the establishment of a risk tolerance threshold for 
compensation is the non-applicability of strict liability for residual risk. The table 
compares the conditions for compensation under tort and strict liability: 
 
 Strict liability  
§ 84 I Abs. 1 Nr. 1 AMG 
(development risk) 
Tort liability  
§ 823 Abs. 1 BGB 
§ 84 I Abs. 1 Nr. 2 AMG 
Intolerable 
damage  
 Compensation Compensation 
Tolerable  
damage  
(residual risk) 
Not 
irrelevant  
No compensation Compensation 
Irrelevant  No compensation No compensation 
 
Under tort liability any relevant damage raises the right to compensation, when 
caused by breach of professional duties (construction, manufacturing, instruction, 
risk management). Instead strict liability gives right to compensation only for 
damages which exceed the legally tolerated threshold: not the damage alone, but 
only the negative sign of the risk/benefit evaluation raises liability consequences. 
Residual risk (below the tolerance threshold) must be shouldered by the damaged 
party. 
This state of affairs is an obvious consequence of the fact that, if, according to safety 
regulation, the risk is considered tolerable, then, when coming to liability regulation, 
the legislator cannot consider the pharmaceutical firm liable for this same damage in 
case of concrete occurrence. The most problematic consequence lies in the fact that 
any risk associated to an approved drug is by definition tolerable: this means that the 
                                                 
243
 See chapter 1 § 2.3.  
244
 Hart; Hilken; Woggan; Merkel, 1988: 160.  Also quoted in Besch, 2000: 54. 
 86 
consumer affected by a risk already taken into account in the approval phase has no 
right to compensation. 
Therefore it can happen that the single user is concerned by a damage which exceeds 
the personal benefit he derives from the drug and nevertheless cannot claim any right 
to compensation on the basis of strict liability.
245
  
 
The threshold between tolerable and intolerable damages constitutes a considerable 
liability limitation in favor of pharmaceutical firms. Only damage whose severity 
exceeds the legally established tolerance threshold give right to compensation. And, 
because this threshold refers to the risk/benefit assessment made for drug approval, it 
tends to be high enough to allow a reasonably loose-fitting selection, so as to permit 
an adequate drug provision to the market: even very severe risks might have been 
accounted for in the evaluation phase either because their incidence is very low, or 
because of the high expected therapeutic effect.  
The general risk tolerance threshold will be higher than the individual would 
allow:
246
 questions arise, as to what extent it is legitimate to apply without 
reservations a general risk/benefit assessment to the single case.  
In case of a minor damage, especially in face of a significant therapeutic importance 
this policy is unobjectionable. However there can be cases where a major damage 
occurs, which is not compensated by an equivalent therapeutic value.
247
  
For instance, given the therapeutic importance of antibiotics, the eventuality of 
anaphylactic shocks is considered socially tolerable. This is unobjectionable if 
related to a fatal risk of pneumonia. Still it seems less unproblematic when a mortal 
adverse reaction to the same treatment is caused within a therapy against a simple 
cold.   
 
 
1.2.3 Time lapse in tolerability judgment of development risks 
 
The fact that the market approval conditions and liability duties are based on the 
same risk/benefit assessment constitutes a tie between the two systems (safety and 
liability), which raises theoretical and technical problems in the resolution of strict 
liability conflicts.  
In fact even damage whose risk was not known at time of approval does not lead to 
liability if it would not have brought to a negative risk/benefit evaluation in the case 
that it were detected before drug approval.
248
 
In order to analyze the implications inherent to the legal concept of development 
risk, legal theorists have investigated the repercussions of pharmaceutical 
environment evolution in the tolerability classification of damage.  
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Given that the tolerability judgment is an upshot of a risk/benefit evaluation related 
to alternative therapies, this evaluation can change from a positive to a negative sign 
whenever the pharmaceutical environment produces products with a better 
risk/benefit profile. This means that a damage which would have been tolerated at 
time t1, because no other alternative was available, would be considered 
unacceptable at time t2, because a better alternative exists. The time parameter 
therefore has a dramatic impact in the evaluation of development risk. 
Damage compensation can be obtained only for those damages, which, if known at 
time of approval, would have changed the risk/benefit assessment from a positive to 
a negative one and led to refusal of approval.
249
  
 
There is a differentiating point in the judgment about tolerability made in the 
approval phase and in the litigation context: the time difference between the risk 
benefit/assessment made in the approval phase and in the litigation can make a 
difference when new data about the drug profile contributes to change it. 
250
 
A risk/benefit evaluation can change in time as a consequence of two different types 
of data: 
i. New knowledge about drug risks (drug toxicity): a drug which is considered 
relatively safe can, after a certain time, reveal severe side effects which change 
the risk/benefit assessment from a positive to a negative one; 
ii. New knowledge about benefits and risks of valid alternatives (pharmaceutical 
environment):
251
 a strong drug is tolerated in consideration of a severe illness, 
but when a new equally effective drug with considerable less damaging effects 
enters the market, the risk associated with the first one is considered intolerable. 
As the graphic illustrates, the risk profile modification of drug x, or of the 
pharmaceutical environment can change its risk/benefit profile from a positive into a 
negative one in the course of time: 
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- 
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Fig. 1: The two factors influencing tolerability judgment in the course of time: development risk 
(red) and changing pharmaceutical environment (blue). 
The risk/benefit profile is positive until the well-founded suspicion of an intolerable 
risk emerges. The tolerability judgment however, is relational and depends both on 
the risks associated to the drug, and on the risks and benefits associated to alternative 
drugs for the same indication. 
 
Also when damage occurs, the tolerability judgment must be related to both 
parameters. The relevant time framework consists however of five possible reference 
points: drug marketing (erstmalige Inverkehrgabe), time at which damaging product 
is placed into the market (Inverkehrgabe des schadensstiftendes Produkt), time of 
drug intake (Anwendung), damage occurrence time (Schadenseintritt), closing of the 
trial (Stand zum Schluß der mündlichen Verhandlung im Haftungsprozeß): 
 
   (1) Marketing ………(2)Introduction of ………(3)Drug intake …….(4)Damage …………(5)Trial closing  
                                        damaging product                                            occurrence 
                                               in the market 
                      ↓                               ↓                                       ↓                                ↓                                    ↓ 
                 
__________________________________________________________________________________________ 
 
 
According to the history and systematic interpretation of § 84 I 1 AMG, the relevant 
knowledge for the judgment of damage tolerability in case of liability trial cannot be 
the same of drug approval. § 84 I 1 AMG has been precisely introduced to cover 
risks which were not detectable at time of approval, and emerged only in the post-
marketing phase.
252
 Therefore (1) is excluded.  
As for the other points, legal theorists agree that a differentiation should be made 
between tolerability judgment in relation to the drug toxicity (i) and to the 
alternatives introduced in the pharmaceutical market since approval (ii).  
For judgments regarding the drug toxicity, relevant knowledge should be the last 
data available, therefore the knowledge at the time of trial (5).
253
  
Legal theorists advance that establishing the same reference point also for the 
comparative judgment (ii) is counterproductive and legally not justifiable. In this 
way, pharmaceutical firms would be sanctioned for the very progress to which they 
collectively contribute. As a consequence innovation would be inhibited and health 
technology provision hindered.
254
  
The knowledge about drug toxicity (i) updated to the trial time should be therefore 
contextualized into an appropriate earlier point in the time framework. On its basis it 
should be then decided whether, were the new knowledge about drug toxicity 
available at that time point, the drug would have been judged safe in connection to 
the related pharmaceutical environment (ii).  
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Having excluded the time of trial as a suitable reference for the tolerability judgment 
in comparison to alternative treatments the choice reduces to points 2 – 4: 
 
 
                                        (2) Damaging ………(3) Drug intake …….(4) Damage ……………(5)Trial 
                                          product in                                                      occurrence 
                                                 the market 
                                                      ↓                                  ↓                                ↓                                  ↓ 
                 
__________________________________________________________________________________________ 
 
                                              ↑                                   ↑                               ↑                                  ↑ 
                                                          pharmaceutical environment (ii: Ds)                          knowledge about 
                                                                                                                                              drug toxicity at time of 
                                                                                                                                              trial (i: Rs) 
Fig. 2: Pharmaceutical environment (drugs present in the market: Ds) and enhanced knowledge 
about drug toxicity (risks: Rs) integrated in the R/B evaluation from different time points. 
 
The time of damage occurrence (4) can be seldom established with certainty: 
sometimes the damage arises after long usage or even concerns only the next 
generation.
 255
   
As for the notion of “Inverkehrgabe” (2) – product placement into the market – it is 
so ample that it comprises also the mere storing of products with the intention of 
marketing it. This means that a great time lapse can pass between the moment when 
the damaging product officially enters the market and the time at which it is 
consumed.  
Therefore the time of intake (3) seems to be the most suited:
256
 
 
                                                                    (3) Drug intake ……………………………… (5)Trial 
                                                                                         ↓                                                                  ↓ 
                 
__________________________________________________________________________________________ 
 
                                                                                 ↑                                                                  ↑ 
                                                          pharmaceutical environment (ii)                            knowledge about  
                                                                                                                                         drug toxicity at time  
                                                                                                                                         of  trial (i) 
 
Knowledge about drug toxicity acquired until the last trial examination should be 
projected back to the time of drug intake and used to make a comparison with the 
pharmaceutical alternatives available in the market at that time. If the resulting 
risk/benefit assessment is positive, the damaged person has no right to 
compensation, otherwise if the risk/benefit assessment resulting from this judgment 
is negative, the risk is considered unacceptable, and consequently the product 
defective, which leads to liability for the connected damage. 
 The implication brought about by this analysis emphasizes the gap between drug 
knowledge at time of approval and in consequent periods. This knowledge gap is 
accounted for in liability terms by comparing the updated toxicity data with the 
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alternatives offered by the market in the risk/benefit assessment which is specific to 
the court case.  
This is an important progress brought about by the introduction of strict liability in 
the pharmaceutical field. Still other questions remain unsolved. The most important 
is the gap between the objective tolerability judgment made for the drug in general, 
and the specific risk/benefit assessment in the damage situation: as already 
mentioned, relevant damage may have been taken into account and endorsed in the 
authorization phase because compensated by a low occurrence probability (and/or by 
therapeutic importance etc.).  
Moreover, the objective risk/benefit assessment and evaluation cannot and does not 
intend to be tailored to the personal values of the damaged individual. Drug 
regulation has not found a way to integrate the personal risk acceptance of the 
consumer in the relevant norms (drug access to the market, product liability). A 
subjective evaluation is possible only prior to the therapy on the basis of the 
information acquired from the physician and the PL.   
 
 
1.3 Concluding remarks  
 
Liability for the pharmaceutical product damage is principally regulated by tort and 
strict liability:  
- Tort liability concerns tolerable and intolerable damages caused by duties 
violation of the pharmaceutical firms: construction and production defects, 
instruction failures, failure to comply to general norms of risk prevention and 
management (§ 823 I and II BGB; § 84 I 2 AMG); 
- Strict liability is limited to intolerable damages (§ 84 I 1 AMG).257  
Historically liability litigations for health damage against pharmaceutical firms are 
very few in comparison to the adverse events calculated by epidemiological 
studies.
258
 Furthermore, most of them are raised on the basis of tort liability related 
to instruction failure. This is due to the difficulties to obtain compensation for 
damage which does not exceed the tolerance threshold, and to procedural points 
regarding causal connection to the damage and the burden of proof, which have been 
however amended.
259
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A forensic consequence for the relevant difficulties traditionally encountered in 
obtaining compensation in strict liability litigations against pharmaceutical firms is 
the prominence of liability sues linked to information duties violation either by the 
doctor – lack of informed consent/inadequate instruction – or by the pharmaceutical 
firm – incomplete or inadequate information in the PL.  
 
 
2. Liability for product instruction 
 
Liability for product instruction falls generally under tort liability and is regulated 
through § 823.1 BGB and § 84 I 2 AMG. 
As illustrated for product liability in general, compensation is linked to the 
tortuousness deriving from the violation of a professional duty which causes 
damage. Professional duties of risk communication have been gradually established 
through court sentences, and than stipulated also through safety regulation and 
liability regulation in AMG 1976 (§ 11, and 84 I 2). However it is only since 1986 
that patient information is specifically addressed. 
 
 
2.1 Judicature 
 
As already mentioned in chapter 1, a major contribution of the Contergan decision, 
was the shift produced in pharmaceutical safety regulation from “danger avoidance” 
to “risk prevention”.260  However, this sentence is important not only for having 
specified important aspects of strict liability, but also for stressing the illegitimacy of 
incomplete risk information as an offence to freedom rights, such as the right to 
autonomous decision about therapeutic risk. 
In fact, the Contergan decision greatly emphasizes the importance of risk 
communication both as a prevention tool and as a guarantee for the right to decision. 
In the inventory of general consumer protection duties, the Contergan decision 
includes and legally grounds specific risk disclosure duties.  
The responsibility to inform the consumer derives from the established or presumed 
dangerousness of the pharmaceutical product and the consumer right to decide, 
whether to undergo the risk connected to it or not, in face of the expected benefit. 
The Contergan justice explicitly parallels these risk disclosing duties to those 
concerning the doctor and steadily confirmed by court decisions since the end of the 
XIX century.
 261
 The doctor duty to inform the patient derives from the violation of 
bodily integrity implicit in any medical intervention, the illegitimacy of which is 
removed through prior adequate information. The same considerations are valid for 
the producer of a product which causes health damage to the user.  
                                                                                                                                                 
Zustand des Geschädigten im Zeitpunkt der Anwendung … Die Vermutung gilt nicht, wenn ein anderer 
Umstand nach den Gegebenheiten des Einzelfalls geeignet ist, den Schaden zu verursachen…” (my 
emphasis). The reversal of the burden of proof and the introduction of the adequacy theory of causality are 
the result of a long debate generated by a second health catastrophe produced by blood transfusions of HIV 
infected blood. See Rehman, 2003: 465-66, 473-474; Besch: 2000: 32, Besch (2000); Kullman (1995). 
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The court decision adds also that the right to decide about one’s bodily integrity is 
not only violated when the information failure relates to a proofed risk. Already by 
danger suspicion the user is concerned by the decision whether they want to risk 
health impairment. This autonomy right entails a risk disclosure duty by the firm.
262
 
The risk disclosure duties obviously regard also prompt and adequate 
communication towards the health professional, in that they take on damage 
responsibility through the prescription of a certain drug, and also because they are on 
their turn obliged to disclose medical risks related to the therapy.
263
 The 
pharmaceutical firm must inform clearly and in a comprehensible fashion, about the 
dangers connected to a drug, so that doctor and patient can decide whether and to 
what extent they want to dare the use of the product.
264
 
Also the risk disclosure threshold is decided from case to case through the above 
mentioned criteria.  
The sentence makes clear that pharmaceutical warning aims not only to avoid risk 
(safety), but also to guarantee the right to self-determination. This is the result of the 
unavoidability of residual pharmaceutical risk. For risks that are inherently 
associated to drug usage, and cannot be avoided through adequate precautions, 
information serves the purpose of allowing the consumer to decide whether to 
undergo them or not in exchange for the promised benefit.  
 
A second milestone in the history of pharmaceutical information regulation is the 
Estil sentence (1972).
265
 This decision takes the opportunity of a damage case caused 
by insufficient warning in order to specify with more detail the information duties 
that the pharmaceutical firm must fulfill.  
The Estil case relates to a severe infection with consequent limb loss, caused by an 
erroneous arterial injection of a narcotic. The arterial injection constituted a misuse 
of the narcotic drug, which should have been instead injected through the vein. 
Nevertheless the pharmaceutical firm, and not the doctor, was held responsible for 
the damage, because of insufficient warning.  
The judgment was based on considerations related to the probability and health 
implications of medical error, and the awareness about it by the pharmaceutical firm 
(tortuousness). The justice remarks that it was an acknowledged fact among health 
professionals that, by an elbow injection, the inoculation of the Estil narcotic into an 
artery instead of a vein could not be excluded with certainty. Given the predictability 
of this fault, the severity of its consequences, and the specificity of this danger, the 
pharmaceutical firm should have adequately emphasized the risk of an arterial 
injection, and explicitly mentioned the consequences of this kind of misuse. The 
simple warning to avoid an artery injection is not considered sufficient because it 
                                                 
262
 “Das Recht des Patienten oder Arzneimittelverbrauchers, über Eingriffe in seine körperliche 
Unversehrtheit zu entscheiden, wird aber nicht erst dann berührt, wenn die schädliche Nebenwirkung eines 
Arzneimittels nachgewiesen ist. Schon wenn auf Grund eines ernst zu nehmenden Verdachts zu befürchten 
ist, dass ein Medikament zu Gesundheitsschäden führt, sieht sich der Verbraucher vor die Entscheidung 
gestellt, ob er eine Verletzung seiner körperlichen Unversehrtheit riskieren will oder nicht”. LG Aachen, 
18. 12. 1970, JZ 515. 
263
 LG Aachen, 18. 12. 1970, JZ 515. 
264
 LG Aachen, 18. 12. 1970, JZ 517. 
265
 BGH 11. 7. 1972, VersR 1972, 1075 (1078). 
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does not point to the specificity of the risk, and can be taken as for granted, given 
that this danger affects also other treatments. It is precisely because this same risk is 
more severe and more probable in the injection of Estil, that it must be prevented 
through special instructions.
266
  
To the objection that the pharmaceutical firm can only be responsible for damage 
caused by an adequate use, the sentence contests that this is valid for conscious 
errors, but do not release the company from warning against a predictable misuse 
(“naheliegendem Mißbrauch”). This is precisely the case, where additional 
communication precaution can prevent damage.
267
 Responsibility for product use 
falls on the doctor, but not exclusively on him: the complexity of the pharmaceutical 
offer and the insufficient knowledge about product development and features 
demand higher information and warning requirements from the side of those, who 
are responsible for the product.
268
  
More importantly, the sentence establishes that the instruction and warning 
requirements related to pharmaceuticals are higher than those concerning other 
products.
269
 
 
The Estil sentence concerns instructions accompanying the product and formulates 
specific requirements for pharmaceuticals:  product information must be determined 
by the purpose of preventing any predictable damage. The company must not merely 
inform about possible risks, but also indicate how the product is to be safely 
assumed, together with countermeasures and actions, which shall be undertaken in 
case of adverse reactions. Specific warnings should also caution about the severity of 
the consequences of not following the instructions.  
 
Another important sentence for the determination of instruction duties is BGH 24. 1. 
1989 – the asthma spray case. 270  It parallels the Estil sentence in emphasizing the 
importance of specific warnings against misuse, especially for drugs which are 
intended to be used in dramatic situations, such as an asthma attack.  
By coming after the separation of patient instructions from specialist information for 
the doctor (AMG 1986), this is the first sentence which specifically addresses the 
package leaflet as a source of information for the lay user.  
The sentence refers to a case of death followed to the overdosage of an asthma spray 
in the course of a severe asthma attack. The pharmaceutical firm is charged of 
insufficient warning about the consequences of misuse. The information provided in 
the package leaflet in fact is complete but does not explain with sufficient emphasis 
the entity of health damage which the spray can produce in excessive dosage.
271
 The 
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 BGH 11. 7. 1972, VersR 1972, 1076. 
267
 BGH 11. 7. 1972, VersR 1972, 1077. 
268
 BGH 11. 7. 1972, VersR 1972, 1076. 
269
 “An die Aufklärung über mögliche Gefahren, die von Arzneimitteln ausgehen, sind besonders strenge 
Anforderungen zu stellen”. BGH 11. 7. 1972, VersR 1972, 1076. 
270
 BGH 24. 1. 1989 (VI ZR 112/88, Frankfurt am Main) VersR, 1989: 399 (401). 
271
 The sentence acts report the incriminated passages: “Dosierung. Bei drohendem oder akutem 
Asthmaanfall genügt meistens ein Aerosolstoß, um eine sofortige Atmungserleichterung zu erzielen. Hat 
sich die Atmung nach fünf Minuten nicht spürbar gebessert, kann ein zweiter Aerosolstoß genommen 
werden. Wenn bei einem besonders schweren Asthmaanfall nach weiteren fünf Minuten noch keine 
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court underlies that in general no duty of warning against overdosage is part of the 
instructions which the pharmaceutical producer owes to the product consumer, 
however it arguments that specific warnings of this type must accompany 
pharmaceuticals, when they are intended to be used in dramatic situations directly by 
the patient.
272
 
The importance of the Asthma-spray sentence lies in its emphasis on product 
instruction as a privileged means of risk prevention for the lay consumer. 
Completeness of information is not sufficient; information must also actively foresee 
and address possible areas of misuse and abuse, to which the consumer might be 
reasonably induced in his particular case.  
 
The Estil and the Asthma-spray sentences are both concentrated on safety aspects of 
pharmaceutical information (risk prevention), whereas the Contergan sentence also 
refers to product information in the context of risk disclosure for self-determination 
(autonomous decision about unavoidable risk).  
 
 
2.2 Product instruction in the AMG 
 
The considerations developed in the Contergan and Estil sentences have been partly 
included into the paragraphs devoted by the AMG to product instruction. However, 
in the AMG, obligations related to safety concerns (“Verkehrspflicht”) more than the 
autonomy aspect of information are on focus.  
No explicit mention is devoted to the qualification of risk information as a condition 
for the respect of lay consumers’ autonomy. This is partly due to historical reasons: 
in fact, only since 1986 did regulation introduce pharmaceutical information specific 
for the drug user.  
In fact, the official motivation for the introduction of product information is that it 
should guarantee a safe and correct use of the product by means of appropriate 
instructions with no distinction between the doctor and the end-user.
273
 
                                                                                                                                                 
befriedigende Atmungserleichterung erzielt wurde, kann eine dritte und für diesen Anfall letzte Inhalation 
vorgenommen werden. Die nächste Inhalation (ein bis drei Atemzüge) soll dann frühestens nach zwei 
stunden vorgenommen werden.  … Nebenwirkungen und Begleiterscheinungen: … Bei besonderer 
Empfindlichkeit und/oder höherer Dosierung können feines Fingerzittern, Unruhegefühl oder Herzklopfen 
auftreten. Auch Schwindel, Kopfdruck oder Schwitzen sind vereinzelt beobachtet worden. Beim 
Vorkommen dieser Erscheinungen soll die Dosis verringert werden … Besondere Hinweise: Bringt die 
Behandlung in der empfohlenen Dosierung nicht den gewünschten Erfolg, so spricht der Krankheitszustand 
auf die Behandlung ungenügend an, weil andere Krankheitsursachen daran beteiligt sind. Es ist daher 
unverzüglich ärztliche Beratung erforderlich, damit der Behandlungsplan neu festgestellt wird“ BGH 24. 1. 
1989 (VI ZR 112/88, Frankfurt am Main) VersR, 1989: 399. 
272
 „Der Revisionserwiderung ist zwar darin zu folgen, dass bei Arzneimitteln grundsätzlich nicht vor den 
bei einem exzessiven Gebrauch eintretenden Gefahren zu warnen ist bzw. vor einer missbräuchlichen 
Verwendung, die als unvernünftig gelten muss. Bei Arzneimitteln jedoch, die dazu bestimmt sind, dass sie 
– wie etwa ein Dosier-Aerosol in Asthmaanfällen – von dem Patienten selbst in dramatischen Situationen 
angewendet werden, sind auch Warnungen vor den bei exzessivem Gebrauch auftretenden Gefahren 
erforderlich“. BGH 24. 1. 1989 (VI ZR 112/88, Frankfurt am Main) VersR, 1989: 401. 
273
 See amtliche Begründung zu § 11 AMG, printed in Kloesel A., W. Cyran, Arzneimittelrecht mit 
amtlichen Begründungen, weiteren Materialien und einschlägigen Rechtsvorschriften sowie einer 
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In general, it can be said, that the law emphasizes the role of risk communication as 
a risk prevention tool and as an instrument of scientific information about the 
chemical molecule. 
However, the acknowledgment of unavoidable risk (“Nebeneffeckte” § 4 AMG) and 
the association of liability sanctions for failures to instruct about them, implicitly 
qualifies this information as information for decision autonomy. 
Product information liability is regulated through the second paragraph of § 84 I 
AMG, which link the conditions for compensation to instruction failure: “the 
damage could have been foreseen by the producer, and has not been communicated 
in the medical information or in the patient package leaflet”. 274 
§ 10, 11 AMG are norms of circulation duties (“Verkehrspflicht”) and prescribe 
strict requirements as to labeling and product instruction that should be included in 
the package.  
According to § 11, which prescribes sequence and form of the contents, the PL must 
contain following sections: indication, contraindications, precautions, therapy 
dosage and duration, interferences with other drugs or specific foods, adverse drug 
reactions, expiry date, last date of information update.  
A fundamental evolution in the regulation of product information has been reached 
through the separation of lay from expert information. This dates back to 1986, with 
the II amendment to the law (16.8.1986 – BGBl. I S. 1296): the purpose of this 
amendment was precisely to facilitate comprehension for the end-user. Product 
information comprises than, the so called “Summary of Product Characteristics 
(SPC)” and the Patient Package Leaflet (PL); the first directed at the health 
professional, the second at the patient.  
By disentangling patient information from information directed at the doctor, the 
legislator explicitly turns the end-user to be the addressee of PL information.  
Through this intervention product information becomes a specific information 
vehicle from pharmaceutical company to the end-user which is autonomous from the 
instructions provided by the doctor during the consultation, and whose purpose is not 
limited to safe use promotion, but, in the case of unavoidable (residual) risk, for 
which no adequate countermeasure can be taken in order to prevent it, also extends 
to the provision of information for an autonomous decision.  
In fact, because of the specific nature of pharmaceuticals as ‘unavoidably unsafe 
products’ not all risks can be prevented through adequate precautions. An absolute 
risk-free guarantee can only be the overall renounce to the therapy. Thus, the reason 
for informing the user about unavoidable side-effects cannot be that of averting them 
through adequate countermeasures, but rather to enable him decide whether to take 
the risk or not. Analogously to the distinction of risk and safety information in the 
doctor liability law, also in the case of product instruction for pharmaceuticals it can 
be distinguished between precautionary warnings and risk disclosure.  
 
In liability litigations a faulty product instruction can constitute a count of 
indictment in two ways:  
                                                                                                                                                 
Sammlung gerichtlicher Entscheidungen, Kommentar, Stuttgart, 1973, cited a. o. in Krudop-Scholz, 2005: 
137, footnote 740.  
274
 § 84 I 2 AMG.  
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- from a safety perspective, the warning could have been not sufficient or not 
sufficiently emphasized as to promote adequate use and correct behavior in the user.  
- from an autonomy perspective, the information about the occurred damage would 
have led the user to a different therapeutic decision – for instance to renounce to the 
drug – and therefore would have prevented the damage.  
Anyhow, because product instruction faultiness falls under tort liability, 
compensation is granted independently of the damage tolerability. The liability table 
is presented again below, with special focus on tort liability for instruction faults: 
 
 Appropriate product 
instruction 
Faulty instruction 
Intolerable 
damage  
 Strict liability:  
Compensation according to  
§ 84 I Abs. 1 Nr. 1 AMG 
Tort liability: compensation 
according to § 823 Abs. 1 
BGB or  
§ 84 I Abs. 1 Nr. 2 AMG 
Tolerable  
damage  
Not irrelevant  No compensation Tort liability: compensation 
according to § 823 Abs. 1 
BGB or  
§ 84 I Abs. 1 Nr. 2 AMG 
Irrelevant  No compensation No compensation 
Tab. 1: Concurring factors in liability distribution as regulated by § 84 AMG (strict liability and 
instruction failure) and civil tort liability § 823.1 BGB: Violation of instruction duties and 
damage entity. 
The direct consequence of the respect for decision autonomy through risk disclosure 
is a discharge from responsibility about disclosed risks,
275
 in that pharmaceutical 
product instruction about unavoidable risks translates in a reallocation of risk 
responsibility from producer to user. 
This parallels the institution of informed consent in medical communication. The 
double character of consent consists namely in two parallel functions:
276
 
- removal of illegitimacy of bodily offence: through consent the bodily invasion 
ceases to be illegitimate in that it is allowed by the owner of the body’s 
jurisdiction; 
- liability disclaimer for disclosed risks: for unavoidable risks related to the 
intervention, which have been disclosed, the doctor assumes no responsibility.  
The drug information provided to the patient in the PL is a form of risk information 
and of expert-to-lay communication which parallels the functions attributed to 
doctor’s communication. Patient’s responsibility in the therapeutic decision has been 
also indirectly emphasized by the separation of specialist (SPC) from lay (PL) 
information.  
In this setting, the pharmaceutical firm is liable for the product and the up-to-
datedness of the related information (to both doctor and end-user); the doctor is 
responsible for adequate prescription and risk information; finally, the patient is 
supposed to shoulder the residual risk coming from the therapy if adequately 
informed by the doctor and by the pharmaceutical firm through PL. 
                                                 
275
 Zacharias, 1986:356 f., speaks of a „Freizeichnung“: exclusion of liability. Similarly Schlund, 1999: 
771. See also chapter 4 for discussion.  
276
 See Koyuncu, 2005b: 290. See next two chapters for detailed discussion.  
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However, in the case of PL information, doubts have been raised as to the real 
contribution brought about by this information means in providing the end-user with 
suitable tools for an autonomous decision.
277
  
Moreover, consent to therapy is given to the doctor during consultation and therefore 
PL information is acquired when a decision has apparently already been made. The 
function of product information needs thus to be investigated in the wider 
framework of therapeutic pharmaceutical communication. 
 
 
3. Summary and conclusion 
 
This chapter has provided an outline of the liability regimes for pharmaceutical 
products. These distinguish among each other for the requirement of breach of law, 
tortuousness, and damage tolerability.  
No damage is required for a pharmaceutical firm to incur in criminal liability, but 
simply a breach of law. Entity and conditions of sanctions are regulated by § 95 
AMG.  
As for civil liability, which regulates litigations between drug consumer and 
producer, relevant liability regimes are tort and strict liability.  
Tort liability (§ 823.1 and 2 BGB) presupposes that the damage has been caused by 
the violation of a professional duty. Compensation is not linked to the tolerance 
threshold: relevant damages are compensated even if they do not trespass the 
tolerance threshold established by the law.   
Strict liability instead has been introduced in order to cover those cases, where no 
duty infringement can be ascribed to the producing firm, but nevertheless the 
importance of the damage requires an economical compensation as minimal 
reparation of the damage suffered by the drug user.  
The practical relevance is however of reduced importance given that it covers only 
damage which fall beyond the tolerance threshold established by the law. In fact the 
residual risk threshold established by the risk/benefit evaluation in the approval 
phase must take into account not only safety concerns but also questions of health 
care provision, and therefore tends to be set high enough as to allow for the medical 
care of the largest possible risk group. This may however result in specific cases of 
damage which exceed the benefit expected by the individual user. Although these 
types of damage are not irrelevant and indeed sometimes are of considerable entity, 
they are not covered by strict liability because they do not exceed the general 
tolerability threshold.  
Liability for product instruction failures falls under tort liability and is regulated by § 
823.1 and 2 BGB and § 84 I 2 AMG.  
PL information belongs both to product liability and safety regulation requirements, 
and responds both to risk prevention purposes and to the legislator’s concern of 
warranting decision autonomy. Within this second function however, risk 
communication results also in a reallocation of responsibilities about eventual 
damage in the realm of residual risk.  
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 See a. o. Henning, 1996: 342 f. 
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As a further contribution to the analysis of the institutional setting in which the PL is 
embedded, doctor’s information duties are examined in the next chapter, with a 
special attention to professional obligations related to pharmaceutical prescription.  
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3 Informed Consent  
 
 
 
 
 
 
 
 
“Vertrauen ist akzeptierte Abhängigkeit” 
 (Trust is acknowledeged dependency) 
Dinnendahl, 1981. 
 
 
 
 
 
1. Introduction 
 
This chapter analyzes the institute of informed consent and investigates its 
implications as for the amount, type and detail of information received by the drug 
consumer.  
Basing on the standard typology which distinguishes among informed consent, and 
shared decision making (entailing a counseling activity from the side of the doctor), 
the actual liability setting will be scrutinized as a steering factor in the consolidation 
of one type of therapeutic decision-making rather than the other.  
This analysis will constitute the basis for examining the legal status of PL 
information within the institute of informed consent and for evaluating PL 
information within this institute.   
 
 
2. Pharmaceutical communication to the patient:  Patient Package Leaflets and 
doctor’s information 
 
In the first two chapters I have illustrated the safety and liability regulation related to 
pharmaceuticals. The two systems both aim to reduce risk to the minimum through a 
set of preventive (approval, risk management) and deterrent (damage liability) 
norms.  
The safety system as illustrated in the first chapter is concerned with the product 
safety evaluation at time of approval – and afterwards – through a system of risk 
prevention. It directly concerns however only the pharmaceutical firm as a norm 
addressee. An equivalent risk prevention system for the doctor’s professional 
performance is limited to the issue of medical directives, guidelines, and 
recommendations.  
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Liability regulation is also asymmetric: whereas the doctor must respond both for 
contractual duties (§280 BGB) and for tortuous acts (§823.1 BGB); the 
pharmaceutical firm is not liable for contract violations towards the patient, but only 
for torts (§823.1 BGB; §84.1.I.2 AMG). 
Risk information delivered to the patient reflects this complex arrangement in that its 
contents and configuration are stipulated by safety norms; but are also indirectly 
shaped by the stakeholders’ interest in avoiding liability charges.  
In figure 1 the drug end-user (patient) is represented at the center of this 
communication flux: The doctor is considered to be the main responsible for 
adequate drug selection, prescription and information: in this setting the PL 
represents a special support for expert-to-lay communication.  
 
 
9
Risk management
Safety regulation
Medical standard 
+ directives, guidelines, 
and recommendations.
Norms for approval and 
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Safety regulation
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Liability regulation
Safety 
information 
Information tailored 
to the patient
General product
information
 
Figure 5 Pharmaceutical information to the patient: safety and liability norms impinging on 
the communication system.  
 
Tailored information is principally delivered through the doctor, who must respond 
for his therapeutic choice and related information. The pharmaceutical firm provides 
both users (doctor and patient) with general product information: Summary of 
Product Characteristics for the doctor and PL for the patient: sequence and contents 
of the information are strictly regulated through §§ 11 and 11a AMG respectively. 
Therefore, the principle responsible for PL configuration and content is the legislator 
that prescribes through these norms the adherence to a standardized information 
design and layout. 
The purposes underlying both PL and doctor information are determined by patients’ 
right to bodily integrity and autonomous choice. However, the norms aiming at 
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protecting autonomous choice have been until recently subordinated to bodily injury 
in that the institute of informed consent which is supposed to warrant the patient’s 
right to self-determination has been traditionally regulated within tort liability (§ 
823.1 BGB), which in the German setting does not comprise violation of immaterial 
rights (such as freedom of choice). This setting has consolidated a specific model of 
informed consent which lends itself to fundamental critics.  
The recent amendment of the compensation law,
278
 which allows claims for 
immaterial damage following from contractual violations, assigns an autonomous 
value to the freedom of choice, independently from bodily injury, and thereby 
extends the doctor’s information duty to a counseling activity which aims at 
enabling the patient’s choice, rather than simply obtaining a valid consent through 
risk disclosure. This chapter investigates the communication model implicated by 
the theory of informed consent (tort liability) and compares it to the template 
outlined by the shared decision making model. The aim is to provide a basis for the 
evaluation of the legal status of PL information within the therapeutic decision 
(chapter 4).  
 
 
3. Medical standards and required level of care  
 
The regulation of the medical profession is not comprised in a single specific law, 
but has rather consolidated through a long series of court decisions on the basis of 
civil norms such as § 280 BGB (compensation for violation of contractual duty) and 
§ 823 (1) BGB (compensation for damage caused by unlawful acts).
279
 In both 
norms the distinction between residual risk and medical error (negligence) is 
essential in order to ascribe responsibility to one or the other party. Only damage 
originated by medical error falls upon doctor’s liability. Residual risk instead must 
be shouldered by the patient, unless it has not been adequately communicated prior 
to the intervention/therapy. It is therefore comprehensible that much attention is 
devoted to the criteria establishing the threshold line between medical error and 
residual risk on one side, and to the determination of the amount and level of detail 
of the information about residual risk on the other.  
The point of reference for establishing when the medical procedure, which led to 
health damage is to be considered as negligence (Behandlungsfehler) is the medical 
standard.
280
 The doctor is not supposed to guarantee therapeutic success, which is 
unfortunately not entirely under his control. But he is requested to perform his task 
with careful endeavor to heal, and according to professional standards of quality.
281
 
According to a prevalent definition, “the medical standard represents the standard of 
medical sciences and medical practice, that are necessary to the achievement of the 
therapeutic purpose, and that have been proofed through experience”282. 
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 II Schadensersatzänderungsgesetz, 2SchadÄndG: 25.7.2002 BGBl I S 2674.  
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 Krudop-Scholz, 2005: 63. See also chapter 2 for details about § 823 BGB. 
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 Krudop-Scholz, 2005: 67. 
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 Krudop-Scholz, 2005: 115.  
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 “Standard in der Medizin repräsentiert den jeweiligen Stand der medizin-wissenschaftlichen Erkentnisse 
und der ärztlichen Erfahrung, der zur Erreichung des ärztlichen Behandlungsziels erforderlich ist und sich 
in der Erprobung belegbar bewährt hat”. Scheu, 2003: 711, drawing with unessential variations on the 
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The medical standard consists therefore of three principal elements, which jointly 
contribute to the articulation of its meaning: 
- scientific knowledge283; 
- medical practice; 
- professional acceptance.
284
  
A practical consequence of this articulation is the interdependence and reciprocal 
balancing of these dimensions when one or more of them do not prove to be at the 
optimal level: for instance, the fewer the scientific proofs at hand, the stricter must 
be the requirements of professional acceptance; the higher the professional 
acceptance, the lower can be the quantity of personal experience with the therapy 
(medical practice).
285
  
In order to institutionally establish and implement the medical standard, three kinds 
of norms are distinguished according to their binding character: directives, 
guidelines, and recommendations.  
Directives are strictly binding, and non-compliance to their rules leads to sanctions.  
Guidelines instead, represent medical decision supports that are systematically 
developed in order to assist practitioners in the adequate procedure for specific 
health problems. Deviation from the proposed measures is allowed (and sometimes 
required) in specific cases. The degree of binding force depends on the level of 
scientific evidence substantiating the guideline: the greater the scientific and/or 
epidemiologic support, the stronger are the conditions required for deviating from 
them.  
Recommendations are the description of one possible procedure with no binding 
force: their value is limited to counseling.
286
  
Directives, guidelines, and recommendations constitute a reference for the doctor in 
determining if he is acting with compliance to the required level of care. However, it 
is the doctor’s task to discern in each single case to what extent he is bound to the 
established norms, or if the specific situation require a deviation from it. 
                                                                                                                                                 
definition of Carstensen: Carstensen, G. „Vom Heilversuch“ in DÄBI, 1989, B-1737, cited in Hart, 1998b: 
170.  
283
 Applied medicine is increasingly influenced by the principles of Evidence Based Medicine. EBM aims 
at the standardization of epidemiological data and improvement of medical decisions through the issue of 
guidelines supported by coordinated statistical data. 
Scientific methodology in this field is deeply influenced by the epidemiological approach with related 
ranking of evidence value as a function of the way data are collected: 
1. double-blind, randomized clinical studies; 
2. controlled clinical studies; 
3. epidemiological studies; 
4. case studies; 
5. therapy observations. Francke, Hart, 1999: 26.  
The medical profession in general and some exponents in particular express their reserves as to the 
exclusive prerogative given to this method to the detriment of the traditional qualitative approach: Ewig, 
2006: 73-74. 
284
 Francke, Hart, 1999: 22. 
285
 Francke, Hart, 1999: 24, 26. 
286
 Francke, Hart, 1999: 23-25.  
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Professional care duty refers to, but must also go beyond standardized rules 
whenever the circumstances demand it.
287
 
Medical error as a result of non-compliance to professional standards represents a 
breach of contractual duty in the sense of § 276 I 1 BGB, which activates 
compensation rights in case of damage for the counterpart (§ 280 BGB).
288
 
If therapy failure or worsening cannot be ascribed to medical error, than it cannot be 
imputed to the doctor’s performance, and is considered residual risk. The task of 
judicature in this field consists precisely in the case to case distinction between 
medical error and residual risk.
289
 
 
 
4. Doctor’s professional duties 
 
The medical professional duty comprises following tasks:
290
 
 
1) Diagnosis.  
The standard of care translates in the gathering of relevant information for a 
sufficiently confident diagnosis: the data comprise patient anamnesis and 
observation, eventual labor tests, and diagnostic interventions. Not only the amount 
of diagnostic measures but also the interpretation of the data deriving from them 
must adhere to the professional standard so that the personal judgment of the doctor 
cannot unjustifiably deviate from it.
291
  
 
2) Therapeutic decision. 
This is principally the doctor’s task292: if the patient refuses or does not comply to 
the therapy, he acts at his own risk. This is a logical consequence of the fact, that the 
patient consults the doctor, precisely as a reference for an expert and informed 
decision. The importance of this perspective is decisive when considering 
information duties.
293
  
 
3) Intervention/therapy. 
This is the core duty of medical care: both for surgical interventions as well as for 
conservative therapies the compliance to medical standards constitute the fundament 
of professional performance and its legitimation.  
 
                                                 
287
 Francke, Hart, 1999: 26-27. 
288
 § 276 BGB refers to an objective level of care specific for the profession (due diligence): Krudop-
Scholz, 2005: 115. The extent of the required level of care also depends from the value of the concerned 
good, from the dimension, probability and reversibility of danger, and from illness severity. The upper 
limits are determined by feasibility considerations and economic factors: Wagner, 2004: 1827, Rdnr 676, 
1832 Rdnr 688. 
289
 Wagner, 2004: 1834, Rn. 692, citing BGH, NJW 1985, 2193 f.  
290
 See Wagner, 2004: 1832 ff. See also Francke, Hart, 1999: 34 ff. for a detailed account of doctor’s duties 
within and beyond the therapeutic task (keep informed, filing of therapy documents, etc.).  
291
 Francke, Hart, 1999: 34 ff.  
292
 Wagner, 2004: 1833, Rn. 689; see also Francke, Hart 1999: 122. 
293
 Wagner, 2004: 1833, Rn. 689. 
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4) Post-therapeutic care. 
Observation of the post-therapeutic course and related counseling duty.  
All these tasks must be performed in compliance with professional standards of care.  
 
 
4.1 Information duties: the protection of safety and decision autonomy  
  
Communication is a paramount factor along the entire course of the medical therapy.  
The information due to the patient is divided into two broad categories: 
“Sicherungsaufklärung” (safety information) and “Selbstbestimmungsaufklärung” 
(information for self-determination).
294
  
Safety information should avoid foreseeable damage by instructing about adequate 
therapeutic behavior; information for self-determination aims to make the patient 
knowledgeable of the residual risk connected to the therapy, and which must be 
taken into account because it is not ascribable to medical error.  
 
 
i. 4.1.1 Safety information 
 
Safety information consists of warning for the safe use of the drug or for a cautious 
behavior during and after the treatment or surgery. It is aimed at preventing avoidable 
damage by instructing the patient about the correct therapeutic behavior.
295
 In the 
post-therapy phase, this can translate in the information about the necessary measures 
for preventing complications and eventually insistence in the danger represented by 
non-compliance.
296
  
Because patient’s compliance is essential to therapy success and safety, it is part of 
the doctor’s information duty not only to provide warnings and instructions, but also 
to create the premises for a cooperative and trustful relationship with the patient.
297
 
He must secure compliance also by informing about the risks deriving from non-
adherence to his instructions, and in general must secure that the patient is aware of 
all necessary diagnostic and precautions measures which the patient should follow 
during and after the therapy.
298
  
 
 
4.1.2 Information for self-determination 
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 See also Francke, Hart, 1999: 55 ff. 
295
 BGH 22.1.1960 (VersR 60, 417-19). See also Krudop-Scholz, 2005: 70. 
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 Francke, Hart, 1999: 49. 
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 BGH 22.1.1960, VersR 60, 418: „[Der Arzt] muss alles in seinen Kräften Stehende tun, um ihn vor 
Schaden zu bewahren“; BGH 7.7.1994, NJW 94, 3012. See also Francke, Hart, 1999: 178-179. 
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Information for self-determination should warrant the patient’s freedom of choice 
and right to self-determination. Because of the risk associated to the medical 
intervention/therapy, this freedom of choice especially relates to the residual risk, 
whose responsibility is not ascribed to medical error and must be therefore 
shouldered by the patient.  
Residual risk represents the risk that accompanies the beneficial offered by the 
intervention, and that the patient can decide to undertake if he does not want to give 
free course to his disease in the light of personal considerations and preferences. The 
right to self-determination prescribes that the patient is aware about it in order to 
make an informed decision. 
Information for self-determination should help the patient make his decision by 
providing him with essential data about therapy importance and risk implications.
299
 
It is further specified in subcategories such as diagnosis disclosure, risk-information, 
information about the emergency of the intervention, probability of success.
300
  
The doctor is not supposed to give all possible medical details, but on the contrary, he 
must select information, which he deems relevant for the personal situation of the 
patient.
301
  
 
 
4.2 Compensation of material damage for violation of information duty 
 
Compensation for material damage claimed on the basis of violation of information 
duties is fundamentally decided along three conditions: 
1. Was there a duty to inform on the basis of the medical knowledge available? (duty 
to inform) 
2. Was the information delivered in sufficient and adequate way? (breach of duty) 
3. Was the failing of providing due information relevant for damage occurrence? 
(causality of breach for damage): Depending on the nature of information, 
causality for damage can be established in two different senses: 
a. In the case of safety information, a warning failure can be at the origin of the 
damage in the sense that the patient would have not been damaged if, 
adequately informed, he would have behaved consequently. 
b. In the case of information for self-determination, the causality link depends on 
the materiality of the information to the decision: Was the missing risk 
information relevant to the decision? Or would the patient have decided in the 
same way, also if adequately informed about the damage for which he is suing 
the doctor?  
The following scheme summarizes the liability framework which regulates doctor 
responsibility in case of health damage: 
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 Krudop-Scholz, 2005: 89. 
300
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Figure 6: Algorithmic scheme for liability compensation in case of health damage 
 
Compensation takes place only if it can be established, that along the medical 
knowledge available at time of therapeutic consultation, there was a duty to inform 
about the risk of a damage, as the one under consideration in the litigation; that the 
doctor has failed to (adequately) inform about it; and that the patient would have 
behaved differently/ would have found himself in a decisional conflict, if informed 
about it.  
A legal consequence of this setting is that the patient shoulders the risks, he has been 
made aware of prior to intervention/therapy.   
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4.3 Compensation for moral damage: violation of the freedom of choice 
 
Until the 2
nd
 Amendment Law of Compensation (2002),
302
 cases of liability 
litigations sued on the basis of information duty violations were exclusively linked 
to material damage.
303
 In fact, compensation for moral damage (damage for pain and 
sufferings) was limited by § 847 BGB to torts, and could not be claimed for breaches 
of contract.
304
 
Through the 2
nd
 Amendment Law of Compensation the norms related to 
compensation for tort and contract liability have been harmonized,
305
 so that 
compensation for the failure to provide information for self-determination needs not 
be necessary linked to damage: therapeutic information disentangles from the theory 
of informed consent and aspires to provide the patient a basis for autonomous choice 
beyond the disclosure of residual risk.  
 
 
5. Legal foundations of the duty to provide information for self determination: 
tort liability and contract obligations 
 
Information about the unavoidable risks related to the intervention is due to the 
patient under the general framework of constitutional norms concerning respect for 
autonomy and the connected protection of constitutional goods such as the right to 
self- determination and human dignity.
306
 This is the concretization in civil law of the 
general freedom rights protected by the constitution through § 2 I GG.
307
  
The right to self-determination though breaks down in the medical choice into two 
distinct rights:
308
 
 
a. The right to allow the doctor invade one’s bodily integrity (jurisdiction 
over one’s own body); 
b. The right to choose the therapy and being enabled to do so. 
 
The role of information in tort liability refers to the first right: within this charge, 
information provided by the doctor prior to intervention acts as a legitimization of the 
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 II Schadensersatzänderungsgesetz, 2SchadÄndG: 25.7.2002 BGBl I S 2674. 
303
 Although liable for both breach of contract and bodily injury (see RG 14.3.1911, JW 1911: 450),   
traditionally, the doctor has generally been prosecuted on the basis of a tort charge (§ 823.1 BGB), rather 
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 Wagner, 2004: 1810, Rn.643. 
305
 This harmonization is related to the amendment of § 253 Abs. 2 BGB and the abolishment of  § 847 
BGB 
306
 See also Wagner, 2004: 1494 for a discussion about the binding force of the constitution in relation to 
civil law. 
307
 Krudop-Scholz, 2005: 85-86. 
308
 See Hart, 1998c: 302 ff. for legally detailed discussion. 
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doctor’s invasion of bodily integrity, and results in a disclaimer of the resulting 
residual risk. Here the right to self-determination is called into question only 
indirectly as a guarantee that through information, the patient has validly consented to 
the intervention.  
The second right is accounted for through the professional duty to inform as it is 
implicated by the expert-to-lay relationship within contract obligations: in this context 
information disclosure is a professional duty owned to the patient, in order to enable 
him to make an informed decision. Here the right to self-determination is treated as a 
right on its own. 
The two forms of information duty result in a different communicative status of risk 
information, and in a different structure of the doctor-patient communication. 
Within the theory of informed consent, the point of providing the patient with 
information for self-determination is the adequate information about the nature of 
the intervention and the related residual risk, so that the patient can knowingly 
undergo the unavoidable risks related to the therapy and the medical invasion of 
bodily integrity is deprived of its illegitimacy through the patient’s informed 
consent.  
Instead, the contractual duty to inform the patient about the residual risks related to 
the therapy is part of a broader counseling duty which should enable the patient 
make an informed choice.
309
 The distinction is all but secondary and leads to 
different communication structures. Fundamentally, the informed consent model is 
blamed to reduce the doctor-patient communication to a risk disclaimer,
310
 whereas 
the contractual model of doctor-patient communication rather approaches a 
counseling model of expert-to-lay communication.  
 
 
5.1 Tort liability and right to self-determination as jurisdiction over one’s own 
body 
 
Tort liability for violation of information disclosure is based on the doctrine of bodily 
offence (“Körperverletzungsdoktrin”). According to this theory, which goes back to 
the first pronouncements on medical liability, the medical intervention is illegitimate 
on principle (tort against bodily integrity and health), unless justified by the willful 
consent of the patient.
311
 This is valid independently from purpose, outcome and 
compliance to standard levels of medical care.  
Because freedom rights protect the autonomy of the single individual, violations of 
these freedoms, when occurring with consent of the concerned person, cease to be 
such.
312
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However, in this setting the reference to freedom rights is only functional to the 
justification of the violation of bodily integrity. Tort litigations, are in fact subsumed 
under § 823.1 BGB
313
, according to which the defendant must respond for health 
damage occurrence.  The independent violation of the right to self-determination is 
not contemplated by tort liability law: § 823.1 BGB covers only fundamental goods, 
such as life, health, body, (physical) freedom, ownership; but not the right to know, to 
choose and to self-determination.  Even if the good protected by risk information duty 
is self-determination, when no health damage occurs, no compensation is granted 
even if there has been no adequate information. 
From a formal point of view, this setting results in the subordination of the 
protection of the right to self-determination to the violation of bodily integrity.
314
 
Only when a health injury has occurred, is the right to self-determination called into 
question. 
In fact, the duty to inform grounds on the right to self-determination only indirectly, 
because its offence invalidates the consent, but violation of this duty does not per se 
constitute a charge.
315
 The legal construction of the information duty requirement can 
be represented as follows:  
1. A medical intervention is fundamentally an invasion of bodily integrity and 
health (Körper- und Gesundheitsverletzung: protected by Art. 2 II GG)
316
; 
2. The illegitimacy of this action is removed by the patient consent (“volenti non 
fit iniuria”); 
3. The consent is valid only if it respects the patient’s right to self-determination; 
4. For this to be respected, the patient must be adequately informed.  
The offence of the right to self-determination is related to the medical intervention 
only through the consent condition and the causality requirement that the due 
additional information would have put the patient into a decision conflict which 
would possibly lead him to give no consent to the procedure.
317
  
A series of incongruities related to this framework have been identified by legal 
literature and health professionals alike.
318
 If some legal theorists lament that this 
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legal setting enslave information to legitimizing medical intervention,
319
 on the other 
side, others (together with the medical profession) refuse the idea implicated by this 
systematization, that a healing intervention has the same legal status as a stab, if not 
previously allowed by the patient.
320
 
The legal literature has underlined the inadequacy of the “Körperverletzungsdoktrin” 
to deal with doctor’s profession: The intervention of the doctor takes place in a 
situation which is already compromised by the illness; moreover, it is driven by 
healing purposes, therefore it should not be qualified as bodily offence on 
principle.
321
 Indeed, it has been underlined that by allowing the claim for moral 
damage also for contract breaches, the legislator has intended to steer the future 
medical liability law into its natural setting, namely breach of contract (rather than 
tort law)
322
. 
On the other side, the point for not distinguishing the two aspects of self-
determination (legitimization of privacy invasion vs. freedom of choice in a wide 
sense) in court decisions has been to dam litigations based on self-determination right 
alone with no damage.
323
 A recent court decision gives a formal argumentation for 
this position: a breach of duty to inform represents indeed an offence to the right of 
self-determination, but in the context of health damage, this right has a relative 
importance if taken separately. The court questions whether between two patients 
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injured in the same way, he who was previously adequately informed suffers 
substantially less than the other who lacked information.
324
   
Also difficult is the application of § 823.1 BGB to cases where the doctor incurs in 
medical errors, from which nevertheless no damage results. According to the law, the 
consent covers only an intervention lege artis, so that in these cases a duty to inform 
has been breached: In these cases though, the good offended cannot be health, 
because there has been no damage, and it can hardly be bodily integrity, given the 
specific situation of medical intervention, for which a physical contact is to be 
considered routine.
325
  
The considerations above recall the argumentation that contributed in the U.S. law 
system to the shift from “battery theory” (breach of duty imposed by the law) to the 
“negligence theory” (breach of professional duty) of informed consent. The 
distinction between the two theories is grounded on the different purposes that the 
information is supposed to accomplish: legitimation of the bodily intrusion in the first 
case, and patient’s enablement in an autonomous decision in the second. 
The official justification of the duty to inform as a professional care duty rather than 
as a legitimization of what otherwise should be a battery comes with the Canterbury 
case (1972): 
  
True consent to what happens to one’s self is the informed exercise of a choice, and that 
entails an opportunity to evaluate knowledgably the options available and the risks 
attendant upon each. The average patient has little or no understanding of the medical arts, 
and ordinarily has only the physician to whom he can look for enlightenment with which to 
reach an intelligent decision. From these almost axiomatic considerations springs the need, 
and in turn the requirement, of a reasonable divulgence by physician to patient to make 
such a decision possible.
326
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 Canterbury v. Spence, 464 F.2d 780 (D.C. Cir.1972) (footnotes omitted), cited in Faden (1986, p. 133-
34), my emphasis.  
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With this argumentation, the court finally establishes the doctor’s duty to inform not 
as a requirement for not incurring in an illegitimate battery, but as a consequence of 
the asymmetric relationship to the patient and therefore as part of his professional 
duty. 
The difficulty in developing an information duty on the grounds of self-determination 
rights alone is due to the fact that whereas in the USA the prosecuted breach is a 
general offence of the right of privacy which comprises both bodily integrity and 
right to self-determination, in Germany the tort under consideration is restricted to 
bodily integrity and health, and only indirectly to the right to self-determination.  
 
 
5.2 Professional duties and right to self-determination as freedom of choice 
 
The fundamental change brought about by the 2nd Amendment Law of 
Compensation is the disentanglement of doctor’s information duties from the doctrine 
of bodily injury (Körperverletzungsdoktrin).
327
 The consequence is that violation of 
the right to self-determination through failure to provide information triggers a right 
to compensation independently of the establishment of a tort. In this legal setting 
doctor’s liability arises not as a consequence of illegitimate bodily intrusion, but as a 
result of the expert-to-lay relationship between doctor and patient: the decision 
freedom of the patient is honored only if he is provided with the necessary 
information to perform it (information and counseling about the illness, available 
therapies, risks and benefits thereof, medium to long term consequences etc.). In 
contract liability, the damage derived from the lack of self-determination information 
consists in the lost chance to decide upon one’s own health, independently of eventual 
material damage.   
The duty to inform is part of the healing task implicated by the professional 
relationship and is aimed at guaranteeing the patient’s right to self-determination in 
therapeutic choice as it is also constitutionally guaranteed by § 2 I GG in connection 
with § 1 I GG (personality rights).
328
 
The immaterial damage of the lost decision chance refers to the decision enablement 
independently of the health outcome and is compensated through damage for pain and 
moral sufferings.
 329
   
The doctor comes to be not only the healer, who must inform about the risks related 
to his intervention, but also a health counselor,
330
 and the information provided by the 
doctor does not aim to disclaim him from eventual damage as a result of residual risk, 
but instead must first of all enable the patient’s choice. This is a counseling 
communication model whose ultimate purpose is not the patient’s consent as in the 
“Körperverletzungsdoktrin”, but rather the promotion of the patient autonomy in a 
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doctor-patient relation, structured through professional information responsibilities.
331
 
In this context, information serves the purpose of grounding a shared decision based 
on the different competencies of doctor and patient.
332
 The freedom to decide about 
one’s own health is protected independently from the fact that health is offended.333  
 
 
6. Concretization of information duties in the Informed Consent model 
 
The legal foundations underlying the IC model and the counseling model reflect in 
the concretization of the related information duties. 
I will first present the traditional regulation as it has been inherited by the judicature 
through the application of the informed consent theory, and than compare it to the 
desiderata entailed by the counseling communication model. 
It should be however pointed out that also the judicature related to tort liability 
shows a tendency to increasingly demand higher information requirements:
334
 this 
could be interpreted as the perception that the informed consent model should be 
amended in order to adequately warrant the principle of self-determination and 
patient’s choice. 
 
 
6.1 Information scope  
 
The doctor is supposed to keep updated about any new advance in medicine through 
scientific literature, newsletters of the health sector, the press in general and official 
bulletins and communications (for instance the “Rote-Hand-Brief”). 335  
However, the duty to comprehensive and continuous updating cannot and must not 
translate in a duty to a total information disclosure towards the patient: this would be 
impossible for practical reasons, and also inadequate to the health communication 
purpose. The doctor is not supposed to pour out all possible risks connected to the 
therapy, instead he is asked to give the patient a general idea of the benefits and risks 
connected to the proposed therapy. As a general criterion, he must disclose the risks 
that can concern the patient specifically and that are relevant for his decision.
336
  
Liability applies only to the damage, whose risk was not disclosed prior to therapy, 
and whose disclosure was due. 
However if the doctor totally fails to give the patient a “general risk disclosure”, 
(“Grundaufklärung”), than he is liable for any damage resulting from the treatment, 
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even if it was not subjected to information duty (“nicht aufklärungsbedürftig”). This 
results from the fact, that the lack of general information about the treatment 
invalidates consent, and therefore the resulting damage qualifies the 
intervention/therapy as invasion of bodily integrity.
337
 
Informed consent is thus treated as granted towards the whole treatment (risks and 
benefits), and not as given in a punctual fashion for each risk disclosed by the 
doctor.
338
 
 
 
6.1.1 Risk disclosure duty: activation criteria, quantity and form 
 
Court sentences have detailed the risk disclosing standards. These regard the amount, 
content, and form in which risk information must be disclosed to the patient.  
In a liability perspective, the causality condition gives an indirect but precise 
selection criterion: any information which can prevent a reasonably foreseeable 
damage must be communicated to the patient.  In the case of safety information, this 
equates to the communication of all warnings and precautions, and to the promotion 
of compliance.
339
 As for self-determination information, the principle of damage 
causality translates in the requirement of communicating information relevant for the 
decision underlying the consent: 
1. Magnitude. The duty to inform is activated whenever a risk is severe, important for 
the life quality of the patient and specific to the therapy under consideration.
340
 The 
principle of proportionality determines the amount of information to be delivered: the 
higher the risk, the greater is the detail and quantity of information which should 
support the decision.  
2. Indication: the less severe is the illness, the more information needs to be provided 
about intervention and related risks: there is an inverse proportion between illness 
severity degree and risk information duty;
341
 
3. Damage relevance for life quality: when the risk is important and relevant for the 
consequences on life quality, it is to be disclosed even if its frequency rate is very 
low.
342
 The frequency therefore is not considered as a basis for a disclosing duty: 
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courts have recognized that incidence rates are of limited informative value for the 
single case: more important is the relevance for life quality.
343
  
4. Risk specificity. Frequency of the risk is not a relevant dimension as for 
information duties, instead specificity is. Even risks which are very improbable to 
occur must be disclosed if they are specific to the intervention, i.e. they are known to 
occur in association with it, rather than for other causes.
344
  
5. The communication of the risk frequency itself is another matter of fact, and 
generally is not part of the duty to inform, but it must be delivered if asked by the 
patient.
345
 
6. Frequency rate must be communicated instead, as far as the possibility of 
therapeutic success is concerned, particularly when the failure rate is high.
346
  
Furthermore, the less important is the expected benefit, the more detailed has to be 
any information about the risks. 
7. Information about alternatives. A general duty to inform the patient about the 
therapeutic alternatives has not been established by judicature. This is a consequence 
of the principle according to which the judgment of the most suited therapeutic 
method to be adopted falls on the doctor.
347
 Merely hypothetical alternatives need not 
to be disclosed for consent to be valid.
348
 Some theorists adduce that a reason for this 
is also to be found in the general unconcern of the patient about the medical details 
related to his case.
349
 This supposition needs further empirical investigation, and 
cannot be considered of general value.  
However the judicature has established a duty to inform about alternatives, which 
constitute a real optional choice because of a different risk/benefit relation. Moreover 
the doctor is supposed to inform about alternatives in the measure that he deviates 
from standard methods of health care.
350
 
8. Urgency: the more urgent is an intervention, the less strict is the requirement to 
inform. In extreme cases also the assumption of hypothetical consent can be invoked.  
9. Time. Risk information must be delivered sufficiently in advance to allow for an 
autonomous and free decision without psychological pressure.
351
  
10. Form. The protection of patient’s safety and autonomy must not only be 
guaranteed through information quantity, level of detail and sufficient time for 
decision, but also by choosing the adequate form. In general the doctor must create 
the best possible conditions for an effective communication.
352
 In general severity of 
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illness and therapeutic risks cannot be understated,
353
 however the doctor must choose 
the most suitable communication strategy in order to promote optimal therapeutic 
results. An essential factor in this respect is a trustful relationship between doctor and 
patient. Personal communication is considered by judicature and sociologists as well 
as the only adequate means to establish, maintain and enhance trust. In the case of 
medical communication moreover, which is characterized by strong intimacy and 
requires empathy, face-to-face conversation is the only adequate context in which a 
confident communication exchange can be encouraged. It is also only through face-
to-face communication, that the patient can receive adequate attention and further 
enquire according to his information need: this is the best means for tailored 
information.
354
 Court decisions have recognized and underlined the empathic aspect 
and the construction of trust as compelling reasons for preferring and requiring this 
form of communication.
355
  
No written pre-drafted message can substitute personal tailored information unless the 
communication relates to routine measures, and the doctor gives the patient the 
possibility to ask for further information, when needed.
356
  
The diffusion of printed formularies for patient information is generally attributed not 
only to saving-time measures, but more fundamentally to the uncertainty experienced 
by doctors as to the legal consequences of patient information liability. The complex 
ramifications of information duties do not result in definite rules for risk disclosure. 
Under these conditions no risk communication, no matter how complete and 
comprehensive it might be, can constitute an absolute guarantee against liability sues. 
The signature of a written form should constitute a proof support in case of legal 
prosecution.
357
 
However the jurisprudence does not confer this kind of document the status of a proof 
for informed consent: at the most it is considered as circumstantial evidence that a 
personal risk communication has taken place.
358
 The fact that an information text has 
been signed does not mean that it has been read and understood, not to mention that 
the content has been discussed with the doctor. Therefore the proof value of such 
forms is very limited.
359
 
11. Tailored information. 
360
Information has to be tailored to the individual in relation 
to his risk profile (see points 1-10) and with respect to his information demand and 
processing capacities:  
- Information demand: depending on several factors such as choice delegation to 
the physician, self-efficacy
361
, coping styles to bad news, and/or control desire 
over events, the perceived need for health information can greatly vary from 
                                                 
353
 BGH NJW 1995, 2410, 2411. 
354
 Wagner, 2004: 1847 Rn. 724. 
355
 BGH NJW 2000, 1784, 1787, f; BGH NJW 1985, 1399; BGH VersR 1973, 244 (246); VersR 1985, 361 
(362).  
356
 NJW, 2000, 1784; NJW, 1985, 1399.  
357
 Krudop-Scholz, 2005: 111. 
358
 Krudop-Scholz, 2005: 112, with reference to BGH NJW, 1985, 1399. 
359
 Krudop-Scholz, 2005: 112. 
360
 BGH NJW 1984, 1807; NJW, 1984, 2629; NJW 1991, 2346; NJW 11996, 777; VersR, 2000, 1283. 
361
 Self-efficacy is the perceived personal capacity to elaborate and make use of information in a sensitive 
way. See the empirical part of this work for further discussion.  
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patient to patient. The optimal quantity should enable participation in the decision 
without overloading the patient and consequently increasing uncertainty. An 
information overload, which, instead of facilitating a decision, loads the patient 
with unmanageable data, is considered as illicit as a failure to inform.
362
 These 
considerations are at the basis of the principle of “gradual information” 
(“Stufenaufklarung”)363, according to which, information should reach the degree 
of granularity that is required by the receiver. 
- Processing capacities. Education, intelligence, profession, and familiarity with 
the specific matter are contributing factors in the establishment of the information 
level that the patient should be able to elaborate for a decision.
364
  
From a survey conducted by the Akademie für Technikfolgenabschätzung in Baden-
Wüttemberg results that 93% of the interviewees categorizes comprehensive and 
comprehensible information as “very important”.365 According to sociological 
studies, this information desire derives a. o. from the need to reduce uncertainty, 
plan future actions, and get reassured.
366
  
However a gap between perceived and expressed desire has been pointed out by 
several studies.
367
 
Paternalistic attitudes can therefore be the result not only of an inherited attitude of 
the medical profession, but also the response to the perceived expectations of the 
patient, when he implicitly or explicitly shows little interest in being informed about 
the risks connected to the illness and the therapy.  
The key to the dilemma between respect for autonomy rights and compliance issues 
seems to be tailored information finely attuned to the information needs of the 
patient. Risk communication is always a double-edged weapon, which can also have 
counterproductive effects: the adequate risk communication strategy should 
therefore account for delicate issues such as those related to the effect of bad news 
on the receiver. The solution does not lie in a radical option for or against 
paternalism, but rather in the distinction between desired and undesired paternalism: 
or better, in a nuanced scale from a zero degree of information need (total delegation 
of the decision to the doctor), up to a full autonomous choice.  
When the patient does not long for any participation in the decision, paternalism 
becomes a way to meet his desires.
 368
  
 
 
6.1.2 Exemption from risk disclosure duty 
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For several reasons, the patient might renounce to be informed: the right not to know 
is part of the right to self-determination. In this case too, the doctor is dispensed from 
information duties. Patient’s waiver can be explicit or implicit, but the doctor is 
supposed to reliably verify to what extent the patient refuses to be informed; 
especially implicit waiver requires strong and clear cues, that the patient does not 
want to be informed.
369
  
In parallel, there are unfortunate cases where the patient cannot possibly give consent, 
because unconscious or severely injured. In these cases the doctor must account for 
the patient’s preferences, and act consequently on the basis of a medical risk/benefit 
assessment.
370
 Information about patient’s values can be obtained from most 
proximate relatives, or by drawing on declarations of will. If no knowledge about the 
patient’s preference is available, the doctor can intervene on the basis of so called 
‘hypothetical consent’: the assumption that a reasonable patient would assent to the 
adopted therapy.
371
  
No information duty is contemplated for risks which are well known
372
 or – for the 
same principle – towards patient who are already familiar with them because of a 
chronic disease.
373
  
The information duty does not apply also in case of so called “therapeutic privilege”; 
i.e. when the foreseeable reactions to the disclosing of information would constitute 
an objective obstacle to the course of the therapy with no specific benefit 
whatsoever.
374
 In these circumstances the two main goods underlying health 
regulation oppose: right to self-determination and right to health and life protection. 
However, according to precedence regulation for constitutional goods, primacy is 
granted to self-determination rights, even in case where the will of the patient seems 
unreasonable from a medical perspective or detrimental for his own health. Through 
adequate communication the doctor can nonetheless reconcile both instances and 
guarantee adequate warranty to both patient’s health and autonomy rights.375  
 
 
6.1.3 Burden of proof 
 
The burden of proof for tort liability is on the doctor. Because an informed consent is 
what removes the illegitimacy on principle of the violation of bodily integrity, it must 
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be proofed not only that the consent has taken place, but that the required information 
has preceded it.
376
 
Given that causality to damage is a condition for compensation, litigations are also 
decided on the counterfactual argumentation about the hypothetical behavior of the 
patient, in case the information would have indeed been provided (alternative 
behavior of the doctor).
377
 In this case the doctor must demonstrate that even by 
complying with the information duty, nevertheless the patient would have decided in 
the same way. In order to rebut this claim, the patient needs to proof, that instead, he 
would have found himself in a decision conflict.
378
 
In the case of contract liability instead, the failure of providing adequate information 
is not considered as an offence to bodily integrity, but rather as negligence 
(“Behandlungsfehler”), and therefore it is up to the patient to proof that such a 
violation of standard care has taken place.  
 
 
7. Counseling  
 
Traditionally, liability sues for violation of self-determination information have been 
raised within the framework of tort liability, and within this framework counseling is 
not considered necessary for consent to be valid. As a consequence, courts have not 
provided a straightforward classification of the counseling activity. Sometimes it has 
been categorized as safety information – which is due to the patient in force of 
contractual obligations and not as a requirement for consent –; sometimes it has been 
considered as a separate performance.
379
  
A court decision differentiates for instance counseling information which cannot fall 
into safety information from information for self-determination through the criterion 
that, although it would not have been material to the decision of undertaking the 
therapy itself (self-determination), still it would have led the patient to adopt further 
safety measures.
380
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The following table presents a synoptic scheme of the legal grounds and status of 
different type of medical information before the changes brought about by the 2
nd
 
Amendment Law for Compensation: the counseling activity falls under contractual 
obligations and is not categorized as information required for consent to be valid: 
 
Doctor’s duty to inform  
 
Disclosure 
typology 
Legal foundation Content requirements Type of offence in 
case of violation 
Burden of 
proof 
“Selbstbestimmungs-
aufklärung”: 
Information for self-
determination 
RISK DISCLOSURE 
 
Remove illegitimacy 
of violation to 
bodily integrity and 
health offence 
through informed 
consent  
 
 
 
 with consent 
patient shoulders  
residual risk  
- Intervention description 
- Direct risks and 
consequences  
- Benefit probability  
- Alternatives 
(only if differ in 
benefit/risk profile)  
- Dangers of zero strategy 
(no medical intervention) 
Breach of duty to 
inform – lack of 
informed consent 
(Aufklärungs- 
fehler):  
 
↓ 
 
 
tort (§ 823.1 BGB) 
& breach of 
contract (§§ 278, 
280 BGB)  
Doctor: 
Must proof that 
the illegitimacy 
on principle is 
cancelled by the 
informed 
consent of the 
patient  
 
causal 
connection with 
damage 
required  
“Beratung” 
COUNSELING 
Prevent avoidable 
risks when they 
depend on patient’s 
health choices 
(within and beyond 
the therapy) 
- Other alternatives  
- Instructions about the 
therapy and post-treatment 
behavior and eventual 
additional 
recommendations 
Medical negligence 
(Behandlungsfehler): 
 
↓ 
 
Breach of contract 
280 BGB 
 
 
Patient: 
Must proof that 
the contractual 
party did not 
meet all 
professional 
standard 
required by the 
law  
 
causal 
connection with 
damage 
required 
“Sicherungs-
aufklärung”: Safety 
information 
WARNING 
Prevent avoidable 
risks when they 
depend on patient’s 
behavior within the 
chosen therapy 
- All instructions about the 
therapy and post-treatment 
behavior 
Figure 7: Synoptic table of doctor's information duties before the changes introduced by the 2
nd
 
Amendment Law for Compensation.  
In this framework, information for consent (“Risikoaufklärung”) and counseling 
(“Beratung”) falls under two different categories and respond to different legal 
requirements.  
A major point of distinction as far as the information content is concerned, is the duty 
to inform about alternatives: missing information about alternatives does not 
invalidate the consent if these do not objectively differentiate from the proposed 
procedure along a standard risk/benefit assessment.
381
 This is precisely because the 
relevance of information for consent is evaluated counterfactually through causality 
connection with the health damage: whenever the damage could have been equally 
probable with an alternative option, then it cannot be assumed that the eventual 
patient’s decision to opt for it would have led to a decreased damage probability. 
Therefore, lack of information about it is not considered causal for the damage 
occurred. As a consequence, alternative options which are not characterized by an 
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objective difference in the risk/benefit profile need not be disclosed for consent to be 
valid, and falls rather under the ‘counseling’ category.   
Along the changes brought about by the 2
nd
 Amendment Law for Compensation, the 
doctor is liable for compensation in the case of failure to provide self-determination 
information also on contractual grounds. Therefore, this legal setting steers the 
doctor’s professional performance towards a more comprehensive activity of both 
health manager and counselor. 
The counseling activity acquires the independent function task of warranting the 
patient’s enablement to make the therapeutic decision, independently of the purpose 
to legitimize the bodily intrusion. 
Indeed, the increased need for a real counseling activity has been emphasized in 
recent development of professional standards for specific medicine sectors such as 
genetic diagnostics, transplantation medicine, procreation medicine, and biomedicine 
in general in Germany and across Europe, and in professional guidelines and 
recommendations as well.
382
 In these contexts “Aufklärung und Beratung” (risk 
disclosure and counseling) represent a conceptual tandem,
383
 where no clear 
terminological definition has been established in order to legally distinguish them. In 
fact, in these medical fields more than in traditional medicine, it is perceived that a 
true informed consent cannot be reached unless a thorough counseling activity 
precedes and accompanies the health choice. Whether the counseling task is 
exemplified through catalogues or defined through general clauses, the general 
principle underlying all guidelines and regulation referring to it is the principle of 
choice enablement for the respect of the patient’s right to self-determination in the 
most comprehensive fashion, i.e. beyond the authorization to a preselected option.
384
 
More generally, information requirements are getting progressively higher in 
accordance to an increased emphasis on autonomy rights and the awareness that the 
quality of therapy depends both on the quality of doctor’s performance and on the 
decision quality.
385
  In this respect, the decision quality is defined as a function of the 
accuracy of the information available and of the attention paid to the decision-
maker’s preferences: “patients cannot properly weigh the benefits and harms without 
examining the evidence in light of personal values”.386  
The stress on patient’s autonomy and empowerment has been fostered not only by 
ethical but also by practical considerations such as: 
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1. Beneficial therapeutic outcome of patient participation in the decision;387 
2. The increased need of knowledge management and information tutoring in the 
information society;
388
  
3. Costs of the health care system.389 
The evidence based medicine paradigm has translated in the persuasion that not only 
the doctor’s decision should take into account the best evidence available, but that 
also the patient’s choice need to be based upon all relevant evidence in order to be 
really informed.
390
 
These instances have been also formalized in 2002 through a charter for the patient’s 
right issued under the patronage of the German Federal Ministry of Health 
(Bundesministerium für Gesundheit).
391
 The same ministry has also funded ten 
research projects focused on the identification and evaluation of methods for the 
promotion of patients’ right to self-determination in the therapeutic choice.  
Standards of medical counseling have not been legally formalized yet.
 
It is also put 
into question whether communication can be regulated, and whether this regulation is 
constitutionally required.
392
  However, with the changing scenarios both in the 
acquisition as well as in the dissemination of health knowledge among the public and 
the consequent addition of an uncertainty component to the insecurity already 
induced by the illness, there is increased awareness that the counseling aspect of 
medical care gains the same rank as the traditional therapeutic job.  
 
 
8. The communicative status of information for self-determination in tort 
liability (Informed Consent) 
 
The influence of the legal settings on the communicative flux between doctor and 
patient is object of controversy in the literature: Hart claims that the qualification of 
the medical intervention as violation of bodily integrity reduces the doctor-patient 
communication to a codicil in a context determined by a paternalistic conception of 
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the doctor role.
393
 Wagner objects that communication between doctor and patient 
depends on many factors but certainly not from the way legal theorists construct 
their case solutions.
394
  
The next two paragraphs bring a little contribution to this debate by comparing the 
communicative status of information delivered for consent and of counseling 
information on the basis of their institutional effects.  
I will recur to basic notions of speech act theory and the theory of agent 
communication, because they have developed a considerable explicative power for 
the analysis of institutional communication.
395
 
The definition of consent given by speech act theory is:
 396
 
  
“…The core principle for consenting is: to give permission in response to a 
request by H to do X that H does not have a right to perform without 
permission, but if granted will be performed by H”.  
 
This definition is the result of a logical analysis of the act of consent mainly devised 
for dealing with sexual crimes.  All the factors included in this definition are also 
entailed by the “Körperveletzungsdoktrin”:  
1. to consent is a subtype of permitting (“Einwilligung”); 
2. the concept of granting a permission upon a specific request (giving a consent) 
includes the fact that without it, the act which is object of the request is not 
allowed (“Unerlaubte Handlung”: tort); 
3. the purpose of asking for consent is to be allowed to do the act, which is object of 
the request (“Behandlung”: medical intervention). 
The Informed Consent model is based on the right to self-determination as a right to 
jurisdiction over one’s body: the medical procedure is going to affect the patient’s 
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 Speech acts as object of philosophical investigation can be first found in earlier works of the German 
philosopher and legal theorist Adolf Reinach. Following the German phenomenological tradition, Reinach 
investigates the ontological nature of obligations. He distinguishes between relative and absolute 
obligations. The obligation contracted by saying “I will bring you to the cinema” is related to the specific 
promise expressed in the proposition. But the obligation itself of keeping promises in general is an absolute 
one, which makes up the basis of the possibility of language at all: Burkhardt, 1986: 22. As a consequence, 
in his framework, linguistic considerations concern how it is at all possible that obligations emerge out of 
speech acts.  
Instead, Austin’s contribution comes from the opposite perspective and lies precisely in the emphasis that 
saying is also doing. His research focus is in the means through which obligations come to be in force. 
Austin, John L., How to do Things with Words (Oxford: Clarendon Press, 1963). Searle further radicalizes 
the contractual and conventional aspect. See: Searle, John The Constuction of Social Reality, (London: 
Penguin Press, 1995). I do not think that the two approaches are the sign of irreconcilable contradictions: it 
is rather a question of investigation object (communication vs. social acts in general) and disciplinary 
perspective (analytical philosophy vs. phenomenology).  
396
 Cowart, 2004: 520.  
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body and health, over which the patient has a (constitutionally protected) jurisdiction 
and therefore the authority to give consent to.   
In order to be valid consent needs to be informed, i.e. given upon knowledge of the 
act which is going to be performed.  
However the more essential factor concerning request for consent in medical setting 
concerns the risk related to the intervention. The concept of consent elaborated 
through years of court decisions exceeds the mere permission to do the act under 
request, and involve the residual risk connected to that act as part of the request. The 
point of the request is not so much the procedure in itself, but rather the risk 
connected to it, because in the Körperverletzungsdoktrin, the legal consequence of a 
lack of informed consent is that the doctor is liable for residual risk.
397
 
Asking for permission translates in a reallocation of risk: the residual risk connected 
to the therapy ceases to be under the doctor’s responsibility, soon after he has 
communicated it to the patient and the patient has consented to the therapy.  
Therefore communication is decisive as a distributor of responsibility and of damage 
liability. The table illustrates this point. 
 
DAMAGE SOURCE: DOCTOR’S LIABILITY IN CASE OF DAMAGE 
Residual risk 
about which the patient 
has been informed 
 
By giving his consent, the patient shoulders the risk 
connected to the intervention: the doctor is not liable for 
damage imputable to residual risk for which adequate 
information has been provided (Information = Disclaimer). 
 
Residual risk 
about which the patient 
has not been informed 
Violation of information duty: If it can be established 
that the missing information would have led the patient to 
a different decision, than the patient has the right to 
compensation. 
The doctor is liable for bodily invasion (lack of informed 
consent. 
 
Medical error 
(avoidable risk) 
 
The doctor is always liable for failing to meet professional 
standards of medical practice. 
 
Table 1: Distribution of risk along the two parameters control and information. Unavoidable 
risk (residual risk) does not fall under the doctor’s control; therefore it must be shouldered by 
the patient, with the provision that he has been made aware about it prior to the therapy choice.  
Medical consent has two institutional effects:
398
  
- it counts as a removal of illegitimacy through permission for the ones who 
gives it,  
- it exempts the one to which it is accorded from responsibility about the 
residual risk associated to the object of consent.  
Consequently, information provided for consent is contemporarily: 
- the condition for consent to be valid,  
- a disclaimer towards the risk communicated in it. 
The disclaiming function is not a primitive element of consent from a 
communicative perspective.
399
 It is rather an institutional construction developed in 
                                                 
397
 Wagner, 2004: 1826. 
398
 Koyuncu speaks of a double legal nature, 2005b: 290. See chapter 3 and 4. Our terminology becomes 
now closer to communication rather than legal studies. 
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order to face uncertainty in medical performance, and generally in every technology, 
whose benefit is associated with some risk.
400
  
To the duty to inform corresponds a shouldering of responsibility by the informed 
person towards the content of the information: If someone asks you the permission 
to do x, and tells you that x implicates risk y, by consenting to x, you also accept y. 
This dynamics is shown in the diagram: 
 
Diagram 1: The double legal nature (institutional effect) of residual risk information: consent 
validation and reallocation of risk responsibility through the legitimization provided by consent. 
Two points emerge from the graphic:  
1) Informed consent consists of an adjacency pair: the delivery of information about 
the therapy and its residual risk, and the consent to the therapy. Given that the 
delivery of information is subordinated to consent, its communicative nature should 
be investigated in the direction of a request for consent rather than in the simple 
transfer of data.   
2) The delivery of residual risk information prior to therapy has a double institutional 
effect: consent validation and consequent reallocation of risk responsibility, precisely 
as an upshot of the legitimacy to therapy provided by consent. 
The communicative nature of medical information in tort liability results precisely 
from the communicative structure of point 1, and from the related institutional effects 
(point 2).  
 
8.1 Informed consent as an adjacency pair  
 
Communication acts can be profitably analyzed as commitment manipulation 
actions.
401
 Commitment to a certain proposition is defined as the responsibility 
bearing towards the truth or the realization of the state of affairs described by the 
proposition.  
For instance for the act of informing and requesting the following is valid:
402
  
                                                                                                                                                 
399
 See the definition of consent presented above. 
400
 See chapter 3 § 3.3. 
401
 Colombetti et al. 2003: 79. 
402
 Colombetti et al. 2003: 80. 
risk transfer 
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B 
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- Information: by informing that “a” is the case, agent x makes a commitment relative 
to the receiver, that “x” is the case. The institutional effect of informing is the 
commitment to the truth of the information delivered; 
- Request: by requesting “a” to y, agent x puts the receiver y in a state of pre-
commitment, where the receiver can decide to commit himself to “a” by accepting the 
request, or do not commit himself to “a” by declining the request. 
Basic commitment manipulations are:
403
 
1) make commitment (ex.: “inform” or “promise”); 
2) cancel commitment (ex.: “retreat”); 
3) make precommitment (ex.: “request” or “ask”); 
4) accept precommitment (ex.: “consent”); 
5) cancel precommitment (ex.: “refuse”). 
From the commissive point of view, “consent” equates to the acceptance of a pre-
commitment. 
Therefore, for the adjacency pair principle, information provided for consent should 
not simply be categorized as “information” (make commitment) but rather as a 
“request” (make precommitment).  
The institutional effects of the consent to this request, however is not exhausted by the 
permission to carry out the therapy but also by the reallocation of the related residual 
risk. Therefore, because of this second institutional effect, the delivery of information 
for consent is not only a request for permission, but also amounts to a disclaimer 
about residual risk, in that the consent given by the patient results in the assumption 
of responsibility about the delivered  risk (commitment).  
Because in tort liability, respect of the right to self-determination is subordinated to 
health damage, the disclaiming function of medical information is in this context 
preponderant and from a legal point of view primary. 
 
 
 
 
 
9. Communicative status of information for self-determination in contract 
liability (counseling) 
 
Self-determination information provided within contractual obligations should foster 
the patient’s right to an autonomous choice per se, independently of eventual damage. 
In the case of information duty violations, the moral damage is represented by the lost 
decision chance or choice impairment. Therefore, medical information is also aimed 
at risk transfer but does not reduce to this function. The professional information 
duties regulated by contract liability are rather aimed at enabling the patient’s 
decision on the basis of adequate and relevant information. This translates in an 
information duty which should warrant the right to self-determination as a right to be 
enabled to choose. 
                                                 
403
 Colombetti et al. 2003: 81. 
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The duty to inform is based on the asymmetric epistemological situation between 
doctor and patient, on the doctor’s responsibility over the medical procedure, and on 
the patient’s right to decide over his body and health. 
This approach changes the relationship not only from a paternalistic one to a 
contractual one, where duties and responsibilities are consciously shared among the 
parts involved. More importantly, it extends the contract duties from the mere 
material beneficence of removing or alleviating the disease to the fiduciary aspect of 
health counseling for a personal informed decision.  
The counseling model confers a specific meaning to risk communication which 
differs from the informed consent model. In the counseling model the point is not to 
ask for permission, but rather to enable the patient’s decision. This is not a two-steps 
communication exchange (asking for permission; granting it), but rather a common 
sharing of competences: the doctor informs the patient about benefits and risks 
connected to the procedure and to eventual alternatives; the patient discloses his 
preferences and than a decision takes place.  
Consequently, the reason for which the patient shoulders the risks connected to the 
medical procedure differ in the two settings: in the IC model, the patient is supposed 
to shoulder the risks connected to the procedure because, having being informed 
about them, he is aware of them; in the counseling model, rather than merely 
consenting to a proposal, the patient actively participates in the decision, and 
shoulders eventual damage because he takes on co-responsibility for the medical 
treatment, and bears the risks which do not fall under the medical control. 
The IC model focuses on the patient’s authority over his body, the counseling model 
(or Shared Decision Making model) on his right to decide about health issues.  
The most evident difference between the two models of medical communication can 
be illustrated by referring to the duty to disclose therapeutic alternatives.  
 
 
10. Information about alternatives  
 
The duty to inform about alternatives imposed by tort liability is restricted to options 
with an objective difference in the risk profile. In fact the only dimension considered 
in litigations about failure to disclose alternatives is whether the damage would have 
been significantly less probable if the patient would have chosen the alternative 
option, which was not disclosed to him.  
This is a direct consequence of the fact that compensation for information failure is 
related to damage causality, rather than to violation of self-determination. In fact only 
those alternatives, which would have presented a lower damage probability, are 
procedurally relevant for classifying information failure under violation of bodily 
integrity (§ 823.1 BGB). Instead, alternatives with a similar risk profile need not to be 
disclosed because they present quantitatively the same risk. The doctor is not 
supposed to disclose in detail all available alternatives and to justify his choice.
404
 
Failing to provide this type of information does not invalidate consent.
 405
  
                                                 
404
 Heilmann, 1990: 1518. 
405
 BGH 11.5.1982 (NJW 1982, 2121-22); BGH 19.11.1985 (NJW, 1986, 780 = VersR 1986, 342); BGH 
8.5.1990 (NJW 1990, 2929); OLG Nürnberg 27.5.2002 VersR 2003, 1444; OLG Dresden 17.5.01, 2002, 
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With the exceptions of few court decisions
406
, the same is valid for options, which 
indeed have a different risk profile, but are not available in the health care structure in 
which the doctor operates. Some court decisions legitimate failure to inform about 
alternative technologies by resorting to the argumentation that the minimal difference 
in risk probability does not require disclosure duty, because not all newest medical 
devices can be available in every health care structure as soon as they enter the 
market. As long as the older technologies comply with medical standards, it does not 
constitute a violation of information duty, not to inform about the new alternatives.
407
  
The argumentation is fallacious in that, indeed not every health technology can be 
part of the diagnostic or therapeutic equipment offered by a health structure, but it 
belongs to the patient’s self-determination sphere to choose to go in another health 
center, where the technology is available, or to stay where he is and be content with 
the older one. But in order to be able to decide between these options he must have 
been informed about both: it is constitutionally illegitimate to deprive him from the 
beginning of this information. The patient must be informed about all concretely 
possible alternatives.
 408
   
The IC model represents a strong limitation of the patient’s freedom of choice: there 
could be in fact options which, even if objectively equivalent with respect to risk 
magnitude/probability, nevertheless could be perceived as different from the patient 
either because he has different feelings towards the types of risks involved, or 
because his system of preferences leads him to favor an option rather than another. 
However he will not be informed about them, just because they do not differ 
quantitatively in the risk probability dimensions, or the small risk difference does not 
justify disclosure duty: 
 
                                                                                                                                                 
VersR 02, 440-41. Also a recent contribution emphasizes this deficiency in the German regulation of 
Patient information: Beller, 2000: 8. Beller cites a. o. a study on disclosure habits in German settings 
(FIGO Committee for the Study of Ethical Aspects of Human Reproduction. Guidelines regarding 
informed consent. Frauenarzt 1997: 36) according to which the uterine carcinoma is removed through 
surgery or treated with radiotherapy depending on whether the first physician consulted is a gynecologist or 
a radiologist. The different early and late complications are seldom communicated to the patient though.  
406
 BGH 12.2.1974, VersR 74, 752-54. 
407
 BGH VersR 1984, 470 ff.; 22.9.1987 (NJW 1988, 763-65). 
408
 It is also insufficient to stipulate the duty to answer to patient’s questions about alternatives, because this 
would already presuppose some awareness about them. This awareness cannot be taken for granted for all 
patients: Francke, Hart: 1999: 125-126. 
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Informed Consent Model
Available options 
benefit risk
8
1
2
3
4
5
6
7
Doctor’s 
preference
Duty to inform 
benefit risk
1
4
Step 1: Doctor discloses alternatives available
and asks for permission to proceed 
with the proposed option (1)
Yes/No
Step 2: Patient gives consent 
to the proposed option and
takes on related risks 
(or refuses it)  
Figure 8: Informed consent model: only alternatives, which significantly differ in the risk profile, 
must be disclosed to the patient. The patient gives than his consent to the proposed option and 
thereby takes on responsibility for the related risks. 
The picture shows that only the doctor’s favorite option is disclosed to the patient, 
and eventual concurrent alternatives, whenever they have a significantly different 
risk/benefit profile. The patient’s task limits to accept or refuse the proposal. The 
decision is left to the physician, and is only marginally integrated with the patient’s 
values and preferences – subjective utility connected to different aspects of different 
modus operandi is substituted by an (objective) standard assessment.
409
 
The shared decision making model instead accounts for those aspects of the decision 
related to patient’s personal preferences and risk attitude. This requires that all 
available and realistically feasible options be discussed between doctor and patient, 
and that thereafter a decision be commonly made.  
 
 
                                                 
409
 „Sonst aber darf der Arzt, wenn keine Umstände entgegenstehen, davon ausgehen, dass der Patient, der 
von sich aus nicht weiter nachfragt, seiner ärztlichen Entscheidung vertraut und nicht eine eingehende 
fachliche Unterrichtung über spezielle medizinische Fragen erwartet; diese kann er in der Regel als 
Nichtfachmann ohnehin nicht beurteilen“ BGH 11.5.1982 (NJW 1982, 2122).“es versteht sich von selbst, 
dass es dem Patienten stets unbenommen bleibt, den Arzt über etwaige neue und überlegene, noch nicht 
überall zur Verfügung stehende Behandlungsmöglichkeiten zu befragen. Dann hat der Anspruch auf eine 
vollständige und wahrheitsgemäße Auskunft” BGH 22.9.1987 (NJW 1988, 765). See also: BGH 19.11.85 
(NJW 1986, 780 = VersR, 1986, 342); OLG Celle 17.3.1986 (VersR, 1987, 591); BGH 24.11.1987 (NJW 
1988, 765); BGH 22.2.2000 (NJW, 2000, 1788-89); OLG Karlsruhe 7.6.2000 (VersR 2001, 860); OLG 
Dresden 17.5.2001 (VersR 2001, 440-41); OLG Frankfurt 14.1.2003 (VersR 2004, 1053) with another 
nuance but with the same conclusion OLG Naumburg 5.4.2004 (VersR 2004, 1461): “Die zivilrechtliche 
Haftung für Aufklärungsversäumnisse knüpft an das Postulat an, dass die ärztliche Behandlung über das 
medizinische Anliegen hinaus auch dem personalen Anspruch des Patienten gerecht werden muss … d.h. 
dass die ärztliche Entscheidung … auch den Entschluss des Patienten als personalen Faktor einbezieht. … 
Zur Aufklärung über die Art des Eingriffs gehört u.a. dann auch eine Aufklärung über 
Behandlungsalternativen, wenn eine echte Alternative mit gleichwertigen Chancen, aber andersartigen 
Beanspruchungen des Patienten bzw. Risiken für den Patienten bestehen”. See also Francke, Hart, 1999: 
124-126. 
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SDM Model
Available options 
benefit risk
8
1
2
3
4
5
6
7
Doctor’s 
preference
Step 1: Doctor disclose to the patient risks and benefits of 
all concretely possible alternatives, even those ones for 
which the patient should be referred to another 
doctor/hospital 
Step 2: Patient and doctor discuss together the options and 
come to a common decision.
Patient takes on co-responsibility in the decision
and therefore shoulders related risk.
Doctors is responsible for damage caused by medical error.
 
Figure 9: Shared decision making model: all concretely possible alternatives are disclosed to the 
patient. Doctor and patient discuss them together and come to a common decision. The Patient 
takes on co-responsibility in the decision and therefore shoulders the related risk. 
 
The discussion of the healing perspectives and uncertainties is a necessary condition 
for a real participation in the therapeutic choice which cannot be reduced to a “yes or 
no” answer after the simple transmission of information.410 It is understood as a sort 
of emancipation process towards “patient empowerment” and as an assumption of co-
responsibility at the same time.
411
 
 
 
11. Summary and conclusion 
 
This chapter has analyzed the institute of informed consent and the recent evolutions 
in the field of therapeutic communication in the German legislation with the purpose 
of providing the background for evaluating the legal status and communicative nature 
of PL information.  
The institute of informed consent responds to the need for warranting the patient’s 
right to self-determination. However it is severely in that the right to self-
determination is reduced to a jurisdiction over one’s own body.  
In the communication model presupposed by the institute of informed consent, 
information serves uniquely the purpose of making consent valid, and therefore 
results in a two-step process where the doctor asks for permission to invade patient’s 
bodily integrity through surgical or therapeutic intervention, and the patient grants it. 
Residual risk is shouldered by the patient, because he has been made aware of it 
through risk disclosure. 
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 Krudop-Scholz, 2005: 60. 
411
 Krudop-Scholz, 2005: 57, 58. 
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The right to self-determination as a right to choose calls instead for a richer model of 
risk communication, the Shared Decision Making model, where the purpose of 
doctor’s information is to enable patient’s therapeutic choice and a common decision 
is taken on the basis of patient’s preferences and doctor’s expertise. Residual risk is 
shouldered by the patient, because he has co-participated in the decision, and 
therefore takes on the risks, which are out of the doctor’s control. 
The 2
nd
 Amendment Law for Compensation brings a relevant contribution to the 
steering of doctor-patient communication towards a SDM model, through the explicit 
protection of the right to self-determination per se, independently of health injury. 
The following chapter is devoted to investigate the interplay between doctor’s and 
product information. I  
The upshot of this analysis is a clear illustration of the responsibility distribution 
among pharmaceutical firm, doctor, and patient resulting from risk disclosure.  
 132 
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4 The legal status of PL information  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Safety protection and self-determination information in pharmaceutical 
therapy  
 
The context in which the doctor practices his profession is characterized by several 
sources of uncertainty. In the pharmaceutical therapy the first source of uncertainty 
is represented by the treatment itself, and its interaction with the patient’s organ 
system. Therefore safety depends not only on the product but also on its right use. 
 
Product safety is guaranteed preventively by safety regulation and by civil and 
criminal liability in the form of pecuniary sanctions or imprisonment. Use safety is 
warranted by doctor’s compliance to professional standards of prescription and is 
based on the product information.
412
  
Product information therefore contributes to safety both by allowing the doctor a 
risk/benefit evaluation based on detailed scientific data, and by warning the patient 
of possible product risks.  
Product information takes the form of SPC (Summary of Product Characteristics) for 
the doctor and of PL (Patient Package Leaflet) for the patient. The second is a 
simplified synthesis of the first, specifically tailored to the lay user. The diagram 
shows the synergy of doctor’s and product information in therapeutic safety: 
 
 
                                                 
412
 Hart, 2003: 603. 
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Figure 10: Pharmaceutical safety as the result of product and use safety: the role of information. 
Product safety is protected through norms regarding risk prevention and liability 
(they have been presented in chapter 1 and 2 respectively). Use safety is the result of 
product safety, adequate prescription (doctor’s professional duty) and of the patient’s 
adequate use upon correct and complete information through both product 
instruction and doctor’s recommendations.  
As can be observed from the graphic, the production and distribution of 
pharmaceuticals is subject of both safety and liability norms, whereas the doctor’s 
activity is only regulated by liability norms: a corresponding “safety” regulation for 
the doctor is lacking,
413
 but an equivalent function is covered by prescription 
directives, guidelines and recommendations, and generally by the requirement of 
compliance to medical standards.  
Therapy information by the doctor aims both at safety and decision autonomy, 
product information by the pharmaceutical firm is regulated within safety norms but 
is also characterized by autonomy components in that it is also object of liability 
regulation. In this respect PL information is also the basis for informing the patient 
about unavoidable – “residual” – risk (self-determination information).414  
As a consequence, the patient is addressed by two distinct information sources, both 
accomplishing safety and self-determination purposes, but meeting different 
requirements of risk communication. 
This chapter is devoted to product information delivered by the pharmaceutical 
company, especially in the form of package leaflets, its interplay with doctor’s 
information, and the discussion about its legal status as a liability distributor of 
pharmaceutical risk.  
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 Hart, 2004: 470. 
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2. Use safety and residual risk 
 
Safety regulation cannot guarantee absolute risk-freeness of the pharmaceutical 
product, but only a general positive risk/benefit relationship, therefore each drug is a 
potential chance and risk for the patient’s health at the same time.415 Through risk 
prevention norms, safety regulation aims to guarantee the highest possible level of 
safety, without inhibiting the production and distribution of pharmaceutical 
technology. The risk margin left as a price for the beneficial effects expected is 
therefore the result of a general evaluation, which needs further consideration prior 
to prescription to the single user.  
With the general safety judgment (“Unbedenklichkeit”) about a pharmaceutical 
product, it is yet said nothing about its safe use.
416
  
For each individual, in fact the same product can be associated to a different 
risk/benefit evaluation depending both on product characteristics, and on the patient 
condition and predisposition to side effects. The more severe is the illness, the higher 
is the allowed toxicity level of the drug; the higher is the patient’s predisposition to 
side-effects specific to the drug under consideration, the more negative becomes the 
individual risk/benefit assessment. A drug which has a general positive risk/benefit 
evaluation can show a negative risk/benefit profile for a specific user. The 
prescription of such an approved drug is considered medical error. The doctor’s task 
consists in minimizing the therapeutic risks by choosing the product which best suits 
the patient’s risk profile for the required indication.  
Pharmaceutical firms are liable for product safety; the doctor is liable for therapy 
safety.
417
 This implicates that he is supposed to keep updated about the level of 
safety of the pharmaceutical offer, and to make the optimal choice under the 
perspective of an individual evaluation of the risk/benefit profile tailored to the 
patient.
418
  
 
The medical prescription is the means through which the doctor acts as a filter 
between the products offered by the pharmaceutical market (and the general 
risk/benefit evaluation associated to them) and the single patient with his personal 
risk profile. The doctor must “translate” the general risk assessment into a concrete 
one, and evaluate on this basis whether the concrete risk for the individual exceeds 
the expected benefit.
419
  The doctor should assess a tailored risk prognosis by 
integrating statistical data registered in product information with patient’s 
information as acquired through anamnesis and other diagnostics.
420
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417
 Hart, 2003, 603. Francke, Hart, 1999: 60. 
418
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 In Bayesian terms, this equates to updating the risk probabilistic hypothesis delivered by frequency data 
related to the product on the basis of patient’s data. For the Bayesian approach regarding the interpretation 
and updating of probabilistic data with reference to pharmaceuticals see chapter 6. 
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Figure 11:  The distribution of residual risk in the pharmaceutical therapy 
 
The drug profile is evaluated in connection to the patient considered for prescription, 
and only if it results in a positive individual risk/benefit evaluation, is the drug 
considered adequate for therapy. Therefore side-effects which are considered 
tolerable in consideration of the product benefit in general (drug residual risk) can 
be judged intolerable when related to a particular therapy for a specific user. This 
can be the result of several factors: the severity of the illness can be of such a level 
that does not demand for dramatic measures, or the patient seems to be sensitive to 
the most severe side-effects, etc. It is the doctor’s task to judge all these aspects and 
decide whether the individual residual risk represented by the drug can be justified 
by a corresponding benefit.  
 
Medical sciences have greatly developed in diagnosis expertise and technologies; 
and also pharmacology has greatly increased its battery of research instruments and 
methods.
421
 Still, the healing course and therapeutic (medium to long) term effects 
depend on such a complexity of factors that no guarantee of success can be provided 
in advance. Genetic predispositions, health history, compliance, drug sensitivity, and 
possible interferences with other drugs a. o. constitute a network of risk factors, 
whose end-effect cannot be predicted.  
The threshold line between product faultiness and product “residual risk” is based on 
a general risk/benefit evaluation (§ 5 II AMG); the threshold line between 
prescription error (medical malpractice) and therapy “residual risk” is established 
through reference to medical standards.  
In analogy to drug residual risk, therapy residual risk is the risk considered 
unavoidable in order to reach the benefit promised by the treatment under 
                                                 
421
 The progress in diagnostics has not been accompanied by equal developments in etiology 
(understanding why illnesses emerge at all) and therapy: only 20% of currently known diseases are treated 
causally, the remaining 80% is treated symptomatically (Krudop-Scholz, 2005: 43).  
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consideration. It is not covered by liability compensation, because it is considered 
the exchange price to be paid for the received benefit.
422
  
Avoidable risk instead is represented by damage which can be prevented either 
through doctor’s compliance to medical standard, and/or through patient’s 
compliance to doctor’s instructions. 
In all cases communication has an essential role in distributing responsibility about 
the risk associated to the therapy.  
 
Because residual risk must be shouldered by the beneficiary party, product 
information responds not only to safety instances, but also to the requirement of self-
determination. The Summary of Product characteristics (SPC) – product information 
for the doctor – should help the doctor determine whether he wants to dare the 
prescription; less clear is the role of PLs, because the patient principally receives self-
determination information from the doctor.  
 
 
3. Pharmaceutical risk communication to the patient 
 
The patient is directly addressed by risk communication fundamentally through two 
channels: the pharmaceutical firm (PL), and the doctor.  
Moreover, the legal system in which patient information takes place is guided by 
two fundamental principles: safety and decision autonomy. Safety regulation 
protects life and health; self-determination norms are the corollary to autonomy 
rights. 
As a consequence, both doctors and PL information are supposed to warrant the best 
possible protection of health, while at the same time allowing for an autonomous 
decision. 
Both information generators have a specific collocation within the legal system. 
Nevertheless, little consideration has been devoted by the literature to the 
consequences of their interplay, and ultimately to the role of PL in this setting.  
 
The doctor is supposed to inform the patient about the risks connected with the 
therapy: this information forms the basis of his correct behavior during the therapy 
(safety information), and of his decision whether he prefers to undergo the therapy or 
the illness risks (information for self-determination).  
The double filtering task, which the doctor is supposed to accomplish – tailored 
product prescription and information –; can be represented through the following 
diagram: 
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Figure 12: Double filtering tasks in medical prescription: product and information selection 
 
The choice of a pharmaceutical therapy entails several specific tasks in comparison to 
the surgical intervention: the doctor is responsible for effectiveness and safety of the 
individual therapy, and is supposed to prescribe the most suited product to the single 
user. This implicates an overall knowledge of the pharmaceutical environment 
(pharmaceutical characteristics and benefit/risk profiles of products relevant for the 
indication under consideration): on the basis of this knowledge and the information 
concerning the patient, he must select the product which optimizes the individual 
benefit/risk profile of the patient.
423
 In a conservative therapy, for instance, an 
erroneous prescription (wrong indication, dosage or duration) constitute a breach of 
professional duties.
 424
 
 
A second filter is than constituted by the selection of information to be delivered to 
the patient for participating in the decision.   
Also information must be selected and tailored to the individual. First of all, not all 
the potential risks affecting a therapy or a medical intervention are foreseeable; 
secondly also predictable risks cannot and need not to be completely communicated 
in the context of doctor-to-patient consultation. Just the contrary: the information 
must be attuned to the need and capacity of the receiver and eventually foster a shared 
decision making process.
425
  
 
                                                 
423
 Francke; Hart, 1999: 51. 
424
 Product quality and prescription quality constitute the two pillars of a dual drug safety system. Hart, 
2003: 603 ff. 
425
 Deutsch,  2003: 102. BGH NJW 1971, 1887; NJW 1974, 1422 (1423); NJW 1983, 333. See chapter 3 §§ 
4, 8 on the theoretical distinction between counseling and informed consent model.   
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However, in the case of pharmaceuticals, the doctor is not the only source of 
information for the patient. Safety law establishes that the drug be accompanied by 
detailed product instruction (§ 11 AMG), and liability regulation foresees sanctions 
for damage, originated by information faultiness (§ 84 I 2 AMG; § 823.1 BGB). In 
reality, the official motivation provided by the legislator in introducing the 
requirement of product information within AMG is not related to self-determination 
and freedom rights, but rather to safe use.
426
 
Nonetheless, because of tort liability norms connected to product instruction, the 
function of this information goes beyond the mere indication of caution measures, 
and assumes the function of a disclaimer for residual risk.
427
 
Since 1986, through the distinction between expert and lay information in the second 
AMG amendment, product information directly addresses the patient. But because of 
the general duty to inform imposed principally on the doctor, the legal status of this 
information is still not clearly assessed.
428
  
 
The first discussion of this issue has been generated by two recent court decisions,
429
 
which have aroused heated debates among legal theorists. The sentences implicate 
that PL or written information can surrogate doctor’s risk disclosure. They explicitly 
declare that it is part of the patient’s self-responsibility to become knowledgeable of 
the information contained in the PL, and therefore discharge the doctor from damage 
liability.
430
 
A third sentence has been emanated recently and reestablishes the doctor’s primary 
duty to inform and the subsidiary function of PLs.
431
 
These contradictory views on the role of PL within the therapeutic communication 
context demand for a deeper investigation of its legal status and communicative 
function. 
 
Sentence LG Dortmund 6. 10. 1999 
The case concerns the information about thrombosis risk related to the intake of a 
mixed compound of estrogen and progesterone. The patient, a paralyzed woman, 
was suffering under menstrual disturbs in the form of uninterrupted bleedings. Soon 
after three days of therapy she experienced beneficial effects. The therapy was not 
interrupted after these first signs of healing, and the patient went on taking the drug 
according to the prescription. Unfortunately, after two weeks she felt strong pains at 
the link leg, and recovered in a community hospital, where it was established, that 
she had been hit by thrombosis.  
                                                 
426
 Reasons grounding the government bill of the 3
rd  
AMG amendment. Printed in Kloesel, Cyran, 
Arzneimittelrecht Kommentar § 11 AMG. V. Hart, 2003, 605. 
427
 Koyuncu, 2006: 345. 
428
 Hart, 2003: 605. 
429
 BGH NJW 2000, 1714 and LG Dortmund, MedR 2000, 331. Through these sentences, the relationship 
between PL and doctor’s information has been addressed for the first time: “Erstmalig wurde von 
Rechtsprechungsseite das Verhältnis von ärztlicher Aufklärungspflicht und Packungsbeilage thematisiert 
und definiert”: Krudop-Scholz, 2005: 21.  
430
 LG Dortmund 6. 10. 1999, MedR 2000, 331: “Den Patienten trifft die Pflicht, sich durch verständliche 
Beipackzettel über die Risiken einer Medikation zu unterrichten” also cited in Rehman, 2003: 92. 
431
 BGH 15. 3. 2005, NJW 2005, 1716 (1718). 
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The patient had not been informed about this eventuality by the doctor, and did not 
read the PL, where an explicit warning was devoted to this risk.
432
 
The court has rejected the law suit against the doctor for breach of information duty 
and has grounded this decision on the assumption that, the patient could and should 
have got notice of the thrombosis risk through the PL. The court acknowledges that 
the patient must be informed about the risk connected to the therapy, but it is denied 
that this task must exclusively be performed by the doctor. Given that the 
pharmaceutical company includes in the drug packaging an information text 
specifically directed at the patient – in fact § 11a AMG explicitly separates expert 
from patient information – than, risk information takes place also through the PL. 
The doctor is obliged to provide risk information to the extent that it is not already 
delivered through the PL. With the due exceptions (aggressive drugs, incomplete 
information), the PL substitutes doctor’s information. 
 
A recent sentence has instead re-established the primacy of the doctor over the PL as 
an information source for self-determination: 
 
Sentence BGH 15. 2. 2000
433
 
The sentence concerns a case of polio vaccination, for which the consent is not 
considered invalid by the prosecutor, even if not obtained through a face to face 
conversation. The case does not specifically regard PL information, but, in parallel 
with the preceding one, the doctor is discharged from liability, because written 
standard information is considered sufficient for consent to be valid.
434
 This form of 
communication is however considered legitimate and adequate under the provision 
that the therapy is familiar to the patient because of its routine character. It is 
explicitly recognized that information consent formularies cannot substitute risk 
communication through the doctor, in that the doctor is supposed to verify, whether 
the patient has taken knowledge of the formulary content. The patient must be 
granted the possibility to eventually ask for further information and clarification.
 
 
  
 
Sentence BGH 15.3.2005
435
 
This is the last sentence to date, which concerns the relationship between doctor and 
PL information. The case is more complex than the preceding ones, because the 
damage (thrombosis) has not been caused by the drug itself (an hormone 
preparation), but by the drug interference with nicotine, the eventuality of which had 
not been sufficiently stressed by the doctor in the consultation phase.  
Information about correct behavior belongs to safety information, however the 
courts underlie that the doctor has to respond also for failure to provide information 
                                                 
432
 „Die Einnahme von Geschlechtshormonen ist mit einem erhöhten Risiko venöser und arterieller 
thrombo-embolischer Krankheiten … zum Beispiel venöse Thrombosen … verbunden. Dieses Risiko kann 
durch zusätzliche Faktoren … erhöht werden … Bei längerer Bettruhe kann die Gefahr einer 
Bluttropfbildung (Thrombose) bestehen.“ From the sentence acts: LG Dortmund, MedR 2000, 332. 
433
 BGH NJW 2000, 1787. 
434
 BGH NJW 2000, 1784 (1788). 
435
 BGH 15. 3. 2005, NJW 2005, 1716 (1718).  
 141 
for self-determination, drawing on the argument that this failure would equate to a 
lack of informed consent.  
As for the charge of lack of informed consent, the court of first instance and the 
Court of Appeal (OLG Rostok) equally reject it, on the basis of two elements: 
1. decision conflict: from the prosecutor’s examination it results that if adequately 
informed about the risks connected to the interference between drug and 
smoking, the prosecutor would have stopped smoking, therefore she would have 
taken the same decision of making the therapy (she would have not found in a 
decision conflict); 
2. PL information: the PL did contain warnings which emphasized the risk of 
thrombosis. Moreover the PL explicitly cautioned from smoking precisely the 
risk group to which the patient belonged to (smoker and 30 years old or more).
436
 
 
The Supreme Court rejects both points as follows: 
1. the prosecutor’s assertion that, if adequately informed, she would have stopped 
smoking rather than decide not to take the drug, does show a lack of decision 
conflict, but also that the missing information has been causal to the damage: 
had the risk been adequately disclosed, the patient would have behaved 
consequently and the damage would have not occurred; 
2. the information contained in the PL is not sufficient for patient’s self-
determination. Precisely in the case where the patient belongs to a specific risk 
group, and where the risk is typical for the prescribed drug, special attention is 
needed for making sure that the patient is aware about damage which can be 
determinant for their life quality. Especially in the case of wrong behavior such 
as smoking addiction, the doctor cannot rely on the supposition that the patient 
will read and follow the instructions contained in the PL. The simple intimation, 
that “pill and smoking do not stand each other” does not display with sufficient 
force the entity of the health consequences implicated by the interference of 
treatment and smoking habits.
437
 
 
With reference to this sentence it can be noticed, that the information would have not 
been material to the decision of taking the drug or not, but to the decision of quitting 
smoking. Therefore the lack of information has been causal to the damage rather as a 
failure of therapeutic information (safety information), than as a lack of information 
for autonomous decision.  
The reason for which lack of informed consent gives right to compensation is that 
the patient must suffer a damage that was not taken into account during therapy 
choice because not disclosed by the doctor.  
The difficulty lies here in the fact that, indeed the risk had not been disclosed and 
therefore could not have been possibly taken into account in the risk/benefit 
                                                 
436
 „Bei Raucherinnen, die östrogen-gestagenhaltige Arzneimittel anwenden, besteht ein erhöhtes Risiko, an 
zum Teil schwerwiegenden Folgen von Gefäßveränderungen (z.B. Herzinfarkt, Schlaganfall) zu erkranken. 
Das Risiko nimmt mit zunehmendem Alter und steigendem Zigarettenkonsum zu. Frauen, die älter als 30 
Jahre sind, sollen deshalb nicht rauchen, wenn sie östrogen-gestagenhaltige Arzneimittel einnehmen“. 
From the sentence acts: BGH 15. 3. 2005, NJW 2005, 1716.  
437
 BGH 15. 3. 2005, NJW 2005, 1717 
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evaluation prior to decision. However, it was not a risk pertaining to the drug alone, 
but to the simultaneity of drug taking and smoking (“and” cause).  
Therefore, in this case the information would have been material to the decision, 
only under the condition that the patient would have had reserves in choosing the 
treatment, precisely because of this information. Yet, the lack of decision conflict, as 
it results from the examination, does not allow for this interpretation: the missing 
information can be therefore classified only as safety information, whose omission 
does not constitute a lack of informed consent.  
 
The flaw contained in this sentence reflects the increased tendency to interpret 
counseling information as self-determination information.  
The diversity of judgmental positions on this matter in general echoes the vagueness 
of the concept of self-determination pointed out at the end of the previous chapter 
and translates in flexible interpretations of the information requirements for consent 
validity.  
The role played by product instruction (PL) nearby doctor’s information comes 
therefore to be all the more vague and difficult to assess.  
Two questions underlie in general the definition and evaluation of the PL legal 
nature in the therapeutic context: 
1) the legal task(s) which it is supposed to accomplish; 
2) the congruity of PL texts to the prescribed tasks. 
 
 
4. The legal status of PL information  
 
4.1 Regulation of PL information  
 
Besides the existence of unavoidable risk affecting drugs safety, this risk is also 
difficult to avert because the pharmaceutical product is particularly opaque. No 
external cues (form, taste or color) can help the user recognize product faultiness. 
Moreover its inscrutability is greatly enhanced by the complexity of its chemical 
structure. This is the reason why product information concerning pharmaceuticals 
has paramount importance and a special place in pharmaceutical regulation.
438
  
The history of pharmaceutical regulation shows the increasing importance assigned 
by the legislator to product instruction as a source of safety information nearby the 
doctor. The result is that even if the PL is a vehicle of communication between 
pharmaceutical company and patient, its information and textual design is 
predominantly due to the legislator, to whom – more than to the company – the merit 
or the blame of a high/low product information quality should be ascribed.  
 
In the origin, no information at all was provided together with the product. Drug 
regulation before 1961 did not even prescribe information to the doctor, which was 
facultative and consisted generally in a list of chemical composition and therapeutic 
indications (often written in Latin). With AMG 1961 a labeling duty is introduced, 
and 1976 AMG stipulates the obligation to accompany the product with specific 
                                                 
438
 Krudop-Scholz, 2005: 148. 
 143 
information:
439
 § 11 AMG
440
 prescribes that pharmaceutical products as defined by § 
2 AMG  must be accompanied by a package insert with the title “Information for 
use” (“Gebrauchsinformation”), whose content must be continuously updated along 
the state of medical and pharmaceutical knowledge. 
 
The norm establishes content and sequence of the information, which must include: 
name of the product (§ 11 I 1 Nr. 1); components (nr. 2); form of intake (nr. 3); drug 
category or effect type (nr. 4); name of the pharmaceutical company and producer (nr. 
5); indications (nr. 6); contraindications (nr. 7); precautions (nr. 8); interferences with 
other drugs or food (nr. 9); special warnings (nr. 10); drug dosage and therapy 
duration according to patients groups (nr. 11); countermeasures in case of overdose, 
intake omission, or early therapy interruption (nr. 12); all side effects and related 
countermeasures, plus the indication that the patient is asked to refer to the doctor any 
drug reaction not enlisted in the PL (nr. 13); date of expiry (nr. 14)
441
; last 
information update (nr. 15).  
In particular, specific risk groups must be separately addressed when 
medical/pharmaceutical knowledge requires special precautions for them (for instance 
risk incidence is significantly higher). It must also be warned against misuse and 
abuse by clarifying eventual consequences, when this can represent a concrete 
possibility. This also includes eventual alert about attention decrease and reduced 
driving capabilities. 
Additional information – except for advertising messages – is allowed insofar as it is 
distinctly separated from official information (§ 11 V AMG); it is forbidden to tone 
down risk information through additional messages: additional information must be 
clear and objective (“sachlich”).442 
 
The following diagram illustrates the sources of information from which SPC and 
indirectly PL, derive their content: 
 
                                                 
439
 The 1976 German Medicines Act follows in this respect §§ 13 – 20 of the Council Directive 65/65/EEC 
and §§ 6 – 7 of the Council Directive 75/319/EEC according to which the inclusion of package leaflet shall 
be obligatory. For more details see a. o. Krudop-Scholz, 2005: 148-151 and Holz-Slomczyk, 2006.  
440
 § 11 AMG is the national implementation in the German safety system of the European guideline 
92/27/EEC.  
441
 For plasma derivatives § 14a AMG prescribes the indication of the plasma-blood. 
442
 Rehmann, 2003: 99, Rn. 16. 
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Figure 13: Information sources and contributors to SPC and PL content. Source: Blasius, 2005: 
62. 
 
The factors contributing to SPC and PL information are integrating part of the risk 
management and prevention system. This is a result of the high value conferred by 
safety regulation to risk communication (see chapter 1). The PL text must comply 
with the exemplar provided as part of the documentation for approval (§ 22 VII 
AMG) and any modification must be promptly notified to and approved by the 
authority (§ 29 I 2a); the authority can also directly influence PL information by 
ordering the addition of special warnings (§ 28 II nr. 2 AMG). 
 
Safety norms of product instruction are also ratified on a liability level:
443
 AMG 
sanctions the circulation of pharmaceuticals without product instructions (§ 97 II 5 
AMG) and violation to information duties and scientific updating is also sanctioned 
through appeal to compensation charges regulated by civil norms of liability (§ 84 I 1 
nr.2 AMG).  
Precisely liability norms related to product instruction and regulating the 
responsibility distribution of residual risk confer PL information the status of 
information aimed at patient’s autonomy in the evaluation of the risk associated to the 
therapy,
444
 in analogy to the information for self-determination provided by the doctor 
about residual risk.
445
 
This is especially valid for information about adverse reactions, which are explicitly 
defined in § 4 AMG as the undesired side-effects possibly produced by drug intake 
(residual risk). Given that unavoidable risk must be shouldered by the patient in case 
                                                 
443
 See also Koyuncu, 2006: 347; 2005b: 295; Blasius, 2005: 62. 
444
 Heitz, S. 2004: 271. 
445
 See Koyuncu 2005b: 291. 
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he has been previously informed about it, this information comes to acquire the status 
of self-determination information.  
Another element confirming the legislator’s intention to assign pharmaceutical 
product instruction also the value of information for decision is point 13.1 of the 1994 
BfArM recommendations for PL information, where it is suggested to indicate 
whenever possible the frequency of side effects, in order to facilitate the patient in his 
risk estimation.
 446
  
Also court decisions have soon established the duty of pharmaceutical product 
information as a requirement determined by the user’s right to self-determination. In 
the Contergan sentence, the distribution into the market of pharmaceutical products, 
which are presumed to cause damage, has been compared to an invasion of bodily 
integrity.
447
 The responsibility to inform the user (doctor and patient) derives from the 
established or presumed dangerousness of the pharmaceutical product, and the 
consumer’s right to decide, whether to undergo the risk connected to it or not, in face 
of the expected benefit.
448
  
Therefore, along the distinction between avoidable and residual risk, and the role 
assigned to PL information within medical therapy, the communicative function of 
PL information with regard to drug consumer is twofold: 
1) instruct the reader as to the measures to be undertaken for averting avoidable 
risks associated with misuse (safety information); 
2) disclose residual risk unavoidably connected with drug use, as to provide the 
drug consumer with risk and benefit data for an informed decision (information 
for self-determination – informed consent).  
PL information follows the same principles and rules illustrated for the liability 
regime regulating doctor’s information duty.449 As a consequence, the congruity of 
PL texts to their institutional task depends on their capacity to promote safety and 
foster an informed consent.  
 
 
4.2 Legislator’s initiatives for readability improvement  
 
The patient’s involvement in the therapeutic decision is indirectly stressed by the 
legislator’s efforts towards readability improvement and user-friendliness. These are 
based on a long-lasting tradition in textual analysis and linguistic studies.
450
  
The requisite of readability derives from the regulation teleology itself and is also 
been explicitly required by § 11 I 1 AMG
451
, which prescribes that information must 
be delivered in comprehensible German and in readable form.  
Both at European and at national level PL content, language and layout have been 
submitted to severe scrutiny and revision. 
                                                 
446
 “die Häufigkeit bei allen Nebenwirkungen, bei denen es möglich ist, [soll] in der Packungsbeilage 
angegeben werden. Damit soll dem Patienten die Einschätzung des Nebenwirkungsrisiko erleichtert 
werden“. Cited in Scheu, 2003: 705-06 (my emphasis).  
447
 LG Aachen, 18.12.1970, JZ, 71: 515. 
448
 LG Aachen, 18.12.1970, JZ, 71: 515. 
449
 For details: Krudop-Scholz, 2005: 123-134; Francke, Hart, 1999: 133-136. 
450
 See next chapter for a brief overview. 
451
 Besch, 2000: 70.   
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In Germany, through the 3
rd
 amendment to the AMG in 1988 the competent authority 
has established the use of model texts (“Mustertexte”). Standardization has also 
concerned the terminology for frequency classification of adverse drug reactions, 
which goes back to 1991.  
With the 5
th
 amendment to AMG in 1994, the European Directive 92/27/EEC is 
definitively implemented in the national law. The 92/27/CEE directive (31. 3. 1992) 
represents a milestone in the development of pharmaceutical labeling. It provides a 
detailed list of information contents that the PL text must cover (particularly at point 
3 of art. 7 and in art. 8) and invites to a closer connection with the layman medical 
background (the notion of “health literacy” is explicitly mentioned).  
 
In 1998  “A Guideline on the readability of the Label and Package Leaflet of 
Medicinal Products for Human Use” has been emanated as a valid companion to an 
enhanced patient information quality. The document presents a set of examples and 
provides a guideline for testing PL readability. 
452
   
The European Readability Guidelines have been recently enforced through the 
2004/27/EC directive and implemented nationally through 14
th
 AMG-amendment
453
. 
These order the performance of readability tests for PLs as part of the procedure for 
drug approval. Tests should examine following parameters: readability, patient-
friendliness, and easiness to find relevant information. With this amendment the 
legislator increases the company’s responsibility in the improvement of text-design 
and information management, and generally legally ratifies the readability requisite 
independently from conformity to the standard texts laid down by authority.  
 
However several questions arise as to the competence of the lay reader in 
understanding not only the meaning of the information provided in PLs, but more 
importantly the (medium or long-term) health implications entailed by a specific 
therapy. Moreover the frequency terms with which risk information is delivered 
(incidence rate of side-effects) raises the question of the interpretation of 
probabilistic information and its contribution to a personal therapeutic decision.  
 
Also recently the BfArM has organized a seminar for investigating the state of the 
art as for PLs readability and patient friendliness.
454
  
The lecturers have stressed that readability and especially patient-friendliness does 
not reduce to the translation of medical jargon into common language: 44% of the 
PL in circulation are by now compliant with the European Readability Guidelines, 
but this does not mean that they are patient-friendly.
 455
 Consumer sovereignty and 
decision autonomy does not only depend from reliable and comprehensive 
                                                 
452
 More on this guideline in chapter 5 § 3. 
453
 § 22 VII, 2 AMG in the 14
th
 AMG-amendment declares: “Der zuständigen Bundesbehörde sind bei 
Arzneimitteln, die zur Anwendung bei Menschen bestimmt sind, außerdem die Ergebnisse von 
Bewertungen der Packungsbeilage vorzulegen, die in Zusammenarbeit mit Patienten-Zielgruppen 
durchgeführt wurden.” This integration is due to § 61 I of the modified European directive 2001/83/EC. 
454
 http://www.bfarm.de/cln_042/nn_599148/DE/BfArM/Publikationen/Praesentationen/060215-
Dialog.html Bonn, 15.3.2006. 
455
 Buchberger, 2006: 35-36 
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information. Readability and usefulness of information to the user is as important as 
complete and truthful communication.
456
 
Overviews of established readability tests have been offered and new methods 
proposed.
457
 In general it is suggested to conceive PLs not as isolated information 
supports but as a part of a communication framework. Moreover the presentation of 
drug benefits should compensate the disclosure of risks, so as to prevent frightening 
effects.
458
   
 
 
4.3 Responsibility spheres for pharmaceutical damage  
 
In order to better understand the role of risk communication within the liability 
framework, I present a synoptic scheme which integrates doctor’s liability (red) and 
company’s liability regulation (black).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Algorithmic scheme of liability compensation for instruction failure in case of health 
damage (red: doctor’s liability; black: pharmaceutical firm’s liability).  
                                                 
456
 Nink, Schröder, 2006: 2. 
457
 Fuchs, 2006. See also Fuchs, 2005, Fuchs et al. 2003; 2004. 
458
 Reimann, 2006: 17. 
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The scheme outlines main norms regulating pharmaceutical liability as they have 
been presented throughout chapter 2 and 3. The conditions for damage compensation 
are: 
1. medical error (erroneous prescription); 
2. or intolerable damage; 
3. or, if tolerable according to the general risk/benefit evaluation, it is considered 
not irrelevant and 
a) product information has failed to warn against it even if it was a risk under 
information duty (either as safety or as self-determination information); 
- and, the information failure has been causal to damage: the patient would 
have decided/behaved in a different way 
b) or, the doctor has failed to warn against it even if it was a risk under 
information duty (either as safety or as self-determination information); 
- and, the information failure has been causal to damage: the patient would 
have foun himself in a decision conflict/would have followed a safe 
behavior.
459
 
The liability role of PL emerges for all risks which are mentioned in the PL, and 
must not be disclosed by the doctor for information duty: these risks fall entirely in 
the realm of the patient’s responsibility.  
Therefore, the detailed information which cannot be provided by the doctor must be 
acknowledged and taken into account by the drug user. In this sense all the 
information included in the PL is relevant from a liability perspective.  
The following diagram illustrates responsibility distribution for drug residual risk as 
it is configured by risk information liability: 
 
                                                 
459
 The condition of causality for PL information vs. the requirement of decision conflict for doctor’s risk 
disclosure have a remarkable impact in the procedural context. In this respect PL information is rather 
comparable to product information (ProdHaftG) than doctor’s information. See Deutsch, 1989: 856, for a 
discussion of the legitimacy of this procedural setting. Charges related to the assessment of consent validity 
are decided upon psychological causality, which cannot rely upon deterministic computations but is rather 
based on the probabilistic evaluation that an instruction would have changed the behavior/decision of the 
reader or not. In the special case of pharmaceuticals, all the more when prescribed by the physician, the 
condition required to the patient that the information would have induced him to make another decision 
seems a challenge which is impossible to satisfy.  
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Figure 5: Liability distribution for residual risk among pharmaceutical firm, doctor, and patient. 
The patient is called to shoulder all the residual risk mentioned in the PL, whether or not 
belonging to the realm of doctor’s information duty. 
Given that the doctor is obliged to give all relevant safety information, there would 
be no safety instructions in the PL, which are not covered by the doctor’s 
information liability (“Sicherungsaufklärung”); instead not all possible residual risks 
are part of the doctor’s information duty, but only a tailored selection of drug side 
effects must be given to the patient in order to respect the patient’s right to self-
determination. The analysis of liability distribution provided by figure 5 shows that 
the remaining residual risks not covered by the doctor’s information duty fall in the 
patient’s responsibility.  
Consent to the doctor equates to a global approval to therapy. Detailed information, 
which cannot and need not be disclosed by the doctor is also part of the consent and 
is provided by the PL. By taking the drug, the consumer accepts also the risks 
enlisted in the PL warnings and not mentioned during consultation.  
Whenever damage follows, which do not result from prescription errors, and the 
mention of which was not part of doctor’s professional duties, the patient has no 
right to compensation, if they are included in PL information.  
Therefore, PLs have a specific role in the distribution of liability related to 
pharmaceutical residual risk.  
 
 
4.4 Pharmaceutical informed consent  
 
A first problem hindering the qualification of PL information as information for 
consent is related to formal questions regarding the procedure of consent giving. 
Conservative treatments such as pharmaceutical therapies are generally decided in the 
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consultation and begin only after buying the drug in the pharmacy. Consent is given 
to the doctor in the surgery, and PL information is generally acquired after the 
decision has already been taken (just a moment before drug intake). This raises 
questions as to its binding force. Furthermore, for the same reason, the doctor is not 
legitimated to accomplish his information duty by simply referring the patient to the 
PL.
460
 
 
It has been recently advocated to solve some of the formal questions related to the 
legal nature of PL information by creating a special IC model for pharmaceutical 
therapy as distinguished from the classical IC model developed around cases of 
surgical interventions.
461
 The justification for creating the special institute of 
pharmaceutical informed consent derives from two main reasons:  
1. In surgical interventions, not only the therapeutic decision, but also its execution 
is in the doctor’s sphere, whereas in the pharmaceutical therapy, the doctor has no 
direct influence in the cure.
462
   
2. Also from a legal point of view, the task of informing the patient about the risks 
connected to the treatment is not only performed by the doctor, but also by the 
pharmaceutical firm through the PL.
463
  
 
The two points are interconnected, in that the patient is called to actively participate 
in the therapy success both behaviorally and also by taking notice of product 
information which is directly addressed at him. Co-participation in the therapy 
equates to an assumption of responsibility both as for compliance to doctor’s 
instructions (point 1), and as to compliance and therefore acquisition of PL 
information (point 2).  
Because the PL content does not limit to safety information and special warnings, 
but also include information about residual risk, the co-participation requirement 
translates in an assumption of responsibility for this risk when it has been adequately 
communicated.  
As an objection to the point according to which, consent as already been provided 
during consultation, it is asserted that, precisely for that reason, the classical IC 
model should be modified and reconfigured. Because PL information comes on its 
own, when the doctor’s responsibility sphere has been left, but before drug intake, 
then consent should be subdivided in two phases:  
 
1. preliminary consent to doctor’s prescription during consultation; 
2. concluding consent to the drug by taking it.464   
 
Information for consent to be valid comes in the first phase from the doctor and in 
the second phase from the PL.  
                                                 
460
 Hart, 2003: 606. 
461
 Koyuncu, 2006: 344 ff.; 2005b: 295 ff. 
462
 Koyuncu, 2006: 343, 344. 
463
 Koyuncu, 2006: 343. 
464
 Koyuncu, 2006: 344; 2005a: 76; 2005b: 291 ff. 
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This setting stresses patient’s responsibility in taking notice of PL information. From 
the fact that information failure must be causal to damage follows that the patient 
must have taken notice of it: whenever this does not happen, than no right to 
compensation can apply even if the information was faulty.  In analogy to the 
implicit or explicit waiver for doctor’s information, failing to read PL, while taking 
the drug, can be considered as a waiver towards pharmaceutical information 
delivered from the pharmaceutical firm. This implicates, in case of damage, the 
renunciation to compensation.
465
  
 
Although the pharmaceutical informed consent model provides a technical 
contribution to the clarification of liability litigations related to the conflict of 
responsibility between doctor, pharmaceutical firm and the patient, nevertheless it 
does not touch deeper problems affecting the congruity of PL information to the task 
of enabling an autonomous choice.  These problems are inherent to its actual 
contribution to lay health decision making. 
 
 
4.5 Prima facie objections against PL information as a basis for informed 
consent 
 
The use of PL information as a tool for patient’s participation and co-responsibility 
in therapeutic decision faces however diverse problems, both from the formal and 
from a substantial point of view.  
Main objections raised against PL information are the following: 
 
1. Incomprehensibility of technical language and lay incompetence in dealing with 
pharmaceutical information. This aspect has been addressed in several occasions by 
the legislator. However both linguistic and empirical studies continue to emphasize 
the low readability level of PL texts and their reader unfriendliness. 
 
2. Lack of risk information tailoredness. The basis for any decision under 
uncertainty, as it is therapeutic choice, is an evaluation of the different options 
available in consideration of the risks connected to them and the beneficial 
consequences.
466
 A rational choice presupposes a comparison of benefits and risks 
weighted by the concrete possibility of occurrence. An abstract probability, say 
1:10
6
, derived from statistical surveys, is of little value for someone considering the 
eventuality of incurring in a certain risk. It is precisely the doctor’s task to translate 
statistical data into a reliable prognosis for the individual. Only he has an overview 
over patient’s organic constitution, health history and other therapies in course, 
additional medications, all essential information for assessing reliable risk estimation 
                                                 
465
 Koyuncu, 2006: 346. Koyuncu 2005a: 79 qualifies this situation also as contributory negligence 
(„Mitvershulden“): this however can only be applied to the safety aspect of product information. For self-
determination information, it should be better categorize failing to read PL information as waiver 
(renouncement to risk disclosure).  
466
 See second part of this work for an introduction to decision theory. 
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about the general risks connected to the drugs. In this respect, the PL cannot possibly 
substitute him.
467
  
PL information grounds on a toxicological-statistical concept of risk, whereas 
doctor’s information is based on a tailored evaluation of therapeutic risk, which is the 
adequate information for the individual decision.  
Hart underlines the safety aspect of product information within a framework which 
guarantees product quality and product safety through information to the doctor 
(therapy safety) and to the patient (use safety). The self-determination aspect instead 
is necessary mediated in this framework through doctor’s risk disclosure. The PL 
cannot substitute the doctor as a source for self-determination information, in that the 
principle of self-determination requires that the individual is made knowledgeable of 
his personal risk/benefit profile, whereas product information is necessary general 
and abstract.
468
 A decision can be considered autonomous, only if made on the basis 
of personally relevant information.
469
  
Therefore, it cannot be considered valid a consent given on the basis of information, 
which does not allow a personal estimation of the risks and benefits concretely 
implicated by the therapy:
470
 Consent is valid in the measure that the patient is aware 
of (short to long term) consequences and implications of his choice.
471
 
Therapeutic courses of the same pharmaceutical product differ substantially in 
function of illness severity, patient’s drug sensibility, etc. Therefore relevant 
information for decision can be very different from case to case even if the drug is the 
same. This is not only valid for dosage and duration or generally safety information, 
but also for the disclosure of risks.
 472
 It is indeed precisely the doctor’s task to 
provide the patient with a tailored estimate of the types of risks, among those listed in 
the PL, which might concern him, and with what probability.  
 
3. Conflict between the doctor’s and the patient’s risk/benefit evaluation.  
If PL information is given some legal value within therapeutic decision, than the 
question arises as to what contribution it should bring.  
If the PL brings an autonomous element to patient’s decision, than it should do it by 
providing him with a different basis for choice, than that provided by the doctor 
(risk/benefit assessment). This brings a contradiction within the decision process. 
Either should the patient rely in the doctor’s risk/benefit assessment; or else make a 
personal risk/benefit assessment on the basis of PL information, perhaps also 
different from the doctor’s one. In the first case, the contribution of PL information 
                                                 
467
 See Koyuncu, 2005b: 292; 2005c: 108. Hart, 2003: 605 ff. 
468
 See Hart, 2003: 605; Krudop-Scholz, 2005: 156. See also Stöhr, 2006: 148. 
469
 “Selbstbestimmt ist die Entscheidung dann, wenn die aus der Sicht des Patienten 
entscheidungsrelevanten Informationen zur Verfügung stehen”: Hart, 2003: 605. Information relevance for 
decision jointly depends on three factors: the information desire of the specific patient, the information 
typically expected by the standard patient, and a general information (“im Großen und Ganzen”) about 
risks which are specific to the treatment, and can have significant consequences for the patient’s life 
quality. (Hart, 2003: 605).  
470
 Krudop-Scholz, 2005: 160. 
471
 Krudop-Scholz, 2005: 162: „ … nur derjenige wirksam in einen Eingriff einwilligen kann, der sich 
dessen Bedeutung und Tragweite bewusst ist“. 
472
 See Krudop-Scholz, 2005: 157-158. 
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is equal to zero; in the second case, the eventual difference between personal and 
doctor’s risk/benefit assessments might lead to non-compliance.473  
 
4. Information about alternatives: as mentioned in the preceding chapter, doctor’s 
information about alternatives is limited in the informed consent model to options 
with an objective difference of risk/benefit profile. This constitutes a limitation in 
comparison to the counseling model. However, product instruction is exclusively 
limited to informing about the product to which the PL is enclosed. Any comparative 
information is totally lacking. 
This results in an exasperation of the IC model yes/no dynamic: if consent to doctor 
has been given with little or no knowledge of alternatives, consent to PL is given 
exclusively with information related to the prescribed product. As Wolz puts it: 
„When the user has it (PL) in his hands, than a decision about a specific treatment has 
already been made. Alternative drugs are not available or only with difficulty, so that 
often the decision reduces to a choice between taking this pharmaceutical product or 
not … Even optimal designed PLs cannot warrant the user an adequate ground for 
decision”.474  
 
5. Risk information overload: The list of side effects notoriously exceeds the relevant 
amount of risk information for the single user. In general it can be said that given the 
high preponderance of risk information
475
 in relation to data about benefit, any 
decision-maker should decide not to take the drug. Obviously this is not the intent of 
the legislator, and also the reader reasons that in some way the risk he is exposed to 
should not surpass the benefit.  
On the other side, the information provided cannot be simply neglected as totally 
irrelevant. In fact, PL information is generally declared as highly important by drug 
consumers:
476
 the tension between the sensation of information unmanageability and 
the high legal value results in contradictory attitudes towards this form of 
pharmaceutical information.  
The main difficulties lie indeed in selecting items of the information which are 
personally relevant and material to the decision. This can be a source of paralyzing 
uncertainty or non-compliance, when it does not lead to the general refusal of PL 
information.
477
  
This is also reflected in empirical data about drug consumption: each year 100 tons of 
pharmaceuticals for a value of 500 Mio. Euros go into the garbage. It is estimated that 
1/5 to 1/3 of the prescribed drugs are thrown away without even opening the blister. 
                                                 
473
 In this respect non-compliance can be considered as the result of the conflict between the patient’s 
perception of doctor’s authority and his perception of the PL’s institutional value as a vehicle of 
information endorsed by the responsible authority. 
474
 Wolz, 1988: 15, 16: “Hat der Verbraucher erst einmal in der Hand, so ist die Entscheidung für ein 
bestimmtes Medikament bereits gefallen. Alternativpräparate werden nicht oder nur unter Schwierigkeiten 
erreichbar sein, so das oft nur die Entscheidung zwischen Einnahme und Nichteinnahme dieses 
Arzneimittels bleibt … Auch inhaltlich optimal gestaltete Gebrauchsinformationen garantieren also nicht 
den Entscheidungsspielraums des Verbrauchers”.   
475
 There are PLs with more than 80 side-effects: Grandt et al., 2005: 511.  
476
 Nink, Schröder: 2005: 31 
477
 See Krudop-Scholz, 2005: 159-162. 
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Most of these are treatments against chronic illnesses, as for instance high blood 
pressure: this can be explained with the fact that users cannot estimate their benefit, 
because they do not feel any direct effect, and on the other side they have reservations 
in taking the drug for a long period because of the side effects listed in the PL.
478
  
 
In general the objections address two aspects of PL information: 
a. Its contribution to  
i) Informed consent;  
ii) Therapeutic safety; 
b. Its effects on the consumer’s confidence in the therapeutic decision 
(compliance). 
 
In order to provide a unitary account of these aspects, PL information will be 
investigated in the following chapters as peace of information embedded in a 
decisional context, precisely within the tools offered by Bayesian theory.  
This methodological choice is justified by the fact that Bayesian theory is the 
privileged discipline in order to account for decision making under uncertainty.  
In fact, the general question underlying the above mentioned points is that most of 
the information contained in the PL is difficult to decipher, even when literally 
comprehensible, because the patient is not capable to judge, whether he will be 
concerned by it or not, and what would concretely be the consequences for his life 
quality.  
In this respect, all main components of Bayesian theory (the theory of knowledge 
updating through probabilistic induction – Bayesian theorem – the theory of decision 
optimization through maximization of the expected utility; and the theory of 
information value) are relevant to our research.  
In this specific framework, this approach provides the instruments for analyzing PL 
information: 
-  as a basis for knowledge updating (probability of side effects occurrence) for a 
risk/benefit assessment about the drug;  
-  as a support for decision optimization based on the expected reward of taking the 
drug vs. not taking it;  
- finally, its perceived value can be estimated as a function of its expected 
contribution to decision optimization. 
 
 
5. Summary and conclusion  
 
This chapter has been devoted to the examination of the interplay between doctor’s 
and product information and to display the role of PL information within liability 
regulation. 
Doctor’s duties comprise drug use safety (optimization of risk/benefit assessment for 
the individual patient) and selection of adequate information for patient’s safe use 
and autonomous decision. 
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 Bronder, Klimpel: 2001. 
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PL information integrates doctor’s information with detailed therapy instructions and 
complete disclosure about residual risks. These are to be taken into account by the 
patient when undertaking the cure. As a consequence of the liability clause related to 
product information, PL acquires the legal status of information for self-
determination.  
As for the problems advanced to this categorization, some scholar propose to change 
the IC model inherited from surgical intervention into a two-phase IC model, where 
the patient consents to the prescription during consultation, and to the drug by taking 
it.  
This liability setting however exasperates the IC model, which is already blamable in 
doctor-to-patient communication with its yes/no dynamic. The patient is not 
provided with a comparison of possible alternatives, but only with full information 
of just one product, unrelated to any other. 
This setting is also critical because, a two-phase consent entails that the patient 
should, at least on principle, be put in the situation to question the decision already 
taken with the doctor on the basis of a risk/benefit assessment made personally on 
the basis of PL information (or by integrating doctor’s with PL information). In this 
sense, PL information represents rather a “decision interference”, and this is 
precisely what is lamented about with reference to non-compliance. 
In general consent should be reached “voluntarily, knowingly, and intentionally”.479 
PL information should be therefore evaluated on the benchmark of its contribution to 
choice awareness. In this respect, it is fundamental in any analysis of PL information, 
to investigate its contribution to an informed decision. Particularly, in order to 
analyze whether PL texts are adequate to accomplish their institutional task, a 
comparison is required between the decision model implied by the legislator and the 
concrete decision environment specific to therapy choice. 
The following parts of this work are concerned with the communicative and 
epistemic nature of PL information, as well as with the cognitive and behavioral 
aspects related to PL information processing. 
                                                 
479
 Kleining, J. (1982) “The Ethics of Consent” in K. Nielsen and S. C. Patten (eds). New Essays in Ethics 
and Public Policy (Canadian Association for Publishing Philosophy: 9-118, quoted in Cowart, 2004: 497. 
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PART II 
 
Communication and Decision 
 
 158 
 159 
 
5 Communicative status of PL information 
 
 
 
 
 
 
 
In the performance of an illocutionary act 
 the speaker performs the subsidiary act 
 of expressing the propositional content  
and this act we will call the propositional act.  
A propositional act is an abstraction from the total illocutionary act  
in the sense that the speaker cannot simply express a proposition 
 and do nothing more. 
 
John R. Searle & Daniel Vanderveken, Foundations of Illocutionary Logic, 1985. 
 
 
 
 
 
1. PL information and residual vs. avoidable risk  
  
The legal analysis of PL information has identified two tasks imposed on this type of 
product instruction, namely safety information and information for self-
determination (informed consent). 
The following part of the thesis is devoted to investigate the extent to which PL 
information can adequately absolve these two tasks.  
Health risk information and specifically package leaflets have been analyzed from 
different perspectives.  
Linguistic analyses have concentrated their focus on the identification of possible 
sources of uncertainty for the lay reader at different levels of text constitution.  
Also research on health risk information seeking behavior and processing has 
addressed drug information to the patient with a special attention to the uncertainty 
effect related to health risk disclosure.  
These studies implicitly address the core issue concerning PL information: namely 
the uncertainty affecting health decision making. 
In the present perspective, the distinction between residual and avoidable risk allows 
distinguishing two functions of risk disclosure, namely risk prevention and 
minimization with respect to avoidable risk, and risk disclosure so as to allow an 
informed decision with respect to unavoidable (residual) risk.  
The explicit distinction between warning (safety protection) and risk disclosure 
(right to self-determination) calls attention on the decisional aspect entailed in the 
disclosure of unavoidable risk, therefore opening the way to the identification of a 
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deeper source of uncertainty than that generated by text incomprehensibility, namely 
the epistemic uncertainty associated to the therapeutic decision.  
Thus, the legal analysis of PL information and the consequent identification of the 
two institutional tasks which it is supposed to accomplish allow clarifying the 
research question: does PL information constitute an adequate basis for informed 
consent and therapeutic safety?  
Furthermore this question also guides the selection of the most promising 
methodological tools in relation to the research issue at different levels: 
1. The institutional account of PL information allows the identification of its 
communicative status as a function of the agents involved, related roles and 
responsibilities. This perspective differentiates the present analysis from 
previous linguistic research on the topic, which has focused on the textual 
characteristics of package leaflets, and has failed to clearly distinguish between 
the two different tasks – safety vs. self-determination information – with a 
consequent emphasis on the directive force of PL information to the detriment of 
the more sophisticated communicative nature of risk disclosure for consent.  
2. The identification of the self-determination function emphasizes the need for an 
evaluation of PL information as a basis for decision, in addition to the traditional 
emphasis on safety. This need results in the search for a methodological tool 
capable of evaluating the contribution of information within decision: this has 
been found in Bayesian decision theory.  
3. Finally, the analysis of PL information in the perspective offered by decision 
theory allows providing a unitary account for apparently unrelated phenomena 
concerning the processing and effect of PL information (information seeking 
behavior). This is considered as a result of the expected value of PL information 
to the therapeutic decision and to safety measures during the therapy.  
The following scheme presents these three fields of investigation unified by the 
same underlying perspective: the distinction between the communicative nature of 
avoidable vs. residual risk information.  
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Figure: Work schedule for the analysis of PL information. To the distinction between avoidable 
and residual risk correspond two different communicative tasks: namely risk prevention (right 
to safety) and disclosure of residual risk (right to self-determination).   
This chapter presents the state of the art in linguistic research on package leaflets and 
proposes a speech act definition of their communicative status on the basis of the 
institutional tasks they are supposed to accomplish. 
Chapter 6 will propose an epistemic analysis of PL information: its role in the 
assessment of a personal risk/benefit prognosis will be analyzed within the 
framework of Bayesian theory.  
Finally, the empirical part of this study will present a series of findings on the 
processing and the impact of health risk information in general and PL information 
in particular. The Bayesian theory of the expected value of information to a decision 
provides a key solution to many apparent contrasting phenomena observed in 
empirical research.  
 
 
2. Linguistic analyses of the package leaflet  
 
The legislator has increasingly ascribed high importance to PL information and has 
promoted various initiatives aimed at the improvement of PL readability and 
consumer friendliness.
480
 
As a basis for these normative attempts a thorough investigation of the PL text has 
been undertaken as to the identification of major problems affecting the acquisition 
and use of PL information. This has generated a number of studies, most of all 
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 See chapter 4 § 4. See also Eckkrammer, 2002: 26 ff. for a comparative perspective.  
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coming from the linguistic field, which have extensively contributed to the 
identification of factors at the basis of patient unfriendliness in PL texts.  
Analyses range from text typology (Bock 1994; Dontscheva 1990; Ehlich 1994; 
Ehlich/Noack/Scheiter 1994; Eckkrammer 1995, 1998, 1999, 2002, 2002b; 
Fickermann 1994; Grosse/Mentrup 1982; Hoffmann et al. 1998, 1999; Langer 1995; 
Mohn 1991; Nickl 2001; Werner/Heyne 1989) to lexicography (Mentrup 1982, 
1988), and pragma-linguistics (Hensel 1989; Hoffamnn, 1983; Saile 1984; Schuldt, 
1992, 1998, Völzing, 1976, Zacharias, 1986). 
Lexicography on one side and “Textsortenlinguistik” on the other, have studied PLs 
as a special token of text for specialists (“Fachtext”: Mentrup, 1988). The focus of 
lexicography was to reconstruct specialist lexicons, whereas text typology was 
concentrated in filtering out convergences and divergences among text types in order 
to identify constitutional properties of the text as a theoretical construct (Spillner 
1981, 1987, 1994, Eckkrammer 2002).  
These studies are generally of normative nature, and therefore aim at evaluating PL 
information quality.  
Information quality is addressed through several parameters, such as pharmaceutical 
reliability, instruction unambiguousness, comprehensibility, and general reader-
friendliness.  
Recurrent issues dealt within linguistic literature are: 
1. Uncertainty induced by vagueness and ambiguity. 
- This is ascribed in some instances to “bad news” concealment strategies 
and product promotion through the lines. 
2. Uncertainty induced by incomprehensibility. 
- This is principally attributed to specialist language and traces of the PL 
original use as information for the doctor. 
3. Uncertainty induced by information overload. 
- This is blamed on the firm’s attempts to possibly avoid liability concerns, 
but it should be rather ascribed to the legislator’s prescription as for PL 
information content and design. The regulation in this field is in fact so 
tight and articulated that very little manoeuvre margins are left to the 
pharmaceutical firm.  
All these phenomena have been analyzed at different discourse levels: 
- Text typology (institutional aspect). 
- Discourse markers (pragmatic element); 
- Grammar (syntactical forms); 
- Vocabulary (lexicon); 
- Design and layout (graphical-semiotic markers). 
 
In general uncertainty is analyzed in all these studies as an effect of PL information 
on the drug consumer.
481
 I will remark at the end of the chapter that however 
uncertainty is also relative to the risk inherent to drug use and that these two sources 
of uncertainties should be clearly distinguished. 
By failing to explicitly discern these two sources of uncertainty, linguistic literature 
has missed the opportunity to account for the uncertainty inherent to the therapeutic 
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 “Verunsicherung” in the German literature. 
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context itself, and to analyze PL information in this respect. This aspect will be dealt 
with in the next chapter.  
 
 
2.1 Text typology 
 
The typological component is the teleological cause for text configuration and 
information design. Point of reference of linguistic studies has been the safety aspect 
of product information, with consequent classification of PL texts as “directive 
texts”.482 
The reason for which linguistic analyses have focused on the instructive aspect of PL 
information and neglected its role within therapeutic consent is to be found in 
historical/legal factors. 
As already mentioned in preceding chapters, the official justification for the 
introduction of PL has been to protect user safety through adequate product 
instruction. Also the official label assigned to PLs by the legislator is “Use 
Information” (“Gebrauchsinformation”). The legislator’s intention to assign PL the 
additional function of autonomy information has emerged only gradually and has 
never been officially introduced in the German Medicines Act (AMG).  
Hoffmann, for instance, defines three illocutionary points
483
 for PL information, 
none of which considers the special status of information about residual risk (which 
is not aimed at preventing risk – warning – but merely at notifying it to the reader). 
In his classification PL content is categorized under the following labels:  
1. presentation (of the text itself and of the product – for others also 
“declaration”484).  
2. warning; 
3. instruction.485  
The table below divides the different parts of PL content under these three headings: 
 
presentation warning instruction 
Text type declaration: “Use information” 
product type declaration  
firm  
components  
components description 
form of intake  
Side effects 
Contraindication  
Interference 
Security from children access 
Specific warnings 
Expiry  
Therapy dosages 
Therapy durations  
Countermeasures in case of 
side effects 
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 Mentrup, 1982, 9; Eckkrammer, 1995: 188-189. 
483
 The terminology comes from speech act theory. Searle and Vanderveken, 1989 distinguish five main 
categories of speech act along five illocutionary points: assertive (e.g. statements); commissive (e.g. 
promises); directive (e.g. orders); declarative (e.g. declarations); expressive (e.g. congratulations). Different 
speech acts with the same illocutionary point can be distinguished on their turn through “operations” on the 
seven components constituting the illocutionary force. For example reporting differs from asserting because 
of the different propositional condition that the event reported be either in the past or in the present, but not 
in the future (p. 187); requesting differs from ordering for the position of authority of the speaker (mode of 
achievement) (p. 201); warning differs from advising for the presupposition (preparatory condition) that the 
state of affair described by the propositional content is bad for the hearer, whereas in the advice this is good 
(p. 203).  
484
 Möhn, Pelka, 1984: 149, cited in Mentrup, 1988: 195.  
485
 Hoffmann, 1983: 141 ff. 
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Table 2: Hoffmann’s categorization of PL information content. 
 
From the legal point of view however, information listed by Hoffmann under 
“warning”, falls both under safety information (instruction for safe use: in blue) and 
information about residual risk (side effects: in red). The declaration of side effects 
is information for consent, given that side effects represent the risk, which the drug 
consumer should knowledgeably take into account by consenting to the therapy. 
Therefore this information should not be put in the same category of safety 
information for preventing avoidable damage. 
The merging of different categories of information under the vague label of 
“warning” can be considered a consequence of the lack of clarity about the two types 
of risk disclosure (safety instruction and information for consent), whose distinction 
is entailed by the separation between residual and avoidable risk. 
The work of Eckkrammer includes package leaflets as an object of contrastive 
textual analysis. This approach investigates the nature of PL texts along both 
pragmatic (“sprachexterne”) parameters such as the editing history, the authors and 
endorsers of this information, and formal parameters such as information design, 
syntactical structures and lexicon compared across different cultures or in relation to 
other text types.
486
 The underlying intention is to discover recurrent textual 
“patterns” associated with specific communicative functions and/or cultures. From a 
syntactical point of view, for instance, given the modular consumption of PL 
information, traditional cohesion elements (such as explicit or implicit cross 
references, causal or consecutive conjunctions, or thema-rhema constructions) are 
considerably fewer than in other text types.
487
  
Eckkrammer defines PLs as a text type with informative-instructive function, 
subjected to strict legal constraints.
488
 Furthermore, she points out the addressee 
inadequacy to deal with such information: “The patient feels inadequate in many 
respects; because a real choice presupposes that he has clearly understood what 
consequences his acting (or non-acting) brings forth”.489  
Notwithstanding this and other allusions to the decisional aspect of PL information, 
linguistic analyses have failed to analyze PL texts as a basis for informed consent, 
and generally define them as “warning” texts. 
 
 
2.2 The communicative status of PL information within the institute of 
informed consent 
 
The outline of PL legal nature presented in the preceding chapters allows us to 
define its communicative status by deriving it from its institutional tasks. 
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 See Eckkrammer, 2002, 1999, 1998 
487
 Eckkrammer, 1999: 91.  
488
 Eckkrammer, 2002: 26: “Bei der Packungsbeilage von Medikamenten handelt es sich um eine Textsorte 
mit informative-instruktiver Funktion, die stringenten rechtlichen Rahmenbedingungen unterliegt”.  
489
 Eckkrammer, 1998: 351-352: “der Patient fühlt sich vielfach überfordert, denn eine richtige 
Entscheidung setzt voraus, dass er genau verstanden hat, welche Konsequenzen sein Handeln (bzw Nicht-
Handeln) nach sich zieht”. 
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As mentioned in the preceding paragraph, package leaflets have been generally 
categorized as warning texts. However, in classical speech act theory, the act of 
warning is defined as a subtype of suggestion: to recommend not doing 
something.
490
 This kind of analysis is adequate for that part of risk communication 
regarding precautionary behavior (the don’ts of the therapy); instead it cannot 
capture that part of health risk communication addressing the eventuality of damage 
notwithstanding adherence to precautions, i.e. communication of “residual risk”. It is 
precisely by resorting to the technical notion of the word “risk” that the speech act 
approach gains a deeper insight in the communicative nature of PL information.  
In fact, being adverse drug reactions unavoidably and unpredictably connected to 
drug intake, the only way to avert them would be to renounce to the therapy. 
Residual risk information is therefore not aimed to avert damage through 
precautionary warning, but rather to honor the patient’s right to self-determination, 
in that he can decide on its basis, whether to undergo the risk or not. Therefore the 
disclosure of residual risk in the PL counts as a request for consent.  
This derives from the institutional effects inherent to PL information in the institute 
of informed consent as it has been illustrated through the preceding chapters. 
Furthermore, because of the risk transfer related to consent, the side effects list also 
counts as a liability disclaimer.  
How can the simple “act of informing” about side effects validly count as a “request 
for consent” and “disclaimer”? In order to analyze this issue I will recur to the 
analysis of communication in institutional settings.  
Institutions can be analyzed by examining their fundamental components:
491
 a “core 
ontology” (fragment of social reality regulated by the institution); a set of 
authorizations (the institutional effects that each member of the institution is 
empowered to bring about); a set of norms (obligations, rights and permissions 
assigned to the institution members); finally, a set of conventions associated to the 
execution of specific institutional effects.  
Communication acts among agents in the institution can be defined in terms of 
institutional effects, i.e. changes which entities may undergo with regard to their 
status, authority, duties rights, and responsibilities (commitments).  
The following chart illustrates the institutional ontology, rules, and conventions 
concerning the institute of informed consent for drug therapy: 
 
 
Core 
ontology 
Competent authority (A) 
Pharmaceutical producer (P) 
Doctor (D) 
Drug consumer (C)  
 
 
Set of 
authorizations 
1. (A) is authorized to prescribe content and form of product information (§§ 11; 
12 28 II nr.2; 29 IIa AMG).  
2. (A) is authorized to sanction product circulation with no or not adequate 
information (§§ 97 II 5 AMG). 
                                                 
490
 See Searle, Vanderveken: 1989. 
491
 Colombetti et al. 2003: 80. 
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Norms  
 
1. (P) is liable for inadequate product instruction (§84 I 1 nr.2 AMG; § 823.1 
BGB; § 95: criminal and civil liability)  
(3) 2. (D) is liable for obtaining consent from the patient and to enable his therapeutic 
decision (§§ 823.1; 280 BGB civil liability: tort and contract) 
3. The consent is not valid without prior information (for § 2 I GG). 
4. By consenting to the therapy, (C) thereby shoulders the residual risk entailed by 
it. 
 
 
Set of 
conventions 
1. For (C) with regard to (D): therapy onset upon due information count as 
consent to the therapy. 
2. For (C) with regards to (P): drug intake counts as renounce to compensation for 
residual risk listed in PL (“consent to drug residual risks”). 
Table 3: Agents, rules, and conventions of the institution of “pharmaceutical” informed consent. 
 
In the institute of informed consent for drug therapy, communication is regulated by 
the authority through prescription norms and liability regulation. These norms make 
the doctor and the pharmaceutical producer liable for providing adequate 
information to the patient. Through this information the consent is considered valid, 
and consequently the responsibility for the residual risk is transferred to the drug 
consumer: the risks not due to professional errors (negligent prescription or product 
faultiness) are shouldered by the patient, as stated by the fourth norm. 
The simple fact of undertaking the therapy upon due information is considered to 
count as consent (set of conventions). This is all the more valid for PL information, 
whose acquisition prior to drug intake is considered as part of the patient’s 
responsibility.  
For the principle of adjacency pair, consent is given to a previous request. Therefore 
the illocutionary point of the information about side effects is not only “informing” 
but “making a request”. Indeed it is a request precisely performed by informing. This 
kind of speech act can be better analyzed by drawing on the concept of declaration in 
institutional settings. 
Institutional contexts make any communicative act (information, request, promise) a 
declaration.
492
 A declaration in standard speech act theory differentiates from other 
speech acts types by the fact that it is a “performative” sentence: which means, that its 
content is made true by the very act of uttering it in an appropriate context:
493
 
“Declaring that an action of type t is performed counts as the actual performance of 
an action of type t”.494 
                                                 
492
 Colombetti et al. 2003: 72, 88-89. 
493
 Searles, Vanderveken, 1989: 3. 
494
 Colombetti et al. 2003: 88. This is valid for the performance of “institutional acts”. Within standard 
speech act theory instead, information is not subsumed into the declarative illocutionary force: informing 
someone that it is raining does not cause to rain. In fact along Searle’s taxonomy, informing is a hearer-
directed assertion. Searles, Vanderveken, 1989: 185. 
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Within an institution, the sharing of information produces at least the institutional 
effect of changing the reciprocal status of sender and receiver with reference to the 
delivered content.
495
  
The act of informing in an institutional context can be therefore considered a 
declaration in that it makes true the status of being informed of the receiver. Once 
the peace of information has been received, than from that moment on it is manifest 
(public) that the receiver is informed about it.  
For the legal requirements of respect for autonomy, the official status of “being 
informed” is a sufficient condition for consent to be valid together with therapy 
onset. 
Correspondingly, information about residual risk is an implicit request for consent, 
and – given the special provisions related to consent in pharmaceutical setting – it 
also amounts to a disclaimer: a declarative speech act aiming at a change of 
informative status in the receiver, with related responsibility reallocation among the 
parties.  
The analysis of PL institutional effects, allows to determine its communicative 
statuses (request for consent and disclaimer) and to explain why the general 
“warning” label only grasps the safety aspect of PL information and fails to describe 
its role within the institute of informed consent. 
 
 
2.3 Scientific, legal, and linguistic constraints of PL information 
 
The importance of the institutional environment within which PL information plays 
its role, has been recently recognized as an essential component of the investigation 
concerning this text typology.
496
  However, it is only in an earlier work of a 
lexicographer that the linguistic perspective most profitably gains depth of analysis 
from legal considerations. This is the work of Wolfgang Mentrup. Mentrup’s study 
originates in that area of research dedicated to the study of “language for special 
purposes” and translation theory.  
Drawing back to Bühler’s “Handlungstheorie” Mentrup describes the parameters 
relevant to the pragmatic situation (“who”: Arzt, Doktor, Medikus; “what”: 
Arzneimittel, Analgesikum, Schmerzmittel; “why”: Krankheit, Beschwerde, Schmerz; 
“to whom”: Patient, Kranker) and takes into consideration the institutional and 
legislative framework (which he calls meta-text corpus) in which these texts are 
                                                 
495
 In fact also Searle and Vanderveken underline this pragmatic aspect of information sharing. While a 
passive form is possible for verbs such as “put into notice” and “inform”, this is not possible for verbs such 
as “state” and “assert” (185): 
 
“Thus, for example, one says, “You are hereby notified” or “You are hereby informed”. 
But one cannot, for example say “You are hereby asserted” or you are hereby stated”  
 
The grammatical difference between assert and inform reveals the possibility of an underlying distinction 
between the act of informing and the act of asserting. This is reflected in institutional contexts; where 
asserting and informing have different institutional effects. The first related to the official position held by 
the speaker on an issue, the second rather to the hearer’s relationship to the information delivered.  
496
 Schuldt, 1992: 41 ff.  
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embedded. In this sense he is particularly interested in the different degrees of 
binding force expressed by different types of product instruction, where the 
prescription/prohibition pair is associated with the maximal force.
 497
 
By combining legal directives with scientific data concerning the product, specific 
information constraints concerning PLs can be derived. This analysis bears 
following interesting implications: 
1) Pharmacological information incorporated in the PL derives its assertive and 
directive force from the degree of confidence provided by the coherence of 
statistical data coming from labor experiments, clinical studies, scientific 
literature etc. For instance, the higher the confidence in the association between 
the drug intake and the occurrence of a severe side effect for a specific risk 
group, the more peremptory should be contraindication warnings for this 
subgroup.
498
    
2) The binding force of each PL message is a function of the commitment implied 
by the institutional effect performed by the message. 
The following table illustrates the categorization of PL content as a function of the 
distinction between information for consent and safety information, and of the sub-
distinction in prescriptive vs. prohibiting institutional effects.  
 
 Information for consent 
(assertive) 
Safety information 
(assertive/directive) 
Request for 
consent/disclaimer  
Prescription  Prohibition  
Scientific information 
supported with different    
degrees of certainty                   
        
(%) (probabilistic data)                                      
Efficacy   
Residual risk (side effects) 
Dosage 
Duration  
Preservation  
Contraindications  
Interference  
Precautions  
Table 4: Scientific, legal, and linguistic constraints of PL information   
 
Information for consent is given in assertive form, even though it bears the 
illocutionary point of a request. Safety information is provided in both assertive and 
directive form, but it fundamentally bears directive illocutionary points such as 
‘prohibition’ or ‘warning’ and ‘prescription’ or ‘recommendation’. The binding 
force of all indications depends on the scientific evidence supporting the data, which 
is determined in probabilistic terms. 
Along this table, PL text type can be defined as a filtered source of probabilistic 
information for the lay user, declined in directive instructions for safe use, and in 
assertive information about risk and benefit data bearing the illocutionary points of 
‘request for consent’ and ‘disclaimer’ at the same time.  
 
 
 
 
                                                 
497
 Mentrup, 1988: 184. 
498
 See chapter 6.  
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2.4 Pragmasemantics of package leaflets 
 
On the benchmark provided by table 2, it is possible to explain some sources of 
uncertainty identified at different textual levels.  
The highest level of uncertainty is represented by pragmatic ambiguity and 
vagueness. Ambiguity originates for instance when instructions are delivered in 
assertive forms through presuppositions or implications rather than explicitly in 
directive form, or when, instead of clearly prohibiting or prescribing a specific 
behavior, the text leaves open more than one alternative.
499
  
The phenomenon of pragmatic ambiguousness is also exemplified by polite 
recommendations substituting strict prohibition, and therefore letting the reader 
uncertain as the nature of the directive instruction (permission with reserve or 
respectful prohibition?).
500
  
Hoffmann qualifies these phenomena as “Entwarnung” (“dis-warning”), i.e. toning 
down of warnings through ambiguous speech acts (“des Offenhaltens”).501  
This kind of ambiguity is also represented by the weakening of the directive 
peremptoriness through concessive sentences: an arbitrary space for deviance from 
the forbidden/prescribed act is opened, which the lay reader does not know how to 
make use of. This is also valid for sentences, followed by an adversative which 
partly contradict, or specifies their content. 
502
 The effort required for bringing these 
contradictions to coherence, is often perceived as unsuccessful/unworthy and 
eventually leads to increased uncertainty (for instance as to drug risk estimation or as 
to the right behavior to undertake). 
To the pragmatic ambiguity of assertive sentences implicating an instruction a 
source of semantic vagueness is added in sentences like “X and Y can influence each 
other”: not only it is left unclear what conclusions the reader should draw form the 
message. More fundamentally, the verb ‘influence’ leaves unclear whether the 
sentence should be interpreted as a warning about toxicity/effectiveness increase of x 
through y, and vice-versa or as a toxicity/effectiveness decrease.
503
  
Pander Maat explains the lack of explicitness of many PL text passages as a 
consequence of the author’s reliance on the reader’s inferential work.504 However, 
this is precisely the core problem of expert-to-lay communication. The expert might 
not appropriately calibrate his discourse to the lay level of inferential capacity, 
which in the case of PLs, is severely compromised by pharmacological and medical 
incompetence. This is all the truer, when considering mass media texts,
505
 directed at 
a heterogeneous audience consisting of readers with different degrees of health 
                                                 
499
 Schuldt, 1992: 185 ff; 205: “Die Einschränkung des Warnhinweises durch die Verwendung mit 
konzessiven Konjunktionen oder Adverbien eingeleiteten Nebensätzen stellt eine Verunsicherung des 
Arzneimittelverbrauchers dar”. 
500
 Zacharias, 1986: 94 f.; Schuldt, 1992: 201 ff; 216 ff. also with improvement proposals: “«Bei Y muss 
das Präparat sofort abgesetzt werden» statt als «Bei Y sollte das Präparat nicht mehr angewendet werden »” 
(249). With a different pragmatic interpretation, Pander Maat, 1997: 118 ff, 124.  
501
 Hoffmann, 1983: 150 ff.  
502
 See Zacharias, 1986: 41 ff.  
503
 Zacharias, 1986: 92. 
504
 Pander Maat, 1997: 124. 
505
 Pander Maat, 1997: 112. 
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literacy and processing capacity. Also in case of procedural knowledge – for 
instance what to do in case of side effects – Pander Maat attributes the low presence 
of instruction as the result of the author’s assumption that one should not consult the 
doctor, unless advised to do so!
506
 By limiting his analysis equipment to pragmatic-
linguistic instruments (cooperation principle, conversational maxims, implicatures) 
Pander Maat fails to identify the institutional origin of many textual formulae. 
However he succeeds in bringing to light the consequences which these formulae 
have on the reader’s side.507  
Another source of uncertainty at the pragmatic level is constituted by the multiple 
addressing. Sentences such as “if the doctor did not prescribe other dosage” are 
followed by sentences such as: “patients with tendency to X should not be prescribed 
this treatment”. The information target is ambiguous and oscillates between doctor 
and patient. The unsteady alternation of passages directed at the doctor with 
passages directed at the patient is considered all the more reproachable, as this is 
done without explicit markers.
508
  
Sometimes the text assumes the tone of “exclusive insider conversation” where the 
doctor is also addressed as an interested addressee of research results.
509
  
Several contributions criticize the exploitation of an instructive text for marketing 
purposes (Hoffmann 1983; Zacharias 1986). Indeed, many studies explore PLs as an 
occasion for the firm to increment user fidelity and image reputation in general 
(Arnold et. Al. 1984; Bönsch, 1986; Gebert 1988; Naether 1984; Petersen et al. 
1985). The critiques moved at these marketing attempts are based on the 
consideration, that PL information cannot be “contaminated” through other 
communicative functions other than the institutional official purpose of use safety. A 
“purist” view which is also confirmed by the legislator through § 11 AMG, where it 
is prescribed to clearly separate additional information spontaneously provided by 
the pharmaceutical firm, from the official information strictly prescribed in § 11, nr. 
1-8. 
 
 
2.4.1 Semantic analysis of frequency descriptors  
 
From the point of view of information for consent, the major uncertainty is 
constituted by the probabilistic form of this information. Probability is inherent to 
the concept of risk, and pharmaceutical risk is no exception.
510
 A probabilistic 
assertion such as: 
 
“(On the basis of available pharmacological data) the occurrence of side effect x can be 
estimated as 10
-6” 
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 Pander Maat, 1997: 125. 
507
 See for instance Pander Maat, 1997: 125-126, 127 ff. 
508
 Zacharias, 1986: 54: “Sollten in Einzelfällen stärkere Beschwerden auftreten, so ist dies dem Azrt 
mitzuteilen … Patienten, die (XYZ) hatten, sollten beobachtet werden”.  
509
 Zacharias, 1986: 58. 
510
 Throughout this work, I have adopted the legal notion of pharmaceutical risk as health injury. The 
probabilistic dimension is considered in this context as an additional attribute, rather than the risk itself. As 
for the polisemy of this term within risk theories see Preuss, S.: 1996: 68. 
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entails a commitment to the truth of the probabilistic assertion.
511
 This sentence 
simply refers to the proportion of cases in which side effects x occurred out of the 
entire population who took the drug. In probabilistic terms, this means that on the 
basis of the available knowledge the hypothesis that side effect x occurs is supported 
by the data to 10
-6 
degree of confidence.   
However, in order for this information to be of any use for the reader, the 
probabilistic assertion should be translated in a prognostic assessment about the 
personal probability that he might be concerned by the side effect mentioned.  
The translation of frequency data into personal probability estimations is a hot topic 
within probability theory, which leads to questions of the type: Is it legitimate to 
derive a personal estimation from general frequency data? If yes, is it feasible? If 
not, what is the value of frequency information in PLs? Can this information be 
considered of any use for giving a rational consent?
512
 This issue will be extensively 
considered in the next chapter. Here a study comparing the interpretation of verbal 
and numeric frequency quantifiers is presented, which sheds some light on the 
meaning attributed to probabilistic information by lay readers. From the study, 
conducted by Pander Maat and Klaassen (1994) it seems in fact that quantifiers are 
rather used in the phase of information processing as a filter for selecting side effects 
on the basis of their occurrence probability. Instead, in a second time, only selected 
side effects are remembered with no associated frequency. Frequency descriptor 
themselves are not memorized.
513
 
This could be illustrated by recurring to the analogy of a “signal detector” system. In 
this model a specific frequency descriptor – for instance “uncommon”) – is assigned 
the minimal level of detection for deciding whether to store a signal or not. Beyond 
this level, no signal is deemed worth of consideration, and therefore all side effects 
associated with frequencies below the threshold level are completely neglected by 
the system.  
 
 
                                                 
511
 This is different from a probabilistic commitment to degree 10
-6
 that the assertion is true. See also 
Carnap: 1962: 30. 
512
 I will address these issues in the next chapters by drawing on categories and instruments devised by 
probability and decision theory. 
513
 It also emerges a tendency to assign verbal quantifiers – such as “sometimes”, “seldom”, “very seldom” 
– a considerably higher frequency in relation to their standard meanings. This is a very interesting datum in 
the context of expert-to-lay communication analysis. The standardization determined by policy 
requirements may be extraneous to the lay reader and therefore lead to misunderstandings. 
These have been recently harmonized by the European agency EMEA through the Summary of Product 
Characteristics Guideline: http://www.bfarm.de/de/Arzneimittel/index.php?more=SPCGuideline-
Bekanntm2.php. Below the German version  implemented by the Bundesinstitut für Arzneimittel und 
Medizinprodukte: BfArM): 
SPC-Guideline German %-indication 
Very common sehr häufig >= 10% 
common häufig >= 1% - < 10% 
uncommon gelegentlich >= 0,1% - < 1% 
rare selten >= 0,01% - < 0,1% 
very rare sehr selten < 0,01% 
**
 
** single cases are listed under this category. 
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Side Effects Frequency 
descriptors 
Memory 
threshold 
Output  
SE1a SE2a SE3a SE4a Very common  
 
 
 
 
Remembered SE  
(without associated 
frequency):  
SE1a -  SE4c 
 
SE1b SE2b SE3b SE4b Common  
SE1c SE2c SE3c SE4c Uncommon  
SE1d SE2d SE3d SE4d Seldom   Deleted SE:  
SE1d - SE4e SE1e SE2e SE3e SE4e Very seldom  
 
In this experimental study, the frequency associated to side effects only indirectly 
contributed to the did evaluation of drug toxicity. The authors conclude “that 
individual differences in FD [Frequency descriptors] interpretations do not 
systematically affect drug evaluations, recall of side effects and reporting rates of 
side effects”.514 
Pander Maat explains this datum with reference to the risk acceptance level. He 
adduces that: “Considering the fact that SEs are the logical consequence of a 
behavior (using a drug) that one is more or less willfully engaged in, it seems 
reasonable to assume that what someone considers to be a normal frequency, will 
often be the acceptable frequency: i.e. the risk that is taken into the bargain. 
Therefore, individual differences between frequency expectations do not necessary 
result in different evaluations of the drug”.515 
It could also be assumed that this phenomenon speaks for a “0 or 1” attitude towards 
SE information. The drug consumer considers that either will he be concerned by the 
SE or not. It makes no difference to his prognosis whether, on a general level, a SE 
concerns 1 out of 1000, or 1 out of 1000.000 users. Therefore, either he decides to 
undergo the risk of being concerned by the side effect or not. Whenever he has 
decided to accept the side effects listed in the PL, their general frequency of 
occurrence does not change his evaluation of the personal danger he is exposed to.  
It seems therefore that uncertainty generated by probabilistic data might be coped 
with by ignoring it, i.e. either by setting the risk at 1 or at 0.  
The way the lay reader deal with probabilistic information is a central issue in the 
investigation of PL role in therapy decision. This will be the major topic of the 
experimental part of this work. As for the study conducted by Pander Maat and 
Klaassen, linguistic considerations need to be pointed out, before their findings can 
be generalized. In fact semantic aspects related to textual interpretation might act as 
a confounding factor in the study of the interpretation of frequency quantifiers.  
This is because in normal contexts, the quantifier acts as a quasi-focus in the 
message but it is not itself on focus.
516
 The consequence is that in the context of PL, 
the quantifier “seldom” is not considered as an autonomous peace of information, 
but just a complement to the side-effect to which it is associated: “Nervous disturbs 
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 Pander Maat, Klaassen, 1994: 401.  
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 Pander Maat, 1997: 134.  
516
 See Rigotti, 1993: 87 for a semantic distinction of sentences with quantifiers as cataforic elements with a 
rhematic function or as fully rhematic elements.  
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seldom occur”. In this format, the message could be pragmatically read as an 
instruction to consider the side-effect as negligible.
517
  
In order to proof that frequency descriptors function analogously to detection 
signals, one should put the sentence in a form where both the side effect and the 
frequency are in focus: 
Side effects 
Head-ache: seldom; 
Stomach-ache: uncommon 
…… 
Or even better in a tabular form: 
 
SE            
frequency Very 
common 
common uncommon seldom Very 
seldom 
Head-ache  x    
Stomach-ache  x     
….     x 
….    x  
 
However, more and more PLs are adopting exactly this display format, and also the 
numerical version of frequency indication (or at least both verbal and statistical 
information) has been introduced in most PLs. These forms of information design 
neutralize the thema-rhema construction and therefore constitute the most suitable 
form to communicate frequencies.  
 
 
2.5 Lexicon 
 
The most investigated characteristic of PL texts is the uncertainty generated by 
medical, pharmacological, chemical and technical vocabulary in general.
518
  
The old PLs contemporarily and ambiguously addressed a multiple and 
heterogeneous audience (both the medical professional and the lay reader). Even 
where separate leaflets have been adopted for doctor and patient, many traces of this 
phenomenon are to be found in the texts. This factor is identified as one major 
source of scarce readability (Beimel 1986; Bürkle 1984; Gloning 1995; Hoffmann, 
1983; Krautmann, 1981; Lehrl et al., 1982; Noack 1991; Schuldt, 1992; Zacharias, 
1986). 
Before and soon after the introduction of separate information for doctor and patient, 
many efforts have been devoted to the identification of formulations and words, 
which could be felt as unfamiliar by the lay reader and therefore skipped over 
because considered to be addressed to the expert (the doctor).  
This phenomenon is not limited to technical words, but also to instructions which 
presuppose expert knowledge. 
Specialized lexicon is categorized in strictly technical terminology – only 
comprehensible to the insider – and specialized language which has entered to a 
greater or minor extent in the common use. Both constitute a source of 
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 See also Zacharias, 1986: 61, 89 for critical analysis of such formulae.  
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 Hoffmann, 1983: 143 ff. 
 174 
misinterpretations and cognitive uncertainty. In the first case text understanding is 
completely blocked, therefore creating “interpretation holes”. In the second case, the 
ordinary use of a specialized term might more often than not differ from its technical 
meaning and therefore generate misunderstandings.
519
  
Thanks to considerable efforts, PL vocabulary has significantly improved towards 
comprehensibility and reader-friendliness. Most of technical words have now been 
substituted by more familiar terms.
520
 
 
 
2.6 Design and layout 
 
A major fault in PLs has been found in a homogeneous text design devoid of textual 
cues and markers for a hierarchical organization of the information to be acquired. 
Also this aspect is due to legal constraints. In fact such an organization of the data 
would imply that some peaces of information are more relevant than others, while 
this is incorrect from a legal perspective, according to which all information 
delivered in the PL is equally important.
521
 The European Readability Guideline (see 
§ 2) has brought a major change to this aspect of readability.
522
 Still, font dimension 
and the repetition of same blocks of information under different subsections are 
critical points, which require further efforts of improvement.  
 
 
2.7 Information overload 
 
Anxiety induction through warnings lists and consequent hindering of compliance 
has been generally attributed to information overload (Aumiller, 1978, 1982; 
Degner, 1982, Karpa, 1991, Kepplinger 1990, 1991, Nickolaus, 1991; Nöthlich, 
1991; Wenzel, 1985; Winckelmann, 1983; Wolff, 1982; Zink, 1985; Zylka, 1986)
523
. 
Referring to the long lists of warnings Eckkrammer (2002) coins the expression: 
“liability offload”.524  
However, also for the concept of “information overload”, it should be distinguished 
between a cognitive overload, which is the perception resulting in general from 
difficult texts and an overload of risk information, which is objectively frightening 
for the reader.  
Cognitive overload is a relational parameter which depends on personal relevance, 
content type and cognitive costs required for elaborating information. The 
relationship can be roughly formulized as follows:  
 
    CO = C/R ∙ T (-∞; +∞) 
 
                                                 
519
 Hoffmann, 1983: 143; Schuldt, 1992: 167-184; Mentrup, 117 ff., 155 f. 
520
 For instance, Latin words have totally disappeared. See Eckkrammer, 1999: 100 ff.  
521
 Mentrup, 1988: 372, also cited in Schuldt, 1992: 161.  
522
 See § 2.7 in this chapter.  
523
 I mention here also Askehave et al. (2003) dedicated to graphical aspects of text design. 
524
 See also Mentrup, 1988: 314 ff.  
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(Where CO stays for cognitive overload; C for cognitive costs; R for relevance; and 
T for topic: the -∞; +∞ signs stay for a continuous function representing the 
positive/negative involvement in the topic).  
For instance, a novel, which is in general much longer than a normal PL does not 
give rise to the sense of information overload experienced by PL reader, even if it 
contains many more data to be elaborated. This is due to the quotient of pleasure 
represented by its content type. 
The sensation of cognitive overload is in general directly proportional to parameters 
such as topic involvement and inversely proportional to difficulty – and topic 
aversion.
525
  
Health risk information is generally categorized as anxiety inducing information 
(“bad news”), a fact which, it is highly relevant and unwelcome at the same time.  
This contributes to explain the schizophrenic attitude towards this sort of 
information.  
In fact, for a lay reader, all listed side effects can be virtually relevant: however he 
will be precisely preoccupied to assess that the least possible information concerns 
him. Yet, given his incompetence he will not be able to assess which risks might 
concern him and which not, eventually falling into a “prognostic paralysis”. 
Chapter 9 will deal with these aspects of health risk learning in detail be explaining 
attitude towards risk information as a function of the parameters determining the 
decision at stake (availability of alternatives, perceived control over the risk a.o.). 
 
 
3. European readability guidelines  
 
The insights in PL information processing derived from linguistic studies have 
received increased attention by the legislator, and finally found the most mature 
implementation in the European guideline issued in 1998 by the European Council:  
“A Guideline on the readability of the Label and Package Leaflet of Medicinal 
Products for Human Use”. 
The document has been officially implemented in the German legislation in 2002, 
through the recommendations for the configuration of package leaflet, and translated 
in legal norms through the 14
th
 amendment to AMG.
526
  
Several advices provide valuable indications as for the graphics, the design and 
preferred syntactic structures; also fixed formulas and criteria for listing side-effects 
or contraindications are included. As for color, it can be used for titles, but red is 
reserved to very special warnings.  
Attention is paid not only to readability in terms of declarative knowledge, but also 
to explicitness and clarity of procedural instructions: “A precaution should be  
presented as implying the action a patient should take, rather than as factual 
information which describes a medical condition” (p.19  Annex 1b);  “Explanations 
should be placed immediately after the instructions when: an instruction is contrary 
to expected behavior, the reasons for an instruction are not self evident, an 
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 The estimation of text length is a function of the perceived difficulty: Bartke, 1987: 33, cited in Schuldt, 
1992: 208. 
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 See chapter 4 § 4.2 
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instruction can be made more memorable by using an explanation” (p. 21 Annex 
1b).
527
 Furthermore, the appendix presents guidelines for readability tests, which the 
pharmaceutical firm can carry out on their own.  
The improvement of these legal initiatives on PL readability is considerable. Both 
general readability and local comprehensibility of PL texts are by far greater than for 
PL texts of the preceding eras. However, as recent studies demonstrate, this textual 
improvement has not been accompanied by an equal decrease of uncertainty
528
 or 
increase in compliance.
529
 
It might be therefore worth investigate, whether uncertainty induced by PLs is 
merely of cognitive nature, or if it is rather linked to more structural questions such 
as the consideration of the unavoidable risk represented by side effects.  
 
 
4. Irreducible uncertainty: pharmaceutical residual risk  
 
In the studies presented above, somehow contradictory charges are moved against 
PL information. On one side, PLs are blamed of toning down risk information, on 
the other side they are accused of hindering compliance through long lists of side 
effects and threatening medical information. Their specialist language is often held 
responsible for incomprehensibility and consequent uncertainty effects in the reader, 
but their medical impreciseness is considered as a source of unsafe use. 
It seems that PL information indeed is a mixture of such reassuring and threatening 
messages. However, information design cannot be held the only responsible for 
these contradictory effects. 
For instance, comprehensibility is not the solution to compliance fostering, if one 
considers that the uncertainty generated by a medical expression, can be even 
augmented if translated in common language, when it discloses a fatal risk: “Heart 
block” is certainly no more reassuring than “Atrioventricular-Block”.530 
Therefore it should be distinguished between a cognitive uncertainty generated by 
the insecurity of lay reader to assign definite meanings to medical words, or to 
interpret vague instructions, and a prognostic uncertainty about the (short, medium, 
long term) risks mentioned in the PL. This is precisely the uncertainty affecting any 
decision under imperfect knowledge. 
The linguistic approach has for obvious reasons studied those aspects of PL 
information, which can be imporved through better communication.  
However, the irreducible uncertainty generated by residual risk constitutes an 
insurmountable barrier to the improvement of patient-friendliness through 
                                                 
527
 These harmonization directives follow two decisions about authorization for market approval: art. 14 
75/319/CEE  and art. 22 81/851/CEE  as well as directives concerning consumer information (dangerous 
substances, fraudulent and comparative advertising: http://europa.eu.int/scadplus/leg/it/s16400.htm). The 
first European directive on pharmaceuticals was issued in 1965: 65/65/EEC. 
528
 Nink, Schroeder, 2006. 
529
 Bronder, Klimpel: 2001. See chapter 4 § 4.3.  
530
 Schuldt, 1992: 176. 
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communication techniques. No matter how readable, comprehensible and well 
designed, no PL could promise a risk-free therapy.
 531
 
In order to analyze the extent to which PL information accomplishes its institutional 
tasks, attention should be paid to its epistemic contribution in providing the 
knowledge required for consent to be informed and for therapy to be safe.  
 
 
5. Summary and conclusion 
 
This chapter has been devoted to the communicative analysis of PL texts. A 
definition of the communicative status of PL information has been proposed, on the 
basis of its institutional tasks. Drawing on categories borrowed from speech act 
theory, and considering its role within the institution of “informed consent”, a 
double illocutionary point, in parallel to its double legal effect has been identified for 
PL information: request for consent and disclaimer about the residual risk connected 
to the therapy.  
From a text-typological perspective, PL texts have been defined as a filtered source 
of probabilistic information for the lay user, declined in directive instructions for 
safe use, and in assertive information about risk and benefit data, bearing the 
illocutionary points of ‘request for consent’ and ‘disclaimer’ at the same time. 
After presenting an overview of major linguistic sources of uncertainty identified by 
lexical, linguistic, and textological literature, an inevitable source of uncertainty has 
been identified, this is related to the therapeutic decision itself. 
This insight requires a methodological turn and calls for the analysis of PL 
information within the framework of decision theory.  
                                                 
531
 „Trotz aller Bemühungen, die Patienteninformationen besser verständlich zu machen, darf nicht 
übersehen werden, dass die Patientenfreundlichkeit dieser Texte ihre Grenzen hat. Sie haben den 
unterschiedlichen Vorstellungen der Beteiligten zu genügen. Haftungsfragen spielen eine Rolle; 
Verbraucher haben den berechtigten Anspruch auf umfassende Information, gleichzeitig wird aber die Fülle 
der Angaben, insbesondere der als abschreckend empfundenen Risikoangaben, beklagt. Dieses Dilemma 
wird kaum aufzulösen sein, und vermutlich wird die Diskussion um verbraucherfreundliche 
Packungsbeilagen nie ganz verstummen“: Schraitle, 2006: 4 (my emphasis).  
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6 Bayesian analysis of PL information  
 
 
 
“No one feels strongly about things he takes for granted” 
Frank P. Ramsey, Truth and probability, 1926. 
 
 
"Socrates argues (Symposium, 200) that Love is not a 
god because to desire something is to be in want of 
it: you cannot desire what you already have…Thus, to vary the 
example of the ´Symposium´ since people do not always 
know when they are loved, it is entirely possible to 
desire someone´s love when you already have it. 
Therefore, it seems better to say that you cannot 
desire what you think you have". 
Richard C. Jeffrey, The logic of decision, 1990 (1965). 
 
 
 
1. PL information as a basis for informed consent 
 
Drug information contained in the Summary of Product Characteristics – from which 
PL information is derived – comprehends data concerning the pharmacokinetics 
(absorption, distribution, metabolism, excretion), pharmacodynamics (receptors, ion 
channels, enzymes, immune system), pharmacoepidemiology and –toxicology (the 
statistical investigation of the drug impact over a population of interest) of the 
molecular entity(ies) which compound the drug.  
Therapeutic indication, efficacy range, interference with other drugs, chemical 
entities or food in general, contraindications and precautions with regards to specific 
risk groups and adverse drug reactions (side effects) observed in the pre-marketing 
phase are also reported in the SPC (and in the PL) and continuously updated in the 
post-marketing phase through pharmacosurveillance.
532
  
These data belong to the documentation required for drug approval, and they are 
fundamentally aimed at providing the basis for a risk/benefit assessment of the 
candidate molecular entity; i.e. they should provide the basis for an informed policy 
decision.
533
 The administrative authority is supposed to substantiate and legitimize 
his decision through reference to the amount of expected benefit and expected risk 
on the relevant population (normally coincident with the group of potential drug 
consumers, i.e those diseased people, whose condition is expected to be favorably 
affected by the drug).  
                                                 
532
 See chapter 4 § 4.1. 
533
 See chapter 1. 
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As already seen in the first chapter, this decision is all but obvious and must take 
into account several parameters, not only purely pharmaceutical-medical, but also 
psycho-sociological and economical.
534
   
The duty to accompany pharmaceutical products with a package leaflet for the end-
user originated within safety regulation with the explicit purpose of fostering use 
safety and efficacy.
535
  
Instead, the legislator does not explicitly refer to PL information as a source for the 
consumer’s decision. Nevertheless, the teleological interpretation of liability norms 
within drug regulation, (disclaiming function from residual risk, information for 
consent) and court judgments qualify the PL as a source of information for 
therapeutic consent.
536
  
Therefore the normative analysis of PL information as a legally binding tool should 
examine to what extent, PL information meets the desiderata entailed by the tasks it is 
supposed to accomplish: i.e. whether PL information enables a safe use, and whether 
consent based on PL information is really informed.  
This chapter will focus on the second issue and investigate PL information with 
respect to its role within informed consent by answering the following questions:
537
  
1. What requirements the legislator establishes for consent to be qualified as 
informed; 
2. Whether PL information fulfils these requirements.  
 
 
1.1 A Bayesian legislator  
 
The legal doctrine of informed consent has not yet explicitly produced a definition of 
what qualifies consent as informed. The institute has originated with the recognition 
of the patient’s right to self-determination and autonomous decision, and it has 
evolved through case law by specifying the conditions which define a choice as 
autonomous and free. The development of disclosure standards has gone hand-in-
hand with a deeper understanding of the factors determining choice.
538
 In general 
                                                 
534
 See chapter 1 § 3.3.4 (risk acceptance).  
535
 See Chapter 1 § 2.2. I represent here § 1 AMG for the reader’s convenience: „Es ist der Zweck dieses 
Gesetzes, im Interesse einer ordnungsgemäßen Arzneimittelversorgung von Mensch und Tier für die 
Sicherheit im Verkehr mit Arzneimitteln, insbesondere für die Qualität, Wirksamkeit und Unbedenklichkeit 
der Arzneimittel nach Maßgabe der folgenden Vorschriften zu sorgen“. 
536
 See chapter 4, especially the sentence LG Dortmund 6. 10. 1999, MedR 2000. 
537
 The emphasis on the self-determination function rather than on the safety function of PL information is 
precisely due to the legal debate around this aspect of drug information as problematized in the literature 
and in recent court judgments. However, at the end of the chapter also the epistemic contribution of PL 
information to therapeutic safety will be briefly discussed. 
538
 “Die Rechtsprechung [tendiert] zu einer ständigen Ausdehnung der ärztlichen Aufklärungspflicht, um 
angesichts der sich vervielfältigenden Möglichkeiten der modernen Medizin das Selbstbestimmungsrecht 
des Patienten zu behaupten”: Emmerich, 2006: 846. See chapter 3 § 5. This is especially valid for the U.S. 
regulation: see Faden et al. (1986). For a comparison between the German and the U.S. institute of 
informed consent see Glatz (1998). 
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court decisions imply that the patient is made aware of the nature of the intervention, 
its risks and benefits, and the probability thereof.
539
 
Essentially, the principle of proportionality determines the amount and level of 
information detail in relation to: 
1. the therapy risk; 
2. illness severity (inverse proportionality);  
3. the benefit magnitude and probability.540 
The notion of risk in this setting equates to the magnitude of the expected damage 
multiplied by the probability of its occurrence. The same is valid for the expected 
benefit: both beneficial and damaging consequences of the choices are weighted by 
the probability of their occurrence. 
The criterion of including probabilities as relevant information for choice mirrors the 
procedure developed in the framework of probabilistic decision making: Bayesian 
decision theory.
541
  
The Bayesian approach to informed consent seems to underlie also the regulation of 
PL risk disclosure, as can be evinced from article 13.1 of the 1994 BfArM 
recommendations for PL information, which suggests giving frequency of side 
effects whenever possible, in order to ease the risk estimation of the patient.
542
  
Thus, PL information is precisely thought of by the legislator as a source of 
probabilistic information for an autonomous decision, with related shouldering of 
residual risk. 
The point is however whether this information source can indeed accomplish the 
tasks imposed on it by the legislator. 
In order to answer this question these steps will be followed: 
1. a Bayesian model of health decision-making will be presented and used as a basis 
for defining the conditions for consent to be informed; 
2. the extent to which PL information can contribute to consent will be investigated 
on the benchmark of this model. 
 
 
                                                 
539
 BGH NJW 1980, 847; NJW 1982, 147; NJW 1985, 2192; NJW 1989, 1533; OLG Köln VersR 1997, 
1491. 
540
 The higher the risk, the greater is the detail and quantity of information which should support the 
decision. The risk disclosure duty also depends from the illness severity: the less severe is the illness the 
more detailed must be the information about the intervention and related risks. See: Krudop-Scholz, 2005: 
97. Also the expected benefit determines the disclosure duty standards: The less important is the expected 
benefit, the more detailed has to be any information about the risks. Wagner, 2004: 1839 Rn. 705; with 
reference to BGH NJW, 1991, 2342, and OLG München VersR, 1988, 525 f. Moreover the magnitude of 
the risk should be gauged not only in abstract terms but also in relation to the specific individual. Any risks 
must be disclosed whose realization can represent a severe compromise of life quality and/or professional 
capability for the individual. BGH, NJW 2000, 1784 (1785). See also Krudop-Scholz, 2005: 96-97; 134. 
Francke, Hart, 1999: 57. (chapter 3 § 5.3). 
541
 With the caveat that in the frame of informed consent – at least within the tort liability setting – the 
decision is understood as a yes/no option rather than a choice among several alternatives. 
The decision-maker needs to be made aware of the risks and benefits of the proposed intervention mainly. 
A duty to inform about alternatives is triggered only insofar they are attached with a significantly different 
risk/benefit profile.
 
See chapter 3 § 4. 
542
 See original excerpt in chapter 4 § 4.2, footnote: 35. 
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1.2 Elements of Bayesian decision theory  
 
Bayesian theory models the choice among different alternatives as the selection of 
the act which brings the highest outcome sum, where each outcome is weighted by 
the probability of the related state of an affair: this is said to be the act which 
maximizes the subjective expected utility. “Expected” refers to the probability 
distribution over the possible outcomes that the act could bring, “subjective” to the 
fact that this probability distribution results from the decision maker’s knowledge of 
the state of affairs at the time of decision.
543
 The maximization formula reads as 
follows: 
 
(1) max {∑i=1 P(Si)U(aj)}.  
 
An example may help illustrate the principle. Listening to the weather forecast on 
different channels, and relying on the sky at sunset, an agent planning his week-end 
judges the probability of rain rather low (1/3 of the probability of variable weather). 
Sunny weather should be twice as probable as variable weather. Therefore the 
probability distribution about the agent’s weather forecast would look like the 
following: sunny weather: .6; unsettled weather: .3; rain: .1. 
The probability distribution applied to the possible weather conditions for the 
decision gives the following matrix: 
 
                                
    S1 
.6 
S2 
.3 
     S3 
  .1 
a1 picnic Outcome11 
             
        100 
Outcome12 
               
      0         
Outcome13 
                 
    -100 
a2 big-town-sightseeing Outcome21 
               
         0 
Outcome22 
                
       70 
Outcome23 
                  
- 20 
a3 museum Outcome31 
                  
      - 100 
Outcome32 
               
      0 
Outcome33 
                 
      80 
 
                                                 
543
 Indeed, the emergence of decision theory is intrinsically intertwined with the evolution of subjective 
probability theory.    Whereas first mathematicians and philosophers of science and than logicians have 
developed a probability calculus, economists and philosophers of mathematics (Frank Ramsey, Leonard 
Savage, Harold Jeffreys, Rudolf Carnap, Richard Jeffrey, to mention but a few) have developed a theory of 
rational decision and action on the basis of probabilistic knowledge: Bayesian theory. The connection 
between probability and decision has been modeled by Neumann and von Morgenstern (von Neumann, 
Morgenstern, 1944). The integration of the probability calculus into the Bayesian theory of belief has been 
carried out by Frank Ramsey in his intent to demonstrate the epistemic reality of probability as a measure 
of the degree of belief upon which one is ready to act. In his account, probability is not functional to 
decision, but rather the contrary: decisional behavior is the observable effect of the extent to which specific 
beliefs are entertained by the agent (Ramsey, 1931: 173 ff). This assumption is formalized in Jeffrey’s 
system, in that the probability is identified with the readiness to act on the basis of a belief and its 
welcomeness: the technical term used by Jeffrey is: “desirability”. See for instance Jeffrey, 1965, 1968. 
Savage develops the “subjective utility principle” for maximizing decision, by applying Ramsey’s 
subjective probability system to von Neumann and Morgenstern model (Savage, 1954). 
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The expected utility formula gives following results for each act under 
consideration: 
 
SEU(a1): ∑ P(S)U(a1) = 100(.6) + 0(.3) + (– 100)(.1) = 50  max 
SEU(a2): ∑ P(S)U(a1) = 0(.6) + 70(.3) + (– 20)(.1) = 19  
SEU(a3): ∑ P(S)U(a1) = -100(.6) + 0(.3) + (80)(.1) = - 52 
 
The maximum result is 50: the principle of expected utility maximization prescribes 
to choose act a1: going out for a picnic.  
Of course different weather forecasts would lead to different results. Therefore 
further information can eventually lead to a decision change. The expected value of 
further information to the decision will depend on its expected epistemic impact on 
the probability distribution related to the relevant states.  
Indeed Bayesian theory results from the development of three distinct but 
interconnected fields of research devised in order to describe (and optimize) the 
management of decisions under uncertainty:  
4) the theory of decision optimization through maximization of the expected utility; 
5) the theory of knowledge updating through probabilistic induction; 
6) the theory of expected value of information as a function of the expected reward 
in terms of contribution to decision optimization. 
“Uncertainty” means in this framework an epistemic state of less than perfect 
knowledge about the actual state of affairs, which is modeled by a probability 
distribution/function over a state partition.
544
  
Bayesian theory therefore allows investigating PL information: 
- as a support for decision optimization based on the expected reward of taking the 
drug vs. not taking it;  
- as a basis for knowledge updating (magnitude and probability of side effects 
occurrence) for a risk/benefit assessment about the drug (information for 
consent);  
- furthermore, PL expected value – and the consequent information seeking 
behavior associated to it – can be examined in this framework as a function of its 
expected contribution to decision optimization. 
 
 
 
 
 
2. Lay therapeutic decision 
                                                 
544
 A decision under uncertainty differentiates from a decision under risk such as that of games of chance, 
where probabilities are objectively determined by the stochastic mechanisms underlying the game (1/6 
probability for any die face in a throw, 1/52 of a Queen of hearts, etc.). However terminology slightly 
varies in the literature, especially objections are moved against the misleading use of the word “risk”: 
Gärdenfors, Sahlin, 1988: 5. Andersson and Littkens, 2002 use the term ‘conventional risk’ for uncertainty 
with known probabilities, in the sense that the individual is sufficiently confident to assign a specific 
probability measure to the events under consideration, and of ‘genuine uncertainty’ for a situation 
approaching ignorance, i.e. where the decision maker has a very vague of no idea about the probabilities 
which he should assign to the relevant events.  
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The application of Bayesian decision theory to therapeutic decisions has a long 
tradition in medical decision practice.
545
  
Health economics has also soon recognized health decisions as a paradigmatic case 
of decisions under uncertainty and has modeled the demand for health and health 
information along the SEU principle.
546
  
Indeed it seems that health choices approach the paradigm of decisions under 
ignorance: i.e. of decisions where the relevant states are assigned no specific 
probabilities: “The individual is likely to be highly uncertain if not completely 
ignorant about the probabilities involved. For example, he may be vaguely aware 
that there is a serous disease called leukaemia while having no idea of whether he is 
likely to get it and no idea about his possibilities to affect the likelihood of getting 
it”.547 In order to account for the variance in the degree of epistemic ignorance, 
Andersson and Littkens (2002) have proposed a mixed model of health decisions 
composed of two components: a standard SEU function and a generalized expected 
utility function which represents the expected utility over the states to which the 
decision maker is not able to assign firm probabilities. 
The first component is referred to as the function characterized by conventional risk, 
in the sense that each relevant state is assigned firm probabilities. The second 
component accounts for “genuine uncertainty”, in that it contains all states for which 
the subject has no precise idea as to their probability of occurrence.
548
 
This is represented in the model through the weighting factor (0 ≤ γ ≤ 1) which 
measures the degree of confidence in the accuracy of the probability function, and 
whose complementary (1 – γ), corresponds to the weight given to the states to which 
the decision-maker cannot assign any probability measure: 
 
U(a) = γ(a) ∙∑s π s (a) u(h
s
, a) + (1- γ(a)) ∙ u0(a).
549
  
 
The formula models health decisions by representing the utility function as depending 
on the anticipated health status (h), where the health states are ranked according to the 
number of (quality adjusted) healthy days. 
                                                 
545
 See for instance Green et al., 1998; Chapman, Sonnenberg, 2000. This tradition has a ‘prescriptive’ 
perspective: it aims at using Decision Analysis for making options as much explicit as possible in order to 
optimize medical resources and enable the practitioner to justify his choice on a rational basis (not 
ultimately as an argumentative point in case of litigation). 
546
 The pioneering and influential article by Arrow (1963) has first emphasized the presence of uncertainty 
in choices related to health. Grossman (1972) has settled the principles for the tradition of studies on health 
demand. See for an introduction to the topic: Lindgren (2002) and Andersson and Littkens (2002) with 
related literature references.  
547
 Andersson and Littkens (2002): 41.  
548
 Andersson and Littkens (2002): 41. 
549
 Andersson and Littkens (2002): 42; 45: “The interaction between risk and uncertainty aspects of the 
model seems to capture an important element in decisions about health related activities. Even when we are 
dealing with risk – so that an individual is implicitly thinking in terms of probability for, say, lung cancer – 
it seems reasonable to argue that he is often unsure about whether he has in fact the correct probability (π s) 
and about the effect of his actions on the probability of ill health (∂π s/∂a), e.g. the effect of smoking on the 
probability of lung cancer. The size of γ reflects the degree to which the individual is confident about π s 
and ∂π s/∂a (though we cannot separate the two attitudes)”.  
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The first component is an ordinary expected utility function with a probability 
distribution over health states h1 through hs (where hn > hn+1, i.e. preference decreases 
with cardinality). Both the utility and the probability function depend from the vector 
of activities (a):  
- the probability function because of state-act dependency,  
- the utility function because of the subjective cost associated to these activities.  
The second component is a generalized expected utility. It refers to health states S + 
1, … S + S′, for which the individual is not able to assign firm probabilities and u0(a) 
is a reduced form of the expected utility over these states:
550
 
 
u0(a) = Ẽ {u (h, a) | S + 1, … S + S′}. 
 
The weighting factor γ allows accounting for the effect of risk information which can 
simultaneously make people more genuinely uncertain (decrease of γ) and more 
pessimistic regarding the probability of a specific disease (higher probabilities are 
associated to less preferred states in π 1 (a), … π s (a)).
551
 In general it serves to 
measure the degree of confidence in the probability distribution of firm states (h1 
through hs). 
An activity (a) makes the distribution more favorable if it induces a shift in the 
distribution in the direction of stochastic dominance.
552
 Consequently the comparative 
utility of two health promoting (or risk preventing) activities should be assessed on 
the benchmark of their impact on the distribution in terms of stochastic dominance.  
This model is based on the assumption of uncertainty pessimism: the states 
surrounded by genuine uncertainty (no probability attached) are also the worst in the 
ranking: hs+s′ < … < hs+2 < hs+1 < hs. This assumption is realistic for modeling health 
demand in healthy individual (who might indeed be totally ignorant about the 
likelihood of being affected by a severe illness in the future). However, the 
therapeutic decision of a diseased patient might require further specifications. For the 
present purpose I will retain this assumption on the grounds that: 
1. the first component of the utility function can be considered to reflect the 
information provided by the doctor (tailored benefit-risk magnitude and 
                                                 
550
 Andersson and Littkens (2002): 43 and related footnote 5. These states are such that the agent does not 
have the roughest idea whether any preventive activity would influence their probability of occurrence: “As 
soon as the individual believes that it is possible to influence the probability of health outcomes – even if it 
is a very vague belief or hope – the probabilistic part of the function is involved”. Andersson and Littkens 
(2002): 46. Uncertainty aversion (ignorance denial) is captured by the assumption that states S + 1, … S + 
S′ are assigned probabilities that need not sum to 1. When the estimation is computed however these are 
“normalized” and transformed into weights summing to 1:  u0(a) = ∑ vs u(h
s
, a).  
551
 “If for example an exogenous event – like the alarm about the mad cow disease in Britain in 1996 – 
simultaneously makes people more genuinely uncertain and more dismal regarding the probability of brain 
disease, this is captured perfectly well by a simultaneous shift in the degree of uncertainty (γ) and in the 
probabilities (π)”. Andersson and Littkens (2002): 43. 
552
 i.e. if the cumulative distribution dependent on the activity ai is such that: 
Fai (h; a) = ∂F(h: a) ≤ 0. 
                      ∂ ai 
One distribution stochastically dominates another if for each outcome, h, something less preferred is less 
probable. The corresponding cumulative distribution functions for each should be such that for each h, G(h) 
≤ F(h). Andersson and Littkens, 2002: 45. 
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probability data), while the second can reflect residual doubts generated by the 
doctor’s or other information sources, for instance the PL; 
2. whenever the PL informs the consumer of risks not previously addressed by the 
doctor, this information should be taken into account according to informed 
consent regulation (relevance assumption), but, given that it is not tailored to the 
individual it is doubtful whether it can be assigned accurate probabilities.
553
 The 
more data about risks learned and surrounded by prognostic uncertainty, the more 
weight the second component of the utility function will have.  
 
Although Andersson and Lyttkens’ model has descriptive purposes, it can be also 
used as a benchmark for assessing the level of information accuracy at the basis of a 
decision, and eventually serve as a normative model for determining the extent to 
which the consent based on PL information can be considered informed.   
In fact the legislator implies that the decision-maker should be aware of benefits, 
risks and probability thereof. Consequently the “genuine uncertainty” component 
should equal 0 for consent to be informed, or at least approach it.  
Following Andersson and Littken’s model, consent could be defined as informed to 
the extent that the decision maker can assign a probability measure to each health 
status (γ→1)and can gauge whether the impact of the act ai (undertake the therapy) 
makes the distribution more favorable with respect to aj (do not undertake the 
therapy).  
As for the contribution of PL information in this respect, even if it is not supposed to 
give all details of the consequences of not taking the drug for the single individual 
(this information should indeed be provided by the doctor), still it is supposed to give 
essential data about ai: take the drug. 
Consequently PL information could be considered adequate for consent to the extent 
that γ for a2 approaches to 1, i.e. to the extent that all relevant health states are 
assigned a probability measure conditioned on the act of taking the drug. Provided the 
principle of proportionality for risk disclosure, the amount of γ should be greater,  
1. the greater the therapy risk is; 
2. the less severe the illness is;  
3. the less probable the benefit is. 
Moreover, consent will be considered informed in the measure that the probability 
distribution π1 (a), … π s (a) in relation to the anticipated health states approaches 
truth.  
Furthermore, because the choice also depends on the expected utility associated with 
the act of taking the drug or not, the contribution of PL information should be 
measured also on the basis of its part in giving relevant information for the utility 
function u (h
s
, a), i.e. information about the magnitude of the drug benefit and of its 
potential damage. 
2.1 PL information within the therapeutic decision 
 
The legislator implies that the decision to take a drug depends from the prognostic 
assessment of health benefit and risk. In accordance with the SEU model, the drug 
purchaser should evaluate the act of taking the drug vs. not taking it on the basis of 
                                                 
553
 This point will be discussed further below.  
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the risk and benefit information provided in the PL. Following the model presented 
above, PL information should concern ai (the act of taking the drug) and provide 
essential information both as to the utility and the probability attached to each 
possible outcome (h1-s). 
PL benefit and risk data should allow the decision maker assign any possible health 
state a probability (π) which depends on the act itself of taking the drug. The greater 
the confidence factor γ(ai), the more accurate is judged the probability distribution 
and the less relevant are health states surrounded by uncertainty.  
The analysis of PL information will therefore focus on both benefit and risk 
information (with a special attention to risk information, which is preponderant in 
package leaflets) with respect to magnitude and probability.  
The perspective of this investigation is not descriptive (modeling health information 
demand and effect in relation to package leaflets) but normative,
554
 i.e. focused on the 
question whether this information is intrinsically capable of bringing its specific 
contribution to informed consent. A descriptive analysis of the effect of PL 
information, and of its expected value will be undertaken in the next chapter and in 
the empirical part of this work. The table illustrates the distinction between a 
normative and a descriptive analysis of PL information: 
 
 Normative  Descriptive  
 Evaluation of PL 
information as a basis 
for informed consent. 
Description and eventual modeling of 
PL information effect on drug users 
(e.g. lack of therapy compliance). 
magnitude  Benefit PL epistemic value 
as to the assessment 
of benefit and risk 
magnitude and 
probability  
 
 
PL effect on the estimation of 
benefit and risk magnitude and 
probability 
- mediated by its expected value 
through information processing 
granularity. 
Damage 
probability Benefit 
Damage 
(Risk) 
prognosis  
diagnosis 
 
The normative analysis takes into account that the main responsibility for therapeutic 
information falls on the doctor and that it is assumed that doctor’s information should 
supersede PL information, anytime the two differ, in that it is tailored to the 
individual (medical errors in prescription or information disregarded).
555
  
 
 
 
 
 
2.2 PL information contribution to the decision utility function 
 
As illustrated in the preceding paragraphs, the utility functions of taking vs. not 
taking the drug depend on the anticipated health outcome. PL information may 
increase accuracy by providing relevant data as to the short-medium-long term 
health implications of taking the drug both in terms of welfare improvement, and of 
                                                 
554
 For a further distinction between the “normative” and “prescriptive” use of Bayesian theory see: Bell et 
al. (1988b) 
555
 I will illustrate this claim especially with reference to the frequency data associated with side effects.  
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potential damage (anticipated health outcome). The relevant parameters, which PL 
information should sharpen, are the probability function over the health states, π s (a) 
and the utility function, u(h
s
, a), through data about probability and magnitude of 
drug benefits and risks. 
 
 
2.2.1 Drug benefit magnitude   
 
The drug consumer indirectly evaluates the drug benefit on the basis of the disutility 
brought to him by the illness. This is why the drug risk/benefit evaluation has often 
been referred to as a risk/risk assessment (illness vs. drug risk). However this is not 
an accurate description in that the illness symptoms are certain, i.e. they are not a 
risk but an ongoing damage. 
An exception to this state of affairs is constituted by treatments concerning specific 
“risk factors” such as high blood pressure (which enhances for instance the risk of 
heart stroke). In these cases the evaluation related to the therapeutic choice is indeed 
a risk/risk assessment.  
Within the therapeutic decision the benefit information is principally provided by the 
doctor during prescription as the main rationale for consent giving. It is indeed 
implicit in the consultation dynamic that the drug prescribed at the end of the visit 
should alleviate or cure the condition which induced the patient to see the doctor. PL 
information constitutes in this context confirmatory information which can 
contribute to the modification of the utility function insofar as the drug information 
also includes the type of pharmaceutical effect (symptomatic vs. therapeutic) 
whenever this information has not been previously (and negligently) delivered by the 
doctor. Also information about eventual addiction effects or indication for other 
conditions in addition to one’s own disease can constitute valuable information 
whenever not already learned from the doctor. However, lack of benefit information 
from the doctor generally invalidates consent, and consequently the question of the 
role of PL information in this respect does not come into consideration. 
 
 
2.2.2 Drug damage magnitude 
 
The assessment of risk magnitude is a function of the number and severity of side 
effects included in the PL. Magnitude assessment can be hindered by a series of 
factors which singularly and jointly constitute a barrier towards the understanding of 
the health implications related to the symptoms and effects mentioned in the warning 
list.  
The following points display some of the difficulties which the reader might face in 
assessing the risk magnitude, when reading a specific side-effect in the warning list: 
a) uncertain implications of the symptoms (clinical-laboratory tests and 
blood serum modifications included);  
b) medical jargon; 
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c) pragmatic aspects of communication (invited inferences).556 
 
a) The greatest uncertainty source is represented by the description of symptoms 
whose (eventual long-term) implications might not be clear for the reader. This leads 
to misunderstandings in both directions: light side-effects might unduly alarm the 
reader, because he draws false conclusions from their description, or vice versa, he 
might erroneously neglect severe side-effects and consider them as negligible 
(eventually failing to take adequate measures timely).  
Example: 
 
“Erkrankung der Nerven (Periphere Neuropathie)”. 
“Nerves disease (peripheral Neuropathy”). 
 
What are the health implications of this side-effect? Is it a transitory disturbance or a 
permanent disease? What does it consist of?  
Also difficult to gauge for a lay reader is the meaning of a laboratory test result 
concerning blood values (blood particles, sugar level, and lever values) or clinical 
kidney tests. The medical implications of such data are not part of his competence 
and therefore uncertainty might arise as to their interpretation. The same holds for 
information concerning changes in the cardio-circular system.
557
  
b) A second source of uncertainty is medical jargon: terms like “lupus erythematosus” 
might not be associated to any adequate illness concept and so get simply not neatly 
categorized as either severe or light side effect. Although in this case we are speaking 
of a very severe side-effect, not many lay readers might get the message in its 
consequences.  
c) Another source of uncertainty lies on a higher order level of text comprehension, 
the pragmatic conversation maxims. The maxim of order, which entails the reader 
interpreting a list of items as displaying a ranking among them (of increasing or 
decreasing importance for instance) is often violated by presenting the side effects list 
in an order that mismatches their ranking as to the degree of severity: 
 
“Gelegentlich (0,1 – 1%): Lungenembolye, Atemnot (Dyspnoe), Wasseransammlung in der Lunge 
(Lungenödem), Nasenbluten (Epistaxis), Blutspucken (Hämoptysis) und Schluckauf”. 
(“Occasionally (0,1 – 1%): lung emboli, difficulty in breathing, water retention in the lungs (lung 
edema), nosebleed, blood spittle and hiccup”). 
 
From the point of view of illocutionary commitment, there are several cases of 
“attenuated” warnings: Text passages, in which the PL formulae provide a piece of 
risk information with no clear illocutionary meaning. Here are some examples: 
                                                 
556
 Linguistic analyses of package leaflet are presented in chapter 5. Here a brief list of main sources of 
uncertainty is presented in order to gauge the contribution of PL information with respect to the utility 
assessment of taking the drug vs. not taking it.  
557
 In fact in some texts these side-effects are explicitly presented as concerning the physician’s 
diagnostics: “Darüber hinaus kann ihr Arzt EKG-Veränderungen sowie Herzrythmusstörungen feststellen” 
(“Moreover, your physician can diagnose ECG-modifications and heart rhythmus disturbs”); 
“Ihr Arzt kann eine abnormal Anhäufung von Stoffen im Lungengewebe (pulmonale Infiltrate) 
feststellen” (“Your physician can diagnose an abnormal accumulation of material in the lung tissues 
[lung infiltrates]”).  
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- Sometimes the warning seems just scientific information for the purpose of 
knowledge sharing: 
 
“Geringfügige Veränderungen des Blutzuckerspiegels und der Elektrolytwerte wurden selten 
beobachtet. Die klinische Bedeutung dieser Veränderungen bei sonst gesunden Patienten ist unklar”. 
“Slight modifications of the level of blood sugar and electrolyte values have been seldom observed. The 
clinical meaning of these modifications is by otherwise healthy patients unclear”. 
 
- In other cases a warning is at the same time communicated and neutralized: 
 
„Häufig tritt eine Verminderung einer bestimmten Untergruppe der weißen Blutkörperchen 
(Neutropenie) auf, ohne dass sonstige Krankheitszeichen zu beobachten sind“ (Propycil 50 – Admeda). 
“It occurs often a decrease of a specific subgroup (neutropenia), with no other observable signs of 
illness” 
  
„Gelegentliche … Gelenkschmerzen ohne erkennbare Gelenk-Entzündungszeichen“ (Propycil 50 – 
Admeda). 
“Occasional articular pain without recognizable signs of articular inflammation”. 
 
The assessment of potential damage is highly prejudiced by the lack of adequate 
indexing of damage magnitude, especially as far as medium to long term 
consequences on the organ system are concerned.
558
  
In general improved communication, reader-friendliness and health literacy have a 
fundamental role in enabling the patient’s capacity to assess the therapy’s benefit and 
risk magnitude. 
Increased health literacy – as partly promoted by the doctor during consultation – 
might moderately contribute to a personal appraisal of the drug risk potential in a 
specific situation. However it cannot absolutely cover all possible items of 
information contained in the PL. For these, the reader will be unable to assign any 
personal disutility measure as an appraisal of their significance. 
 
 
2.3 PL information contribution to the probability distribution  
 
The therapeutic decision is considered informed to the extent that the patient can 
assign a probability function to the anticipated health status, and no health states are 
surrounded by uncertainty (γ →1). 
Moreover, this probability distribution should mirror as close as possible the real risk 
and benefit to which the patient is exposed to.  
However, PL frequency information lacks of specificity with regard to the individual 
user and therefore does not enhance accuracy to the doctor’s risk-benefit assessment.  
The contribution of frequency data in connection to those side-effects which have 
not been addressed by the doctor is positive but very low in terms of probabilistic 
accuracy.  
 
 
2.3.1 Benefit probability  
 
                                                 
558
 See suggestions for improvement in Waller, Evans, 2003: 22. 
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Information about the drug benefit is generally given in the PL in assertive form, and 
therefore implicitly presented as certain. This can be in contrast to the trial and error 
attitude which guides many therapeutic decisions, where the doctor prescribes a 
treatment without being certain of the healing effects. Sometimes treatments are 
prescribed also with diagnostic purposes: if the patient reacts to the treatment, this 
can constitute favorable evidence that he is indeed affected by the illness which the 
drug is supposed to cure. In this sense, benefit information given as certain can 
induce false beliefs in the reader. 
Anyway, efficacy data (the probability of healing effects) is also considered to be 
part of the doctor’s information duty, and therefore PL information is not supposed 
to give any specific contribution to informed consent in this respect.  
 
 
2.3.2 Damage probability: risk 
 
Information about side effects frequency is derived from laboratory experiments, 
clinical studies and relevant literature on the topic. This information should represent 
the strength of association between a specific side effect and drug use.  
Data about adverse drug reactions are derived from several statistical sources, whose 
degree of predictive value differ considerably: randomized control trials (RCT), 
observational studies, and pharmacosurveillance spontaneous reporting of adverse 
drug reactions. The evidence value of these types of studies depends on the 
experiment design, on the sample size, and on the type of side effect considered. 
The experiment design should guarantee that the effect observed can be really 
ascribed to the parameter investigated and that possible confounders are neutralized 
through randomization or controlled through adjustment. Sample size warrants for 
representativeness of data with respect to the population of interest. Finally, different 
types of side effect (rare vs. frequent, short-term vs. long-term) require different 
types of experiment design in order to be detected and quantified.
559
  
The strength of association between a cause and an effect is computed out of data 
about their joint occurrence, joint absence, and joint occurrence of one in the 
absence of the other:  
 
 
 
 C ¬C  
 E a b a+b 
¬E c d c+d 
 a+c b+d  
 
The strength of association is directly proportional to cell a and d, and inversely 
proportional to cell b and c. It can be assessed through different measures (for 
instance by computing the odds: ad/bc).  
                                                 
559
 For an epistemological discussion on the evidence value of RCTs with respect to other methodological 
approaches in the natural and social sciences see: Cartwright, 2007.  
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In clinical trials a/a+c is compared to the control datum b/b+d relative to the effect 
observed in absence of drug use (generally a placebo), in order to assess the 
treatment efficacy with respect to the control.
560
  
In the case of side effects the strength of association between a certain side effect 
and a specific drug is generally represented by the difference of side effect incidence 
in the users group with respect to non-users:  
The following contingency table presents a hypothetical example:
561
 
 
 Drug  ¬Drug  
 Side effect .01 .03 .04 
¬Side effect .02 .94 .96 
 .03 .97  
 
Strength of association between drug and side effect =  
P(S/D) – P(S/¬D) = P(S&D)    P(S/¬D) =  .01     .03 = .33 – .0003 = .3207 
                                    P(D)        P(¬D)       .03     .97 
 
In order to dispose of all the cell data, information about the proportion of sample 
population exposed to the drug with respect to population is necessary. This 
information is available in clinical trials and observational studies with a control 
group, but not in pharmacosurveillance data. However each type of study has 
advantages and shortcomings with respect to the others: 
I. Clinical trials provide a good control of confounders through randomization,
562
 
however their results should be evaluated in consideration of three fundamental 
aspects: 
1. They are not representative of the user’s population because the recruitment 
cannot account for multimorbidity cases, elderly subjects and in general the 
combination of factors present in clinical setting. Therefore the generalizability 
of these findings to ordinary practice is not guaranteed by the study.
563
   
2. They are based on relatively little samples. This heightens the probability of 
excluding persons of higher susceptibility than average and results in the failure 
to detect rare, particularly type B (non-pharmacologically mediated) adverse 
drug reactions.
564
  
3. Clinical trials cannot detect long-term side effects due to prolonged drug use.  
II. Observational studies, especially cohort studies, range over a longer period and/or 
are based on a large population but are compromised by lack of randomization, and 
therefore cannot completely control for confounders.
565
 This means that the 
proportions in the cells could reflect the hidden effect of some confounding factor 
rather than the effect of the treatment itself.  
                                                 
560
 The traditional asymmetry in efficacy vs. risk research is especially reflected in the insufficient 
investigation of side effects in randomized control trials. See Steckelberg, 2005: 345; Waller, Ebans, 2003: 
20; Wilcken, 2007: 370.  
561
 For an introduction to the interpretation of contingency tables within the framework of 
pharmacoepidemiology see Bender, 2001.  
562
 Bartons, 2000: 256. 
563
 Waller, Evans, 2003: 20; Wilcken et al., 2007: 368. 
564
 Waller, Evans, 2003: 20. 
565
 Barton, 2000: 255.  
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III. Postmarketing surveillance data lacks both randomization and control. 
Confounders are only partly controlled through a selection of ADR reports on the 
basis of a causal assessment,
566
 and there are seldom epidemiological data about 
drug exposure which provide the basis for incidence assessment.
567
   
Furthermore, pharmacosurveillance data are statistically flawed because of practical 
reasons. Post-marketing surveillance is blamed to be affected by underreporting and 
lack of standardization in symptoms description and causal assessment. From the 
point of view of evidence based medicine criteria, pharmacosurveillance tends to 
rely considerably on low quality evidence with respect to hierarchies.
568
  
The observed variance in the prescription materials (SPC, PL, data sheets) available 
for the same drug in different countries – and within the same country among 
different brands of the same drug –569  constitute and indirect proof that evidence for 
each single drug happens to be collected, assessed and evaluated differently in 
different environments.  
The epistemic value of side effects probabilistic information is therefore very limited 
as to its accuracy – because data coming from pharmacosurveillance are not 
supported by epidemiological data about drug exposure and relevant alternative risk 
factors, and observational study cannot completely control confounding – and 
exhaustiveness – because clinical trials cannot detect rare and long term side effects.  
A shortcut to the lack of adequate data for a precise estimation of side effect 
occurrence is the broad categorization into which frequency estimates – as proposed 
by the legislator – are slotted in: 
> 10% 
1 – 10% 
.1 – 1% 
.01 - .1% 
< .001% 
The probability interval of any side effect in each of the five levels falls in a 
considerably large range. As a consequence, PL information about side effect 
frequency is also vague.  
                                                 
566
 See chapter 1. § 4.2. Pharmacosurveillance retains however an indispensable value as a detection 
system. Waller, Evans, 2003: 20. 
567
 Talbot, Nilsson, 1998: 429.  
568
 Waller and Evans, 2003: 19. A paradigmatic case can illustrate this claim vividly. In the 1930s, soon 
after amidopyrine was identified as a cause of agranulocytosis, also dipyrone was, and cross-sensitivity 
between the two components was demonstrated: the incidence of agranulocytosis was assumed for both 
substances to reach a proportion of 1 out of 120 treated patients. Given this association the drug was 
banned in most industrialized countries (but it is still available in Germany, France and Spain). This 
assessment was questioned and reduced as low as 1.1 case per million users along the results of an 
international case-control study (International Agranulocytosis and Aplastic Anaemia IAAA). In Sweden 
the drug had been withdrawn from the market on March 1974 due to an estimated incidence of 1 case in 
3000 patients and commercialized again from 1995 onwards because of the low incidence found in the 
IAAA research. In 1999 it was again suspended thanks to a study conducted on the basis of all ADRs 
reports to the Swedish Adverse Drug Reactions Advisory Committee in the period 1966-1999, which 
assessed the risk at 1 out of 1:1439 (C.I. 95%: 1:850 to 1:4684). Along its commercial history, dipyrone has 
been associated with a largely variable range of frequency estimations with respect to its association with 
agranulocytosis: this variance illustrates the problems inherent with the assessment of drug risk probability. 
Hedenmalm, Spigset, 2002.   
569
 Reggi et al., 2003. 
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Low accuracy, non exhaustiveness and vagueness are amplified when it comes to the 
individual risk prognosis for the single drug consumer.  
 
 
2.3.2.1 PL information and individual risk 
 
It is acknowledged in pharmacological literature that both drug efficacy
570
 and risk is 
strongly dependent on the individual susceptibility to the drug (given dosage and 
therapy duration): “risk is not evenly distributed … Some patients are at very high 
risk and others at essentially zero risk, the challenge is to define that individual 
risk”.571  
Age
572
, sex, genetic make up, physiological changes, exogenous factors (drug-drug 
or food-drug interference) and disease-drug interaction influence the patient’s 
susceptibility to adverse drug reactions. Also ethnicity seems to be a carrier of 
factors (environment, genetics, lifestyle) determining higher or lower susceptibility 
to drug efficacy
573
  and side effects as well.
574
  
The table below presents paradigmatic cases of altered susceptibility to adverse drug 
reactions: 
 
Sources of 
susceptibility 
 
 
Examples 
 
Related literature 
Genetic  Porphyria   
Succinylcholine sensitivity   
Malignant hyperthermia   
CYP isozyme 
polymorphisms  
 
Age  Neonates 
(chloramphenicol) 
Mulhall A., de Louvois J., Hurley R. Chloramphenicol 
toxicity in neonates: its incidence and prevention. BMJ, 1983; 
287: 1424-7. 
Elderly people (hypnotics)  Greenblatt D.J., Divoll M., Harmatz J.S., MacLaughlin D.S., 
Shader R.I. Kinetics and clinical effects of flurazepam in 
young and elderly noninsomniacs. Clin Pharmacol Ther, 
1981; 30: 475-86. 
Sex Alcohol intoxication   
Mefloquine, Schwartz E., Potasman I., Rotenberg M., Almong S., Sadetzki 
                                                 
570
 Goldstein et al. 2007. 
571
 Spielberg, 1993: 31, 32. See also Waller, Evans, 2003:22. For the implications related to the 
communication of risk probability in these settings see Calman, 1996.  
572
 The risk of contact allergy to neomycin sulfate seems for instance to vary with age and increase with the 
number of additional positive reactions to other standard series allergens. Menezes de Pádua et al. (2005). 
573
 “Ethnic group may act as a marker for underlying genetic or environmental differences in this 
susceptibility” McDowell et al. (2006): 4. McDowell et al. (2006): 1. Relevant cases with regard to this 
point are the recent approval of isosorbide dinitrate plus hydralazine (BiDil) specifically for use in black 
patients: McDowell et al. (2006): 1.  
574
 A meta-analysis on the literature devoted to the investigation of the relationship between ethnicity and 
ADRs to cardiovascular drugs has for instance delivered the result that the relative risk of angio-oedema 
from ACE (angiotensin converting enzyme) inhibitors in black patients is 3.0 compared to non-black 
patients(C.I. 95%: 2.5 to 3.7); the relative risk of cough in concomitance with ACE inhibitors is 2.7 when 
compared between East-Asians  and white patients(C.I. 95%: 1.6 to 4.5); and the relative risk of 
intracranial haemorrhage with thrombolytic therapy is 1.5 (C.I. 95%: 1.2 to 1.9). McDowell et al. (2006): 2-
3. See also Henry et al., 1996 for gastrointestinal reactions to NSADs. The cited literature intends by no 
way to exhaust the literature on drug susceptibility variance, which is lately continuously gaining 
importance also as a consequence of the contributions coming from pharmacogenomics.  
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neuropshychiatric effects S. Serious adverse events of mefloquine in relation to blood 
level and gender. Am J trop Med Hyg 2001; 65: 189-92.  
Angiotensin converting 
enzyme inhibitors, cough 
 
Lupus-like syndrome  Batchelor J.R., Welsh K.I., Tino R.M., Dollery C.T., Hughes 
G.R., Bernstein R. et al. Hydralazine-induced systemic lupus 
erythematosus: influence of HLA-DR and sex on 
susceptibility. Lancet, 1980; i: 1107-9.   
Physiology 
altered  
Phenytoin in pregnancy Dickinson R.G., Hooper W.D., Wood B., Lander C.M., Eadie 
M.J. The effect of pregnancy in humans on the 
pharmacokinetics of stable isotope labeled phenytoin. Br J 
Clin Pharmacol, 1989; 28: 17-27.    
Exogenous 
factors  
Drug interactions  
Interactions with food (e.g. 
grapefruit juice with drugs 
cleared by CYP3A4) 
Aronson J.K., Forbidden fruit. Nature Med, 2001; 7: 7-8. 
Disease Renal insufficiency (e.g. 
lithium) 
Clericetti, N., Beretta-Piccoli C., Lithium clearance in patients 
with chronic renal diseases. Clin Nephrol 1991;36: 281-9.  
Hepatic cirrhosis (e.g. 
morphine) 
Hasselstrom J., Eriksson S., Persson, A., Rane A., Svensson 
J.O., Sawe J. The metabolism and bioavilability of morphine 
in patients with severe liver cirrhosis. Br j Clin Pharmacol 
1990; 29: 289-97.  
Table 5: Examples of drug risk variability determinants (Source: Aronson, Ferner, 2003: 
1223).  
The individual degree of susceptibility to a specific drug depends on the 
combination of the diverse parameters: conditional on their personal health profile, 
two individuals can show dramatic different reactions to the same molecular entity.  
The level of personal susceptibility cannot be obviously taken into account in 
product information. As a consequence, PL frequency data might be not very 
informative for the individual facing a therapeutic decision.  
The combination of the parameters determining the individual level of susceptibility 
is potentially infinite and therefore its effect in terms of individual susceptibility to a 
specific product cannot feasibly be anticipated in product information, but can at 
most be assessed by the health professional in possession of all relevant data both 
about the drug and the individual at stake (age, sex, genetic predispositions, health 
history, standard of living).  
In a formula, the probability of side effect occurrence should be computed out of 
drug toxicity information (SPC and PL among other sources), quantity (dosage and 
duration) and personal susceptibility:  
 
P(SE) = P(DT = i, Q = l, PS = h),
575
  
                                                 
575
 Because drug toxicity and personal sensitivity are given, while dosage (Q) can be calibrated at will, the 
probabilistic formula for assessing the personal probability of a side affect, could be also reformulated in 
counterfactual language: P(SEx/take drug y) = P(Ql SEx/(DT = I; PS = h)).  
A counterfactual is a belief entertained by an agent about the causal relation between an act ai and its 
capacity to bring about state Si. The symbol used for the counterfactual relation is: . “I do a  S” 
should be read: “If I were to do a, then S would hold”. Let a world Wa be the most close to the actual world 
at time t, if Wa is the world which unfolds after time t in such a way that if “I do a” is true in Wa, then “I do 
a  S” is true iff S is true in Wa.  Causal decision theory has emerged in order to account for the so 
called Newcomb paradox by distinguishing between evidentiary value of an act as a symptom that some 
state will obtain and its genuine contribution to the state occurrence. Gibbard, Harper, 1988 (1978): 342. 
Lewis has underlined that indeed even when independency between acts and states can be assumed, 
precisely because of this assumption “the full story” is causal (Lewis, 1988: 377). However, even if the 
distinction between causal and symptomatic state-act dependency has fundamental implications for the 
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Where the level of drug toxicity (DT = i) also depends on dosage and duration 
(Quantity Q = l) and the level of personal susceptibility to the drug components (PS 
= h) depends from both drug toxicity and quantity: 
 
= P(DT = i/Q = l) x P (PS = h/ DT = i; Q = l).    
 
The integration of PL data with relevant parameters is however out of the lay 
reader’s competence (and indeed very challenging for the health professional too). 
The legislator implicitly recognizes this state of affair by invoking the doctor’s 
responsibility in assessing the personal risk/benefit assessment specific to the 
individual patient.
576
  
The doctor is deemed responsible for checking the patient’s personal susceptibility 
on the basis of his genetic parameters, his health history, clinical profile, lifestyle 
and actual health conditions. He is responsible for prescribing him a therapy with an 
individually favorable risk/benefit assessment and for communicating him both risks 
and benefits associated with the therapy.
577
  
It is therefore his task to evaluate the individual risk and positive response to the 
drug, so as to make a rational choice.  
The doctor’s information cannot cover all items contained in the PL though. Indeed, 
the majority of the side effects listed in the PL are not generally addressed by the 
doctor – in consideration of their negligibility in relation to the patient at hand.  
However, even if the eventuality of these side effects is not explicitly considered by 
the doctor, still the patient must take them into account in his choice, because 
however negligible, their occurrence cannot be excluded with absolute safety.  
But, as the above considerations show, PL frequency data are not informative as to 
the actual risk to which the individual is exposed and the patient is not in the position 
to tailor PL information to his risk profile. Thus, their contribution to risk assessment 
is questionable. The probability assignment π s (a) would not get closer to truth by 
taking PL frequency information as a best estimate of one’s own risk exposure. 
Eventually, the awareness of this fact would also impact the degree of uncertainty (γ). 
Indeed each side effect mentioned in the list raises the question as to its possible 
occurrence, a question which the probabilistic data associated to it only marginally 
help answer. Given that the patient is hardly able to select which side effects are 
going to affect him, this information is bound to enter in the second component of the 
utility function and increase genuine uncertainty (thereby decreasing γ).  
 
 
3. PL information as an alerting device  
                                                                                                                                                 
mathematical model proposed by Savage, it has no repercussion at the level of probability computation, and 
therefore can be left apart in this context. 
576
 In the U.S. the theory of the learned intermediary relates precisely to the inadequacy of product 
information as a basis for individual prognosis: the doctor intermediates between the pharmaceutical firm 
and the drug consumer by selecting the appropriate product on the basis of an individual risk/benefit 
assessment and is also supposed to be in the best position for informing the consumer about his personal 
risk/benefit prognosis. See Ferguson, 1992, for discussion. 
577
 See chapter 4 § 2.  
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The analysis of PL information with respect to its potential contribution to the 
decision parameters (degree of accuracy γ, probability distribution π s (a), utility 
function u(h
s
, a)) has delivered following results: 
1. Most information is surrounded by uncertainty in terms of magnitude (health 
implications in the medium to long term effects).  
Because utility is defined in terms of quality adjusted health states, lack of clarity 
about the health implications related to drug intake constitutes an insurmountable 
obstacle to the integration of PL data in the decision maker’s utility function u 
(h
s
, a). Therefore these data will either fail to be taken into account or contribute 
to increase the weight of the second component of the utility function, thereby 
increasing genuine uncertainty (therefore decreasing γ); 
2. Also probabilistic information does not help the reader increase his accuracy in 
terms of personal risk exposure: the frequency data resulting from clinical trials, 
observational studies and pharmacosurveillance reports have a low predictive 
value in relation to the single user. For this reason all side effects not previously 
addressed by the doctor cannot be assigned an accurate probability (π s). These 
should therefore contribute to increase the weight of the second component of 
the utility function, correspondingly decreasing γ. 
3. As for benefit probability data, they are generally given as certain thereby 
misrepresenting the fact that not only side effects, but also efficacy is dependent 
on the user’s susceptibility. This leads to the construction of a probability 
distribution which fails to take into account benefit uncertainty (fallacious π s).  
Along these observations it is hard to define the therapeutic choice made on the basis 
of PL information as “informed”.  
Indeed the epistemic status of PL information can be rather compared to that of an 
alerting device: risk data contained in the PL and previously not contemplated in the 
therapeutic decision made with the doctor cannot be assigned an accurate probability 
measure and therefore decrease γ. Furthermore, given the high preponderance of risk 
over benefit information, they are able to shift the median of the probability 
distribution towards the worst health states. 
This double effect is at the origin of much research on the psychological effects of 
health risk information and will be treated in the last chapter.  
 
 
4. PL information and therapeutic safety 
 
The value of PL information as a risk prevention/minimization tool should not be 
hidden away by the above exposed considerations about the role of PL information 
for informed consent. 
In fact, as an expert of his own health history the patient should be considered 
responsible for checking all information regarding adequate precautionary behavior 
(precautions, and eventually also contraindications) and notify the doctor about 
related facts who he might not know of. Avoidable risk totally depends on the user’s 
(and the doctor’s) behavior per definition. 
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Also information about side effects, which is to be considered information for 
consent in that it discloses residual (unavoidable) risk, can be contextually 
considered as safety information. The side effect list might help the reader identify 
an unexpected symptom eventually occurring during the therapy as drug conditioned 
rather than caused by the illness. This awareness might than help him take adequate 
countermeasures and call for the doctor up to eventually stop the cure. 
In this sense, PL information can be considered as a support to diagnosis:
578
  when 
the consumer is already taking the drug, the list of side-effects with associated 
frequencies might help the consumer consider the possibility that the origin of the 
unexpected occurring symptom is (more probably) associated to the drug than to the 
illness itself or to other factors, and act consequently. 
Finally, PL information contributes to drug safety also indirectly by recommending 
the user to notify to his doctor or pharmacist any adverse reaction which is not 
written in the leaflet.
 579
 
In this second sense the drug consumer functions, as it were, as a terminal for the 
pharmaco-surveillance detection system,
580
 and the PL message raises the awareness 
that the side effect list is not exhaustive.  
5. Consequences for the legislator 
 
The distinct contribution brought about by PL information as a basis for prognosis 
(and therefore therapy consent) vs. its role in risk minimization/prevention (safety 
function) should be acknowledged by the legislator through adequate articulation of 
the liability distribution.  
In particular, the patient’s responsibility of taking notice of risk information should be 
emphasized as far as its preventing function is concerned. In this sense, also the list of 
side-effects can be considered safety information when consulted as a reference for 
identifying the origin of an unexpected symptom.  
Whenever damage occurs which could have been prevented or minimized if the 
patient would have taken notice of precautions and warnings written in the PL, then 
he should be deemed responsible for (contributory) negligence.  
This is also the case of unavoidable risk (side-effects) when recognized in time to 
hinder severe damage. In this respect information about side-effects accomplishes a 
safety function with respect to which the patient should be considered partly 
responsible. 
Instead, failing to take notice of residual risk information as a basis for therapeutic 
choice cannot be equated to an information waiver as proposed by some legal 
theorists in analogy to doctor’s liability.581  
                                                 
578
 See also Amery, 1999: 125.  
579
 As prescribed both by the European – Directive 2001/83/EC of the European Parliament and of the 
Council of 6 November 2001 on the Community code relating to medicinal products for human use Art. 59 
(e): OJ L 311, 28.11.2001: 86 – and by the German legislator (§ 11 I 5 AMG). 
580
 Indeed, the introduction of a molecular entity into the market has been compared to a “population 
experiment”: Berger, Mühlhauser, 2000:155; Stricker, Psaty: 2004: 44). Some treatments are retired from 
the market even decennials after their approval: in a recent French study on product withdrawal, market life 
has been estimated on average 25.2 years for drugs with type-B ADRs, and 38.9 years for drugs with type-
A ADRs (Olivier, Montastruc, 2006: 809).  
581
 Koyuncu 2006 a. o.  
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In fact, PL information cannot be readily considered an adequate basis for an 
individual prognosis such as that provided by the doctor. Instead it only functions as 
an alerting device, which put the reader into notice about the risks observed to be 
associated with the drug in clinical trials, observational studies and pharmaco-
surveillance. The frequency data emerging from these studies though are provisory 
and susceptible to continuous revision, because of the limitation inherent to their 
design: either they are non-representativeness because of limited sample size (RCTs) 
or they lack of control over confounders because of lack randomization and of control 
groups (observational studies, pharmaco-surveillance reports). More importantly the 
accuracy of these frequency data as predictors of risk for the individual is very 
limited, given the significant differences in drug susceptibility across risk groups and 
from individual to individual. 
However, consent is informed to the extent that the consent-giver is made aware not 
only of the potential damage and risk, but also of its probability of occurrence. 
Therefore the consumer should not be considered committable to residual risk on the 
basis of PL information.  
 
 
 
 
6. Summary and conclusion 
 
This chapter has undertaken the task of answering the following questions: 
3. What requirements the legislator establishes for consent to be qualified as 
informed; 
4. Whether PL information fulfils these requirements.  
As for the first point, the requirements are derived from the right which the institute 
of informed consent should honor, i.e. the right to self-determination: Information 
prior to consent should enable the patient to make an autonomous choice and 
therefore provide him with relevant data about the intervention/therapy and the risks 
and benefits involved. In order to allow a risk/benefit prognosis also probabilistic data 
about the therapeutic effect and potential damage should be given.    
In order to analyze the role of PL information in this setting, it has been considered its 
role as a contributor to epistemic accuracy within the therapeutic choice. The 
introduction of a Bayesian model for health choices accounting for the presence of 
genuine uncertainty (Andersson and Littkens, 2002) has allowed us to identify and 
distinguish relevant parameters in relation to the role of information in health 
decisions. The model is constituted by a two-components function. The first 
component is a traditional expected utility function (where utilities are weighted by 
probability assignments); the second is a generalized expected utility where health 
statuses (utilities) are surrounded by “genuine uncertainty” (tending to ignorance) and 
cannot be assigned firm probabilities. 
Along this model, consent has been defined to be informed to the extent that it 
approaches a decision under risk (known probabilities), i.e. to the extent that the 
decision maker can assign a probability measure to each relevant health state in a 
ranking from the most favorable to the worst – being health states nothing else then 
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quantities of quality adjusted healthy days – and that he knows whether the act of 
taking the drug (a) shifts the probabilistic distribution towards stochastic dominance 
with respect to the act of not taking the drug.  
This means that the weight factor associated to the first component of the utility 
function (which assigns a probability measure to each health status) tends to 1 (γ→1) 
in the case where the decision is “informed”.  
Against the framework of this model, PL information seems to provide the drug 
consumer with data whose personal relevance, and therefore prognostic value for the 
individual, is difficult to assess.  
There are in fact no legitimate epistemic grounds for directly assuming the statistical 
frequency associated with side effects in the PL as a prognostic judgment about the 
probability that a single user might be concerned by the side effect. 
In order for it to ground the prognostic assessment, PL information should be 
integrated with other parameters such as personal susceptibility given 
dosage/duration. This is precisely the task accomplished by the doctor when he 
discloses the therapeutic residual risk. However, the doctor is not supposed to inform 
the patient about all possible side effects contained in the PL, but only about those 
that he considers concretely possible in the single case.  
Given that all side effects must however be taken into account by the drug user in 
accordance to the responsibility shouldered within informed consent, these data are 
bound to contribute to the weight factor assigned to the uncertainty component of the 
utility function.  
Furthermore the probabilistic assessment should be combined with the perceived 
importance of the eventual damage (subjective disutility), the evaluation of which is 
most of the times hindered by the lay incompetence to appraise the magnitude and 
health implications of the risks mentioned in the PL. 
This means that consent on the basis of PL information rather approaches a decision 
under ignorance than one under risk: as a prognostic device, PL information 
fundamentally asks more questions than it answers. 
Given that the legislator implies that consent is given with knowledge of the 
probabilities of risks and benefits, PL information cannot be considered adequate for 
consent.  
As for the safety function which PL information should also accomplish, the 
contribution of PL information in this respect does meet the minimal legal 
requirements, in that the drug consumer can actually profit from it in order to use the 
product correctly and safely insofar as instructions comply with readability standards 
established by the law. In this respect, also information about residual risk (side 
effects) accomplishes a safety function in that it might help the consumer identify 
eventual unexpected symptoms as side effects, whenever they are already listed in the 
text.  
The legislator should account for this asymmetry and regulate liability clauses 
consequently: the consumer should not be considered committable to residual risk on 
the basis of PL information, but instead it should be emphasized his contributory 
negligence whenever safety aspects of PL information are not sufficiently taken into 
account by him.  
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PART III 
 
Empirical Findings 
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7 PL information and therapeutic choice: 
An exploratory study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
The preceding chapter has been devoted to a normative analysis of PL information 
and to demonstrate its different contribution to risk prognosis and diagnosis 
respectively.  
It results that from a mere epistemic perspective PL information cannot constitute a 
valid reference for the individual assessment of risk and benefit prognosis.   
Instead, it can eventually bring a valid contribution to the causal assessment of 
unexpected symptoms occurring during the therapy (diagnostic value). 
The conclusion is that PL information cannot be considered as a valid support for the 
consumer’s autonomous decision, but that it can validly help the consumer diagnose 
unexpected symptoms and act consequently. In this respect, the side effect list 
accomplishes a safety function in that it allows the patient take adequate measures for 
minimizing adverse drug reactions.  
As a consequence, we have proposed that, corresponding to the different purposes of 
PL information, i.e. risk prevention/minimization (safety aspect) and risk disclosure 
(self-determination aspect), liability regulation should be correspondingly articulated 
into two distinct sectors.  Failure to comply with safety information should indeed be 
categorized as (contributory) negligence from the side of the drug consumer. Instead, 
the simple disclosure of side effects in the PL cannot be considered as an adequate 
basis for informed consent and therefore cannot completely offload the 
pharmaceutical firm from responsibility about health damage.  
The common objection to the qualification of PL information as a valid source for an 
autonomous decision moved in the legal literature and jurisprudence does not touch 
its epistemic foundations though, but rather takes into account psychological 
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considerations related to the effective fruition of this sort of information by the lay 
user.
582
 
This type of objection is echoed for instance in court decisions which consider 
invalid the consent obtained through standardized formularies and generally written 
pre-drafted communication.
583
 In the specific case of PL information, this attitude is 
mirrored in the latest pronouncement of the BGH concerning health damage 
compensation on the basis of information insufficiency: the information contained in 
the PL is not considered information for self-determination, so that the doctor is 
cautioned that a simple reference to the PL does not absolve him from the duty to 
inform the patient personally, because he cannot take for granted that the patient will 
read and follow the instructions contained in the PL.
584
 
On the other side, legal theorists and the health professional alike raise a somehow 
opposite objection to PL information: this regards the frightening potential of PL 
information and its detrimental effects on compliance and therapeutic safety. 
Patients are assumed to get anxious about the therapy by reading the PL and 
consequently suspend the therapy.  
Indeed, as already emphasized by the analyses conducted by linguists, given the 
uncertainty sources identified by them at all discourse levels (lexical, semantic, and 
pragmatic)
 585
 an ideal reader, should at least loose part of his confidence in the 
therapy, when not straightforwardly refuse it.  
Empirical data about drug waste could be an indirect evidence of this reaction: each 
year 100 tons of pharmaceuticals for a value of 500 Mio. Euros go into the garbage. It 
is estimated that 1/5 to 1/3 of the prescribed drugs are thrown away without even 
opening the blister.
586
  
However, a variety of responses to PL information has been empirically observed. A 
recent study on PL information evaluation conducted by the Wissenschaftliches 
Institut der AOK (WidO) reported 29% of the participants being less confident 
(“verunsichert”) after reading the PL.587 This is a considerable figure, but still does 
not provide evidence of a general decrease in therapeutic confidence.  
This chapter presents a quantitative study (of limited sample size: n = 55)
588
  with the 
aim to explore PL information as basis for the therapeutic decision. A sort of “paired 
comparisons test” has been devised. Questions related to the risk/benefit estimation 
and decision confidence were asked before and after reading the PL accompanying 
the drug. 
Bayesian categories such as knowledge updating, expected net value of information 
and decision sensitivity to further information have been integrated with specific 
dimensions concerning the therapeutic decision: trust in the doctor, shared decision 
making, experience with treatments and side effects.  
 
                                                 
582
 See also chapter 4 § 4.5  
583
 BGH NJW 2000, 1784, 1787, f; BGH NJW 1985, 1399; BGH VersR 1973, 244 (246); VersR 1985, 361 
(362). 
584
 BGH 15. 3. 2005, NJW 2005, 1717 
585
 See chapter 5.  
586
 Bronder, Klimpel: 2001. See chapter 4 § 4.5.  
587
 Nink, Schröder, 2006: 76. 
588
 The original version of the questionnaire can be found in the appendix.  
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1.1 Method 
  
Like most empirical surveys many efforts had to be devoted to sample recruiting. In 
this case the difficulties were also increased because of the restricted relevant 
population: people under treatment at the time of survey, but not hospitalized. This 
choice was determined by the investigation purpose. In fact only people really 
concerned by the drawbacks of the illness can make a risk/benefit assessment in 
relation to the drug.
589
 On the other side, I wanted to check the use of PL information 
in out-patients because its importance is very reduced in hospitalized patients, who 
anyway are seldom given the package leaflet of the drugs they are taking. 
The questionnaire was administered in the university campus of Bielefeld in the 
period April-June, 2005. Participants were asked whether they wanted to take part in 
a survey concerning package leaflets and drug information, with the condition that 
they were actually taking a treatment. Most of the people contacted were not under 
treatment, but among the ones who were (ca.10%) I had a considerable feedback 
(82%). People were contacted in the university campus among the personnel and 
among students. Students were contacted in the mensa, and personnel was contacted 
in their bureaus. Reliability (avoidance of selection bias) could be partly secured by 
the fact that most of them participated because of the circumstance that it was a study 
conducted by the university in which they studied/worked, rather than for personal 
reasons. 
Among them also a series of structured interviews were made (15) for the qualitative 
part of the study.  
 
 
1.2 Sample population 
 
The sample population is composed of 55 participants under therapy at the time of the 
survey. The distribution of treatment types is rather heterogeneous, as the table can 
show, but two main groups are preponderantly represented: antibiotics and blood 
pressure drugs. Blood pressure medication is subdivided in three beta-blockers, two 
angiotensin antagonists, two vasodilators, one ACE inhibitor, one calcium canal 
blocker, one anti-cholesterol medicament and one other treatment for which only the 
indication but no name has been provided by the participant.   
 
 
Drug Type  Frequency  
blood pressure 11 
antibiotics 10 
thyroid 5 
non-steroidal 
antiinflammatory drugs 
(NSAIDs) 
5 
antihistamines 3 
cortisone 3 
 
 
Drug Type Frequency 
Antidepressant 2 
pill 2 
antiestrogen 2 
anticoagulant 2 
osteoporosis 2 
asthma 2 
benzodiazepin 2 
other 4 
Total 55 
 
                                                 
589
 See also Schuldt, 1992: 120; Edwards et al., 2003: 702. 
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According to therapy duration, the cases were classified as chronic (n = 31, more than 
6 months since therapy inception) or acute (n = 24, less than six months). The time 
scope among the chronic cases is very large ranging from the 1
st
 January 1975 until 
20
th
 June 2005. Among the acute cases, the relative majority of them are distributed 
in the first week.  
 
Acute cases: therapy inception time 
 
Therapy 
inception time Frequency 
≤ 1 week 11 
≤ 2 weeks 2 
≤ 2 months 3 
≤ 3 months 4 
≤ 4 months 2 
≤ 6 months 2 
Total 24 
 
  
As for demographic data, the majority of the sample population is composed of 
female subjects (n = 42 against 13 male subjects). This reflects the preponderance of 
medication in female population.
590
 Age has a “bimodal” distribution along the entire 
adult life span.  
 
Age 
Age group Frequency Percent 
Cumulative 
Percent 
17 to 20 2 3,6 3,6 
20 to 29 10 18,2 21,8 
30 to 39 7 12,7 34,5 
40 to 49 12 21,8 56,4 
50 to 59 9 16,4 72,7 
60 to 69 7 12,7 85,5 
70 or more 8 14,5 100,0 
Total 55 100,0   
 
The sample is mainly composed of medium-to-highly educated persons, which is also 
reflected in the profession variable.  
                                                 
590
 In recent studies the difference in drug use according to sex lies between 36% and 50% more 
consumption for women (with a higher gap for psychotic drugs). Knopf, H; Melchert H.-U. (1999) 
Subjektive Angaben zur täglichen Anwendung ausgewählter Arzenimittelgruppen- Erste Ergebnisse des 
Bundes-Gesundheitssurveys 1998. In: Das Gesundheitswesen 61, Sonderheft, 2: 151; cited in Krudop-
Scholz, 2005: 38. 
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Education Freq. Valid  
Percent 
Hauptschulabschluss 
(primary school) 
11 20,8 
Realschulabschlus 
(secondary school) 
11 20,8 
Abitur 
(secondary school) 
15 28,3 
Universität 
(University degree) 
11 20,8 
Other  2 3,8 
Medicine student 3 5,7 
 Total 53 100,0 
Missing 2  
Total 55  
 
 
Profession 
 
Freq.  Valid 
percent 
blue collar 5 9,3 
white collar 14 25,9 
executive 
officer 
4 7,4 
free lance 1 1,9 
housewife 4 7,4 
Student 13 24,1 
health 
professional 
6 11,1 
other 7 13,0 
Total 54 100,0 
Missing 1   
Total 55   
 
 
As far as the health condition is concerned, this parameter has been measured by two 
questions:  
- number and severity of diseases affecting the participant apart from the one for 
which the subject was under treatment with the drug related to the questionnaire (Q. 
72): 
 
health condition: number of diseases
32 58,2 65,3 65,3
17 30,9 34,7 100,0
49 89,1 100,0
6 10,9
55 100,0
one
> 1
Total
Valid
SystemMissing
Total
Frequency Percent Valid Percent
Cumulat ive
Percent
 
health condition: severity of diseases
16 29,1 32,7 32,7
6 10,9 12,2 44,9
27 49,1 55,1 100,0
49 89,1 100,0
6 10,9
55 100,0
light
sev ere
chronic
Total
Valid
SystemMiss ing
Total
Frequency Percent Valid Percent
Cumulat ive
Percent
 
 
- the number of other drugs, apart from the one for which the subject was making 
the questionnaire (Q. 74):  
other drugs: how many
29 52,7 53,7 53,7
8 14,5 14,8 68,5
3 5,5 5,6 74,1
5 9,1 9,3 83,3
4 7,3 7,4 90,7
2 3,6 3,7 94,4
1 1,8 1,9 96,3
2 3,6 3,7 100,0
54 98,2 100,0
1 1,8
55 100,0
,00
1,00
2,00
3,00
4,00
6,00
7,00
8,00
Total
Valid
SystemMiss ing
Total
Frequency Percent Valid Percent
Cumulat ive
Percent
 
 
the sample was almost equally distributed in a group of people, taking just the 
questionnaire drug (n = 29, 52,7%) , and another group taking other drugs in addition 
to it (n = 26, 47,3%: from one to eight).  
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2. Overview of the survey’s result 
 
The survey is far from describing systematic patterns of risk/benefit assessment. 
However it uncovers a series of phenomena worth of further investigation.  
The descriptive analysis has given following results:
591
  
1) PL reading has practically no average impact on the risk/benefit assessment. This 
is due both to the lack of a systematic change direction, and to the considerable 
proportion of no change responses in the sample. The expected frightening effect 
is not systematically observable: some respondents have a decreased instead of an 
increased risk perception after reading the PL (and the same is valid for all other 
parameters).  
2) More importantly PL information seems to have absolute no impact in the 
decision to take the drug in this sample: all participants crossed the 100 score to 
the question asking whether the respondent was thinking of not taking the drug 
after reading the PL. 
These data apparently contradict following results:  
3) PL information ranking among other non-tailored sources of health information is 
fairly high with a mean value of 70.6 (sd 20.8, n=49, in a scale from 0 to 100) 
where all other sources of information (the press, the internet, mass media) are 
ranked significantly lower and range from a maximum of 37.4 (sd 26.3, n=43) for 
the internet to a minimum of 14.1 (sd 17.8, n=45) for advertisements.  The 
reliability of the doctor as a source of information has by far the highest average 
score: 81.1 (sd 20.7, n=53); the pharmacist has a good second position with 
reliability mean score 72.7 (sd 23.6, n=52); one’s own experience is valued 67 
points on average (sd 24.2, n=47), whereas the opinion of friends and relatives 
only reaches a mean value of 34.5 (sd 22.3, n=49). 
4) The declared value of PL information is also high: PL information is sufficient 
(mean = 74.8, sd 25.2, n=53) and useful (73.9, sd 26.9, n=47), not excessive 
(18.7, sd 28.9, n=44), a little bit disquieting (34.2, sd 31,8, n=45), but rather old 
(60.21, sd 30.7, n=46). However the majority of respondents do not want to have 
further information in the PL (mean value of desire to have further information in 
the PL: 40.32 in a 0-100 scale). A good 29.1% does not absolutely want any 
further information in the PL (0 score) and 20% are totally uncertain as to whether 
they desire further information in the PL (50 score).  These data speak for 
contrasting feelings towards PL information. 
5) More importantly, the only significant parameter change among those 
investigated in the paired comparisons test: the respondent’s perceived level of 
information. This is in fact declared to be significantly higher (Z. -4.013, .000) 
after reading the PL: mean value 65.74 (in a 0-100 scale with sd: 27.7, n = 54) 
before reading the PL, and 82.12 after (sd: 20.7, n = 54).  
                                                 
591
 Demographics data are presented in the appendix. The strength of associations has been measured 
through non-parametric tests: either Chi-Square for the Kruskal-Wallis Test (henceforth χ2) and/or Kendall-
Tau b value (henceforth τ). Asymptotic and approximate significance for the χ2 and τ value respectively 
will be given in brackets, e.g.: (.001). 
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The more reasonable hypothesis that can be advanced in order to account for 1-2 and 
3-5 is that the decision settings of the participants were not sensitive to the 
information received in the PL.  
In fact, even the systematic patterns of association between the presence of a specific 
topic of concern and some decision parameters does not result in a decision change by 
any of the study participants. 
It seems however that, rather than by the overall amount of PL information, the reader 
is struck by selected items: this phenomenon has been categorized in the risk 
perception literature as absence of ‘spill over effect’.592 The decision parameters 
related to this presence of a specific topic of concern are: 
1) Degree of confidence. Both in the pre-PL phase, τ -.283 (.015, n = 50), and in the 
post-PL phase, τ -.418 (.000, n = 52), the presence of a specific topic of concern is 
associated with a lower degree of confidence in the therapeutic choice. 
2) Risk/benefit assessment. In the post PL phase the presence of a specific topic of 
concern is associated with a higher risk assessment: χ2 7.526 (.006, n = 48). 
3) General benefit prognosis. The absence of a specific topic of concern is 
associated with a higher general estimation of the drug benefit: χ2 4.417 (.036, n = 
23). 
4) Personal benefit prognosis. The absence of a specific topic of concern is 
associated with a higher estimation of the personal benefit: χ2 4.964 (.026, n = 
41). 
The presence of a specific topic of concern has an impact on the risk and benefit 
assessments before and after reading the PL, but not on the change patterns. This may 
be explained by the fact that by reading the PL some readers solve their uncertainties, 
some other become uncertain, and others remain as uncertain as before.  
As far as the relationships between risk and benefit assessment changes and other 
decision parameters, general and personal assessment changes show discrepant 
patterns of associations as fosterer or inhibitors of change: 
i. The level of concern (measured by asking what would be the consequences of not 
taking the drug) seems to have an impact on both personal risk assessments 
changes: the Kruskal-Wallis test gives significant results for the personal risk 
prognosis change: χ2 8,570 (.014, n = 30), and the risk/benefit prognosis change χ2 
7,890 (.019, n = 44).  
ii. The level of risk acceptance has some impact on the personal risk assessment: τ -
.333 (.012, n = 31). The same is valid for the relationship between personal risk 
assessment change and degree of confidence in choice: τ -.324 (.007, n = 33). 
However neither the level of risk acceptance nor the degree of confidence has any 
influence on the other change parameters.  
iii. Past experience with side effects only influence the assessment change of general 
risk quantity: τ .257 (023, n = 34); whereas past experience with benefit has some 
association with a positive change in risk/benefit assessment: τ .255 (.041, n = 
45). 
iv. Health condition (dichotomised parameter: light disease vs. severe-chronic) has 
some impact on the general assessment change of risk severity: τ -.295 (.041, n = 
40). respondents with a light disease all increase their risk assessment after 
                                                 
592
 Viscusi, Magat, Huber, 1987: 169 
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reading the PL or leave it unchanged but do not decrease it. The same is valid, but 
for few exceptions for the risk/benefit assessment change: respondents affected by 
a light disease tend to increase their risk perception after PL reading, whereas the 
majority of severely ill participants do not change their risk/benefit assessment: τ -
.267 (049, n = 34). 
v. Total indifference about the perceived level of information (50 in a range from 0 
to 100) is associated with risk severity increase after reading the PL: χ2 8,665 
(.034, n = 39).  
vi. The PL content has no influence on the personal risk and benefit assessment 
changes apart from a slight tendency of personal risk assessment decrease for PLs 
with numeric rather than verbal frequency descriptors: τ -.249 (.083, n = 31). 
Instead the number of indefinite side effects (neither clearly light nor severe) 
seem to influence the assessment change of risk severity by creating a sort of 
shaking effect: τ. 303 (.018, n = 35) and a lower than average number side effects 
in general is associated with an increase in general benefit prognosis: τ -.603 
(.000, n = 19).  
Topics of discussion:  
1) Decrease in personal risk perception is influenced by the level of concern, and 
level of acceptance of side effects. This suggests that health risk estimation should 
be dealt with by drawing on prospect theory, which accounts for degree of risk 
aversion/proneness on the basis of the status quo and the prospect offered by the 
available options in relation to it (loss or gain).  
2) The absence of an average impact is not only due to conservatism risk 
assessments but also by the neutralization of assessment changes in either 
direction. It is however difficult to explain those cases where risk estimation not 
only does not change but even decreases after reading the PL. A pragmatic 
explanation of this phenomenon is advanced, i.e. that the risk found in the PL is 
less than expected before reading it, where expectations are formed through 
acquaintance with the text type. 
3) The PL content in terms of number and severity of side effects influences the 
benefit rather than the risk assessment change. This phenomenon can be explained 
by the joint influence of two distinct phenomena: the lack of clear distinction 
between risk and benefit in the lay assessor,
593
 and reappraisal strategies.
594
 
The results are presented in the following. The topics of discussion are dealt with in 
more detail in the qualitative part of the study and in the discussion at the end of the 
work. Method and demographics data are presented in the appendix. 
 
 
 
 
                                                 
593
 Vander Stichele, 2002: 206; Alkahami, Slovic, 1994: 1090. Traditional studies on perception of 
technological risk at societal level have also observed that a high benefit perception obscures the perception 
of potential risk (which goes in the contrary direction to expert risk/benefit assessment, where high benefit 
should balance high risk): Slovic, et al. 1980: 149. Starr, 1969. 
594
 See Afifi, Weiner, 2004: 181 ff.; Preuss, S: 74 ff.; Witte, 1998: 437, 438. More on this in the discussion 
and in the last chapter. 
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3. Descriptive statistics 
 
3.1 PL information impact 
 
The benefit and risk assessments before and after reading the PL did not register any 
significant change in average. It can be assumed that the commonly held opinion that 
PL information threatens the reader should be treated with more caution. The study 
indeed shows that this does not invariably happen, and that instead a variety of 
different attitudes to this type of information leads to very different reactions. The 
table below shows the main descriptive statistics:  
  
   Before PL reading  After PL reading  
 
N Mean 
Std. 
Deviation N Mean 
Std. 
Deviation 
general benefit 28 66,2500 29,39592 25 71,7200 32,12284 
personal benefit 37 74,4865 27,61000 41 76,9756 26,86772 
severe side effects 41 28,9024 22,65260 46 39,6304 29,21671 
side effects quantity 40 36,4500 24,23702 45 42,5111 25,88666 
personal risk 42 41,7143 41,7143 40 39,5000 32,57654 
Risk/benefit 48 20,5750 20,5750 49 24,4510 21,81802 
Valid N (listwise) 15     17    
 
The lack of impact is also due to the neutralization effect of different directions in 
assessment change.  
However, as the graphic shows, the number of stable assessments after reading the PL 
is considerable in the sample, especially for the general risk estimation (side effects 
quantity and severity) and the overall risk/benefit assessment. More importantly, half 
of the participants have not changed their degree of confidence in choice after reading 
the PL. 
Indeed the average assessment of the degree of confidence in the therapeutic choice is 
rather high and it seems to be hardly shaken by reading the PL: before reading the PL, 
75.46 in a 0-100 scale (sd 24.22, n = 54); after 76.69 (sd 22.98, n = 55).  
The impact of PL information has been measured by carrying out Wilcoxon signed 
ranks tests on the same questions made before and after reading the PL. These tests 
have delivered following results: 
 
Wilcoxon Signed Ranks Test: 
Degree of confidence in choice before and after reading the PL 
 
  N Mean Rank Sum of Ranks 
Negative Ranks 14(a) 12,11 169,50 
Positive Ranks 13(b) 16,04 208,50 
Ties 27(c)     
Total 54     
a  degree of confidence in choice (POST) < degree of confidence in choice (PRE) 
b  degree of confidence in choice (POST) > degree of confidence in choice (PRE) 
c  degree of confidence in choice (POST) = degree of confidence in choice (PRE) 
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Degree of confidence in choice has decreased for 14 participants and increased for 13 
of them. The great part has not been shaken by PL reading (27 ties). 
Also the impact on the overall risk/benefit assessment has been preponderantly 
ineffective:  
 
Wilcoxon Signed Ranks Test: 
Benefit/risk assessment before and after reading the PL 
 
  N Mean Rank Sum of Ranks 
Negative Ranks 12(a) 12,42 149,00 
Positive Ranks 10(b) 10,40 104,00 
Ties 24(c)     
Total 46     
a  benefit (POST) < benefit (PRE) 
b  benefit (POST) > benefit (PRE) 
c  benefit (POST) = benefit (PRE) 
 
At the analytical level, changes are slightly more evident, but none of them reaches a 
level of statistical significance.  
Focusing on the risk perception change, following percentages derive from the 
frequency table: 
 
 General risk 
SE severity 
General risk 
SE quantity Personal risk  
no change (ties) 36.8 41.0 30.3 
more risk 42.1 35.9 36.4 
less risk 21.1 23.1 33.3 
Table 6: Risk perception change groups: percentage. 
If we consider increase in personal risk perception, than 36.4% of the sample 
respondents can be said to have become more aware of the risks associated to the 
therapy after reading the PL. This result is in line with the AOK (WidO) findings, 
which reported 29% of the participants being less confident (“verunsichert”) after 
reading the PL.
595
 However, as table 1 shows, PL information produced all three 
possible effects in the same measure (increase, decrease and no change of risk 
assessment). 
 
 
 
3.2 Perceived level of information  
 
The above data seem even more puzzling when considering that the only significant 
difference between pre and post PL phase was registered by the variable “information 
level”, which measured the perceived information sufficiency of participants. In a 
scale from 0 (no information at all) to 100 (I have no need of more information), the 
participants declare that their level of information reaches an average point of 82.12 
after having read the PL (sd 20.77, n = 54), whereas before the mean is attested at 
65.74. (sd 27.7, n = 54). The means are significantly different: Z. -4,013 (.000). 
Correspondingly, ties and positive ranks are significantly more than negative ranks: 
                                                 
595
 Nink, Schröder, 2006: 76. 
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Wilcoxon Signed Ranks Test: 
Perceived level of information before and after reading the PL 
  N Mean Rank Sum of Ranks 
Negative Ranks 6(a) 11,75 70,50 
Positive Ranks 29(b) 19,29 559,50 
Ties 18(c)     
Total 53     
a  perceived level of info: POST < perceived level of info: PRE 
b  perceived level of info: POST > perceived level of info: PRE 
c  perceived level of info: POST = perceived level of info: PRE  
 
Therefore, participants feel that they are much more informed after reading the PL. 
Also the explicit evaluation of PLs after reading them is more positive than not.  
 
 
3.3 PL evaluation  
 
The participants were asked to make an estimate as to their opinion about several 
dimensions concerning PL information. The estimation means are given in the 
introductory overview. The estimations were clustered into three categories (rather no 
– uncertain – yes) as to obtain frequencies for the different levels.   
PL evaluation 
 PL information: sufficient Frequency Percent Valid Percent 
Valid rather no: 0 - 30 9 16,4 16,4 
  uncertain: 31 - 60 15 27,3 27,3 
  rather yes: 61 - 100 31 56,4 56,4 
  Total 55 100,0 100,0 
PL information: useful 
Valid rather no: 0 - 30 5 9,1 10,6 
  uncertain: 31 - 60 11 20,0 23,4 
  rather yes: 61 - 100 31 56,4 66,0 
  Total 47 85,5 100,0 
Missing System 8 14,5   
Total 55 100,0   
 PL information: old 
Valid rather no: 0 - 30 9 16,4 19,6 
  uncertain: 31 - 60 12 21,8 26,1 
  rather yes: 61 - 100 25 45,5 54,3 
  Total 46 83,6 100,0 
Missing System 9 16,4   
Total 55 100,0   
PL information: excessive 
Valid rather no: 0 - 30 33 60,0 75,0 
  uncertain: 31 - 60 6 10,9 13,6 
  rather yes: 61 - 100 5 9,1 11,4 
  Total 44 80,0 100,0 
Missing System 11 20,0   
Total 55 100,0   
 PL information: disquieting 
Valid rather no: 0 - 30 25 45,5 55,6 
  uncertain: 31 - 60 12 21,8 26,7 
  rather yes: 61 - 100 8 14,5 17,8 
  Total 45 81,8 100,0 
Missing System 10 18,2   
Total 55 100,0   
  
Table 7: PL information evaluation after reading. Positive categories (sufficient, useful) have 
higher frequencies than negative ones (disquieting, excessive, old). 
More than half of the participants have evaluated PL information as sufficient useful 
and not superfluous. However, between 1/4 and 1/5 of them are “rather uncertain” 
about the sufficiency and usefulness estimation. Instead, uncertain judgments 
regarding information excessiveness have a low frequency: 10,9%.  
Contrary to expectations, PL information is not declared to be disquieting by 45,5% 
of the participants. The same proportion of respondents considers it old. The 
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percentages of these last two dimensions show ambiguity towards PL information as 
to its threatening potential and as to its informativeness.  
However the number of missing cases is significant across the parameters. In fact, 
whereas all participants were able to give an evaluation about sufficiency, about 14 to 
21 per cent of them could not give any judgment as to the other dimensions (missing 
cases for each category: ‘sufficient’ = 0; ‘useful’ = 14,5%; ‘old’ = 16,4%; 
‘superfluous’ = 20%; disquieting = ‘18,2%’). 
The variance of attitude towards PL information can be also evinced from the 
frequency table regarding the desire of further information in the PL (Q. 58), where 
assessments are concentrated on the 0, 50, and 100 values:                      
 
Further info in PL? 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid ,00 16 29,1 29,1 29,1 
  5,00 3 5,5 5,5 34,5 
  10,00 1 1,8 1,8 36,4 
  15,00 1 1,8 1,8 38,2 
  18,00 1 1,8 1,8 40,0 
  20,00 2 3,6 3,6 43,6 
  25,00 2 3,6 3,6 47,3 
  40,00 1 1,8 1,8 49,1 
  50,00 11 20,0 20,0 69,1 
  60,00 2 3,6 3,6 72,7 
  65,00 1 1,8 1,8 74,5 
  70,00 2 3,6 3,6 78,2 
  80,00 1 1,8 1,8 80,0 
  85,00 1 1,8 1,8 81,8 
  90,00 1 1,8 1,8 83,6 
  100,00 9 16,4 16,4 100,0 
  Total 55 100,0 100,0   
  
Table 8: Frequency table of the expressed desire to  
include further  information in the PL after reading it. 
 
By looking at the cumulative percentage, one can see that almost half of the 
respondents do not want any further information in the PL (0-40 = 49.1%), and a 
good 20% of the participants are absolute uncertain as to their desire of having further 
information in the PL. The mean value is 40.32 (sd, 37.36, n = 55).  
 
 
3.4 PL ranking among other health information sources 
 
The highest ranked health information sources are the doctor, the pharmacist, the PL, 
and one’s own experience. However, the sample shows a high concentration on high 
values for the doctor, whereas both the pharmacist and the PL have larger ranges 
within the upper and lower quartile – and sensibly lower mean values. All other 
sources of information are ranked far lower. The following table gives the main 
statistics: 
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Information source reliability 
 
  N Minimum Maximum Mean Std. Deviation 
Doctor 
53 ,00 100,00 81,1887 20,70587 
Pharmacist 
52 20,00 100,00 72,7308 23,64037 
Friends/relatives 
49 ,00 100,00 34,5102 22,30202 
My own experience 
47 5,00 100,00 67,0213 24,24198 
PL 49 16,00 100,00 70,6327 20,87731 
TV/ radio 
48 ,00 65,00 24,6042 20,56307 
Press 
49 ,00 100,00 28,0816 24,45901 
The internet 
43 ,00 90,00 37,4651 26,35594 
Advertising 
45 ,00 50,00 14,1111 17,87866 
  
The gap between the doctor, the pharmacist, one’s own experience and PL 
information in relation to all other sources may indicate that the requirements of 
expertise and tailoredness guide the search for health information. 
 
 
3.5 Uncertainty  
 
Uncertainty has been measured through different parameters throughout the topic. 
First of all its increase/decrease in the post PL phase has been measured through the 
distance of benefit and risk assessments to the even estimation (.50). Secondly, it has 
been measured through the proportion of “I don’t know” answers to the risk and 
benefit assessments. 
Finally, it has been directly elicited both before and after reading the PL in relation to 
a specific topic of concern (Q. 12/45: “Is there something that makes you 
uncertain?”).   
 
 
3.5.1 Prognostic uncertainty, uncertainty denial, extremeness 
 
The uncertainty represented by vagueness and fuzziness of estimation has been 
measured by the numbers of “I can’t judge” answers, and by the tendency towards .50 
judgments. 
A considerable part of the sample could give no assessment either before or after 
reading the PL and rather opted for the “I can’t judge” answer. The mean average for 
this answer was (2/110 = 18%) in the entire sample. 
Neglecting those that give the “I can’t judge answer” both before and after PL 
reading, one can measure the contribution of PL information in knowledge 
sharpening by comparing the number of cases where this option has been crossed 
only before but not after (mean: 7.5/55 = 13%), or only after and not before (mean: 
4.1/55 = 7.4% ): this gives a ratio of 1.75: not extremely significant indeed. 
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The uncertainty inducing effect normally attributed to PL was also quantified by 
measuring the distance from the middle value (.5) before and after PL reading. This 
effect can be graphically described as follows. Whenever the assessment goes from 
values below or above .5 towards it, then it can be assumed that uncertainty relative 
to the parameter has increased: 
 
On the contrary, when values tend to go towards the extreme of the scale, than the 
contrary hypothesis of increased judgment confidence can be entertained.  
 
This effect was measured through the formula √∑(50 –v)2  . 
                                                                                         Nv 
Where “v” is each parameter value, and Nv the number of valid cases in the 
parameter. None of the variables registered a significant increase or decrease in 
uncertainty as can be evinced from the comparisons of the obtained results across the 
same questions before and after reading the PL:  
 
 POST/PRE POST-PRE  
ratio difference 
General benefit  1,14 3,85 
Personal benefit  1,11 3,77 
Side effect severity 1,06 0,28 
Side effect quantity  1,03 0,92 
Personal risk  1,18 4,96 
Benefit/risk odds 0,98 -0,38 
Table 9: Approach towards the .5 value or departure from it after reading the PL (measured 
through ratio - < 1, and difference < 0).  
 
No significant tendency towards uncertainty increase can be assumed along these 
measures.  
The inclination of lay assessors to lean towards extreme judgments (0, 50, or 100) as 
observed in the literature on judgment elicitation,
596
 is also present in the sample 
where extreme estimations have a considerable part: 0 or 100 assessments 15.84% 
(pre) and 16.62% (post). Also substantial is the number of complete uncertainty 
assessments (50): 12.98% (pre) and 12.46 (post). Non-extreme judgments made up 
71.16% of responses before and 70.64% after PL reading.   
 
 
3.5.2 Specific topics of concern generating uncertainty 
 
Respondents who expressed uncertainty about a topic of concern are18 out of 55 
before reading the PL and 22 afterwards. However a “two x two” contingency table 
                                                 
596
 See Slovic, 2000: 109, 222. Highly sophisticated elicitation techniques have been especially devised to 
counteract this tendency, which however could not be used in the context of a survey. See: Edwards, von 
Winterfeldt, 1986: 116 ff. ; Yates, 1990: 16 ff. The tendency to extreme assessment is part of the judgment 
overconfidence phenomenon first analyzed by Oskamp (1965) and further investigated a. o. by Fischhoff, 
Slovic, Lichtenstein, 1977. 
Yes
 .50 0 
1 .5
 .50 
0 
0 
No
 .50 
0 
Yes
 .50 0 
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 .50 
0 
0 
No
 .50 
0 
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shows that PL information has also removed the uncertainty in some case (5), and 
raised doubts in other cases (9), where previously no uncertainty affected the subject. 
 
 
 POST  
PRE No uncertainty Uncertainty   
No uncertainty  28 9 34 
Uncertainty 5 13 18 
 30 22 52 
Missing:  3 55 
  
 
 
Topics of concern more often address specific items of information than side effects 
in general.
597
 
In many cases, reading the PL does not remove it, but rather adds other uncertainties 
(see cases 2, 9, 10, 34, 35, 41, 44). In other cases the uncertainty before reading the 
PL is less worrying than after reading it (13, 27). At any rate, in general, topics of 
concern seem to be more focused and specific in the post PL phase (see: 12, 32, 50). 
Apprehensions are rather vague and indeterminate before reading the PL, whereas 
they become rather focused and pressing afterwards.  
In five cases the worries expressed before reading the PL have been removed 
afterwards.  
 
 
3.5.2.1 Impact of the specific topics of concern on decision parameters 
 
The presence of a specific topic of concern is related to the degree of confidence in 
choice both before, χ25.127 (.024, n = 50) and after reading the PL, χ2 11.661 (.001, n 
= 52) seems to be influenced by the presence of a specific topic of concern.  
The Kruskal-Wallis test is confirmed also by symmetric measures of correlation and 
χ2 tests: 
Chi-Square Tests
22,080a 12 ,037
25,288 12 ,014
4,041 1 ,044
50
Pearson Chi-Square
Continuity  Correction
Likelihood Ratio
Linear-by-Linear
Assoc iation
N of  Valid Cases
Value df
Asy mp. Sig.
(2-sided)
23 cells (88,5%) have expected count less than 5.  The
minimum expected count  is ,32.
a.  
 
Symmetric Measures
-,283 ,113 -2,431 ,015
-,342 ,141 -2,431 ,015
-,323 ,130 -2,368 ,022c
-,287 ,139 -2,077 ,043c
50
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
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 Tables with the transcription of the specific topics of concern are presented in the appendix.  
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Chi-Square Tests
23,399a 13 ,037
29,445 13 ,006
13,434 1 ,000
52
Pearson Chi-Square
Continuity  Correction
Likelihood Ratio
Linear-by-Linear
Assoc iation
N of  Valid Cases
Value df
Asy mp. Sig.
(2-sided)
25 cells (89,3%) have expected count less than 5.  The
minimum expected count  is ,42.
a.  
 
Symmetric Measures
-,418 ,103 -3,966 ,000
-,534 ,135 -3,966 ,000
-,478 ,118 -3,850 ,000c
-,513 ,110 -4,229 ,000c
52
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 10: Measures of correlation between the presence of a specific topic of concern and the 
degree of confidence (in the previous page: before reading the PL; above: after reading the 
PL). 
As for the analytical benefit and risk assessments, the presence of a topic of concern 
generating uncertainty does not impact them in the pre PL phase, apart from the 
personal benefit assessment where the mean rank between the two groups 
uncertainty/no uncertainty is respectively 13,29 and 20,46 which means that the 
prognosis of personal benefit is significantly higher for participants who perceive no 
uncertainty: χ2 4,073 (.044, n 35). 
In the post PL phase the presence of a specific topic of uncertainty has a strong 
impact on the benefit prognosis both general: χ2 4.417 (.036, n = 23) and personal: χ2 
4.964 (.026, n = 43), as well as on the overall risk/benefit assessment: χ2 7.526 (.006, 
n = 48). 
These results can be interpreted as an indirect confirmation, that specific topics of 
uncertainty arising from the PL text (uncertainty POST) have a higher capability of 
affecting the risk/benefit assessment than vague uncertainties (uncertainty PRE) 
deriving from perceived domain incompetence. However, oddly enough, correlation 
coefficients with risk perception dimensions are not significant. It seems that rather 
than influencing the risk perception, the presence of uncertainty about a specific topic 
tends to have a downplaying effect on the benefit assessment. This phenomenon is 
recurrent all along this study.
598
  
Interestingly, the presence of a specific topic of concern is also related to the 
reliability level assigned to the doctor as an information source. This is not only valid 
for the presence of a topic of concern before reading the PL, but also afterwards. The 
following tables present the significance measures for the association between the 
presence of a specific topic of concern and the reliability score assigned to the doctor 
before (above) and after (below) PL reading: 
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 For discussion see next paragraph and following chapter.  
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Chi-Square Tests
8,585a 3 ,035
8,395 3 ,039
7,579 1 ,006
49
Pearson Chi-Square
Continuity  Correction
Likelihood Ratio
Linear-by-Linear
Assoc iation
N of  Valid Cases
Value df
Asy mp. Sig.
(2-sided)
5 cells (62,5%) hav e expected count less than 5. The
minimum expected count  is 1,53.
a.  
 
Symmetric Measures
-,373 ,125 -2,822 ,005
-,387 ,137 -2,822 ,005
-,398 ,133 -2,973 ,005c
-,397 ,137 -2,969 ,005c
49
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
 
Table 6: Measures of correlation 
between the presence of a specific topic 
of concern and doctor’s reliability 
(above: before reading the PL; on the 
right, after reading the PL). 
 
People perceiving no special topic 
of uncertainty are more likely to 
have a higher reliability in the 
doctor. The direction of the 
relationship cannot be derived from 
these data though.  
 
Symmetric Measures
-,257 ,127 -2,002 ,045
-,285 ,142 -2,002 ,045
-,275 ,136 -1,978 ,054c
-,261 ,136 -1,874 ,067c
50
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
 
In the post PL phase an additional question has been asked in order to assess whether 
therapy incept would be conditioned on the acquisition of further information: Q. 49: 
“Would you look for further information before keeping on with the therapy?”. Also 
this parameter has been found to be positively related to perceived uncertainty about a 
specific topic. A very strong intention to further enquire before keeping on with the 
therapy is equally likely to be associated with both the presence and the absence of a 
specific topic of concern. But low and absolute no desire to further enquire is 
predominantly associated with the absence of a specific topic of concern:  
Symmetric Measures
,244 ,119 2,044 ,041
,308 ,150 2,044 ,041
,277 ,135 2,019 ,049c
,309 ,134 2,272 ,028c
51
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 7: Measures of correlation between the presence of a specific topic of concern and the 
desire to further enquire about the drug.  
 
Similar considerations hold for the correlation between the perception of uncertainty 
about a specific topic of concern and further desire to enquire the doctor again: 
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Chi-Square Tests
27,426a 10 ,002
34,165 10 ,000
15,999 1 ,000
47
Pearson Chi-Square
Continuity  Correction
Likelihood Ratio
Linear-by-Linear
Assoc iation
N of  Valid Cases
Value df
Asy mp. Sig.
(2-sided)
19 cells (86,4%) have expected count less than 5.  The
minimum expected count  is ,45.
a.  
 
Symmetric Measures
,500 ,105 4,673 ,000
,605 ,129 4,673 ,000
,555 ,117 4,478 ,000c
,590 ,113 4,899 ,000c
47
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 8: Measures of correlation between the presence of a specific topic of concern and the 
desire to further enquire about the drug.  
 
The relationship is mostly due to the different distribution of the no-uncertainty 
assessments in the two extreme points of expressed desire to further enquire the 
doctor. This finding can be explained by the fact that the emergence or persistence of 
uncertainty after having read the PL, might be associated, with a certain trust loss in 
the physician at least for a portion of the sample.  
 
 
4. Decision dimensions and PL impact 
 
Because the average PL impact did not show any significant trend, the assessments 
parameters have been investigated along dimensions relating to the therapeutic 
decision, in order to identify factors hindering or fostering change in risk and benefit 
assessment: 
 
PL PL content; 
Declared PL value; 
Information reliability. 
Decision model: Degree of participation in decision making 
Decision/information 
dimensions: 
Level of concern (motivation in undertaking therapy), health condition; 
confidence in choice;  
information relevance to decision;  
information promise;  
perceived level of information;  
risk acceptance.  
Prior knowledge: chronic vs. acute therapy; 
experience with drugs efficacy and side effects.  
 
The change has been measured both including the direction dimension and in absolute 
terms (absolute amount of change irrespective of the direction). 
 
 
4.1 PL information design 
 
The first parameter under investigation has been the package leaflet itself. The 
parameters investigated are number of light side effects, number of “indefinite” side 
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effects, number of severe side effects, total number of side effects, and the indication 
of numeric frequency for side effects.
599
 
The only content variable affecting personal risk perception seems to be the numeric 
indication of side effects frequencies.  
Lower than average numbers of light side effects shows a tendency to be associated 
with a decrease in risk perception quantity. “Indefinite” side effects rather have a 
“shaking” effect, precisely because of the non interpretability of their importance. 
The lower than average total number of side effects also shows the tendency to be 
associated with increased benefit.  
In general, the results that emerge from the investigation of general and personal 
assessments in relation to the PL content show that pragmatic considerations linked 
to text interpretation should be considered in the analysis of PL information effect. 
Expectations about the text type and hypotheses about its function might guide the 
reader in gauging the drug risk and benefit associated to the drug.  
 
 
4.1.1 Number of light side effects 
 
The number of light side effects shows only a tendency to influence the risk prognosis 
change, and among the different risk assessments, only the prognosis regarding the 
quantity of side effects: Pearson’s r .299 (.068, n = 38). Personal risk prognosis and 
severity of side effects instead are not changed by the number of light side effects.  
The association however is due to an interesting phenomenon, which has been 
observed also in the variables “number of severe side effects” and “number of 
indefinite side effects”: the less than average amount of side effects, not only 
contribute to inhibit increase in risk perception, but seems to be associated with 
decrease.  
 
 
4.1.2 Number of indefinite side effects 
 
Non-parametric tests give no significance coefficient for the parameter measuring the 
number of indefinite side effects and risk or benefit change.   
The impact of indefinite side effects is however significant when measured in 
absolute terms. The group with higher amount of indefinite side effects is associated 
with greater change in the parameter risk severity (irrespective of the direction): 
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 Methods for PL classification are presented in the appendix. 
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Symmetric Measures
,303 ,127 2,356 ,018
,305 ,129 2,356 ,018
,356 ,152 2,191 ,036c
,374 ,127 2,317 ,027c
35
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 9: Measures of correlation between the number of indefinite side effects and risk severity 
assessment change. 
This could mean that indefinite side effects have a “shaking effect”, in that they can 
both contribute to decrease and to increase the risk severity perception.  As accounted 
for in the PL classification, indefinite side effects can be over- and underestimated as 
well.  
Pragmatic aspects of text interpretation help explain this phenomenon. It might in fact 
be assumed that, when confronted with a PL text, the average reader has implicit 
expectations about its content and form: it can happen that the reader interprets the 
indefinite side effects in the PL at hand as less or more dangerous than subjectively 
expected, and therefore perceives the drug as less or more threatening than expected 
before reading the PL. However further investigations are required in order to 
consolidate these conjectures. 
 
 
4.1.3 Number of severe side effects 
 
The amount of definitely severe side effects seems to have no precise impact pattern 
on risk perception change. This could also be explained by pragmatic factors: it can 
be assumed that people presume to learn about the eventuality of severe side effects 
from the doctor, so that whenever the reader encounters side effects, which he does 
not know of but that are undoubtedly severe, he reasons that he is unlikely to be 
concerned by them, because otherwise the doctor would have mentioned them (more 
on this in the qualitative analysis, next chapter).  
 
 
4.1.4 Total number of side effects 
 
The variable measuring the total number of side effects confirms the associations 
found for the variable “light side effects”: change in risk quantity perception: τ .278 
(.012, n = 38) and for the variable “indefinite side effects”: absolute change in risk 
severity perception: τ .234 (.068, n = 39). 
However the significance levels of the relationship with the absolute change in risk 
severity perception is lower than for the number of indefinite side-effects, which 
could strengthen the hypothesis, that more than the overall number of side effects, 
their ambiguity and vagueness (indefinite side effects) are the major responsible for 
risk severity perception change. 
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The highest significance level of correlation between assessment change and amount 
of total side effects is to be found in the parameter general benefit: 
Symmetric Measures
-,603 ,109 -5,136 ,000
-,673 ,131 -5,136 ,000
-,714 ,112 -4,210 ,001c
-,698 ,095 -4,018 ,001c
19
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 10: Measures of correlation between the total number of side effects and general benefit 
assessment change. 
This datum strengthens the hypothesis that the source of potential benefit and risk is 
seen in its overall effect with no clear-cut distinction between the two parameters, and 
that when forced to assess the parameters separately, subjects tend to adjust their level 
of perceived benefit, rather than changing the perception of risk potential.  
The most remarkable datum however, is that no correlation has been found between 
number of side effects, whether light, indefinite or severe and change in personal 
benefit and risk prognosis. In this sense a gap opens between the objective perception 
of the damaging and beneficial potentialities associated with the drug in general, and 
the expected personal efficacy and risk.  
In addition to the findings related to uncertainty perception, this is a further 
confirmation, that personal risk and benefit perception is affected by specific topics of 
concern, which are deemed personally relevant by the subject, rather than being 
influenced by the overall risk message.  
In the qualitative part of this work the rationale of this distinction will be further 
investigated. 
 
 
4.1.5 Numeric frequency indicators 
 
The indication of the numeric frequency of side effects seems to be one of the few 
variables linked to personal risk perception change: precisely, numerical frequency 
indicators tend to be associated to a decrease in personal risk perception. The ordinal 
tests only point to a tendency: τ -.249 (.083, n = 31). However, the t-test for 
dependent groups also suggests a trend worth of consideration: correlation 
coefficient: -.330 (.069 n = 31). The means difference between the two groups is: 
2,2632 average increase for the group “no numerical frequency” and  -15,2500 
average decrease for the group “numerical frequencies”.  
Given the low percentages generally associated to side effects in the PL list, this can 
be cautiously interpreted as a sign of Bayesian integration of probabilistic information 
into a personal prognosis.  
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4.2 Declared PL value  
 
Also the dimensions related to PL information evaluation (sufficient, old, excessive, 
disquieting, and useful), are rather associated to general risk and benefit perception 
change than to personal risk and benefit assessment change. 
1. The parameter “sufficiency” has a significant relationship with positive changes in 
degree of confidence: χ2 6,315 (.043, n = 52). 
2. The perception of PL information as disquieting is associated to change in general 
benefit: χ2 5,765 (.056, n = 16) and general risk (SE severity) perception: χ2 6,713,( 
.035, n = 32).  
3. The Kruskal Wallis test gives no other significant associations among assessment 
changes and PL evaluation categories. However symmetric measures of correlation 
indicate a correlation between the perception of PL information usefulness and 
increase in general benefit perception: τ .447 (.01, n = 17). 
  
 
4.3 Information source reliability  
 
As already illustrated in paragraph 2, PL reliability ranks fairly high within the other 
sources of pharmaceutical information. However, the expected relationship between 
high reliability in the PL and impact in risk/benefit perception has not been observed.  
Instead an association has been found between the perceived reliability of the doctor 
and the change in general risk assessment quantity: χ27,607 (.055, n = 37); and 
between one’s own experience as a source of information and the change in the 
risk/benefit assessment: χ26,678 (.035, n = 40).   
In general, deeper research is needed for analyzing drug consumer’s change in risk 
perception through different, eventually conflicting, information sources.   
 
 
4.4 Perceived relevance of further information to decision 
 
The correlation of assessment changes and decision dimensions is all but systematic 
and consistent. The questions measuring decision dimensions are the following:  
1. Level of concern 
Q. 9: “What would happen, if you do not take the drug?” 
2. Degree of confidence in decision 
Q. 10/40: “Are you satisfied with the treatment choice?” 
3. Perceived level of information  
Q. 11/44: “How much information do you have about the treatment?” 
4. Relevance of missing information to the decision  
Q. 15/48: “Are you considering not to take the treatment because of eventual missing 
information?” 
5. Promise (estimated potential to remove the uncertainty)  
Q. 14/47: “Could an eventual clarification about it [topic of uncertainty] eliminate the 
uncertainty?” 
6. Acceptance of side effects 
Q. 21: “You must take side effects into account, when you take a drug” (0 to 100 assessment). 
7. Experience with drug 
Q. 18: “How much experience do you have with drugs?” 
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Q. 19: “In my case drugs are effective … (from 0 = never to 100 = always)” 
Q. 21: “I had side effects in the past, when I took drugs … (from 0 = never to 100 = always)”; 
Q. 20: “When I am ill, it is difficult for me to distinguish between side effects and illness 
symptoms”. 
  
 
4.5 Level of concern 
 
Level of concern has not been elicited directly on a continuous scale but derived from 
the responses to a counterfactual question (Q. 9): “What would be the consequence of 
not taking the treatment?”. The possible answers ranged from “I should stay home for 
a couple of day” (which was assigned low level of concern) to the necessity of a 
surgical operation (high level of concern). In-between, the possibility of worsening 
and complications was contemplated (medium level). The answers battery allowed 
also for a personal response (assigned to one of the three categories depending on the 
content) and for the “I don’t know option”, which nobody crossed.   
Descriptive statistics are given below: 
level of concern
11 20,0 21,6 21,6
33 60,0 64,7 86,3
7 12,7 13,7 100,0
51 92,7 100,0
4 7,3
55 100,0
low
medium
high
Total
Valid
SystemMissing
Total
Frequency Percent Valid Percent
Cumulat iv e
Percent
 
 
The level of concern is one of the few parameters which seem to show a significant 
correlation with change in personal assessments. 
The Kruskal-Wallis test gives significant results for the personal risk prognosis 
change: χ28,570 (.014, n = 30) and for the risk benefit assessment change: χ27,890 
(.019, n = 44).  
Change in risk/benefit assessment seems to undergo an increase in risk perception for 
low concerned participants and to show the opposite tendency for high concerned 
ones. This can be read within the framework of prospect theory
600
 as the result of 
different initial choice outsets: low concerned consumers will tend to risk aversion 
and therefore perceive the drug risk as higher than the inconveniences brought about 
by their illness, instead people with severe diseases will tend to be risk prone and 
therefore have higher tolerance for the drug risk read in the PL. 
Yet, the decrease in risk perception after reading the PL can only be explained if 
readers are also assumed to have expected more risk than found in the PL. This can 
only be investigated within the framework of expectations related to the text type.   
                                                 
600
 Kahneman, Tversky (1979); Tversky, Kahnemann (1992). The survey was not designed to investigate 
the data in this respect though and therefore deeper analysis of this phenomenon is not allowed by the 
findings. Also the discussion in chapter 9 will not consider prospect theory in the analysis of PL 
information processing, because this theory rather addresses the decision maker’s risk attitude, whereas the 
final chapter deals with his degree of processing accuracy as a function of the expected value of PL 
information.  
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4.6 Health condition 
 
An indirect measure of the level of concern is also the health condition. This 
parameter has been investigated as a dichotomic variable: light vs. severe-chronic 
disease.  
Illness severity seems to be associated with the overall risk/benefit assessment and 
risk severity, but only loosely associated with the assessment change in risk quantity.  
Patterns are similar to those seen in the level of concern: risk increase in the 
risk/benefit assessment is more frequent in participants affected by a light disease: 
Symmetric Measures
-,295 ,137 -2,039 ,041
-,320 ,157 -2,039 ,041
-,327 ,153 -2,135 ,039c
-,328 ,149 -2,137 ,039c
40
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 11: Measures of correlation between health condition and risk/benefit assessment change. 
 
Also the increase of risk severity is more frequent in respondents affected by a light 
disease:  
Symmetric Measures
-,267 ,129 -1,965 ,049
-,315 ,160 -1,965 ,049
-,303 ,148 -1,796 ,082c
-,335 ,155 -2,009 ,053c
34
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not assuming the null hy pothesis .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 12: Measures of correlation between health condition and risk severity assessment change. 
 
Participants affected by light diseases more probable than not adjust their risk 
assessment in a positive direction. This pattern however is not observed for change in 
personal risk assessment.  
 
 
4.7 Degree of confidence in choice 
 
The degree of confidence in choice is relatively high in the sample: there is however 
also a consistent part of totally uncertain respondents (50 score: 16,7%, n = 9). Main 
statistics are given in the tables: 
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Statistics
degree of  conf idence in choice
54
1
75,4630
75,0000
100,00
24,24849
,00
100,00
Valid
Miss ing
N
Mean
Median
Mode
Std.  Dev iation
Minimum
Maximum
 
degree of confidence in choice
1 1,8 1,9 1,9
1 1,8 1,9 3,7
2 3,6 3,7 7,4
1 1,8 1,9 9,3
9 16,4 16,7 25,9
1 1,8 1,9 27,8
3 5,5 5,6 33,3
10 18,2 18,5 51,9
2 3,6 3,7 55,6
1 1,8 1,9 57,4
5 9,1 9,3 66,7
3 5,5 5,6 72,2
15 27,3 27,8 100,0
54 98,2 100,0
1 1,8
55 100,0
,00
25,00
30,00
40,00
50,00
60,00
70,00
75,00
80,00
85,00
90,00
95,00
100,00
Total
Valid
SystemMiss ing
Total
Frequency Percent Valid Percent
Cumulat ive
Percent
 
The degree of confidence in choice seems to be correlated to personal risk perception 
change: respondents with low degree of confidence or rather uncertain about the 
therapeutic choice are more frequently associated with personal risk increase. 
Participants declaring high or very high confidence in their choice tend to either leave 
their personal risk assessment unchanged or to decrease it after PL reading. Below the 
table gives the level of significance of this association:  
Symmetric Measures
-,324 ,117 -2,702 ,007
-,335 ,124 -2,702 ,007
-,415 ,142 -2,538 ,016c
-,329 ,128 -1,939 ,062c
33
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 13: Measures of correlation between degree of confidence in choice and personal risk 
assessment change. 
 
This data might suggest that PL information impact tends to be biased by a high 
degree of confidence in decision. In fact, a decrease in risk estimation is hardly 
understandable as the sole product of PL reading. The fact that high degree of 
confidence contributes to no change or decreased risk perception suggests that it 
predisposes the reader towards an optimistic bias (similarly to the high degree of 
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confidence in the doctor). This phenomenon can be traced back to strategies against 
cognitive dissonance, which have been already observed in the literature devoted to 
health risk information processing.
601
 
However, no corresponding association has been founded between the degree of 
confidence in choice and the change in personal benefit perception.  
 
 
4.8 Perceived level of information before reading the PL 
 
Main statistics and the frequency distribution of the variable measuring perceived 
level of information are presented below: 
 
Statistics
perceiv ed lev el of  information
54
1
65,7407
60,0000
50,00
27,70136
,00
100,00
Valid
Miss ing
N
Mean
Median
Mode
Std.  Dev iation
Minimum
Maximum
 
'perceived level of information'
1 1,8 1,9 1,9
1 1,8 1,9 3,7
1 1,8 1,9 5,6
1 1,8 1,9 7,4
3 5,5 5,6 13,0
19 34,5 35,2 48,1
1 1,8 1,9 50,0
1 1,8 1,9 51,9
5 9,1 9,3 61,1
2 3,6 3,7 64,8
1 1,8 1,9 66,7
2 3,6 3,7 70,4
5 9,1 9,3 79,6
11 20,0 20,4 100,0
54 98,2 100,0
1 1,8
55 100,0
,00
5,00
10,00
25,00
30,00
50,00
55,00
65,00
70,00
80,00
85,00
90,00
95,00
100,00
Total
Valid
SystemMiss ing
Total
Frequency Percent Valid Percent
Cumulat ive
Percent
 
  
The perceived level of information is associated to the change in risk severity 
prognosis: χ2 8,665 (.034, n = 39). 
Interestingly, the mean ranks show that increase in risk severity perception is mostly 
associated to total uncertainty about the perceived level of information before reading 
the PL: 
 
 
perceived level of 
information N 
Mean 
Rank 
general risk prognosis 
(SE severity): change  
  
  
  
  
0-> 49 4 17,75 
50 12 27,08 
51 -> 89 8 12,94 
90 -> 100 15 18,70 
Total 39   
 
Whereas all but one respondent in the total uncertain group (50) have increased or 
maintained the prior level of SE severity perception, participants with high 
information level awareness before reading the PL are rather associated with stable or 
                                                 
601
 Steckelberg, 2004b, 2005. 
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decreased SE severity. Very high and very low perception of information level is not 
neatly associated with any specific pattern. 
 
 
4.9 Information relevance and promise 
 
No correlation at all has been found between assessments change and the variable 
related to the perceived relevance of further information to decision (Q.15). Neither 
has it been found for the variable eliciting the perceived information promise (Q.14). 
 
 
4.10 Risk acceptance 
 
The following tables give the main statistics for the parameter measuring the level of 
risk acceptance in the questionnaire’s respondents: Q. 21 “You need to take side-
effects into account when you take a drug”.  
 
Statistics
acceptance of  side ef f ects
52
3
58,7500
60,0000
50,00
32,40181
,00
100,00
Valid
Miss ing
N
Mean
Median
Mode
Std.  Dev iation
Minimum
Maximum
 
acceptance of side effects
3 5,5 5,8 5,8
3 5,5 5,8 11,5
1 1,8 1,9 13,5
1 1,8 1,9 15,4
1 1,8 1,9 17,3
2 3,6 3,8 21,2
1 1,8 1,9 23,1
1 1,8 1,9 25,0
1 1,8 1,9 26,9
10 18,2 19,2 46,2
1 1,8 1,9 48,1
4 7,3 7,7 55,8
2 3,6 3,8 59,6
1 1,8 1,9 61,5
1 1,8 1,9 63,5
3 5,5 5,8 69,2
6 10,9 11,5 80,8
2 3,6 3,8 84,6
8 14,5 15,4 100,0
52 94,5 100,0
3 5,5
55 100,0
,00
5,00
10,00
15,00
20,00
25,00
30,00
35,00
40,00
50,00
55,00
60,00
65,00
70,00
75,00
80,00
90,00
95,00
100,00
Total
Valid
SystemMiss ing
Total
Frequency Percent Valid Percent
Cumulat ive
Percent
 
  
The parameter risk acceptance seems to be related to the personal risk assessment 
change. The symmetric measures of non-parametric tests give rather high significance 
levels: 
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Symmetric Measures
-,333 ,127 -2,513 ,012
-,343 ,137 -2,513 ,012
-,400 ,148 -2,348 ,026c
-,424 ,118 -2,521 ,017c
31
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 14: Measures of correlation between acceptance of side effects and personal risk 
assessment change. 
 
Whereas participants with high risk acceptance distribute over the entire range, 
respondents with low risk acceptance tend to increase their risk perception after 
having read the PL. Respondents who are uncertain as to their readiness to accept side 
effects show an intermediate pattern between the two.  
 
  
4.11 Experience with drugs 
 
Experience has been elicited in relation to drugs in general and to drug side effects 
and benefits in particular.  
Descriptive statistics about the variables are given below: 
Statistics
54 53 45
1 2 10
59,5741 74,3774 43,9778
50,0000 75,0000 50,0000
50,00 75,00a 50,00
28,33066 17,58411 26,91273
,00 15,00 ,00
100,00 100,00 100,00
Valid
Missing
N
Mean
Median
Mode
Std.  Dev iation
Minimum
Maximum
past
experience
with drug
past
experience
with drug:
benef its
esperience
with s ide
ef f ects
Mult iple modes exist . The smalles t v alue is showna. 
 
No significant correlation between experience in general and change in risk or benefit 
assessment has been observed.  
A significant association has instead been found between positive experience with 
drug benefits and risk/benefit odds change τ .255 (.041, n =  45). 
Experience with side effects seems to have some influence only on the general risk 
prognosis about risk quantity:  
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Symmetric Measures
,257 ,111 2,271 ,023
,258 ,114 2,271 ,023
,327 ,135 1,957 ,059c
,275 ,130 1,619 ,115c
34
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 15: Measures of correlation between past experience with side effects and risk quantity 
assessment change. 
 
Subjects who declared to have had side effects more often than not in the past either 
do not change their personal risk assessment or they increase it. The contrary holds 
for people with low experience with side effects. Totally uncertain subject (those who 
assess a 50 judgment) as well as respondents declaring low experience with side 
effects distribute over the entire range. 
The questions related to prior experience were devised in order to assess consumer’s 
bayesianism. However no patterns of correlation have been found between risk and 
benefit assessments and past experience about drug benefits and risks. This is 
puzzling but could be explained by the hypothesis that drug users rather stick to the 
risk/benefit assessment delivered by the doctor as for the personal benefit and risk 
prognosis.  
 
 
4.12 Participation in decision 
 
Participation in decision has been measured through a multiple response question:  
 
Q. 17: “How was the treatment chosen?” 
a) My physician has prescribed it to me. 
b) My physician recommended it to me and I accepted the proposal. 
c) After reflecting together with the physician, it turned out that this is the most effective treatment for 
me. 
d) After reflecting together with the physician, it turned out that with this treatment I will have the 
least possible adverse reactions. 
e) There’s no alternative. 
f) I don’t know of any alternative. 
g) Other.  
 
The responses have been given a score depending on their content: a = 0; b = 1; c = 2, 
d = 2, e = 1, f = -1. The total sum for each case has been considered as the value of a 
new variable measuring the level of participation in the therapeutic decision. 
The variable “choice participation” shows no important correlation with the change 
variables apart from a significant value for the association with change in risk 
quantity assessment:  
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Symmetric Measures
-,273 ,111 -2,404 ,016
-,248 ,103 -2,404 ,016
-,341 ,136 -2,179 ,036c
-,319 ,135 -2,019 ,051c
38
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 15: Measures of correlation between level of participation in decision and risk quantity 
assessment change. 
 
Analogously to the effect of high degree of confidence on the personal risk 
assessment change, higher participation in the choice is associated with side effects 
quantity decrease. 
 
 
 5. Interrelations among decision parameters 
 
Because decision parameters seemed to have unsystematic influence over risk and 
benefit assessment change, their reciprocal interrelation has been investigated in order 
to check if they captured the dynamics related to information seeking behavior in a 
decision under uncertainty.  
As far as experience is concerned, a significant relationship as been observed between 
therapy type (chronic vs. acute) and perceived level of information: 
Symmetric Measures
,347 ,106 3,272 ,001
,439 ,134 3,272 ,001
,393 ,119 3,084 ,003c
,370 ,124 2,876 ,006c
54
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 16: Measures of correlation between therapy type (acute vs. severe/chronic) and perceived 
level of information (before PL reading). 
 
Chronic cases are associated with higher perceived level of information. Furthermore, 
as predicted by the Bayesian model, degree of confidence in choice is associated to 
the perceived level of information:  The table gives the tests results:  
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Symmetric Measures
,261 ,114 2,270 ,023
,259 ,114 2,270 ,023
,307 ,134 2,300 ,026c
,290 ,129 2,163 ,035c
53
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 17: Measures of correlation between degree of confidence in choice and perceived level of 
information (before PL reading). 
 
High and very high degree of confidence in the choice is associated with high and 
very high perceived level of knowledge, whereas the level of information of uncertain 
participants spreads all over the distribution range, and respondents with low 
confidence in the decision are distributed in the 25-30 level of information slot. 
Perceived relevance of missing information is also related to degree of confidence in 
decision. Subjects perceiving a high importance of missing information for the 
decision are extremely unlikely to have a high degree of confidence in the decision: 
 
 Symmetric Measures 
 
  Value 
Asymp. 
Std. 
Error(a) 
Approx. 
T(b) Approx. Sig. 
Kendall's tau-b -,422 ,103 -3,783 ,000 
Kendall's tau-c -,425 ,112 -3,783 ,000 
Ordinal by Ordinal 
Spearman 
Correlation 
-,483 ,115 -3,936 ,000(c) 
Interval by Interval Pearson's R -,551 ,113 -4,719 ,000(c) 
N of Valid Cases 53       
a  Not assuming the null hypothesis. 
b  Using the asymptotic standard error assuming the null hypothesis. 
c  Based on normal approximation.  
 
Table 18: Measures of correlation between degree of confidence in choice and perceived 
relevance of missing information (before PL reading). 
 
In the post PL phase same correlations between decision categories are confirmed: 
degree of confidence is positively correlated to the perceived level of information: τ 
.419 (.000, n = 54) and negatively correlated to the perceived relevance of missing 
information: τ -.332 (.001, n = 51).  
An additional question introduced in the post PL phase as to elicit the subject’s 
intention to further enquire about the drug (Q. 49: “Would you look for further 
information before keeping on with the therapy?”), has been found to be correlated to 
the perceived relevance of missing information:  
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Symmetric Measures
,355 ,110 3,076 ,002
,339 ,110 3,076 ,002
,395 ,123 3,012 ,004c
,355 ,129 2,658 ,011c
51
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 19: Measures of correlation between desire to further enquire about the therapy and 
perceived relevance of missing information (after PL reading). 
 
The relationship between the intention to look for further information and the 
perceived relevance of missing information is significant especially because of the 
considerable coincidence of 0 assessment cases in both variables. The relationship is 
however strong for low assessments and loosens for high assessments: whereas a low 
intention to look for further information is related to a low relevance perception of 
missing information, the reverse does not hold, and participants might desire to 
further enquire about the therapy even if the missing information is not material for 
the decision. 
This finding might hint at a gap between the desire for information and the potential 
impact of this information on the decision in the therapeutic setting. 
 
 
6. Decision parameters and desire to further enquire the doctor  
 
The parameter measuring the desire to further enquire the doctor after PL reading has 
significant correlations with almost all variables measuring decision dimensions: 
degree of confidence, perceived information level, uncertainty about a specific topic 
of concern, perceived information promise (persuasion, that it will remove 
uncertainty), and general intention to look for further information before keeping on 
with the therapy.  
The negative relationship between degree of confidence in choice and desire to 
further enquire the doctor is mostly due to the distribution of the 100 assessments of 
enquire intention: 
Symmetric Measures
-,380 ,132 -2,871 ,004
-,360 ,125 -2,871 ,004
-,419 ,149 -3,097 ,003c
-,420 ,145 -3,103 ,003c
47
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 19: Measures of correlation between desire to further enquire the doctor and degree of 
confidence in choice (after PL reading). 
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Subjects with absolute confidence in decision distribute unevenly between the two 
extreme values of absolute no or a totally strong intention to further enquire the 
doctor: most of the respondents with very high degree of confidence assign a 0 score 
to their desire to further enquire the doctor.  
The intention to further enquire the doctor is vaguer for participants with a moderate 
to high degree of confidence in choice.  
The intention to further enquire the doctor is positively related to the perceived level 
of information after having read the PL too. Because most of the participants have a 
very high perception of information level, the relationship is mostly due also here to 
the distribution difference of high perceived level of information cases in the groups 
‘absolute no intention to enquire the doctor again’ (0) and ‘extremely strong intention 
to enquire him again’ (100):  most of respondents with high perceived level of 
information assign a 0 score to the intention to further enquire the doctor. The table 
gives significance levels for this association:  
Symmetric Measures
-,371 ,112 -3,280 ,001
-,364 ,111 -3,280 ,001
-,432 ,129 -3,214 ,002c
-,432 ,127 -3,213 ,002c
47
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 20: Measures of correlation between desire to further enquire the doctor and perceived 
level of information (after PL reading). 
 
The relationship between general intention to further enquire and specific intention to 
enquire the doctor is more articulated. 
Whereas uncertain and high intention to look for further information is significantly 
related to the intention to enquire the doctor again, extremely high intention to search 
for further information is equally distributed among absolute no intention and very 
strong intention to enquire the doctor:  
Symmetric Measures
,363 ,127 2,819 ,005
,340 ,121 2,819 ,005
,399 ,148 2,889 ,006c
,436 ,131 3,216 ,002c
46
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not  assuming the null hy pothes is .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
Table 21: Measures of correlation between desire to further enquire the doctor and intention to 
further enquire about the therapy in general (after PL reading). 
 
Similarly to the correlation regarding the desire to enquire the doctor, and the 
presence of a topic of uncertainty, this finding can be explained by the fact that 
extremely high intention to look for further information before keeping on with the 
therapy after PL reading might be associated with a certain trust loss in the physician 
at least for a portion of the sample.  
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The correlation between low scores is due to semantic reasons: the absolute lack of 
intention to look for further information presupposes the lack of intention to enquire 
the doctor. However, some respondents declare to have no intention to further enquire 
before keeping on with the therapy, and still manifest a high desire to enquire the 
doctor about it. This might be the result of a strict interpretation of the enquire 
question (enquire on my own).  
The most interesting relationship regards the correlation between the persuasion that 
further information will remove the uncertainty (promise) and the intention to enquire 
the doctor again.  
 
Symmetric Measures
,546 ,149 3,363 ,001
,564 ,168 3,363 ,001
,628 ,161 3,612 ,002c
,716 ,131 4,587 ,000c
22
Kendall's  tau-b
Kendall's  tau-c
Spearman Correlation
Ordinal by
Ordinal
Pearson's RInterval by  Interv al
N of  Valid Cases
Value
Asy mp.
Std.  Error
a
Approx. T
b
Approx. Sig.
Not assuming the null hy pothesis .a.  
Using the asymptotic standard error assuming the null hy pothesis.b.  
Based on normal approximation.c.  
 
 
enquire doctor again
100,00
95,00
80,00
50,00
30,00
15,00
,00
C
o
u
n
t
6
5
4
3
2
1
0
promise - post 
0 -> 49
50
51 -> 100
 
Left: Table 22: symmetric measures of correlation between the intention to further enquire the 
doctor and information promise. Right: bar diagram, where bars height refers to the frequency 
of cases corresponding to different degrees of information promise. 
As the diagram illustrates, the intention to enquire the doctor is linked to the 
persuasion that the information will remove the uncertainty. Interestingly, the same 
relationship does not hold for the intention to introduce further information in the PL. 
Neither are other decision dimensions (degree of confidence, information relevance to 
decision, perceived information level, information promise) found to be associated to 
the parameter measuring the desire of further information in the PL. 
The data presented in this section illustrate a relative consistency of interrelations 
among decision dimensions. This seems to be at odds with the substantial lack of 
regular relationships among these variables and risk/benefit assessment changes after 
reading the PL.  
This gap can be the sign of different interrelated phenomena:  
1. With certain respects, health information seeking is Bayesian: i.e. it is 
proportional to the information need in the context of a decision, moreover 
confidence in decision is proportional to the perceived level of information.  
2. The fact that PL reading does only irregularly impact the benefit and risk 
assessments, notwithstanding its explicitly acknowledged importance can be due 
to a gap between its perceived value and its usability; 
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3. The high correlation between perceived uncertainty about a specific topic of 
concern, need for further information and intention to enquire the doctor again 
rather than desire to have more information in the PL precisely hints at this 
phenomenon, in that expert information is tailored to the individual both with 
regards to its form and its relevance. 
Along these considerations, the importance of PL information as a source of 
information for consent should be probably toned down and reconsidered, all the 
more because only an exiguous part of the participants did show awareness of its 
legal nature as liability disclaimer (21,8%).  
 
 
7. Study limitations  
 
The results of this exploratory study are rather fragmentary and do not allow for the 
construction of a theoretical model. The following points highlight the limits affecting 
the analysis: 
1. The sample characteristics do not allow measuring the effect of PL information on 
respondents assigning low reliability to the doctor as an information source, because 
the great majority of participants assign an extremely high reliability score to the 
doctor. In certain respects this might also be the reason for a lack of systematic 
differences within the parameter measuring the degree of shared decision making vs. 
delegation to the doctor in relation to the risk and benefit assessment changes. In fact, 
greater decision autonomy (for instance in shared decision making) should predict 
more variance after consulting an additional source of information (in this case the 
PL), whereas choice delegation should predict a tendency to conservatism. Neither of 
the two associations has been observed in this sample.  
 
2. The distinction of benefit and risk into two distinct parameters may find the lay 
assessor unprepared: the separation of these two components is rather artificial and 
contrary to observed cognitive processes of patients’ health information processing.602 
However with respect to this point two considerations are needed: 
i. The extent to which this separation is artificial for the lay appraiser determines the 
measure of perplexity in making a personal risk/benefit assessment on the basis of 
disconnected benefit and risk data.  
ii. Our study allows this type of uncertainty to be expressed in the “I can’t judge 
option”. Even if this option might be crossed also because of genuine uncertainty, 
still it remains the fact that whenever participants have opted for making a benefit 
and a risk assessment, they can’t be said to have been forced to do so.  
 
3. Another hot topic in the field of risk learning is the lay interpretation of 
probabilistic risk assessment: scholars’ debate about the lay capacity to rationally 
update probabilistic information and to deal with probabilities without falling into 
computation fallacies or biases.
603
 Indeed this study was also aimed at observing the 
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 Vander Stichele, 2002: 206; Alkahami, Slovic, 1994: 1090.  
603
 Supporter of lay fallacy in dealing with probabilistic assessments: Kahneman, Slovic, Tversky 1982; 
Bar-Hillel 1980; Kahneman, Tversky 1982, 1973, 1972; Tversky, Kahneman 1983, 1982, 1974, 1971. 
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effect of PL information in terms risk and benefit estimation updating: no evidence of 
a systematic computation has emerged from the data. However this cannot 
corroborate the hypothesis that lay assessor do not integrate different data rationally 
(either in a Bayesian fashion or adopting heuristics), because the experiment design 
could not control for an important unobservable parameter in this respect: the level of 
desired information accuracy. Indeed it has been acknowledged
604
 that information 
processing – which entails the integration of old and new knowledge – is performed 
at different levels of precision depending on the task at hand and the expected cost of 
information elaboration and knowledge updating. 
Therefore the lack of systematic correlations between past knowledge, PL 
information and risk and benefit updating can be due to different levels of precision in 
information processing, which on its turn depend on the expected value of 
information to the decision and the expected cost in relation to the perceived personal 
capacity to deal with the information.
605
 
 
4. Another strong limitation of this study regards the lack of a control group for the 
identification of reappraisal and cognitive dissonance strategies in processing risk 
information. This should have been composed by healthy participants not concretely 
concerned by the drug risk exposed to the same treatment (PL reading). The 
difference between the average changes in the two groups could then be ascribed to 
self-reassurance strategies, such as reappraisal and cognitive dissonance.
606
 In general 
the intent to investigate risk and benefit updating with participants really concerned 
by a choice has strongly limited the design sophistication with the consequent lack of 
control over many latent variables.  
 
5. Obviously the main limitation of this study regards its extremely reduced sample 
size and therefore low level of representativeness.  
The size dimension has also made impossible any sophisticated analysis of the data, 
such as factor analysis, regression analysis, or even the simple control for common 
causes of interrelated parameters.     
Notwithstanding these shortcomings, the study presents interesting phenomena worth 
of further investigation.  
 
 
 
                                                                                                                                                 
Advocates of the lay capacity to deal with probabilistic information ascribe these fallacies to economic 
shortcuts and herustics: Gigerenzer, 1998, 1996, 1994, Gigerenzer, Hofrage, 1995; Gigerenzer et al. 1999; 
Cosmides and Tooby, 1996; Kleiter, 1994, Kohler, 1996; Girotto, Gonzales, 2001; Reyna et al. 2003. See 
also Magat, Viscusi, Huber, 1987, and Viscusi et al., 1987 who provide findings of lay rational 
probabilistic updating.  
604
 See Kahlor et al. 2003; Reyna et al. 2003; Dougherty et al. 2003; Martignon and Krauss, 2003, 
Schneider Schanteau, 2003; Griffin et al. 2002; Gigerenzer, 2001; Slovic, McMackin, 2000; Gigerenzer et 
al. 1999; Trumbo, 1999. 
605
 This explanation integrates the classic Bayesian account of expected value of information with cognitive 
accounts of information processing: more on this in the last chapter.  
606
 These phenomena have been recurrently observed in the literature devoted to health risk information 
processing: Preuss, 1986; Bealneaves, Long, 1999; Steckelberg, 2004b, 2005. More details in the last 
chapter.  
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8. Summary and conclusion  
 
Assessment changes seem to be differently influenced by the decision parameters. 
The following table summarizes the results: 
 
 Assessment changes 
 General 
benefit 
General risk 
(quantity) 
General risk 
(severity)  
Risk/benefit  
assessment 
Personal 
risk  
Personal 
benefit  
a. Perceived 
level of info  
      
b. Health 
condition  
      
c. Past 
experience 
  
(with SE) 
  
(with benefits) 
  
d. PL info   
(tot) 
  
(indefinite 
SE) 
  
(numeric 
frequency) 
 
e. Level of 
concern  
      
f. Risk 
acceptance 
      
g. Degree of 
confidence 
      
 
a) Increased risk severity is associated with the absolute uncertainty to have further 
information in the PL. 
b) Participants affected by a light disease are more likely to increase their risk 
assessment both in terms of severity and in the overall risk/benefit assessment.  
c) A positive past experience with drug benefits is associated with benefit increase in 
the risk/benefit assessment. Furthermore, all respondents assessing a higher than 
average experience with side effects (score: 51 to 100) also increase their risk 
assessment in terms of quantity after reading the PL.  
d) PL content acts as an inhibitor of risk quantity assessment increase whenever the 
light side effects in the list are lower than average. Lower than average number of 
all side effects also fosters benefit assessment increase.  
e) The level of concern is the only parameter significantly associated with both 
personal risk assessments. Both high and low levels of concern are related to 
personal risk assessment increase whereas a medium level of concern bears no 
association with any change pattern. Instead, low and high level of concern are 
associated to increase and decrease of risk in the risk/benefit assessment 
respectively.  
f) Respondents declaring low risk acceptance more probably increase their personal 
risk assessment after reading the PL. This is also valid for uncertain respondents. 
Instead participants declaring high risk acceptance spread all over the change 
distribution with high modality on the 0 value (no change).  
g) Respondents with high degree of confidence in choice decrease their personal risk 
prognosis or leave it unchanged, whereas participants with low to high confidence 
tend to increase it.  
The observed associations (a-e, and 2) have been traced back to heterogeneous 
sources of bias in risk learning: 
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ii. Cognitive dissonance. This phenomenon has been long recognized as an 
important aspect of information selection and processing:
607
 people tend to select 
and store information which confirm their opinion or their wishful thinking: 
“rewarding information”. Cognitive dissonance might explain associations a, c 
and g.  
iii. Lack of distinction of risk and benefit as separate entities for the lay assessor. The 
health technology tends to be considered as a whole without clear-cut separation 
of benefits and risks.  
iv. The conjunction of factors I and II may explain the increase of benefit assessment 
for participants with a PL containing lower than average number of side effects 
(d), and the association between the presence of a topic of uncertainty and a lower 
benefit assessment (general and personal) (2). 
v. Reappraisal strategies in the face of incontrollable risk. These strategies lead to 
act on the risk perception whenever it is not possible to minimize or avoid the risk 
itself: this might explain the decrease in risk perception after reading the PL. Risk 
reappraisal seems to hook in this case on a pragmatic cue: the lower than average 
number of side effects in the PL (d).  
vi. Prospect theory. Both parameters health condition (b) and level of concern (e) 
seem to reflect the considerations developed within prospect theory. This theory 
accounts for risk proclivity vs. aversion by considering the status quo of the 
decision maker with respect to the prospect offered by the options available (loss 
or gain). In the health condition parameter, participants with a light disease will 
tend to risk aversion and therefore perceive the drug risk as higher than the 
inconveniences brought about by their illness, instead people with severe diseases 
will tend to be risk prone and therefore have higher tolerance for the drug risk. 
This is also partly confirmed by the relationship between low risk acceptance and 
increase in risk perception.  
vii. Level of information processing accuracy. This phenomenon might function as an 
alternative explanation to the reason why both low concerned participants and 
high concerned ones increase their personal risk perception after reading the PL 
(e): both low and high level of stress predict less than accurate information 
processing and can lead to over-alarm or risk underestimation (reappraisal).
608
  
 
The main result deriving from this study is however the gap between increased 
perceived level of information and  
1. insignificant PL impact on benefit and risk assessments; 
2. absolute no impact on the decision. 
The presence of a specific topic of concern seems to have some effect on the degree 
of confidence in choice and on the personal benefit assessment before reading the PL. 
In the post-PL phase the persistence or emergence of a specific topic of concern is 
associated with lower degree of confidence in choice, less favourable risk/benefit 
assessment, lower benefit assessment (both general and personal), and higher desire 
to further enquire about the drug.  
                                                 
607
 Frey, 1982.  
608
 See Bealneaves, Long, 1999. 
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However, the presence of a specific topic of concern seems to have no influence on 
the final decision which remains as definite as before (100 score for all participants). 
Considering the generally positive evaluation of PL information and the increased 
perceived level of information after PL reading, these data support the hypothesis that 
the therapeutic decision concerning prescription drugs is quite insensitive to PL 
information. The concept of decision sensitivity can indeed provide the framework 
within which cognitive dissonance, reappraisal strategies, level of information 
processing accuracy – can be subsumed and investigated in an integrated picture. This 
enterprise will be undertaken in the last chapter of this work.  
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8 PL information processing:  
the relevance paradox 
 
 
 
 
 
 
 
 
What patterns of experience would justify calling a connection “causal”? Moreover:  
 What patterns of experience convince people that a connection is “causal”?.  
Judea Pearl, Causality, 2000. 
 
 
 
 
 
 
 
 
 
1. PL information processing: Think-aloud experiment  
 
The quantitative analysis has evidenced a discrepancy between the importance 
attributed to package leaflet and their exiguous impact in the development of an 
autonomous risk/benefit assessment: the degree of confidence in the decision seems 
to be hardly shaken by PL reading. 
More importantly increased awareness perception never leads to a decision change. 
The hypothesis has been advanced that the decision settings of the survey participants 
were not sensitive to PL information.  
However the presence of a specific topic of concern rather than the undifferentiated 
amount of PL information has been found to be associated to important parameters 
such as the degree of confidence in choice and the risk/benefit assessment. 
This chapter is devoted to investigate PL information selection and the dynamics 
related to the presence of uncertainty through a qualitative study.  
In the survey context 15 participants accepted to fill in the questionnaire in the 
presence of the analyst [the author of this study] in a think-aloud fashion. The analyst 
task was limited to record commentaries and eventually elicit responses when 
subjects found it difficult to give an answer whatsoever. Additionally, also the written 
comments to open questions given by the other participants in the questionnaire have 
been integrated into the corpus. 
 
2. Health risk information avoidance 
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The first phenomenon observed from the first interviews has been the reluctance with 
which PL texts were dealt with, and the exceptional status of reading the entire 
text.
609
 Reluctance to systematically process PL information is artificially acted 
against in the special interview context.   
Interview 14 provides an example of this sort of phenomenon:  
 
(813) I: “I […] not always. Well, I don’t read it so intensely as I read it now”. 
(875) I: (To the question whether the questionnaire is interesting): “At any rate it is interesting, 
because I reflected over things, because before I never reflected it over that way”. 
(897) I: (To the question whether the questionnaire is useful): “Also for myself – yeah. Yes, because I 
am involved for the first time so intensively with it, and I see that in fact something is wanting”.  
 
Generally there are explicit requests to obviate reading the PL, and indeed many 
participants show a real aversion to PL information: 
 
# 8: Q.16 (Information source reliability – PL: Score: 50): “They […] a total confusion, when you 
read that –“ 
“But is it reliable or not?” 
“What shall I say – you have to trust them, you can – otherwise you can prove nothing, can you? I 
find there’s too much on such, too much in these –“ 
 
# 8, 1: “Can’t we simply find out what concerns my illness?” 
 
# 8, Q. 38: “Now some questions about your reading experience. In reading the PL it was important 
“Countermeasures to side-effects: then I don’t need to read the all thing through”.  
 
# 13“Completely boring, but ok [I keep on reading it]”. 
 
# 14, 437 ff. “Ok. Now let’s  start read the PL. You read and I write down your comments, Anyway 
they are also [recorded]” 
“Read side effects or?” 
“No, from the beginning, everything” 
“Everything from the beginning? Oh bother!” 
 
Feelings of uneasiness in dealing with PL information are also explicitly expressed: 
 
Interview # 8: 
 
Underlined text passages Comments 
19) Frequency table  „These numbers don’t concern me at all“ 
„In what sense?“ 
„Because actually I have …– „very often“ – I 
don’t make all these trials there – one should 
evaluate it but one didn’t participate in it“. 
20) „Central nerve system. Very seldom, an 
aseptic meningitis (inflammation of the 
meninges not caused by pathoenes) and head 
aches were reported 
„They make you anxious, when you have a 
little head-ache, you should immediately 
think, that it is  …, no” 
21) „Hallucinations“ „No, you can forget it“. 
22) „Arthralgy (rheumatism)“ „What shall I say? This has nothing to do with 
my – that my knee is ill here, that I feel pain 
here. That is – well you can forget it. This 
goes back to old times, what you have here – 
this has nothing to do with it [the drug]”. 
23) “Sense organs: Eye. Transitory  “You can forget it too. My eye – this is – they 
                                                 
609
 This datum is not at odds with the quantitative datum that almost all participants declare to regularly 
read the PL (71,3%, see chapter 8, § 3.3), because this does not imply that they read it all. 
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shortsightedness and inflammation of the 
choroids were seldom observed” 
 
have nothing to do with it. Ok, I have a 
glaucoma, that is treated with eye-drops. You 
cannot see the difference. They are always the 
same now”. 
“What is the difference that you cannot see?”  
“That something worsened because of these 
tablets. That’s not possible at all”. 
24) „Lever and pancreas“ „No, you can forget it“ 
25) “Hypokaliemy (reduction of kalium in 
the blood) or hyperkaliemy (increase of 
kalium in the blood): in connection with 
Hyponatriemy” 
 
“No, you can go on, you can forget it too”. 
“Why?” 
“Because it does not concern me”. 
“And why?” 
“Why? That is-” 
“Metabolism. Do you know what’s about?” 
“Metabolism and blood- mineral – no – no, 
forget it, otherwise you go crazy here. You 
fall ill, when you read all that through. 
What have you had”. 
26) „Very seldom. Hypersensitivity 
reactions at the lungs“.   
„You can forget it at the lungs I have 
nothing, nothing”.  
27) „Blood (the entire paragraph)“ „None. These tablets, I got them also in the 
hospital now, and nothing of what was read 
has come off. And now I take them at home 
and nothing happens“. 
28) „Hypersensitivity reactions. Aalergic 
reactions. Skin and mucus“.  
 
 
„Rash, redness, spots, lumps, or-“ 
„Nothing. Look, when now I take half a dosis 
– but for the first  time at home – and what big 
things can you expect to happen-„ 
 
„No, I have none of these, no the skin is 
normal“.  
29) „Countermeasures to side effects“ „This is maybe the most important chapter. 
This is what one should pay attention to”. 
 
Two cases mention anxiety as a reaction to learning “bad news”: 
#  16, 3: “Side effects”: “When you read this, you wouldn’t like to take the treatment”. 
# 34, 2: “Precautions. Drug interference” (the entire paragraph is marked): “New.    Frightening”. 
#  34, 4: “Side effects” (the entire paragraph is marked): “Frightening”. 
 
These excerpts confirm the phenomenon of health information avoidance as already 
acknowledged in the literature
610
 and explained through the theory of cognitive 
dissonance,
611
 and reappraisal strategies
612
.  
 
 
 
 
3. PL information selection 
 
The experiment has evidenced an extensive selection of PL information by the lay 
reader. 
Many participants show to be self-confident in filtering out what they deem to be 
personally irrelevant information, as the following example illustrates: 
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 Åstrom et al., 2000; Duggan, Bates, 2000; Laaksonnen et al., 2002. See also next chapter.  
611
 Steckelberg, 2005b, 2004. 
612
 Afifi, Weiner, 2004; Bealneaves, Long, 1999; Preuss, 1986. 
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Interview #6: 
 
Underlined text passages Comments  
1) „Precautions: Thyronajod 75 Henning cannot be 
taken if you are hypersensitive towards the chemical 
entities or other components contained in 
Thyronajod 75 Henning“. 
Am not 
2) When you are affected by thyroid hyperfunction  Neither 
3) When the thyroid shows areas that produce 
thyroid hormone irregularly …  In this case no 
treatment should take place, even by not yet 
unambiguous thyroid hyperfunction.  
I have no hyper-function too.  
4) When you are affected by one of the following 
diseases or one of the mentioned conditions: 
A recent heart infarct; 
An acute heart muscles inflammation  
An acute heart inflammation.  
  
 
 
don’t. 
don’t either. 
Don’t either … What is an acute heart 
inflammation? What ist that?  
 5) Before starting the therapy you must exclude or 
treat following diseases:  
coronary vessels disease  
pain in the heart regions 
blood vessels calcification   
High blood pressure 
 
 
Pituitary gland feebleness.   
 
 
Don’t have 
Don’t have either 
neither 
In the meanwhile I have it, but before I didn’t. 
This is obviously something, that I should clear 
up: one should enquire again. 
Don’t have  
 
 
# 6, Q. 33: “Now some questions about your reading experience: While reading the Patient Package leaflet 
it was important … To compare the information with my experience with treatments”.  
“How did you select the information?” 
“What was important for me and what not”. 
“And according to what did you decide, that something was important and other things not?” 
“Because most of the things did not concern me”. 
 
In these excerpts most precautions and warnings are rapidly got rid of with no 
residual uncertainty (topics of uncertainty are printed in italics and will be treated 
later on in this chapter). A strong similarity to this pattern can be seen in interviews 9, 
11, 13, but this phenomenon leaks out in any of the interview. This obviously 
strongly depends on the familiarity with the drug. However, also participants 
processing information about a new drug (as an example take #14) are far from taking 
into serious account all the information available.  
We may roughly quantify this phenomenon with the help of our data by calculating 
the ratio between the number of side effects explicitly taken into account while 
reading the PL and the total number of side effects actually mentioned in the list. In 
our corpus of interviews the mean percentage of side effects actually taken into 
account by the reader (included those from which he excludes to be possibly affected) 
is 28%. In order to appreciate how low this figure is, one should consider again the 
artificial setting of the interview, and how this elicited a much deeper attention than 
normal, in prompting the participant to give account of the text.  
Principally there is no reason for discounting the drug from causing each of the side 
effects mentioned in the list. The question is therefore: How do drug consumers 
distinguish personally relevant information form irrelevant data? 
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The “think-aloud” procedure has brought to light some implicit shortcuts, which the 
readers use when faced with the necessity of assessing personal relevance of side 
effects. 
 
 
3.1 The relevance paradox 
 
In the quantitative analysis, PL information is evaluated as not excessive by 60% of 
the respondents. However, 29,1% of them declare absolute no desire to introduce 
additional information in the PL after reading it, and almost the half of them would 
rather have no further information in the PL.  
This phenomenon might be explained as follows. On the one hand, the PL text has on 
principle a high personal relevance associated to high stake goods such as health and 
well being. Therefore any peace of information contained in it has virtually extreme 
importance and cannot be done away unless one feels justified in neglecting it for 
some reason.  
On the other hand, the probability that all the items of information will jointly 
concern the reader is extremely low. Indeed only a minor proportion of the 
information items do refer to the special health condition in which the reader finds 
himself.  
This situation produces a phenomenon which I called ‘relevance paradox’: considered 
as a whole, the PL text provides much more quantity of information than needed, 
because the probability that all of it will concern the single reader is very low, but the 
importance of each item of information is generally very high: 
 
Items of information:
Ia
Ib
Ic
Id
Ie
If
I…
Ix
Potential importance
of each item x 
of information 
for drug user 
= very high
PL Text
Probability that all the items 
jointly concern the single drug user 
= very low
Relevance Paradox
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Figure 15: Relevance paradox for the PL text: each item of information might result to be very 
important for the user, but the conjoint probability that all the PL information concerns him is 
very low. 
The awareness that the message is directed at any potential user of drug x, leads the 
single user to consider the text as constitutively over-informative: there are so many 
peaces of information as many traits related to all the individuals who might use this 
drug. Since only few of these traits concern any single individual, most of the 
information is for each addressee superfluous and not worth processing. The question 
however arises as to the criteria of this selection, given that the average drug 
consumer does not possess sufficient competence to discriminate relevant from 
irrelevant information. 
 
 
3.2 The PL as a co-text to doctor’s information 
 
One factor that helps explain the confidence with which readers filter out irrelevant 
information traces back to coherence aspects of knowledge updating.
613
 The selection 
of PL information is a function of its familiarity with old knowledge, especially if 
previously acquired from the doctor in the prescription phase. In this sense the PL can 
be also said to function as a co-text to what already learned during the consultation.  
In the interviews this phenomenon especially comes to light either through explicit 
text account on the light of doctor’s quotations or through discrepancies noted 
between instructions given by the doctor and the terminology used in the PL: 
 
# 1, 7: “Interference with other drugs”: “I may take head-ache tablets, told me the doctor, when I 
don’t have head-ache every day”. 
 
# 4, 3: “Indications. Mizolastin is long effect H1 –antihistaminic, that is indicated for the symptomatic 
treatment of season allergic rhino-conjunctivitis (hay fever), of perennial allergic rhino-conjunctivitis 
and of urticaria”:  
“I have hay fever… Skin problems. The doctor said, the skin becomes sensitive through all the 
allergies”. 
 
# 5, Q. 39: “I find this information … already known (Score: 50)”: “Yes, indeed my doctor told me 
what can happen”. 
 
Note that the score associated to the last comment is not 100 but 50: from this the 
reader manifests the belief that half of the information is old for her, however also 
letting understand that this information is assumed to exhaust the entire range of 
possible events that can concern her. As a consequence the half of unknown 
information can be dismissed as not concerning her.  
The following two examples are especially interesting in this sense. Not only does the 
knowledge acquired in the consultation acts as a filter for PL information, but also the 
way around, some information contained in the PL may prompt actualization and 
further elaboration of doctor’s instructions. In the first example an adverse reaction, 
which in itself could bear no personal relevance to the reader, gains salience by 
finding connection to the instructions given by the doctor: 
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 For a formal treatment of these phenomena see: Gärdenfors, 1988; Bovens, Hartmann, 2003.  
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# 13, 15: “In single cases blood circulation disturbs of the littlest vessels in the skin (skin infarct) and 
the dying out of little skin areas (skin necrosis) were observed”:  
“Yes, here I ask myself, if this is what the doctor meant: ‘pay attention to bigger brown spots on the 
skin – then inform me immediately’”,  
#13, 16: “In some cases, this led to death or permanent disability”:  
“Ah, cool, that’s cool: in some cases – mhm what are skin necrosis spots like? – they might be 
brown” 
# 13, 17: “It seems that necroses are accompanied by local thromboses, the occurrence of which 
takes place some days after beginning the anticoagulant therapy” 
“Yes ehe – then now I could – indeed I don’t need any more to pay attention to it, well it must be 
something else”. 
 
The information coming from the consultation – ‘Pay attention to bigger brown spots 
on the skin’ - is retrieved and made available for processing PL information which is 
at first incomprehensible (“skin necroses” #13,15). If a matching between the 
doctor’s instruction and the PL information can be ascertained, then context 
enrichment takes place: both the doctor’s instruction is integrated in a wider model, 
and the PL warning can be better understood (#13,16). Until this point, the doctors 
‘brown skin spots’ are still identified with the ‘skin necrosis’ in the PL text. But 
thereafter, further information about inception time turns out to contradict observation 
(the patient has been taking the tablets already for some months now), then following 
interpretation steps follow (#13, 17): 
1. necroses are accompanied by thromboses which appear at the therapy 
beginning; 
2. the fact that they did not materialize until now makes the probability of their 
occurrence negligible; 
3. therefore I don’t need to pay attention to the skin spots any more. 
The reader realizes that this very identification is not sufficiently supported by the 
elements at hand and therefore leaves the topic there. The context enrichment is 
abortive. 
Context enrichment phenomena prompted by “intertextual” inferences come in 
interview 14 even more explicitly to the surface: the filtered processing strategy is 
illustrated by several linguistic traces, which manifest the interaction between 
background information and PL processing. 
The point at which the excerpt starts is where the first part of the questionnaire has 
already been answered, and the PL reading follows: 
 
460 I: {h} mhm. Indications (4) here we have already grampositive gramnegative   
461  pathogens [mhm] never heard of. I heard  Staphilococcus (6) mhm (..)  
462  but here there are always so many special terms (4) but […] only the all list (.) 
463 of the diseases for which this treatment is indicated – it tells me nothing.  
464  Everything in Latin. (3) And sometimes absolutely unpronounceable. [hh] well, it 
465  mostly doesn’t mean a thing to me.  
466 Q: But is there anything that - 
467 I:            - that I can recognize again? Absolutely not.   
468 Q: Nothing [no] really? 
469 I: No. Well, I recognize Pathogen  and think, ok Pathogen is what the doctor said 
470 – Germs, Bacteria [ok] I think, ok – this was also – by the doctor – but 
471 what exactly, well I, E. coli I don’t suppose [mhm] and everything else, that 
472 is there  - I can tell – difficult – I can tell absolutely nothing [mhm] – I can 
473 definetly tell nothing [mhm ok] I have only pathogen back and - [mhm mhm] I 
474 know that I have it. Also here: It is indicated for the treatment of infections, that 
475 are caused  by germs sensitive to Sulta (.)micillin- I don’t know, if the germ was 
476 sensitive against it for it, or whatever [mhm] anyway (.) I know that I had a germ 
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477 and  that it has caused the infection, but whether it was sensitive to that there (.) 
478 [mhm] no doctor told me. I don’t know it ehm - I reads on (6) – it is for the skin 
479 and private parts (..) so it is fort the skin actually, this is comprehensible, here I 
480 find myself again - [mhm] (13)  
481 contraindications (11) e – this happened to me too. Before the – before the therapy, 
482 eventual sensitivity reactions to  Cephalosporin and other allergens should be 
483 carefully investigated. 
484 Q: Did he ask you if -? 
485 I: Well in the end not, no: - Is it what he asked me, when he asked me, whether  
486 I am allergic to Penicillin? [ja] Is it? [ja] Ok, then he asked me. But then 
487 I don’t know again (..) what are Cephalosporin and  other allergens. Had it 
488 directly said ‚Penicillin’ – so that it refers directly (.)  
489  to Penicillin-  
490 Q: Yes, it’s a type of it- 
491 I: Yes, but this is what I mean, this technical language in there (..) [exactly] […] does 
492 not mean much - well: [mhm mhm] 
 
Line 467: “- that I can recognize again (in the original: Das ich wieder erkenne?”) 
tells us much of how the reader processes PL information: As the questioner of the 
interview, I was trying to elicit some comments to the PL (466), and, if not 
interrupted by the interviewee, I would have ended the question by asking if there 
was something that caught her attention. Instead the interviewee has given a 
completion in a completely different direction, which has surprised me.
614 
 
By interpreting the task of commenting the PL as a request to identify already known 
information, the interviewee explicitly mentioned the tacit criterion, which she 
resorted to in interpreting this sort of information. This criterion is constituted by 
drawing on old familiar knowledge and matching as much PL information as possible 
with it. 
How inferences and recognition patterns work in this sense needs further 
investigation. For instance, what makes the reader reflect about the penicillin question 
(lines 482-91)? It seems that the only way she could have come to connect 
cephalosporin with penicillin is via the word “allergens”. It might be that searching in 
her “data base” for the peace of knowledge which most suited the information at 
hand, she remembered about the doctor asking her if she was allergic to penicillin, 
and then, given that no other ‘allergy issue’ had emerged during the consultation, she 
inferred that penicillin and cephalosporin could be the same thing. Still, context 
enrichment could take place only after verifying the soundness of the inference by 
asking to the questioner. 
Awareness of the role played by the knowledge provided by the physician can help us 
identify the rationales underlying information selection.  
In the PL context, one might hypothesize that, the higher the trust in the physician 
(and generally the lower any motivation factor to process information autonomously) 
the stricter will the reader adhere to the ‘agenda’ given by him.  Any information with 
no relationship to any item of knowledge in one’s own database is perceived as 
                                                 
614
 Elizabeth Gülich (personal conversation) let me notice that completion of the communication partner’s 
line is a much studied conversation phenomenon in linguistics (so called “co-enunciation”). A more 
detailed discussion of this interesting phenomenon is unfortunately out of the scope of this work. 
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irrelevant and dismissed as such.  Paradoxically one might say here, that information 
that sounds “new” at this stage of post-consultation, will be considered irrelevant.615  
 
 
3.3 Counterfactual neglect 
 
The filtering process described so far is also acting at a pragmatic level: when 
information is encountered which not only ‘sounds new’ because it has not been 
mentioned by the physician, but which is also incomprehensible, either literally or in 
its health implications, then pragmatic maxims, such as the cooperative principle, 
build the basis for information selection. In fact incomprehensibility of words or text 
passages can be taken as an instruction to skip the text. In combination with the “co-
textuality phenomenon” evidenced in the preceding paragraph, the reader might 
consider that information which he does not understand does not concern him, 
because otherwise he would have been informed about it by the doctor.  
Counterfactual neglect can be considered as a pragmatic inference about health 
communication in the PL context: “if I cannot understand this peace of information, 
this means that it does not address me; therefore I can skip it”. The argumentation 
goes as follows: 
 
Counterfactual Conditional: 
if I were concerned by this peace of information  
I would be informed about it – either through the doctor or through facts - (counterfactual);  
 
Real Facts: 
but I don’t even understand it, 
which is a clear sign that I am not informed about that; 
 
Inference: 
therefore I am not concerned about it. 
 
Counterfactual neglect cannot be presented with examples for obvious reasons, but 
the proof that skim reading and counterfactual neglect are deeply interrelated can be 
illustrated by the following comments:  
 
# 8, 15: “The contemporaneous use of anesthetization drugs …”: “This does not concern me either. If 
it concerns anesthetization, I have no influence there. It is the doctor that makes it …” 
 
# 10, 2: “Contraindications”: “Well, also this here is important: ‘Contraindications. When not …’ but 
I don’t find this as important as the first one [indications], because for this, it is the doctor which is 
responsible”. 
 
# 12, 11: “Effects on blood and blood components”: “How can you see it? Superfluous information: 
the doctor should consider it”. 
 
#13, 6: “First something about contraindications: I would never read them. It does concern the doctor, 
before he pokes this in my paw, he must already have clarified -” 
“Pardon?” 
                                                 
615
 The paradox however is only apparent, in that relevance is a relational dimension which is not only 
determined by novelty but also depends on the connection with old knowledge.  See Sperber, Wilson, 1986: 
143. 
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“ [hh] Well, I think, this is simply information, that can be done without by such a message, if you 
consider it as information for the patient, because this should have been clarified by the doctor – this 
is information that belongs to the doctor. You notice it also by the halting reading: which disease …” 
“And you cannot know if you have a risk for some diseases or -” 
“No, no. Well, ok, maybe still by high blood pressure -  or I can ascertain if I am pregnant, but the rest 
– this is somehow – this is completely in the wrong place […] most of the information cannot be 
ascertained by the patient”. 
 
# 13, 8: “Angiography. Completely a nonsense. There’s information inside it that absolutely – like 
angiography for instance. This concerns doctors and above these […] On the other hand here – there 
are people […] that must know this: this should be emphasized much more, this is […] but it must be 
marked. – Children too – The leaflet is not adequate to the target group –” 
 
# 50, 1: “Thyronajod 50 cannot be used if you are hypersensitive (allergic) to the chemical entities or 
the other components contained in Thyronajod 50”: “Incomprehensible. Only the doctor who treats 
can judge it”. 
 
In these cases the conviction is explicitly expressed, that what cannot be understood 
lies in the doctor’s responsibility. 
Counterfactual neglect and co-textuality with the doctor’s information jointly 
constitute the processing filters of PL information:  
Processing Filters
Items of information:
Ia, Ib, Ic, Id, Ie, If, I…, Ix
Connected 
with doctor’s 
info?IT DOES NOT 
CONCERN ME 
(doctor = responsible)
SKIP
IRRELEVANT
INFO
RELEVANT 
INFO
Not comprehensible
comprehensible
NO YES Relevant?
 
Figure 16: Economizing filters in PL information processing.  Not comprehensible information (the most 
part) goes unprocessed in the “irrelevant info” bin, unless a connection with doctor's information is 
established. 
When data are incomprehensible, the reader tends to treat them as not relevant (the 
doctor is responsible) unless a connection can somehow be established to what the 
doctor has said: in this case context enrichment takes place, and the information item 
falls in the ‘relevant info’ bin.  
Where the peace of information is comprehensible and connected with the knowledge 
acquired through the doctor’s consultation, then it is considered undoubtedly relevant.  
It seems that incomprehensibility is taken as a pragmatic instruction indicating that 
the reader shouldn’t consider himself as the actual addressee.  
Indeed, along these considerations, we can say that, the institutional context in which 
PL communication is embedded provides the pragmatic clues, through which PL 
information processing is at all possible. Without the cues provided by the doctor’s 
information, the reader would find himself in front of an amount of unmanageable 
 253 
information, which only becomes intelligible through the knowledge previously 
acquired in the consultation. 
On the other side, the expected outcome of any informative transaction is that 
information is shared. Therefore, questions of mutuality left for the moment apart, the 
patient can suppose to be partly responsible about the issues, that the doctor decided 
to communicate to him, especially for instructions related to aspects that only the 
patient has under control. As a consequence, on reading the PL, he will pay more 
attention to these aspects than to others.  
Uncertainty may arise when the peace of information is comprehensible but not 
connected to the doctor’s instructions. The bifurcation of the dashed red arrow stands 
for the uncertainty as to the personal relevance of this sort of data. For these, an 
autonomous interpretation space opens up, where personal relevance must be 
assessed recurring to other information sources: personal past experience or 
knowledge acquired from other sources than the doctor.  
This case is illustrated by the following excerpt:  
 
# 6, 5: “Precautions. High blood pressure. In the meanwhile I have it. But before I didn’t have it. This 
is something that I must clear of course, one should enquire again”. 
# 6, Q. 43: “I would like to talk again with the doctor about the treatment“. (Score: 100).  Because, 
what makes me suspicious: I take this drug since – 96 Op, 97 – let’s say 97. And since two years ago 
– was it two years ago? Yes, well no, three years, they diagnosed that I have high blood pressure. 
Well it NEEDN’T be in connection with the drug – it CAN though … this was under side-effects, 
wasn’t it?”. 
“No, under precautions”. 
“BEFORE the intake. At the time I had no high blood pressure. That’s it: ‘Before starting the therapy 
you must…’ at the time I had no high drug pressure; i.e. before. I have been having it for three years 
now. But I will ask him nonetheless”. 
# 6, Q. 45-46: “Is there anything left that makes you uncertain? What is it?” 
“Yes, well. On the other hand, this high blood pressure, they diagnosed it three years ago, since then I 
have been under treatment, and I also have always been anyway. The test results have always been in 
order. So from that, I am almost sure, that it does not have a connection”. 
 
 
The respondent seems concerned about a piece of information found in the precaution 
paragraph. This passage cautions subjects affected by high-blood pressure from 
taking the drug. As her blood pressure has indeed registered an increase in recent 
years, she entertains the hypothesis that the drug might have contributed to the 
development of this disturb. Her perceived incapacity to solve her doubts prompts her 
to express the desire to further enquire the doctor on the matter.  
However, there are cases of uncertainty which are left unsolved with no trouble, 
presumably because they are not deemed worth of further investigation: 
 
# 4, 9: “Tiredness. I am not ‘power-charged’ too, but you can’t say if it depends on the drug”. 
 
# 9, 18: “And do you notice memory disturbs or don’t you, because it’s also important for our job, an 
academic job-” 
“I have always had concentration or memory disturbs, but you never know what it is, if it depends on 
depression, with the anxiety, which compromises also the concentration capacity”. 
 
# 9, 20: “Occasionally: tiredness. I can’t distinguish, if it comes from the drug or if it is a disease 
symptom”. 
 
# 15, 6: “Nightmares. This can depend on these tablets”. 
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In these examples, it is evident that the uncertainty generated by PL information does 
not necessary leads to further information need. Uncertainty might be left unsolved, 
when stakes are not high enough to require active information seeking. This is 
precisely the type of phenomena investigated within the framework of the Bayesian 
theory of expected information, which will be presented in the next chapter.  
 
 
4. Prognostic uncertainty 
 
Generally, participants declare to read the PL, precisely in order to have an idea about 
what it may occur: 
 
# 2, 1: “I always read it through and see what might come”. 
 
# 4, 1: “At the beginning [of the therapy] I read the PL, to know what may come, but as nothing 
happened-” 
# 4, 8: “I read at that time also to know what may come: incorrect use … This is the most important 
for me. As the doctor’s dose did not correspond to that of the PL, I read what could happen in case of 
overdose”. 
 
# 10, 9: “Side effects …”: “This is important” 
“Do you believe that you might be affected by any of these side effects or you can exclude it without 
any worries?” 
No, you cannot exclude it, well here the irritation and dryness of the nose mucus, you have to take it 
into account, well normally I have nose bleeding, I had never before that way – and here: nose 
stimulation, this is always the case. As soon as I take it, I must always sneeze, but this is normal”. 
 
# 15, 5: “Nebenwirkungen … It can happen even if it has not happened before”. 
 
However a great variance characterizes the sample as to the epistemic status assigned 
to probabilistic information. In the test phase I happened to interview an old lady with 
a skin fungus: while reading the side effects list, I could see her nodding her head and 
saying: “This won’t possibly affect me”, “Neither this” and so on, but then stopped at 
the percentage frequencies and wondered: “What does it mean to me, that it seldom 
happens, or 1 out of 10.000 times. Either does it happen to me or not. There’s no 
graduation”. This is what might be called a radical frequentist attitude.616  
A similar example is in questionnaire # 55: 
 
# 55, 4: (about the frequencies accompanying the side-effects list). 
“What side effects are possible? Very incomprehensible for me. Seldom or very seldom: either, or. So 
one can also do without writing side-effects“.  
 
The most typical reaction to risk information is a sort of helplessness feeling: 
 
# 14, 175 ff: (Reliability of info sources) “You mean, whether it’s correct what you find there or it’s 
not. This is also a thing; generally speaking, I don’t know it. Precisely as far as side effects are 
concerned, well not necessarily with reference to it [the PL at hand], but in principle – it stays there 
everything that could occur,  but I don’t know in this regard … Can it really happen? Because it says, 
well it’s always there somewhere – yeah, in case you notice other – yeah – notify these - ”.  
                                                 
616
 More on the different philosophical interpretations of probabilistic information in the next chapter. See 
also Gillies, 2000. 
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# 4, 4: “Precautions. By clinically relevant retarded heart pulsation (Bradychardie)”: “I don’t have it. 
Or at least I don’t know”. 
 
# 14, 490, ff: “Yes, but this is what I mean – this technical language in there (..) [right] […] it’s of no 
use [mhm] (13) {h} under special condition (9) {h} What’s a “absorption”? I don’t know. The 
problem is, yes, - that sometimes I don’t know at all: ‘Am I concerned’? Does this concern me? 
Because I simply cannot understand, so that then I say, mhm, maybe I have it and I don’t know it yet 
because I don’t know the technical term?”.  
 
# 2, 4: “The doctor decides the therapy duration. By rheumatic diseases it can be required the intake 
of Diclofenac-ratiopharm over a longer time”: “Whether this is good”. 
 
# 12, Q.61: “Would you do without the following information paragraphs in the PL? Q. 61: “Why 
would you do without it?”: “Others: ‘hidden side effects’, because you cannot identify them”. 
 
These excerpts present a situation of total prognostic uncertainty on principle. The 
impossibility to attain the probability assessment tailored to the individual, leads the 
reader to divergent strategies which not necessarily lead to knowledge updating.  
Chapter 6 has been devoted to illustrate the probabilistic computation implied by 
Bayesian updating of personal risk assessment on the basis of PL information. This 
entails a probabilistic assessment about the eventuality of being concerned by each 
side effect listed in the PL. The probability of side effect occurrence has been defined 
as a function of the level of drug toxicity, the quantity (dosage/duration) and the 
degree of personal sensitivity: 
 
P(SE) = P(DT = i/Q = l) x P (PS = h/ DT = i; Q = l).    
  
The corpus was examined as to whether drug consumers indeed venture in a personal 
risk assessment, and what role PL information plays in this task. It should be noted 
that in all interviews very little mention is made of PL frequencies as a reference for 
risk assessment. Precisely, only two readers out of the entire survey sample (n = 55) 
explicitly refer to the frequency information provided by the PL in order to assess 
their risk prognosis: 
 
# 12, Q. 54: “According to the information that you have received from the PL: How probable is that 
you will be affected by the side-effects of this drug?” 
“One of them will affect me for sure. … 0,1% is not little for a lung embolism”. 
 
# 53, 7: she underlies the frequencies in the PL:  
“Many side effects, which I was not aware of, but that only seldom occur”. 
 
PL information is used to know which side effects are possible, rather than to learn 
how much they are probable. Therefore it represents a source of information about the 
risk magnitude. Instead the personal probability of being concerned by risk is 
computed – whenever it is – out of other data, mostly past experience. This might 
explain why, in the absence of personal experience about the side effects mentioned 
in the PL, a sense of helplessness overruns the reader in assessing his personal risk 
prognosis. Especially in the case where the reader was not even aware about the side 
effect mentioned in the PL, this information produces rather than reduces uncertainty.  
The probabilistic assessment seems in most cases to be based on an underlying 
etiological model about the symptom considered. 
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4.1 Lay causal models  
 
PL information provides general probabilistic information on drug toxicity and 
efficacy. These data should be converted into personal assessments.  
Many of the responses to open questions and commentaries to the PL indicate that 
causal models of illness and drug underlie the probabilistic assessment provided in 
the questionnaire.  
Causal information can be derived from past experience (eventually with the aid of 
other sources of information). Lay causal models can be considered in this framework 
as the crystallization of accumulated experience over a series of observations.  
The role played by causal models in risk prognosis and the assessment of the drug 
contribution to the occurrence of side effects can be represented as follows: 
Frequencies of associations between
symptoms and possible causes (drug, stress, 
other treatments, interference with other treatments) :
Likelihoods assessment
Prior Knowledge
Past experience 
with illness(es) 
& treatment(s)
General
Personal
Decision Making Models
Information about 
alternative treatments
Risk-Benefit Judgment
Decision Making Process
Etiological 
models
Patient Package Leaflet 
Personal Risk Prognosis in the light of PL Information
 
Figure 17: The role of etiological models in the assessment of personal risk 
In this model, the integration of general frequency data into a personal risk prognosis 
is made possible through resort to causal models of illness and drug adverse reactions, 
which on their turn are based on frequency data coming from past experience.  
Causal models detected in the sample vary as for sophistication and solidity: most of 
the observations manifest categorical judgments of causality (either is the drug 
responsible for a certain side effect or it is not), however some respondents are less 
extreme and leave open the possibility of more than one causal factor.  
In the former case the causal model is deterministic, in the latter it is probabilistic.  
Deterministic models emerging from the corpus contemplate either the absolute 
exclusion of the drug as the cause of the side effect, or its absolute categorization as a 
causal contributor:  
- the drug is neither sufficient nor necessary for the side effect to occur:  
¬ (E  D) & ¬ (D  E ).  
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- the drug is identified as the only responsible for side effects: (sufficiency & 
necessity): D ≡ E.  
When more causal factors are contemplated, then the way is open for a probabilistic 
modeling of causality: the effect is produced by the drug in concomitance with other 
factors. In this case the drug can be considered necessary but not sufficient for the 
effect to occur: D  E, or it can be considered as a sufficient but not necessary cause 
for the effect to occur (sufficiency): E  D. 
The following paragraphs are devoted to illustrate instantiations of these models in 
the corpus at hand.  
 
 
4.1.1 Discounting the drug as a possible cause for side effects 
 
In the first model, the drug is excluded from the beginning as a possible cause for the 
effect under consideration. In general, discounting is the effect of alternative causal 
attributions: other causes are better candidate for explaining it. 
 
# 4, 10: “Leukozytenzahlen. Had it. But something acute. Not in connection with this drug”. 
 
# 4, 11: “Arthritis and muscle pain. I have every now and then. But I don’t believe that it depends on the 
drug: I had a spinal column surgery … also before I had it”. 
 
# 7, 36: “Hematoma. Yes, I tend to have hematoma, but I always did”. 
 
# 7, 40: “Irritability. Well, which woman is not irritated. That’s not a permanent mood”. 
 
In all these cases the causal connection between symptom and drug is definitely 
excluded with no residual doubt. 
 
 
 
 
4.1.2 The drug as the only responsible for side effects. 
 
In the second model, the drug is the only responsible for an eventual side effect. This 
model is exemplified by participant # 4, who is pretty sure that he will be affected by 
side-effects in general (Q. 28: score 100): His prognostic probability of being affected 
by side effects, given that he takes the drug is certain: P (E/D) = 1. Furthermore he 
adds as an explanation: “any drug causes side-effects”.  
In fact this assertion equates to: = ¬ (D Λ ¬ E) = ¬  D Λ ¬ ¬ E = ¬ D Λ E = D  E.  
This model fails not only to recognize the fallacy lurking out of the explanation – 
even if it were true that all drugs have side effects, nevertheless, they do not 
necessarily affect all users – but also identifies the drug as the only possible cause for 
eventual symptoms occurring during the therapy:   
 
# 2, 5: “Head-ache. At least you know the cause of head-aches”. 
 
This belief is supported by considerations coming from personal experience: given 
his healthy past with no disturbances at all, in the case where disturbances occur, he 
 258 
cannot but think that the cause for them is to be found in the drug. The fact that he 
cannot think of any alternative cause, induces the participant to think that the drug is 
indeed “the” cause of side effects. This equates to E  D. 
Therefore the underlying causal model should be modelled as the conjunction of both 
entailments: (E  D) Λ (D  E) = D ≡ SE (the necessity & sufficiency causal 
model). 
Also interviewee #11 clearly identifies the side effects as drug conditioned. Moreover 
in this case an analgesic (A) accomplishes the task of neutralizing the drug adverse 
reactions (D). The causal model is consequently articulated into two contributors (a 
negative and a positive one): 
D
A
Side effects
_
+
 
Figure 18: Postitive (Drug) and negative (Analgesic) contributors to a set of side effects. 
The interviewee is able to recognize the weight of the analgesic contribution as 
adverse reactions neutralizer, by comparing her health condition when she takes both 
the analgesic and the drug to when she just takes the drug: 
 
Q. 10: Are you satisfied with the drug treatment? 
(Score: 90): „Well it’s stupid  to - […] at least, and the day after I am also always  a little bit run out but- „  
„Ah, then you notice side effects a little -“ 
„Yes, I do a little – I take Paracetamol here against them“ 
„I take Paracetamol too against – also headaches-“ 
„Yes, yes. When I don’t take it, then I really have head-aches the following day, shivering fit in the night, 
and I feel very very worn out”. 
„And this occurs in connection with the drug?“ 
„Yes, yes“. 
„Unambiguously?“ 
„Yes, This has very strong side effects“. 
„Long term or only short term side effects?“ 
„Nee, short term, when I take it, then – but I inject it before going to bed and then most of the times I have a 
quiet night”.  
 
Also interesting is the case where the patient can distinguish between different 
nuances of the symptom and identify if they are drug conditioned or not: 
 
# 9, Q.30 (positive vs. negative effects ratio: positive) 
‚What side effects do you have with this drug?“ 
„Side effects, it’s sleepiness the day after“. 
„And do you have to take the treatment regularly? – You sad discontinuously-“ 
„Discontinuously“. 
„So when you don’t take it, you don’t have this sleepiness?“ 
„Yes”. 
„So, it’s no doubt the drug?“ 
„Yes”. 
„Mhm. Are you also able to recognize different sorts of sleepiness?“ 
„Yes“.  
„And when it is drug conditioned, then you recognize it, that it comes from the treatment“. 
„Yes, yes, yes, I can recognize it. I also take other drugs, that are lighter, still the day after – doctors 
say: ‚to have the overhang’“.  
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The term sleepiness is here a vague term for different symptoms: A drug conditioned 
sleepiness, and a normal one, which in the experience of the patient can be recognized 
as two distinct conditions with related different etiologies. 
 
 
4.1.3 The drug as a necessary but not sufficient causal factor 
 
In the third model the effect is a product of several conjoint factors, where the drug is 
considered as one among other equally possible causes. The drug is considered 
responsible for a side effect, but there is uncertainty as to the amount of this 
contribution: 
 
# 7: 45: “Leucocytosis. Yes”. 
“What’s a Leucocytosis?” 
“Well, There’s an alteration of leucocytes, well I have many, many more. Normally there are 6000 pro μl 
Blood, and I have more than 10.000. And they call it already, well above 10.000 they call it Leucocytosis”. 
“And this depends also on the drug?” 
“This depends also on the disease, well, the disease as well causes a Leucocytosis, but also this drug 
produces Leucocytosis. Through that it can also result a hidden effect”. 
 
The ‘hidden effect’ is a formula to express uncertainty as to the extent to which the 
drug responsibility in contributing to leucocytosis can be “masked” by the disease. 
The effect might be attributed entirely or mostly to the disease, even if part of it is 
also due to the drug:  
 
           
Dr
Di
Leucocytosis
+
+?
 
Figure 19: Joint causation for Leucocytosis: Drug (Dr) as possible and Disease (Di) as certain 
cause candidate. 
It must be noted that such a diagnostic sophistication is present in only three 
participants out of 15 in the sample, and among these one can be considered as an 
almost-expert participant (# 7, a student of alternative medicine).  
Fig. 6 illustrates the presence of two alternative causal models as implied by comment 
#7,34: 
 
# 7, 34: “Skin. Thinning of the skin. Yes, I have this too, but it may comes also from the long use of 
creams”. 
 
     a                 b                                                        
  
 260 
Dr skin thinning+
 
 
Dr
Cr
Skin thinning
+
+
 
Figure 20: Two alternative etiological models for a side effect: a) single cause model b) joint causes model.  
Here two alternative causal models are available and equally plausible. Moreover the 
second one, which presents two conjoint causes, leaves open the amount of 
contribution which each single factor brings to the effect. Prognostic uncertainty 
increases with the number of alternative models, which the subject entertains for the 
same symptom.  
 
 
 
 
 
4.1.4 The drug as a sufficient but not necessary causal factor 
 
In the fourth model, the effect can be caused either by the drug or by other causes. As 
an example we present interviewee #3 and her sight disturbs.  
In reading about possible head-aches and sight disturbs associated with the treatments 
she comments: “I have head-ache every now and then, it can be …I also have sight-
disturbs, but it must not necessary be: I sit all day long before a computer, I wear 
glasses too …”.    
In this case the etiology is in a certain sense left unsolved: the drug might be the 
cause for her sight disturbs, but also her short-sightedness and/or the fact that she 
stays much of the time in front of a computer screen might as well be plausible 
explanations of her head-aches and sight disturbs.  
Narrowing down to the most likely cause or set of conjoint causes and identifying the 
most plausible one might cost a high cognitive effort and eventually lead to failure 
because of medical incompetence.  
When the causal model is complex, self-efficacy considerations
617
 lead the subject to 
leave the question open if no severe loss is at hand. Here are some other examples 
(presented once again for the reader’s convenience): 
 
# 4, 9: “Tiredness. I am not ‘power-charged’ too, but you can’t say if it depends on the drug”. 
 
# 9, 18: “And do you notice memory disturbs or don’t you, because it’s also important for our job, an 
academic job-” 
“I have always had concentration or memory disturbs, but you never know what it is, if it depends on 
depression, with the anxiety, which compromises also the concentration capacity”. 
 
                                                 
617
 The concept of self-efficacy refers to the perceived capacity to accomplish a specific task. In this case, 
with the attainment of the desired level of confidence about the causal attribution. More on this on the next 
chapter.   
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# 9, 20: “Occasionally: tiredness. I can’t distinguish, if it comes from the drug or if it is a disease 
symptom”. 
 
# 15, 6: “Nightmares. This can depend on these tablets”. 
     
In these examples more than one causal model are considered at a time as a plausible 
explanation for somatic disturbs. If stakes are not high enough, certainty as to the 
legitimacy of one model rather than the other might be left in “stand-by”.    
      a                                                         b 
Dr tiredness+
 
X tiredness+
 
Figure 21: Two alternative etiological models for a side effect: a) the drug; b) other possible causes.  
The examples presented so far refer to etiological models for symptoms which the 
drug consumer has had in the past. It seems that frequency information coming from 
past observations helps build an etiological model which on its turn plays a 
determinant role in assessing the prognostic probability that one will be affected by a 
specific side effect or in estimating the probability that one’s occurring symptoms are 
originated by the drug rather than by other causes.  
Whether causal models can be built out of other information sources other than 
personal (probabilistic) experience should be deeper investigated. Moreover, it should 
be also investigated how likelihoods are assessed, i.e. whether an underlying causal 
model influences the selection of events and therefore contributes to the frequency 
pattern, or vice-verse or both.  
The etiological model might also reveal fallacious:  
 
#10, Q. 20: (Score: 50) 
„For instance, when is it difficult to distinguish?“ 
„Well, when I had this Bronchitis, then I had - through antibiotics, through the first antibiotic 
treatment - I had rather heavy problems at the stomach, but I thought, that they may come from the 
mucus, and they probably came from the drug”. 
„Did you have them as soon as you took the treatment or not suddenly – how comes that you 
thought the side effects came from the mucus membrane?” 
„That’s my experience. Well, when I had a strong cold, then normally it was like that – first there 
was some sore-throat and the nose ran, then came cough, and then at a certain point it slid into the 
stomach. That was my typical cycle, and then by this bronchitis I had the same, but the doctor said 
to me, no this is, this must be the antibiotic“. 
„Alright, when was it simple to distinguish, that it was absolutely a drug side effect“. 
„Well, this was of course, that I had experienced it, then I obviously paid a little more attention to 
it, then I read the PLs“.  
„So after a little experience-“ 
„Yes, precisely, yes“. 
„And anyway, in order to be sure that it was a side effect you had to read the PL or-  “. 
„Yes, whether this – I read PLs more often then, whether it is a possible side effect“. 
 
In this case a consolidated illness model interfere with symptoms interpretation, and 
therefore needs to be put into question before coming to terms with observational 
data.  
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The integration of information from the expert allows for a revision of the causal 
model.  
It is important to note again, that PL is mentioned as a reference document for 
establishing whether the drug might indeed be the symptom cause in a 0 or 1 fashion, 
i.e. with little attention to the probability with which symptom and drug are 
associated. 
 
 
5. The PL as a source of safety information 
 
This study is preponderantly devoted to the analysis of PL information as a source for 
self-determination information (informed consent). However, the nature of the PL as 
a modular text, exhibiting all possible negative outcomes, seems more suited to a 
reference use in case of countermeasures in the face of possible side effects, rather 
than to a choice support at the beginning of the therapy.  
In this context, the reader refers to PL information in order to give a meaning to what 
he is already experiencing (bodily symptoms). 
Indeed the very habit of reading the PL can emerge precisely as a consequence of 
being affected by adverse reactions.  
Overall 60% of the participants declared to always (Score: 100) read the PL when 
side effects occur.  
Two participants have also declared to observe how their body reacts to the treatment 
and then check if the symptoms might correspond to some of the side effects listed in 
the PL: 
 
# 9, 15: “During the treatment with Benzodiazepin and similar chemical entities reactions such as agitation, 
irritability, aggressiveness, …can occur, especially by elder patients. I don’t have it, but it was important 
for me to know that”. 
“So at the beginning, when you read these side effects, then you simply tried the drug, in order to see, 
whether these side effects would occur, and then, as they did not occur you went on-” 
“Yes” 
“Did you have this ‘trial-attitude’ or-?” 
“I observed myself”. 
 
# 17, Q. 66: “In the PL I read principally… Everything all through and then I observe my body, what 
concerns me”. 
# 17, Q. 67: “What function do PL have in your opinion? You can observe yourself and observe the side 
effects in your body”. 
 
In the end, the cost/benefit analysis of PL information results in a double balance: A 
positive balance with respect to PL information as safety information, and  a negative 
estimation determined by the high cognitive costs demanded for using it as a basis for 
therapeutic decision.  
This might be the reason for some skeptical comments: 
 
# 55, Q. 67 (PL function): „Information about treatments. The patient understands only in part, 
because one has no idea of the medical special terms. If you read it or not is the same. Either you 
take it or you let it be. Not all PLs can be precisely understood“. 
 
# 4, Q. 16 (reliability of information sources): 
(PL, TV, Radio: Score: 50): “They are ok, but they are not tailored to the individual: I already 
noticed that”. 
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# 13, 8: “… The leaflet is not adequate to the target group – The best would be a sort of check list 
for the patient: ‘You shouldn’t do this, you should talk about that to the doctor …’” 
“You told they are not?” 
“Adequate to the target group, because you find there information for the doctor, mixed with 
information for the patients”. 
 
 
 
 
 
6. Conclusion  
 
PL information seems to raise more questions than it answers. Generally people 
perceive it as highly important, but are not in the position to adequately select 
personally relevant information. This might lead to the overload sensation accounted 
for through the notion of “relevance paradox”. Common heuristics to bypass these 
shortcomings are reappraisal, counterfactual neglect, idiosyncratic causal models, and 
uncertainty neglect.  
As a result, PL information is not processed in its entirety and is selected through the 
most diverse filters. This raises some doubts as to its legitimacy as a basis for a 
personal risk/assessment and to its specific contribution to the consumer’s informed 
consent. 
Along these considerations the role of PL in risk estimation might be strongly scaled 
down.  
However, as observed in the last paragraph, PL information has indispensable safety 
functions, which also the lay reader recognizes.  
Rather then being a basis for an evaluation of the treatment choice, the PL is rather 
conceived as a modular reference text to be consulted at the beginning for 
precautionary reasons, and then during the therapy in order to identify eventual side 
effects.  
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9 Towards an integrated model of health 
risk information processing 
 
 
 
 
 
In a world where information is relatively scarce,  
and where problems for decisions are few and simple, 
 information is almost always a positive good.  
In a world where attention is a major scarce resource, 
 information may be an expensive luxury, 
 for it may turn our attention from what is important to what is unimportant.  
We cannot afford to attend to information simply because it is there.  
 
Herbert Simon, Rationality as process and as product of thought, 1988. 
 
 
 
 
1. Introduction 
 
The main empirical finding emerging from the quantitative study presented in chapter 
4 is the observed gap between the increased level of information after reading it on 
one side, and the lack of any impact on the final decision to take the drug.  
The qualitative study has underlined the key role of the information previously 
received from the doctor during consultation as a selection filter in processing PL 
information.   
This chapter posits the therapeutic decision as the teleological determinant for the 
information processing. Thereby, the therapeutic decision, which is established by the 
legislator as the communicative purpose of the PL text, suggests the theoretical 
framework within which the behavior concerning PL information processing can be 
investigated, namely: decision theory.
618
 
The theoretical structure is provided by the Bayesian theory of expected information 
value. This frame is integrated with the insights gained by cognitive approaches to 
information processing (“Bounded rationality” theory), and emotional accounts of 
health risk information processing.  
The added value brought about by this integrated model is that it accounts for the 
accuracy level of PL information processing and impact in consideration of the 
decision sensitivity to the information at hand.  
                                                 
618
 I will consider here only the main parameters of investigation developed in the framework of standard 
Bayesian theory of decision. Specifically the accuracy of PL information processing will be considered as a 
function of its expected value to the decision at hand.  
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The following paragraphs will show that this parameter provide the framework for 
integrating the diverse phenomena observed in the literature on (health) risk 
information processing into a unitary model.
619
 
 
 
2. Cognitive accounts of information seeking behavior  
 
More or less explicitly, cognitive literature on information seeking behavior has 
generally focused on uncertainty (mostly interpreted in terms of perceived 
information need) as a motivating factor to seek for information.
620
  
The principle of sufficiency for instance (Chaiken et al., 1996) assumes that 
individuals assess their actual level of confidence (AC) and the desired level of 
confidence (sufficiency threshold: ST) and will search for further information 
depending on the gap between the two (ST – AC): 
 
 
 
 
 
 
 
 
 
 
 
 
The perceived information gap motivates the search for additional information and 
determines the level of processing accuracy. People will exert whatever efforts are 
required to attain a ‘sufficient’ degree of confidence, that they have accomplished 
their processing goals” (Eagly & Chaiken, 1993). 
Depending on the efforts exerted in acquiring the information, two modes are 
generally identified as typical processing modes: the systematic mode and the 
heuristic mode:
621
  “Whether processing goals … are set high or low influences one 
of two processing modalities: heuristic and systematic”.622 A systematic processing is 
defined by the depth of scrutiny, the quantity of connections and comparisons made, 
and in general the level of content examination.  
Being cognitively less demanding, the heuristic mode is the default mode of 
information processing. Information is in fact normally processed with adherence to 
the least effort principle, i.e. cursorily and resorting to cues and rules of thumbs as 
shortcuts to attain the desired amount of data.  
                                                 
619
 As far as recent court decisions let suppose, this part of the work could be profitably used as a reference 
for the judge, who must evaluate to what extent a specific drug consumer can be deemed responsible for 
contributory negligence on having failed to take notice of PL information.  
620
 See Afifi, Weiner, 2004 for related literature. 
621
 See Chaiken et al. 1996, 1989; Trumbo, 1999; Griffin et al. 2002; Kahlor et al. 2003. 
622
 Griffin et al. 2002 706. 
 
Perceived 
knowledge gap 
(information need) 
Perceived level of 
actual knowledge 
 
Information processing: 
Efforts/gain optimization 
(sufficiency principle) 
Perceived level of 
required knowledge 
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Individuals can switch back and forth between the two modes within the same task,
623
 
however they will tend to gravitate more on one or the other based on their capacity 
to deal with the information, the motivation to invest energy, and time constraints.  
 
 
2.1 Risk information processing  
 
Also the dynamics underlying risk information processing and related fallacies have 
been explained within a least effort principle paradigm.  
To a first wave of studies emphasizing the incapability of lay subjects in dealing with 
probabilistic information (Kahneman, Slovic, Tversky 1982; Bar-Hillel 1980; 
Kahneman, Tversky 1982, 1973, 1972; Tversky, Kahneman 1983, 1982, 1974, 1971), 
an ecologic approach has followed, which has provided an explanatory model for 
fallacies in probabilistic computation. 
Many of these apparent inconsistencies are explained as the result of optimizing 
processing efforts and heuristic modes of information processing in general 
(Gigerenzer, 1998, 1996, 1994, Gigerenzer, Hofrage, 1995; Gigerenzer et al. 1999; 
Cosmides and Tooby, 1996; Kleiter, 1994, Kohler, 1996; Girotto, Gonzales, 2001; 
Reyna et al. 2003;).  
It seems indeed that a variance of information processing strategies has emerged in 
empirical research as for the interpretation of risk information: both rational learning 
and biases are found to characterize risk information impact on perceived risk.  
Along a Bayesian approach to the impact of risk information on precautionary 
behavior, Viscusi et al. could establish that “Consumers responded in a manner that 
was broadly consistent with the main predictions of an economic model of rational 
safety-related actions” (p. 81): rational learning implies in their model that prior risk 
over- or underestimation are corrected by frequency information (p. 62-64). 
Nevertheless other studies report about divergences in decision, which were not 
consistent with the difference in probabilities between the decision sets.
624
  
In Smith, Desvouges, and Freeman’s (1985) study about consumer willingness to 
avoid risks from hazardous wastes, it results that subjects attach a higher marginal 
valuation to risk reduction in case of low-probability accidents than to higher 
probability ones, showing thereby to treat lower probabilities as equivalent to higher 
ones.  
Several theoretical arguments have been put forward to explain what has been 
identified as a low probability bias: Magat, Viscusi, Huber (1987) argue that people 
try to simplify their processing costs by taking into consideration only one of the two 
main risk components, namely either probability or magnitude:  
 
“By focusing on either the magnitude of the loss or the probability of its occurrence and 
ignoring the second characteristic, they tend either to overreact to the risky event or to ignore it. 
If people have difficulty internalizing low probabilities but are forced by a survey to consider 
them in making decisions, they may respond by mentally augmenting the probability to a 
familiar level. In contrast, if decision-makers are allowed to ignore low-probability events, as in 
                                                 
623
 Trumbo, 1999: 392; Kahlor et al. 2003: 356. 
624
 See Magat, Viscusi, Huber, 1987: 90ff. 
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making actual flood insurance decisions, they may do so in order to simplify the processing 
costs of making those decisions” (p.91).  
 
A possible alternative explanation could also be that under a certain threshold all 
frequencies are considered equivalent and a difference in risk probability does no 
longer translate in an analogous (not even marginal) difference in risk perception: the 
stochastic meaning of 10
-6
 and 10
-7
 might make no difference to the perception of 
risk. Thus findings about the tendency to overstate true probabilities could be 
explained by the level of granularity with which frequencies are estimated. This 
hypothesis can be confirmed by another study of Magat, Viscusi, Huber (1987) about 
job risk perception with larger risk probabilities, where no evidence of overreaction 
has emerged, and on the other hand by studies where extremely low probabilities, no 
matter how small, didn’t prevent the subjects to perceive the risk, as long as the mere 
possibility still constituted a threaten.
625
 In fact “thinking about low probability events 
imposes considerable demands on individuals’ cognitive capabilities” (p. 97) and one 
might hypothesize that under a certain threshold the very process of figuring them out 
more precisely than needed might be not worth undertaking. 
The relationship between cost/benefit estimation and degree of processing accuracy 
seems to underlie the dynamics related to risk information. However, in the specific 
health setting contradictory reactions to risk information have been observed (from 
active information seeking to information avoidance) which cannot be exhaustively 
explained by the least-effort principle.  
 
 
3. Perceived desirability of health risk information 
 
Information about side effects is generally considered very important among drug 
consumers: when asked, 90% of patients express desire to receive information on side 
effects, which they consider the most important aspect of drug information 
(McGavock 1998). Furthermore, information about adverse drug reaction is among 
the highest ranked when compared to other pieces of information related to the 
therapy (van Grootheest et al. 2004; Laaksonen et. Al. 2002; Bouvy et al. 2002; 
Åström et al. 2000; Howard et al. 1999; Vigilante, Wogalter 1997). Moreover, risk 
issues are the most recurring concerns when evaluating drugs (Kare, Kucukarslan, 
Birdwell 1996).
626
  
But, on the other hand, in a study on Intrinsic Desire for Information (IDI; Åstrom et 
al. 2000) a correlation between IDI low scores and anxiety was observed, either 
coped with by trusting the health professional or by predominantly looking for 
                                                 
625
 SOURCE … In contrast, Kunreuther et al. (1978) found that for catastrophic events probabilities are so 
low that their possible outcome tends to be ignored. 
626
 Indeed discontinuation of drug treatment as a reaction to development of side effects, occurs particularly 
in cases when no information on side effects has been given by the practitioner (Enlund et al. 1991). This 
means that confidence in the health professional and in his decision is not shaken when the drug consumer 
knows that side effects are “part of the bargain” and are under control.  
In fact satisfaction with the information received has been found to affect adherence (O’ Brien et al. 1990; 
Coulter et al. 1999). 
 
 269 
reassuring information (see table 1). The intrinsic desire for health information (factor 
1) was distinguished from the expressed desire of information (factor 2) in order to 
account for inhibition in information request.  The subgroups emerging from factor 2 
were obtained through a qualitative analysis of open answers: no expressed desire; 
expressed desire but no expressed purpose; expression of both desire and purpose. 
IDI high scorers tended to express desire of factual information in order to make an 
autonomous judgment, instead low scorers tended to seek for reassuring information 
or to avoid information and rather rely in the health professional as a delegate for 
decision. 
 No expressed desire 
for information 
A desire for information, 
but no expressed purpose 
A desire for information, and 
an expressed purpose 
High score No real interest in 
further information 
Specific interest in side 
effects, expected benefits 
and interactions with other 
drugs.  
Specific interest in side effects, 
safety issues and general 
effects of drugs, including 
benefits. Desire to keep control 
of my ‘body’. Wanted choices 
and information about 
alternatives. 
Low score Lack of interest in 
information; 
information provokes 
anxiety; rather trust 
decision of HPs. 
Main interest in reason for 
drug and how to take it. 
Want reassurance on benefit 
if drug, but willing to put 
trust in HPs. Decisions 
Want reasons for drug choice 
and reassurance of benefit. Feel 
they should know what they 
are taking. 
 
Table 11 Qualitative results of a study on Intrinsic Desire for Information (IDI). Source: Åstrom 
et al. 2000. 
 
In general, low scorers were more concentrated on benefit information, whereas high 
scorers were interested in data about the risk associated to the treatment and eventual 
alternatives (p. 161-162).  
Previous work of the same group has shown that providing information about 
medicines to patient who desires it makes them more satisfied and empowered, whilst 
providing the same information to those who do not want it makes them more anxious 
and less empowered (Duggan, Bates 2000).  
Laaksonnen, Duggan, Bates (2002) have found information seeking attitudes to be 
positively related to past experience with side effects, but further research is needed to 
establish the causality direction: it might be that more information leads to more 
awareness and therefore to side effects perception when they occur, or else the 
reverse. In fact low scorers where evasive about adverse drug reactions and not sure 
about their being correlated with the drug. Moreover, high scorer were not only aware 
of side effects but also of the drug being helpful: “It’s about a balance between the 
good and bad effects”, while low scorers manifested the tendency to take the 
medicine for duty and to lack any information need: “I just don’t know if knowing 
will help … I mean, a bad effect is a bad effect.”  
What emerges from these studies is that information insufficiency and the desirability 
of health information do not necessarily associate. The perceived knowledge gap and 
the desire to become knowledgeable about health risks do not necessarily go hand in 
hand.  
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3.1 Emotional elements in processing risk information 
 
The empirical findings emerging from studies on risk information seeking behavior 
show a discrepancy between the information need predicted by the gap between 
actual level and required level of knowledge for confident judgment/decision and the 
perceived desirability of further information. Indeed, cognitive and socio-
psychological research has addressed the message type and personality dimensions as 
relevant aspects of information seeking behavior.
627
 
In general four main strategies have been identified among concerned people 
addressed by sources of risk:
628
 
1. Seek relevant information; 
2. Avoid relevant information; 
3. Reappraise the situation; 
4. Seek for counterbalancing reassuring information.  
 
1. Relevant information seeking is the normative behavior, which is however 
constrained by cost considerations.  
 
2. Avoiding relevant information can be a reasonable strategy either when it is 
considered too costly, or when it is perceived unhelpful, because things can hardly be 
changed. 
For instance, it has been reported that 57% of individuals with hereditary risk of 
colon cancer declined an offer for genetic testing.
629
 Sometimes the perception arises, 
that more information does not resolve the problem.
630
  
 
3. In the cases where risk is perceived as unavoidable and therefore no active 
countermeasure can be taken, coping strategies can be activated which reduce the 
anxiety level by reappraising the perceived menace.  
Reappraisal is a common phenomenon in situations where risk is characterized by 
lack of control. The impossibility to act against it induces the subject to act on his 
emotions and reevaluate the threatening source thereby reducing its perceived danger. 
As a consequence, risk perception decreases and also perceived information need.
631
 
Witte (1998) assumes that this ostrich’s policy is a consequence of low efficacy in 
relation to a threat. In this sort of situation the subject “ignores the threat and 
recommended responses and instead engages in coping responses to reduce fear”.632 
This “perceptual defense” typically manifests in the individuals “distort[ing] or 
ignor[ing] any incoming information about a threat”.633 
                                                 
627
 See Bealneaves, Long, 1999 and related literature.  
628
 Afifi, Weiner, 2004: 181. 
629
 Lerman et al. 1999. 
630
 Babrow, 2001:563, cited in Afifi, Weiner, 2004. 
631
 Afifi, Weiner, 2004: 181 ff.; Preuss, S, 1986: 74 ff.  
632
 Witte, 1998: 437, cited in Afifi, Weiner, 2004: 182. 
633
 Witte, 1998: 438, cited in Afifi, Weiner, 2004: 182. 
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In general, the effect of reappraisal is to lessen the perceived outcome value 
(disutility); to decrease the desired level of confidence; and to reinterpret uncertainty 
so as to abort the information seeking process.
634
 
 
4. If the ostrich’s policy leads to uncertainty ignorance, the perceived importance of 
health information counteracts this tendency and enhances need for control: a 
proactive information seeking attitude has been found to be correlated with either 
need for control or need for reassurance (or both) (Morris & Aikin 2001). An 
important role which is linked to perceived control is played by the perceived 
capacity to process and make use of information: Self-efficacy (or efficacy).
635
  
Active information seeking may be biased by the cognitive dissonance phenomenon: 
this kind of selection bias leads the reader to seek for information confirming his 
opinion or his wishful thinking while neglecting data which might contradict his 
beliefs or hopes.
636
 
 
Drawing on the conflict theory model of decision (Janis & Mann, 1977) Balneaves 
and Long (1999) try to account for the specific situation of treatment decision making 
by integrating decisional, stress and coping theories. Balneaves et al. explicitly define 
treatment decision making as “a multifaceted process, composed of numerous latent 
variables (i.e. stress, appraisal, coping) that describe the person-environment 
relationship”.  
Along Janis and Mann, five main coping strategies in uncertainty management are 
identified depending on the perceived threat and self-efficacy: unconflicted inertia, 
unconflicted change, vigilance, procrastination, hypervigilance. These modes are 
associated with stress level.  
10050
INFORMATION PROCESSING
STRESS
Low High
Paralysis/panic
0
Unconflicted inertia 
VIP mode
Unconflicted change Hypervigilance
 
 
On a continuum representing the stress level, the first two coping strategies are 
considered the result of a situation posing low levels of threat. The question behind 
the first strategy is: ‘Is there any serious risk if I don’t change?’, if the answer is 
negative than no change takes place. If the situation asks for change, than the question 
                                                 
634
 Afifi, Weiner, 2004: 183. 
635
 However, generally self-efficacy is related to heuristic rather than to systematic information processing.  
Trumbo, 1999. 
636
 The role of this phenomenon in health risk information processing has been empirically observed by 
Steckelberg, 2004b, 2005.  
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is: ‘Is there any serious risk if I change?’, if the answer is negative, the agent opts for 
the first salient alternative and unconflicted change occurs.  
With a moderate level of stress, the decision maker is motivated to switch to a 
vigilant information processing mode (VIP). However it is emphasized that, given 
time and other resources constraints, this is the exception rather than the rule.  
As the level of stress increases, emotional response modes, rather than rational ones 
are activated. Especially if the risk is perceived as unavoidable, the subject faces the 
decision situation either by procrastinating and through reappraisal of the perceived 
risk, or by making ‘panicked choices’. Also Connolly has reported with regard to 
high risk, that it “seems to produce either paralysis or catastrophe for the layperson 
(manager, consumer, parent or whatever) – paralysis, from contemplating the 
insolubility of the problem; catastrophe, from acting without awareness”.637 
Balneaves’ account of health risk information processing explicitly takes into account 
the decision context as a determinant factor for the coping strategy adopted, rather 
than tracing it back exclusively to personality factors.   
This differentiates their approach from the cognitive account of risk information 
processing, in that it makes explicit the role of the decision context in determining the 
extent to which further information is desirable.  
In fact, with respect to risk perception and related anxiety, risk information can 
generate four types of effect, depending on whether it increases/decreases uncertainty 
about the risk: 
 
 Increase uncertainty Decrease uncertainty  
risk 0  .5 1  .5 .5  0 .5  1 
anxiety increase decrease decrease increase 
 
In a scale between 0 and 100, the highest prognostic uncertainty is in the middle (.5): 
this is where you would not bet for either of the possibilities. At 0 you are certain that 
damage will not happen. At 100 you are certain of the contrary.  
If you esteem a risk at 50 before reading the PL, and at 70 afterwards, your prognostic 
uncertainty concerning it has decreased, because you are more confident than before, 
that indeed it will occur, but your perceived risk has increased. The diagram shows 
this double effect: 
 
                                                 
637
 Connolly, 1980: 70. 
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100 = 
Certain that damage
will occur
50
Uncertainty curve
Risk estimation
Low
High
Very high
low low
max
0 = 
Certain that no damage
will occur  
Figure 22: Risk perception curve and the uncertainty curve in comparison: a decrease in 
uncertainty can lead to lower or higher health risk perception, depending on whether it confirms 
or disconfirms side effect occurrence. 
 
The more obvious (Bayesian) strategy for reducing prognostic uncertainty would be 
to collect further information in the hope to decrease it. 
However, this strategy could induce in the health setting to an even higher anxiety 
level, which explains why reactions to health risk information are so idiosyncratic.  
Reduced prognostic uncertainty related to risk information can in fact either lead to 
greater confidence about safety or, on the contrary, to the certainty of damage. 
If risk estimation increases then, depending on factors such as perceived control and 
capacity to process information, the above mentioned strategies are activated, which 
are not necessarily congruent with rational learning.  
In the end, when things can hardly be changed, no benefit can be expected from 
further information, apart from a useless additional dose of anxiety.  
The uncertainty “scissor” can explain why information eventually leading to 
uncertainty decrease about “bad outcomes” is not always welcome. 
This means that the desirability of further information not only depends from its 
epistemic contribution to uncertainty reduction, but also from the decision context, 
i.e. from the potentiality that the decision can be changed by the expected 
information.  
The categories developed within the Bayesian account of the expected value of 
information to decision can help identify the distinct aspects which contribute to the 
estimation of its expected impact on the decision, and therefore possible antecedents 
for the degree of accuracy with which it is processed.  
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4. Information and decision 
 
The integration of cognitive and context factors (the decision at hand) in the 
explanation of information processing strategies traces back  to Herbert Simon and its 
coinage of the concept of “bounded rationality”.638  
Bounded rationality theories explain processing accuracy through an articulated set of 
factors the most salient of which are: 
1. the task at hand (stakes involved, decision type, time and other pragmatic 
constraints),  
2. and the perceived capacity to gather and process relevant information to 
accomplish it: self efficacy.
639
  
These factors integrate in the estimated benefit/cost of information processing, and 
therefore indirectly influence the degree of its accuracy: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The task at hand, with its perceived importance and the stakes at issue, determine the 
perceived knowledge gap: this predicts the level of perceived benefit of further 
information. The estimation of processing costs depends from self efficacy and the 
content and design of the information support.  
The difference of this model with respect to the sufficiency principle approaches is 
that here the decision situation and its pragmatic constraints (time, resources) plays a 
determinant role in the assessment of the information need.   
                                                 
638
 Simon, 1982. The distinction between the Bayesian computation of optimal sample size, and the 
sufficiency principle can be best illustrated by recurring to Simon’s distinction between “optimizing” and 
“satisficing” analyses. In the former type, the correct point to terminate information is found by equating 
marginal costs of search with expected marginal improvement of alternatives. In the latter type, search 
terminates when the best offer exceeds an aspiration level that itself adjusts gradually to the value of the 
offers received so far. Simon, 1988: 67, 69. 
639
 See Kahlor et al. 2003; Reyna et al. 2003; Dougherty et al. 2003; Martignon and Krauss, 2003, 
Schneider Schanteau, 2003; Griffin et al. 2002; Gigerenzer, 2001; Slovic, McMackin, 2000; Gigerenzer et 
al. 1999; Trumbo, 1999. 
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In particular for risk information, psychological literature has underlined the 
relationship between perceived benefit of risk information, perceived risk, and actual 
information processing: subjects are likely to ignore information, if they feel it has 
high costs relative to its benefits, and are unlikely to seek out and process risk 
information if they perceive little risk (Bettman, Payne, Staelin, 1987). 
The explicit reference to the decision context helps explain the different attitudes 
towards health risk information better than the mere consideration of the perceived 
uncertainty.  
Specifically, the parameters determining the value of information to a decision, build 
a structure where emotional, cognitive, and contextual factors integrate and provide a 
comprehensive account of health risk information processing. These parameters are 
presented in the next paragraph and then applied to the specific case of PL 
information.   
 
 
4.1 Expected value of information to a decision  
 
In the Bayesian theory, the information value is established by its expected 
contribution to decision optimization: this contribution is measured as the difference 
between the expected reward under the current state of knowledge, and the expected 
reward brought about by the act that would be chosen on the basis of the expected 
information. 
The value of further information to decision will therefore depend not only from its 
epistemic contribution (belief change), but also from its capacity to reverse the 
decision and thereby bring a higher reward. This capacity is a relational property 
which depends from the information impact on the probability distribution and from 
the decision sensitivity to this epistemic change.  
The decision sensitivity to potential changes in the probability distribution of the 
states of the world is strictly connected to the utility matrix.  
The closer the different payoffs are in the preference ranking, the more sensitive is 
the decision to even slight changes in probability assessments, vice verse, the higher 
the differences in the expected payoffs connected to the different acts, the greater 
must be the change in probability distribution in order to affect the decision. The 
information capacity to change the decision will depend on whether the posterior 
probability distribution balances the preference ordering so as to alter the acts 
ranking 
From the point of view of decision change, the effect of information is categorical: 
either does it change the decision or not. However, depending on the anticipation that 
the expected information could indeed lead to a decision change, than its value is 
measured out of the difference between the expected rewards under the current 
choice, and the payoff brought about by the act that would be chosen under the new 
state of knowledge.  
The decision to acquire further information, “preposterior decision”, will depend on 
its expected value to the decision, and on its estimated cost (economic or cognitive).  
The diagram shows the fundamental components contributing to the expected impact 
of the information to decision change, and the eventual decision to acquire it.  
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Figure 23: Fundamental dimensions determining the impact of information on a decision and the 
related decision to acquire it (preposterior decision). 
The net information value is a relational dimension which depends on the expected 
value of the information to decision optimization and on the cost of acquiring it. 
On its turn, the expected value of information depends both on the expected impact 
of information on the agent’s belief and on the decision sensitivity to this change.  
The information impact is a function of the prior state of knowledge, the difference 
between the prior and posterior probability distribution – information relevance – 
and in the increase or decrease in uncertainty.
640
 
The Bayesian analysis of the expected net gain of information to decision defines the 
expected gain of information not simply in terms of uncertainty reduction, but in 
terms of its effective contribution to decision change. The value of information 
depends in this framework not only on its epistemic input, but also on the extent to 
which the decision can be improved by it. 
 
 
4.2 Decision sensitivity to new information 
 
In the decision context, belief change produces a modification of the probability 
distribution assigned to the relevant states. The new distribution can lead to a decision 
change to the extent that it favors a different act.  
Therefore, the contribution brought about by a peace of information within a 
decision context entails but exceeds its epistemic impact. In fact, belief change is a 
necessary but not sufficient condition for decision change. In order for an agent to 
change his opinion about the best act to choose, the decision itself must be sensitive 
to this information.  
                                                 
640
 For a detailed account of the computation of the net gain of information see Winkler, 1972. 
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The value of hypothetical information to decision is therefore strictly connected to 
the payoffs related to each act-state pair: only information which changes the 
preference ordering of the acts can be said to have a value for the decision. 
Let’s consider again the example of the decision matrix concerning the week-end 
out.
641
 Note that utilities differ from the matrix presented in chapter 6, because here 
the decision maker is really looking for a week-end in the nature with outdoors 
activities, so that the other alternatives are just a makeshift solution, because neither 
museums nor the crazy crowd are your favorite Sunday’s pastime. But of course a 
picnic in the rain is not the best you can wish. So, considering your optimistic 
estimations about the weather (S1 = good weather, S2 = variable weather, S3 = rainy 
weather), this is the hypothetical decision matrix: 
 
 S1 (.45)   S2 (.35)      S3 (.20) 
a1 picnic Outcome11 
    100 
Outcome12 
     90 
Outcome13 
    -100 
a2 big-town-sightseeing Outcome21 
  - 100 
Outcome22 
     50 
Outcome23 
       0 
a3 museum Outcome3        
  - 100 
Outcome32 
      25 
Outcome33 
      30 
 
Here your strong preference for outdoor activities can be evinced from gap in 
utilities distribution between a1 and a2, a3.
642
 
The expected utilities for each single act are: a1: .335; a2: .130; a3: - .3035. 
In this case, given your strong preference for nature and quiet, only a strong change 
in the states probability distribution can lead you to change your decision. With a 
moderate weather forecast which predicts sunny weather with probability .10, 
variable weather with probability .70, and rainy weather with .20 probability, the 
new expected payoffs for each act are: a1: .53; a2: .25; a3: .13. Therefore a1 would be 
again the optimal act. 
Only a much more pessimistic weather forecast would be able to change your mind. 
If storm is predicted with probability .85, unsettled weather with probability .10 and 
good weather only for a tiny .05, your decision matrix would rather look like that:
643
  
 
 S1 (.05)  S2 (.10) S3 (.85) 
a1  
picnic 
Outcome11 
.05                 
Outcome12 
.09 
Outcome13 
-.85      
 a2  
big town  
Outcome21 
       -.05 
Outcome22 
.05 
Outcome23             
0 
a3 
museum 
Outcome31          
-.05 
Outcome32        
.025 
Outcome33 
.25 
 
The expected payoffs for each act are: a1: - .71; a2: 0; a3: .25.Therefore the optimal 
act would be this time a3: going to the museum.  
                                                 
641
 See chapter 6 § 1.2 
642
 The difference in utilities distribution between a1 and a2, a3 requires an equally strong unbalance in the 
probability distribution of possible states in order to change the outcomes preference order.  
643
 The payoffs in the cells are already weighted by related probabilities in order to ease the appraisal of the 
effect produced by the probability distribution on outcomes ranking. 
 278 
The decision sensitivity and expected information impact are fundamental 
dimensions in the estimation of information value. This has on its turn dramatic 
consequences in the preposterior decision of purchasing further information or else 
being content with the current state of knowledge. An application of these 
considerations to the perceived value of PL information will help us integrate the 
diverse phenomena observed in the empirical studies and in previous research with 
regards to health information seeking behavior and PL information processing.  
 
 
5.  An integrated model of health risk information processing  
 
Antecedents for information seeking behavior have been generally identified in 
perceived uncertainty and knowledge gap mediated by cost considerations (which in 
cognitive terms depend on the level of text readability on one side and on self-
efficacy, health literacy, education and demographic data on the other).  
Discrepancy between the uncertainty possibly perceived by the subject and 
information avoidance or low desire of further information have been traced back to 
emotional aspects underlying the health choice: cognitive dissonance, reappraisal 
strategies. Balneaves and Long account however allows tracing back these strategies 
to the decision type faced by the individual: ultimately it is the expected impact of 
the information on the decision change rather than its uncertainty decrease potential 
which determines whether this information will be valuable for the individual.  
Information will profit from systematic processing whenever it is considered valuable 
for a better decision. Whenever no alternative is at sight, the cost of acquiring it is 
considered worthless. Also when it is perceived as useful, but too demanding in terms 
of information design in relation to one’s own processing capacities it tends to be 
dismissed.  
Bayesian decision theory provides in this sense a “reductionist” explanatory model 
for reappraisal, in that the decision to avoid information is explained by the relatively 
little reward of acquiring new information when there is little hope that the 
information will make a difference.   
The disentanglement of uncertainty reduction from the impact on the decision allows 
accounting for the idiosyncratic coping strategies registered in the literature about 
health risk information processing. 
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Figure 24: Pragmatic and cognitive constraints related to therapeutic information management. 
Bayesian categories such as estimated decision impact through belief change (ΔP) and change in 
preference ranking are integrated with personality factors such as uncertainty tolerance and self 
efficacy, and contextual aspects related to decision types. 
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The diagram shows that the information seeking behavior is determined by the 
expected information value as postulated by Bayesian theory. This not only depends 
from the level of uncertainty as normally assumed by cognitive theories of 
information processing, but from the decision sensitivity to incoming information.   
The least effort principle is accounted for in the diagram by considering cognitive 
costs of processing determined by: 
1. the information design: cryptic language and generally low readability heightens 
the cost of information processing, and therefore decreases its net value; 
2. (health) literacy level and code competences of the reader. 
Therefore, in this domain, health literacy, in addition to linguistic competence is a 
fundamental factor in the decision to process risk information. Self-efficacy, the 
perceived capacity to process the information at hand, does also influence the cost 
estimation of information processing.  
Coping strategies adopted towards this kind of information are not solely dependent 
on personality factors but ultimately depend from the cost/benefit assessment which 
bases on expected net gain of information to decision. Therefore reappraisal strategies 
are considered to be the combination of the subject’s demographic/psychological 
profile and of the constraints determined by the decision (e.g. lack of alternatives).  
When applied to the analysis of PL information processing, this model can be 
considered a valid starting point for capturing relevant parameters determining its 
impact on the consumer’s decision:  
1. expected cost of processing PL information – determined both by the information 
design and by the subject’s level of (health) literacy; 
2. expected net gain of processing this information – determined by the expected 
value of this information to the decision in relation to the decision sensitivity to it; 
The results provided by the survey presented in chapter 7 provide evidence that the 
therapeutic decision made with the doctor is hardly shaken by PL information, even 
when this information is declared to have brought a positive contribution in terms of 
knowledge. The qualitative study show that doctor’s information also functions as a 
filtering key for coming to terms with information overload and the relevance 
paradox.  
This suggests that decision sensitivity to PL information is strongly influenced by 
reliance on the doctor, and that a promising field of future research is the 
investigation of knowledge integration from different sources of information with 
diverse reliability and tailoredness factors.  
 
 
6. Summary and conclusion 
 
This chapter has presented a theoretical account of the contradictory attitudes towards 
health risk information observed empirically.  
Cognitive theories of information seeking behavior and psychological accounts of 
health risk information processing have been presented and integrated into the 
Bayesian approach to the analysis of information value. 
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Cognitive theories of information seeking behavior posit the uncertainty derived from 
a perceived knowledge gap as the motivating factor determining the search for further 
information and the degree of processing accuracy.  
Theories of “Bounded rationality” emphasize the task at hand as the factor which 
determines the level of knowledge required, and therefore the perceived information 
gap. Within these theories, the “satisficing” level, where no need for further 
information is required, is determined by the decision at hand. This specification 
distinguishes the mere epistemic value of information from its contribution to 
decision change. 
Balneaves’ account of the different coping strategies to health information processing 
indeed explicitly considers the decision as the context within which different 
processing strategies are activated, depending on the decision maker’s faculty to avert 
the risk through more information.  
An explicit and articulated account of the relationship between information and 
decision is offered by the Bayesian analysis of the expected net gain of information, 
where the information value is analyzed not only in terms of its epistemic relevance, 
but also by taking into account the decision sensitivity to the information.  
The integrated Bayesian model of health risk information processing accounts for the 
apparent contradictions observed in the empirical literature by tracing emotional 
reactions back to the decision characteristics (decision sensitivity to the expected 
information) and to the perceived capacity to deal with the expected information and 
use it to improve the decision.  
The integrated Bayesian-cognitive model implies for instance that whenever no 
alternative is at sight, the cost of acquiring further information is considered 
worthless. Also when information is perceived as useful, but too demanding in terms 
of information design in relation to one’s own processing capacities it tends to be 
neglected. 
By applying the Bayesian instrumentation to the analysis of the expected value of PL 
information, the model identifies relevant parameters which contribute to the 
perceived expected value of PL information, and therefore to the degree of accuracy 
with which it is processed. The degree of accuracy depends on a cost/benefit 
estimation which, on the benefit side considers the epistemic contribution brought 
about by PL information in terms both of uncertainty reduction (information 
relevance), and in terms of the decision sensitivity to the expected information.  
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  10 Conclusion and outlook 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This research has undertaken the task to evaluate PL information within its legal 
setting in the attempt to bring a contribution to the debate on its role as a basis for 
informed consent. 
The resulting claim is that PL information cannot totally dispense the 
pharmaceutical firm from taking on responsibility for relevant residual risk, in that 
this information cannot be considered adequate for consent to be valid.  
The argumentation is articulated in three parts: 
I. A legal analysis of PL information; 
II. A normative evaluation of PL information; 
III. An empirical research on the impact of PL information on the therapeutic 
decision.   
 
 
I 
 
Notwithstanding the official qualification of PL information as product instruction 
within safety regulation, liability norms related to the distribution of residual risk 
translate it in a risk disclaimer in analogy to the information provided by the doctor 
within the institute of informed consent.  
Therefore two main legal functions can be identified for PL information: 
1. warning and risk prevention function, in observance of the consumer’s right 
to safety; 
2. disclosure of residual risk, in observance of the constitutionally protected 
right to self-determination. 
The notion of residual risk is fundamental in this setting (chapter 1), because it is 
the risk which the beneficiary party needs to shoulder unless he has not previously 
been informed about it by the doctor and/or by the pharmaceutical firm.  
In fact, safety information should prevent avoidable risk to occur; instead self-
determination information should declare the unavoidable risk, so as to insure that 
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the drug user is aware of it when he decides whether to undertake the therapy or 
not.  
Because disclosure of residual risk is also performed by the doctor, two preliminary 
steps were needed in order to evaluate the communication role of PLs in this 
framework: 
 
2.1. the analysis of risk disclosure within the institute of informed consent (chapter 
3); 
 
2.2. the analysis of the responsibility spheres regarding the information of   
residual risk (chapter 4); 
 
Within point 2.1 two issues have been touched:  
The repercussions of the 2
nd
 Amendment Law for Compensation on doctor-patient 
communication;  
The communicative status of therapeutic information under the tort and the contract 
liability regime respectively. 
 
2.1.1 Through the amendment of § 253 Abs. 2 BGB and the abolishment of § 847 
BGB, the 2nd Amendment Law of Compensation extends compensation for moral 
damages (damage for pain and sufferings) – which were previously limited by § 
847 BGB to torts – to breaches of contract.  
This has important consequences for the doctor-patient communication. In fact, 
under tort liability, compensation is only granted when a causal nexus can be 
established between damage and failure to provide adequate information. The right 
to choice is not protected per se, in that compensation is granted not for the lack of 
information but for the physical damage. 
For instance, lack of information about alternative therapies, which do not 
essentially differ from the proposed procedure in their risk/benefit profile, does not 
lead to tort liability in that the damage would not have been less probable if the 
patient would have chosen one of these alternatives.  
This setting models the doctor-patient communication as a risk transfer transaction 
rather than as a counseling relationship, where information for decision is a value 
per se.  
The counseling relationship is precisely fostered by the extension of compensation 
duties for moral damages also to contract liability. In fact, within this framework 
information about therapy and alternatives is due to the patient not as a 
legitimization of bodily intrusion, but as a consequence of the asymmetric 
relationship to the patient and therefore as part of his professional duty. 
Compensation is granted also for the simple violation of the right to self-
determination independently of health damage. 
 
2.1.2 In the informed consent model entailed by the tort liability regime, doctor 
patient communication serves the purpose of legitimizing the medical procedure. In 
the counseling model inherent to contract liability, communication should enable 
freedom of choice. Consequently, the reason for which the patient shoulders the 
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risks connected to the therapy differ in the two settings: in the IC model, the patient 
is supposed to shoulder the risks connected to the procedure because, having being 
informed about them, he is aware of them; in the counseling model, rather than 
merely consenting to a proposal, the patient actively participates in the decision, 
and shoulders eventual damages because he takes on co-responsibility for the 
medical treatment, and bears the risks which do not fall under the medical control. 
 
The point of this discussion was to evaluate the communication model fostered by 
tort liability in comparison to contract liability and thereby identify the 
communicative status of PL information. In fact, given that liability for product 
instruction faults falls under tort liability (chapter 2), PL information ends up to 
conform to the IC model of therapeutic information and thereby to serve the 
purpose of residual risk reallocation. This task qualifies it as a risk disclaimer with 
the additional drawback that no comparative data about therapeutic alternatives are 
given.   
 
2.2 The analysis of the responsibility spheres leads to following conclusions: 
Consent to the doctor equates to a global approval to therapy. However, the doctor’s 
information duty does not include all possible residual risks, but only those 
considered relevant for the patient’s decision. Detailed information, which cannot 
and need not be disclosed by the doctor is also part of the consent and is provided 
by the PL. By taking the drug, the consumer accepts also the risks enlisted in the PL 
warnings and not mentioned during consultation.  
Whenever damage follows, which do not result from prescription errors, and the 
mention of which was not part of doctor’s professional duties, the patient has no 
right to compensation, if they are included in PL information.  
From this it results that, the residual risk disclosed in the PL and which is not part 
of the doctor’s information duties, totally falls on the patient’s shoulders.   
 
 
II 
 
Once it has been established that PL information is not only a means of safety 
protection, but also part of the therapeutic informed consent, the point is then to 
evaluate whether PL information can be considered adequate for consent to be 
“informed”, i.e. valid.  
 
1. Prima facie objections to this claim are: 
 
1.1. Lack of timeliness of PL information. PL information comes on principle too 
late, when consent has already been given to the doctor. A solution to this problem 
has been proposed by Koyuncu with his bi-phased model: preliminary consent to 
the doctor, conclusive consent through drug intake. 
1.2. Possible conflict between the doctor’s and the patient’s risk/benefit assessment 
made on the basis of PL information. If the PL brings an autonomous element to 
patient’s decision, than it should do it by providing him with a different basis for 
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choice than that provided by the doctor (risk/benefit assessment). This brings a 
contradiction within the decision process: either should the patient rely on the 
doctor’s risk/benefit assessment; or else make a personal risk/benefit assessment on 
the basis of PL information, perhaps also different from the doctor’s one.  
1.3. Absolute lack of information about alternatives. If consent to doctor has been 
given with little or no knowledge of alternatives, consent to PL is given exclusively 
with information related to the prescribed product. As Wolz puts it: „When the user 
has it [PL] in his hands, than a decision about a specific treatment has already been 
made. Alternative drugs are not available or only with difficulty, so that often the 
decision reduces to a choice between taking this pharmaceutical product or not … 
Even optimal designed PLs cannot warrant the user an adequate ground for 
decision”.644 
1.4. “Non-tailoredness” of PL information. PL information grounds on a 
toxicological-statistical concept of risk, which needs to be integrated with the 
patient’s personal data on the basis of the doctor’s tailored evaluation of therapeutic 
risk. Therefore the PL cannot substitute the doctor as a source for self-determination 
information, in that the principle of self-determination requires that the individual is 
made knowledgeable of his personal risk/benefit profile, whereas product 
information is necessary general and abstract.
645
 A decision can be considered 
autonomous, only if made on the basis of personally relevant information.
646
  
1.5. Risk information overload and lay incompetence to discern personally relevant 
from irrelevant information. In general it can be said that given the high 
preponderance of risk information
647
 in relation to data about benefit, any decision-
maker should decide not to take the drug. The main difficulties lie indeed in 
selecting the items of information which are personally relevant and material to the 
decision. This can be a source of paralyzing uncertainty or non-compliance, when it 
does not lead to the general refusal of PL information.
648
 
1.6. Risk assessment uncertainty due not only to incomprehensibility, but to a 
general incapacity to understand the health implications related to the information 
items contained in the PL.  
 
These points touch epistemological aspects of PL information as a basis for 
knowledge updating, risk/benefit assessment and therapeutic decision.  
Therefore the evaluation of PL information has gone beyond its linguistic and 
communicative aspects (chapter 5) and has investigated the role of PL information 
in the therapeutic decision within the framework of Bayesian theory, which is the 
                                                 
644
 Wolz, 1988: 15, 16: “Hat der Verbraucher erst einmal in der Hand, so ist die Entscheidung für ein 
bestimmtes Medikament bereits gefallen. Alternativpräparate werden nicht oder nur unter Schwierigkeiten 
erreichbar sein, so das oft nur die Entscheidung zwischen Einnahme und Nichteinnahme dieses 
Arzneimittels bleibt … Auch inhaltlich optimal gestaltete Gebrauchsinformationen garantieren also nicht 
den Entscheidungsspielraums des Verbrauchers”.   
645
 See Hart, 2003: 605; Krudop-Scholz, 2005: 156. See also Stöhr, 2006: 148. 
646
 “Selbstbestimmt ist die Entscheidung dann, wenn die aus der Sicht des Patienten 
entscheidungsrelevanten Informationen zur Verfügung stehen”. 
647
 There are PLs with more than 80 side-effects: Grandt et al., 2005: 511.  
648
 See Krudop-Scholz, 2005: 159-162. 
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theory developed for the analysis of the relationship between information and 
decisions under uncertainty, such as therapeutic decisions typically are (chapter 6).  
 
2. The normative analysis has demonstrated the substantial incapacity of PL 
information to provide a solid contribution to the lay autonomous decision.  
PL information can in general provide a basis for assessing the drug toxicity and 
efficacy in general, however its epistemological and therefore predictive value for 
the single user is very difficult to specify.  
The doctor’s task is precisely to combine both knowledge of the drug and of the 
patient in order to predict the risk level to which the patient is exposed to by taking 
the drug.  
PL information about side effects rather represents the hypotheses to be confirmed, 
than the answer to them: Each side effect mentioned in the list raises the question as 
to its possible occurrence, a question which the probabilistic data associated to it 
only marginally help answer.  
This is a fundamental objection to the legitimization of this instrument as a valuable 
basis for informed consent.  
 
III 
 
The empirical part of the work consists of a quantitative study (a survey with n = 55 
sample size), and a think aloud experiment (n = 15). Participants for both studies 
were recruited among drug consumers with the aim to investigate the role of PL 
information in their therapeutic decision.  
 
1. The survey was designed as a paired comparisons test, where participants were 
asked to give their risk and benefit assessments about the drug before and after 
reading the PL (chapter 7).  
The main result deriving from this study is the gap between increased perceived 
level of information and  
3. insignificant PL impact on benefit and risk assessments; 
4. absolute no impact on the decision. 
The presence of a specific topic of concern seems to have some effect on the degree 
of confidence in choice and on the personal benefit assessment before reading the 
PL. In the post-PL phase the persistence or emergence of a specific topic of concern 
is associated with lower degree of confidence in choice, less favourable risk/benefit 
assessment, lower benefit assessment (both general and personal), and higher desire 
to further enquire about the drug.  
However, the presence of a specific topic of concern seems to have no influence on 
the final decision which remains as definite as before (100 score for all 
participants). 
Considering the generally positive evaluation of PL information and the increased 
perceived level of information after PL reading, these data support the hypothesis 
that the therapeutic decision concerning prescription drugs is quite insensitive to PL 
information. The concept of decision sensitivity to incoming information can indeed 
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provide an explanatory framework for the discrepancy between increased level of 
knowledge after PL reading and lack of impact on the therapeutic decision.   
 
2. The qualitative study (chapter 8) investigates the dynamics underlying PL 
information selection and processing. In general a certain reluctance to read the 
entire text has been observed in the sample. On the other side, PL information is 
perceived as highly important. This schizophrenic attitude has been explained by 
the relevance paradox phenomenon: any peace of items contained in it has virtually 
extreme importance and cannot be done away unless one feels justified in 
neglecting it for some reason. On the other hand the probability that all the items of 
information will jointly concern the reader is extremely low. Indeed only a minor 
proportion of the information items do refer to the special health condition in which 
the reader finds himself. This leads the single user to consider the text as 
constitutively over-informative.  
Information filtering is mainly performed by drawing on the knowledge acquired 
through doctor’s consultation, but also reappraisal strategies, uncertainty neglect 
and cognitive dissonance selection play an important role in explaining information 
seeking/avoidance in the health setting in general and in relation to PL information 
in particular.  
This raises some doubts as to the legitimacy of PL information as a risk disclaimer 
also on empirical grounds.  
However, as observed in the last paragraph, PL information has indispensable 
safety functions, which also the lay reader recognizes.  
Rather then being a basis for an evaluation of the treatment choice, the PL is rather 
conceived as a modular reference text to be consulted at the beginning for 
precautionary reasons, and then during the therapy in order to identify eventual side 
effects.  
 
3. The last chapter is devoted to integrate the phenomena observed in the empirical 
studies and in the literature previously devoted to the topic in a unitary model based 
on the Bayesian analysis of the expected value of information to decision. This 
framework provides the basis for tracing cognitive and emotional accounts of risk 
learning behavior back to the least effort principle (as already advanced by 
Bounded Rationality theories) and to the concept of decision sensitivity.  
 
At the end of this investigation, some suggestions for improvements are proposed to 
the legislator and the text designer.  
 
 
1. Suggestions for the legislator  
 
The contribution of PL information within the institute of informed consent should 
be more clearly defined. 
This demands an examination of the concept of autonomous decision in the health 
context, and a definition of the PL binding force on the basis of its actual 
contribution to autonomy rights. Following questions could guide the discussion: 
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1) The institute of “informed consent” should protect the right to self-determination 
and autonomous choice: does the communication model fostered by it really 
warrant these rights? 
2) What is an autonomous choice at all? What does the autonomous choice of a lay 
decision maker in a highly specialist sector consist of? Is it at all possible? 
3) If yes, does PL information provide an independent contribution to the 
information provided by the doctor? 
4) Does the liability setting determined by the institute of informed consent 
correspond to the real responsibilities ascribable to the stakeholders involved in 
therapeutic decision making (pharmaceutical firm, doctor, drug consumer)? 
 
The regulation of pharmaceutical risk communication in particular and medical risk 
disclosure in general should take into account these issues in an interdisciplinary 
perspective. Precisely, it is proposed to analyze the communicative nature of medical 
risk information by integrating legal concepts with categories devised by 
communication theories and decision theory.  
A possible consequence of this examination could be the partial disentanglement of 
PL risk disclosure from risk responsibility reallocation. Flexible legal tools are 
needed in order to account for the specific risk inherent to drug usage.  
Patient’s responsibility should be therefore articulated as follows:  
 The patient’s contributory liability for damage caused by non-compliance to 
safety instructions should be maintained. Indeed along the analysis proposed in 
the thesis, this sort of information can be validly used by drug consumers for 
averting or minimizing risk.   
 Instead PL information cannot be considered adequate for consent to be valid. 
Therefore it cannot offload the pharmaceutical firm from the responsibility 
related to residual drug risk, whenever the doctor cannot be considered liable for 
it. For some types of adverse drug reactions, it could be suggested, that 
pharmaceutical firm takes on damage liability, even if declared in the PL and do 
not exceed the tolerability threshold but can be considered relevant. As a 
consequence strict liability of pharmaceutical firms should be extended to 
damage which is below the tolerance threshold level, but which is nevertheless 
relevant for the damaged person.     
These claims can be also supported by the consideration that damage liability is 
only a monetary compensation for injuries which touch high valued goods such as 
psychophysical wellbeing.  
Liability threshold lowering from intolerable to relevant damage should not be felt 
as a punitive measure, but rather as an incentive for the overall system, so that more 
“virtuous” enterprises are not damaged by unfair concurrence of reckless ones. 
Moreover, given the declared low incidence of adverse reactions in comparison to 
market turn-over, this would not constitute a severe economic loss for 
pharmaceutical companies – at least not comparable to the loss suffered by the user.  
From the perspective of law steering functions, an extension of pharmaceutical 
strict liability would increment efforts towards a more systematic approach towards 
safety research within pharmaceutical research innovation.  
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A “damage warranty” would on the other side greatly contribute to the restoration 
of the reputation and image loss suffered by firms on the wave of pharmaceutical 
injuries.  
To the patient’s responsibility should instead be ascribed the duty to check 
consistency of doctor’s with PL information, and to control if some important 
information should be delivered to the doctor before taking the drug, in 
consideration of the safety instructions contained in the PL: hypersensitivity to 
components about which the doctor is not aware; interference with drugs, of which 
the doctor might have no knowledge, etc. up to the verification of dosage 
correspondence.  
This task corresponds to the cooperation duty entailed by the doctor-patient 
reciprocal contractual obligations. 
More generally, with an explicit separation of the safety and self-determination 
aspects related to PL information, patient’s contributory negligence in safety issues 
could be more clearly emphasized and contribute to balance the distribution of 
responsibilities around drug consumption.  
 
 
2. Proposals for text improvement 
 
1. In addition to the uncertainty generated by the probabilistic assessment of side 
effects occurrence, also the disutility associated to each of them is difficult to 
evaluate for the lay user. This is mainly due to the incompetence perceived by the 
lay reader in appraising the importance of the drug effects mentioned in the PL.  
There is widespread opinion which considers PL texts overwhelming and 
redundant. The relevance paradox shows that this overload sensation would be 
overcome precisely by adding explanatory information, rather than reducing its 
volume. A description of the health implications and importance of side effects and 
symptoms should be provided. This “indexing” procedure would constitute a 
valuable interpretation key for selecting information and appraising the risk 
magnitude. This would also promote compliance, when this is caused by over-
alarm.  
 
2. Furthermore, countermeasures should be associated to each side-effect as 
exemplified below:  
 
Transitory side effect  keep on with the therapy; 
Important side effect  call the doctor; 
Severe side effect   stop the therapy and call for the doctor; 
Severe to fatal side effect  stop the therapy, emergency measures are required, go to 
hospital immediately.  
 
3. Iconic – eventually standardized – signs could beneficially accompany the verbal 
text.  
 
4. Finally, more transparency on the communication point in general (prohibition, 
advice, precaution, disclosure of unavoidable risks, countermeasures to side effects, 
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etc.) would certainly contribute to enhance PL comprehensibility and applicability. 
This is eased by letting the grammatical form adhere to the substance of the 
message (instructions and prohibitions in imperative form, risk disclosure in 
assertive form) and by avoiding to connect messages which bear underlying 
opposite presuppositions or implications.
649
  
Also the avoidance of redundancies and an improved textual design as 
recommended by the EU readability guidelines would significantly enhance PL 
readability and user-friendliness. 
 
Notwithstanding communication improvements, there is a limit to patient 
friendliness though: it is the limit imposed by the margin of risk which is inherent to 
drug use itself. However comprehensible and well designed no package leaflet 
could cancel the uncertainty induced by information about side effects.  
In this perspective, the role of PL information as a distributor of responsibility 
about residual risk should be reconsidered in the light of the observations presented 
in this research. 
 
                                                 
649
 See chapter 5 and 9 for some examples. 
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Survey method and demographic data 
 
1. Information impact 
The information impact was measured by the difference between risk/benefit 
assessment before (pre) and after reading the PL (post). These questions elicit 
responses as to the magnitude and probability of risks as well as to the expected 
benefit both in general and in personal terms:  
 
Benefit assessment 
 
Q. 24 (pre PL)/ Q. 50 (post PL):  
General benefit prognosis: 
“How much effect do you ascribe to this drug in comparison 
to alternative treatments for the same disease?” 
Q. 25 (pre PL)/ Q. 51 (post PL):  
Personal benefit prognosis:  
“How much effect will the drug produce on you?” 
 
Risk assessment 
 
Q. 26 (pre PL)/  Q. 52 (post PL): 
Drug toxicity  (side effects severity):  
“Do you think that this drug has severe side-effects in 
comparison to alternative treatments for the same disease?” 
Q. 27(pre PL)/  Q. 53 (post PL): 
Drug toxicity (side effects quantity):  
“Do you think that this drug has many side-effects in 
comparison to alternative treatments for the same disease?” 
Q. 28 (pre PL)/  Q. 54 (post PL):   
Personal risk perception  
(chance of being affected by side effects): 
“How probable do you judge the eventuality of being affected 
by the side-effects of this drug?” 
 
Benefit-risk assessment 
 
Q. 30 (pre PL)/ Q. 56 (post PL):   
Benefit-risk assessment: positive?  
“Do you think that the positive effects of this drug are greater 
than eventual side-effects?” 
 
Benefit-risk odds 
 
Q. (pre PL)/ Q. 58 (post PL):  
The subject is asked to give his personal benefit-risk assessment within a sum-estimation (positive and negative) adding up to 
100. The format is shown below: 
 
Positive effects  Side effects   
     
  
    + 
 
  
= 
 
100 
 
 
In order to assess whether PL information is integrated with old knowledge deriving 
from experience with drugs and illnesses, a series of questions eliciting one’s own 
amount of experience have been included in the first part of the questionnaire: 
Experience 
 
Q. 6:  
Experience with the drug at hand 
“Are you taking this drug for the first time?”  
Q. 18: 
Experience with drug in general 
“How much experience do you have with drugs?” 
Q. 19: 
Past positive reaction to drug treatments 
“When it comes to you drug are …effective” 
(from never to always in 100 point scale) 
Q. 22-22: 
Past negative reactions to drug treatments 
 “I had side-effects in the past when I took a drug”  
(from never to always in 100 point scale) 
 
The intent of these questions was not only to test “lay bayesianism”, but also to 
investigate the relation between PL information impact and previously hold 
experience. In the case of pharmaceutical products in fact, familiarity does not 
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necessary mean greater amount of knowledge (for instance about long-term health 
implications). However, familiarity with a product might induce an artificial sense of 
acquaintance with it and traduce in a low need for information.  
 
 
2. Expected value of information to decision 
 
In order to establish the expected value of information in this context, a battery of 
questions was proposed to the participant as to assess his degree in decision 
confidence, his perceived information level, and the expected relevance of further 
information to decision (all answers should be given in the form of a 0 to 100 
assessment).  
 
Q. 10: “Are you satisfied with the treatment choice?” 
Q. 11: “How much information do you have on the treatment?” 
Q. 12: “Is there anything that makes you uncertain?” (Yes/No answer) 
Q. 13: “What about?” (Open answer). 
 
Furthermore, the expected value of information in terms of informativeness (extent to 
which further information may reduce uncertainty) and promise (probability that 
expected information will result in a different decision)
650
 have been tested through 
questions 14 and 15:   
 
Q. 14: “Could an eventual clarification about it eliminate the uncertainty?” 
Q. 15: “Are you considering not taking the treatment because of eventual missing information?”. 
 
Level of concern (therapy motivation) has been tested through a counterfactual 
question: 
Q. 9: “What would be the consequence of not taking the treatment?” 
 
 
3. PL declared value 
 
The perceived value of PL information has been also addressed by direct evaluation 
questions:  
39. I find the information included in this PL (From “Not at all”: 0 to “Definitely Yes”: 100): 
a. sufficient;  
b. already known;  
c. excessive; 
d. disquieting; 
e. useful; 
f. other. 
 
Furthermore, the desire to introduce additional information in the PL after reading it 
was elicited, together with questions related to PL information behavior: 
 
58. Would you let insert further information in the PL? (From “Not at all”: 0 to  “Definitely yes”: 
100).  
                                                 
650
 See Hammit, 1999. 
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59. How important would be this further information? (From “not important at all”: 0 to “very 
important”: 100). 
a. How the treatment functions in my body; 
b. Probability of treatment success; 
c. Other. 
60. Would you do without the following information paragraphs in the PL? (From “Do not do 
without” to “Do without”: 100). 
a. Chemical components; 
b. Indications; 
c. Warnings; 
d. Duration and doses; 
e. Others. 
61. Why would you do without it? (Open question). 
 
Now a couple of questions about your reading habits: 
62. I read Patient Package Inserts … (From “Never”: 0 to “Always”: 100). 
I read the Patient Package Insert … (From “Never”: 0 to “Always”: 100): 
63. Before beginning the therapy.  
64. Just when adverse reactions occur. 
65. I read the whole text. 
66. In the PL I read principally … (Open question). 
67. What kind of function/functions do PPI have in you opinion? (Open question). 
  
 
4. Decision delegation 
 
The most important parameter in this setting is represented by the reliance in the 
doctor who prescribed the drug.  
As stated above, information seeking behavior in a decision context is predicted by 
the degree of uncertainty in the choice to be made. In an expert-to-lay domain this 
uncertainty might be endemic and therefore different strategies may be devised in 
order to avoid the costly task of acquiring information which is difficult to 
understand: even when the form itself is comprehensible, nonetheless many doubts 
may be left as to the interpretation of the health implications that some messages 
bear.  By delegating the decision to an agent, the layperson not only avoids the task of 
computing a risk-benefit assessment, but can also be confident that the expert, being 
in possess of all relevant information, can make a better decision than he. 
Therefore only the conjunction of motivation, self-efficacy, and uncertainty about the 
expert decision can induce the layperson embark in the possibly frustrating task of 
trying to make a personal assessment of benefit and risks in a certain health decision.  
The extent to which the choice was delegated to the physician is captured by question 
17, which enquires how the drug choice has been made. Responses range from simple 
prescription to discussion of alternatives.  
Trust in the expert is measured in question 16 (reliability of several information 
sources). 
 
 
Methods of analysis 
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The tests have been carried out with non-parametric methods (Kruskal Wallis test, 
Kendall Tau). Paired samples t-tests and t-test for independent samples have also 
been used for comparing means differences of dichotomic variables, when parameter 
distributions approached normality. 
 
 
 5. Judgment elicitation  
 
The elicitation of probability judgments is itself a branch of decision theory (drawing 
its methodological tools on psychometrics: a discipline devoted to measuring 
subjective perceptions of physical qualities such as sound or light intensity).
651
 
Extensive experimentation has led to a wide spectrum of elicitation techniques and 
vivacious debates about the most appropriate methodologies for probability elicitation 
from experts or decision makers. In sum, Edwards and Winterfeldt list three major 
methods: direct numerical estimation, procedures based on equality judgments among 
events with known and unknown probabilities, and gambles (based on the expected 
value assumption: e.g. scoring rules).
652
  
Although direct elicitation is considered to be the less reliable among the three, still it 
is the only one feasible in a survey context. All answers relating to probability and 
value estimations were formulated in a quantitative fashion:  
 
 
How probable do you think is the eventuality of being affected by the side-effects of this drug? 
a)  
I cannot judge it. 
 
b) 
     ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
     0                                       50                                       100 
Impossible                        probable                               certain 
 
 
Also recent contributions in risk communication studies have made use of direct 
numerical estimation in survey questionnaires (Trumbo, 1999; Kahlor et al. 2003). 
 
 
6. PL classification 
 
The impact of the information should obviously be measured along the data provided 
by the PL to each drug user. Therefore package leaflets have been classified 
according to the quantity of risk information delivered, and to its potential impact. 
The side effects were subdivided in three groups: 
1. definitely light; 
2. definitely severe; 
3. ‘Indefinite’ cases with following uncertainty sources: 
d) uncertain implications of the symptoms (clinical-labor tests and blood 
serum modifications included);  
e) medical jargon; 
f) semantic aspects; 
g) pragmatic aspects. 
                                                 
651
 See for an introduction Yates, 1990. 
652
 Edwards, von Winterfeldt, 1986: 118 ff.  
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6.1 Definitely light and definitely severe side effects 
 
Whenever the word “vorübergehend” (transitory) accompanied the description of a 
symptom, this was considered as definitely light. Examples are typical stomach-ache, 
constipation, etc.  
When a clear indication was given, that the symptoms mentioned would last only 
during the therapy, then they were classified as “light”: 
 
“Störung der Blutbildung, die jedoch nach der Behandlung wieder verschwinden”  
(“Blood count modifications, that however disappears after the treatment”).  
 
Also the opposite holds: when the adjectives “schwer” (severe), “gefährlich” 
(dangerous), “lebensbedrohlich” (life threatening), and “tödlich” (fatal), “chronisch” 
(chronic) appeared as word modifier, the effect was classified as severe. Severe cases 
were considered also those side-effects, where an indication of interrupting the 
therapy was given:  
 
“Sollten die genannten Symptome auftreten oder sich verschlimmern, so müssen Sie Diclac Dispers 
absetzen und sofort Kontakt mit Ihrem Art aufnehmen”  
(„In case the mentioned symptoms occur or worsen, you must interrupt the therapy with Diclac Dispers 
and put yourself in contact with your doctor immediately”).  
 
„Wenn Sie glauben, dass eine solche Reaktion bei Ihnen vorliegt … beenden Sie die Einnahme von 
CoAprovel, und suchen Sie sofort ärztliche Hilfe“ (CoAprovel –Sanofi).  
(„If you believe that these reactions occur to you … Stop to take COAprovel and look immediately for 
the help of a health professional“). 
 
Therefore the same side-effect was classified as indefinite or severe/light according to 
the way it was presented: “Darmenentzündung” (intestines inflammation) without any 
further explanation was classified as ‘indefinite’ because of the difficulty for the 
patient to assess the health implications linked to the disturb (transitory and 
negligible? Or severe disease?), but whenever a modifier could help the reader assess 
the severity of its health implication, then the side-effect was classified accordingly: 
“Chronische Darmentzündung”: severe side-effect. 
Sometimes short explanations may accompany the disease name: Propycil 50 
(Admeda) for instance, adds to the side-effects list an explanation of “Lupus 
erythematoides”, “Periarteriitis nodosa” and “Coombs test”. In these cases the 
description might provide a cue as to the health implications related to the illness, and 
therefore the cases were considered accordingly.  
 
 
6.2 Indefinite side effects 
 
When clear severity indexes are missing, and the symptoms described are not familiar 
to the reader, then uncertainty as to their importance and health implications arises. 
The following points are intended to display some of the difficulties the reader might 
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be faced with in assessing the risk magnitude, when reading a specific side-effect in 
the warning list: 
 
a) The greatest uncertainty source is represented by the description of symptoms 
whose (eventual long term) implications might not be clear for the reader. This leads 
to misunderstandings in both directions: light side-effects might unduly alarm the 
reader, because he draws false conclusions from their description, or vice versa, he 
might erroneously neglect severe side-effects and consider them as negligible 
(eventually failing to take adequate measures timely).  
The classification considered these cases as indefinite, not because of their possible 
objective consequences, but because they are neither presented as clearly light nor as 
severe, and also not as “medium” adverse reactions. 
Also difficult to gauge for a lay reader is the meaning of a labor test result concerning 
blood values (blood particles, sugar level, and lever values) or clinical kidney tests. 
The medical implications of such data are not part of his competence and therefore 
uncertainty might arise as to their interpretation. The same holds for information 
concerning changes in cardio-circular system.
653
  
b) A second source of uncertainty is medical jargon. 
c) On a semantic level, many symptoms are described which are not to be considered 
side-effects in themselves, but which are rather alarming signs of more dangerous 
disturbs:  
 
„Zeichen einer Nierenerkrankung bis zum Nierenversagen: 
Verminderung der Harnausscheidung, Ansammlung von Wasser im Körper (Ödeme), allgemeines 
Unwohlsein 
(“Signs of kidney disease up to kidney failure: 
Urine decrease, water retention (edema), general indisposition” - Followed by the instruction to stop the 
therapy)” 
 
Unfortunately these symptoms are not always presented as such in a cluster which 
identify them as a consequence of a common cause, but rather singularly and without 
any seemingly relevant relation to each other. Signs of disturbs linked to the drug 
have been counted themselves as side-effects if no overarching framework linked 
them to a common underlying disturb. Otherwise, they have been subsumed under the 
side-effect of which they are symptoms.  
‘Scope ambiguity’ also disorients the reader as to the interpretation of determinants: 
 
“Sollten die genannten Krankheitszeichen auftreten oder sich verschlimmern, setzen Sie Dioflenac-
ratiopharm 74 SL ab und nehmen Sie sofort Kontakt mit einem Arzt auf”. 
                                                 
653
 In fact in some texts these side-effects are explicitly presented as concerning the physician’s 
diagnostics:  
“Darüber hinaus kann ihr Arzt EKG-Veränderungen sowie Herzrythmusstörungen feststellen”;  
(„Moreover, your physician can diagnose ECG-modifications and heart rhythmus disturbs as well“); 
“Ihr Arzt kann eine abnormal Anhäufung von Stoffen im Lungengewebe (pulmonale Infiltrate) 
feststellen”; 
(Your physician can diagnose an abnormal accumulation of material in the lung tissues [lung 
infiltrates]).  
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“In case the mentioned illness signs occur or worsen, interrupt the therapy with Dioflenac-ratiopharm 74 
SL and contact a doctor immediately”). 
 
The text remains ambiguous as to the scope of the determinant (“die genannten”, the 
mentioned) over the preceding list: all of them or just the last paragraph? 
d) Another source of uncertainty lies on a higher order level of text comprehension, 
namely the pragmatic conversation maxims. From the point of view of illocutionary 
commitment, there are several cases of “attenuated” warnings: Text passages, in 
which the PL formulae provide a peace of risk information with no clear illocutionary 
meaning.  
All cases falling under the points a-d have been classified as ‚indefinite’.  
PL themselves were rated according to the number of light, severe and indefinite side-
effects listed in the warnings. Although taken into account in the coding phase, 
frequency was not considered during the analysis, because it resulted to be a 
redundant dimension in ranking the PLs (i.e. PLs with higher numbers of side effects 
had also the most severe plus the most common).  
 
 
7. Topics of concern 
 
The 9 topics of concern emerged through PL reading information are the following:  
 
Topics of uncertainty after reading the PL 
 
 DRUG/ILLNESS UNCERTAINTY ITEM  
AFTER READING THE PL 
Δ RISK  
# 1 Atorvastatin/High cholesterol Hair loss + 10 (odds) 
# 6 Iodides/Hypo-thyroid  High blood pressure - 45 (odds)  
# 7 Prednisolon/Arthritis  Difficulties in assessing optimal 
individual dosage  
0 
# 8 Antibiotics/Post-OP therapy  Information overload  + 70 (SE severity)  
# 14 Antibiotics/Skin infection  Ulcerous colitis  + 10 (SE quantity); 
+ 35 (SE severity). 
# 15 Mirtazapin/Depression Epilepsy  + 5 (personal risk) 
# 17 Phenprocoumon/Thrombosis 
prevention 
Side effects in general 0 
# 38 Tetrazepam/Lumbago “It helps alleviate your pain, but it 
cannot remove the spasticity” 
+15 (odds) 
+ 30 (SE severity) 
# 47 Phenazon eardrops/Light ear 
infection 
Dosage  +10 (odds)  
Table 12: Cases of no uncertainty before reading the PL, and uncertainty afterwards. 
Topics of uncertainty before and after reading the PL 
 
 DRUG/ 
ILLNESS 
UNCERTAINTY 
ITEM  
BEFORE PL 
UNCERTAINTY ITEM 
AFTER PL 
Δ RISK  
# 2 Diclofenac/ 
Rheumatic pains  
Side effects Long term side effects + 20 (SE quantity) 
+ 20 (odds) 
# 9 Benzodiazepn/ 
Depression 
Dependency Dependency and long term 
effects 
+ 30 (SE quantity) 
+10 (SE severity) 
# 10 Cortisone spray/ Cold Cortison No cortisone information  + 10 (personal 
risk) 
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# 12 Antibiotics/ 
Respiratory tract 
infection  
Side effects Tendinitis. I would like to 
ask the doctor - I know that 
normally drugs have side 
effects, but I would like to 
know whether the situation 
gets worse if I take it again 
(increased personal 
sensitivity through 
repeated treatments). 
+10 (SE quantity) 
# 13 Phenprocoumon/ 
Thrombosis prevention 
Therapy duration Skin necrosis. Control of 
lever values. Nervus 
femoralis: what is that? 
+10 (SE quantity) 
+ 10 (personal 
risk) 
# 27 Anti-histamines/ 
Seasonal allergy  
The chemical 
entity means 
nothing to me 
Whether the level of 
tiredness could be lower as 
it is by me. And whether it 
comes from the illness or 
from the drug. 
+ 10 (SE quantity) 
+10 (SE severity) 
# 32 Potassium –magnesium/ 
Heart attack prevention 
Eventual side 
effects 
Relationship with 
homeopathic therapy. Why 
did the doctor not simply 
prescribe magnesium? 
+ 10 (personal 
risk) 
# 34 Antibiotics/ 
Vaginal infection 
Dosage and 
interference with 
other drugs  
Dosage and therapy 
duration. Resistance.  
+20 (SE quantity) 
+20 (personal risk) 
+50 (SE severity) 
# 35 Diclofenac/Articulation 
inflammation 
Drug efficacy  Little perspective of a 
speedy recovery  
+ 30 (SE severity) 
+10 (odds) 
# 41 ACE inhibitor / 
High blood pressure 
Hydration 
precautions during 
therapy 
Hydration and loss of salts. 
How often should check 
ups (blood and so on) be 
carried out by the doctor? 
+20 (SE quantity) 
+30 (personal risk) 
+70 (SE severity) 
# 42 Nitrendipin/ 
High blood pressure 
Side effects, for 
instance dizziness 
and tiredness  
The special dosage of the 
treatment. 
- 20 
# 44 Homeopathic drug/ 
Fungal infection 
Enough efficacy? Enough efficacy? 0 
# 50 Thyroid/ 
Hypothyroid  
Side effects Interferences with other 
drugs. Some words 
unknown. 
+15 (personal risk) 
+2 (SE severity) 
 
 
Topics of uncertainty before reading the PL (and absent afterwards) 
 
CASE  DRUG/ILLNESS UNCERTAINTY ITEM BEFORE 
READING THE PL 
Δ RISK  
# 3 Pill/menstruation regulation  Risks and side effects: for instance 
thrombosis  
+ 20 (SE quantity) 
+ 20 (odds) 
# 11 Interferon beta/Multiple sclerosis I notice that I get haematomas but it 
is not so bad. 
+ 30 (SE quantity) 
+10 (SE severity) 
# 29 Tetrazepam/lumbago Do also respiratory muscles get 
relaxed? This would be bad.  
+ 10 (personal risk) 
# 39 Antibiotics/vesica inflammation Resistance in the long term +10 (SE quantity) 
# 55 Biphosphonate (etidronic acid)/ 
osteoporosis 
The drug was prescribed in a 
different dosage than in the package  
+ 10 (SE quantity) 
+10 (SE severity) 
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Wissenschaftliche Studie über 
Beipackzettel von Medikamenten 
 
 
Liebe Befragte, lieber Befragter, 
 
Sie haben diesen Fragebogen in Ihrer Arztpraxis oder bei Ihrem Apotheker bekommen, weil Sie 
zurzeit mit einem verschreibungspflichtigen Medikament behandelt werden. Dieser Fragebogen 
behandelt, wie Packungsbeilagen verstanden werden. Durch Ihre Mithilfe tragen Sie zu deren 
Verbesserung bei. 
Dieses Projekt ist eine Zusammenarbeit der Universität Bielefeld und der Universität Lugano. Die 
Daten werden innerhalb einer Doktorarbeit ausgewertet.  
 
Selbstverständlich werden die Daten anonym behandelt.  
 
Sehr wichtig:  
 
1. Bitte lesen Sie die Packungsbeilage des Medikamentes erst nach dem ersten Teil des  
      Fragebogens. 
2. Wenn Sie mehrere Medikamente verschrieben bekommen haben, dann wählen Sie die 
Packungsbeilage desjenigen, mit dem Sie am wenigsten Erfahrung haben. 
3. Falls Sie Antibiotika bekommen haben, dann wählen Sie bitte die Packungsbeilage 
      dieses  Medikamentes aus.  
4. Wenn Sie den Fragebogen zurückgeben, bitte legen Sie auch Ihre Packungsbeilage bei. 
5. Bitte bringen Sie den Fragebogen sobald wie möglich in die Arztpraxis oder Apotheke 
zurück, in der Sie ihn bekommen haben.  
 
Das Projekt wird unter der Anleitung von Frau Prof. Elisabeth Gülich und Prof. Hans 
Strohner, Fakultät für Linguistik und Literaturwissenschaft, durchgeführt. 
 
Wenn Sie Fragen dazu haben, wenden Sie sich bitte an: 
 
Barbara Osimani 
Universität Bielefeld 
Fakultät für Linguistik und Literaturwissenschaft 
 304 
Raum C6-213 
barbara.osimani@uni-bielefeld.de 
Tel: 0162 – 1585563 
 
FRAGEBOGEN 
 
Dieser Fragebogen besteht aus zwei Teilen. In dem ersten Teil wird an Hand Ihrer Angaben Ihr 
Informationsbedürfnis bewertet.  
Erst nach dem ersten Teil werden Sie gebeten, die Packungsbeilage zu lesen.  
Bitte machen Sie zu jeder Frage Angaben (Bei einigen Fragen und Aussagen sind auch 
Mehrfachangaben möglich). 
 
Erster Teil 
 
In den ersten Aussagen geht es hauptsächlich um Ihre Erfahrung mit dem  Medikament, mit dem 
Sie behandelt werden. 
 
1) Name des Medikamentes:_______________________________________________ 
 
2) Anwendungsbereich des Medikamentes: 
a) Ernährungsorgane (Bauch, Magen, Darm, Verdauungsstörungen, etc.) [  ]a    
b) Kreislauf  [  ]b    
c) Haut [  ]c    
d) Atemwege (Husten, Halsschmerzen, etc.) [  ]d    
e) Knochen/Muskel (Muskelkater, Gelenkentzündungen, etc.) [  ]e    
f)  Sonstiges:  [  ]f    
 
3) Typ des Medikamentes: 
a) Antibiotika [  ]a    
b) Schmerzmittel [  ]b    
c) Blutdruckmedikamente [  ]c    
d) Antidiabetika [  ]d    
e) Sonstiges:  [  ]e    
 
4) Krankheit:____________________________________________________________ 
 
5) Seit wann leiden Sie unter dieser Krankheit? Seit ___________________________ 
 
6) Nehmen Sie dieses Medikament jetzt  
a) zum ersten Mal? 
b) a) Ja……………………………………… 
c) b) Nein…………………………………… 
 [  ]a    
 [  ]b 
7) Haben Sie auch andere Medikamente  
für die Behandlung derselben 
Krankheit benutzt? 
a) a) Ja……………………………………… 
b) b) Nein…………………………………… 
c) (machen Sie bitte mit der Frage 9 weiter) 
[  ]a 
[  ]b 
8) Warum haben Sie das Medikament gewechselt?  
  (Mehrangaben möglich) 
a) a) Das andere Medikament wurde vom Markt genommen…………………………………… 
[     
 
[  ]a 
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b) b) Das andere Medikament hatte eine geringere Wirkung…………………………….......... 
c) c) Das andere Medikament konnte ich nicht gut vertragen…………………………………… 
d) d) Der Arzt hat eine Alternative zum alten gefunden ………………………………………… 
e) e) Sonstiges………………………………………………………………………………………. 
 [  ]b 
 [  ]c 
 [  ]d 
  [  ]e 
 
 
9) Was wäre die Konsequenz einer Nicht-Behandlung?  
a) a) Ich müsste ein paar Tage zu Hause bleiben ……………………………………………… 
b) b) Es könnte eine Verschlechterung geben, die noch schwerer zu behandeln wäre…...... 
c) c) Ich müsste mich operieren lassen …………………………………………………………… 
d) d) Ich weiß es nicht ……………………………………………………………………………… 
e) e) Sonstiges: __________________________________________________________ 
f)  
g) ______________________________________________________________________ 
h)  
i) ______________________________________________________________________ 
 
 
[     
 [  ]a 
 [  ]b 
[  ]c 
 [  ]d 
  [  ]e 
 
Zum Beispiel 
Im Folgenden werden Sie gebeten, Ihre Angaben in einer Skala von 0 bis 100 numerisch 
anzugeben. Die Zahl sollte an der entsprechenden Stelle in der Linie eingefügt werden.  
So z.B., bei der folgenden Frage:  
  
 Ich mache gerne Urlaub in der  
 Schweiz. 
 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
  0                                    50                                 100 
  nicht gern                                                                  sehr gern 
 
wenn Sie gerne in der Schweiz Urlaub machen, aber nicht gerade sehr gerne, können Sie z.B. 
einen Wert von 75 angeben. Dann tragen Sie bitte an dieser Stelle ein X in die Skala ein und 
schreiben den entsprechenden Wert darunter:  
 
 Ich mache gerne Urlaub in der  
Schweiz. 
 
 ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
 0                                    50                                 100 
  nicht gern                                                                  sehr gern 
 
 
Bitte geben Sie Ihre Angaben bei den folgenden Fragen nach dem eben erklärten 
Schema ein: 
 
10) Sind Sie mit der Wahl des 
Medikamentes zufrieden?  
 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) überhaupt nicht              einigermaßen            völlig zufrieden 
b) zufrieden 
11) Wie viele Informationen  
haben Sie über das  
Medikament? 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) überhaupt keine                 einige                      mehr brauche 
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b)                                                                       ich nicht 
12) Gibt es noch etwas, das Sie   
unsicher macht? (Bitte ankreuzen) 
a) a) Ja………………………………………………. 
b) b) Nein  (machen Sie bitte mit der Frage 15 weiter)…. 
[  ]a 
[  ]b 
 
13) Was ist das? 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
14) Könnte eine eventuelle 
Aufklärung darüber die Unsicherheit  
abschaffen? 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein                              Ich weiß nicht                                 Ja 
 
15) Erwägen Sie, auf Grund  
eventuell mangelnder Information  
das Medikament nicht einzunehmen? 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein                              Ich weiß nicht                                 Ja 
 
16) Für wie verlässlich halten Sie die folgenden Informationsquellen?  
a) Arzt ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt nicht             Ich weiß nicht                              sehr   
verlässlich                                                               verlässlich 
b) Apotheker ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
c) Freunde/ Angehörige ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
d) Meine eigene Erfahrung ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
e) Packungsbeilage ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
f) Fernseh- /Radiosendungen ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
g) Artikel in der Presse ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
h) Information im Internet ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
i) Werbung  ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
h) Sonstiges:_____________________ 
________________________________ 
________________________________ 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
 
17) Wie wurde das Medikament gewählt?   
  (Mehrfachangaben möglich) 
a) Der Arzt hat es mir verschrieben……………………………..…………………………………. 
[     
 
 [  ]a 
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a) b) Der Arzt hat es mir empfohlen und ich habe den Vorschlag angenommen …….............. 
b) c) Nach gemeinsamer Überlegung mit dem Arzt, hat sich herausgestellt, dass dieses 
Medikament auf mich am besten wirken kann……………..…..………………………………... 
c) d) Nach gemeinsamer Überlegung mit dem Arzt, hat sich herausgestellt, dass ich mit  
d) diesem Medikament am wenigsten Nebenwirkungen haben werde. ..……………..………... 
e) e) Es gibt keine Alternative. ……………………………………………………………………… 
f) f) Ich weiß von keiner Alternative………………………………………………………………… 
g) g)  Sonstiges: _______________________________________________________ 
 [  ]b 
  
 [  ]c 
  
 [  ]d 
 [  ]e 
 [  ]f 
 [  ]g 
18) Wie viel Erfahrung haben Sie  
bereits mit Medikamenten? 
a)  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
b) überhaupt keine                 einige                                sehr viel 
19) Bei Ihnen wirken  
Medikamente: 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
nie                                   manchmal                               immer 
 
Ihre Erfahrung mit Nebenwirkungen: 
20) Wenn ich krank bin, dann ist es  
schwer für mich zwischen Symptomen  
der Krankheit und Nebenwirkungen  
des Medikaments zu unterscheiden. 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
stimmt nicht              stimmt manchmal                stimmt völlig 
21) Man muss Nebenwirkungen in  
Kauf nehmen, wenn man ein  
Medikament einnimmt.  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
Nein                              Ich weiß nicht                                 Ja 
 
Zum Beispiel 
Bei den folgenden Fragen können Sie entweder die linke (a) oder die rechte (b) Antwort 
geben. So zum Beispiel bei der folgenden Aussage können Sie Antwort a) ankreuzen falls Sie 
keine Idee davon haben, wie teuer ein Urlaub in der Schweiz ist:  
 
 Urlaub in der Schweiz ist teuer. 
a) Ich kann es nicht beurteilen 
 
 
 
                
a) b) 
b) ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
c) 0                                    50                                 100 
d) überhaupt nicht           nicht unbedingt                 extrem teuer   
e) teuer                            günstig 
 
Falls Sie b) wählen, dann sollte die Antwort in einer Schätzung nach dem bekannten Schema 
bestehen.  
Hier kann aber die Einschätzung in zwei Varianten angegeben werden: Entweder nach dem 
bekannten Schema: 
 Urlaub in der Schweiz ist teuer. 
a) Ich kann es nicht beurteilen  
 
  
  
           
f) b) 
g) ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
h) 0                                    50                                 100 
i) überhaupt nicht           nicht unbedingt                 extrem teuer   
j) teuer                            günstig 
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Oder in der folgenden Weise: Falls Sie nicht eine genaue Nummer angeben können, aber ihre 
Schätzung zwischen zwei Nummern liegt (z.B. zwischen 60 und 90) dann kennzeichnen Sie 
diesen Bereich mit einem Kreis: 
Urlaub in der Schweiz ist teuer. 
a) Ich kann es nicht beurteilen     
 
 
 
          
k) b) 
l) ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
m) 0                                    50                                 100 
n) überhaupt nicht           nicht unbedingt                 extrem teuer   
o) teuer                            günstig 
22) Ich habe in der Vergangenheit Nebenwirkungen gehabt, wenn ich ein  
Medikament genommen habe.  
a)  
Ich kann es nicht beurteilen 
(Machen Sie bitte mit der Frage 24 weiter). 
b) 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
nie                                    manchmal                         jedes Mal 
 
23) Von diesen waren ungefähr _____ % schwere und  _____ % leichte 
Nebenwirkungen (Bitte Prozent angeben). 
 
24) Wie effektiv finden Sie das vorliegende Medikament im Verhältnis zu alternativen 
Behandlungen zur selben Krankheit? 
a) Ich kann es nicht beurteilen                   a) b) 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
b) überhaupt nicht               so und so                      sehr effektiv 
c) effektiv 
25) Wie optimal werden Sie auf die Behandlung reagieren? 
a) Ich kann es nicht beurteilen                   a) b) Meiner Meinung nach werde ich: 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
b) überhaupt nicht               so und so                              optimal 
c)  
d) auf die Behandlung reagieren. 
 
26) Glauben Sie, dass das vorliegende Medikament im Verhältnis zu 
alternativen Behandlungen zur selben Krankheit schwere Nebenwirkungen hat? 
a)  
Ich kann es nicht beurteilen                   
 ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) überhaupt nicht                tolerable                     sehr schwere 
b) schwere Nebenw.            Nebenw.                             Nebenw. 
27) Glauben Sie, dass das vorliegende Medikament im Verhältnis zu 
Alternativen Behandlungen zur selben Krankheit viele Nebenwirkungen hat? 
a)  
Ich kann es nicht beurteilen                   
 ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) keine                          durchschnittliche                     sehr viele 
b) Nebenw                     Zahl von Nebenw                    Nebenw.                                 
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28) Wie wahrscheinlich ist es, dass Sie von den Nebenwirkungen dieses  
Medikamentes betroffen werden? 
a)  
Ich kann es nicht beurteilen 
(Machen Sie bitte mit der Frage 30 weiter). 
b) 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
Unmöglich                   wahrscheinlich                            sicher 
 
29) Von diesen werden _____% schwere und  _____% leichte Nebenwirkungen sein. 
 
30) Finden Sie dass die positiven 
Wirkungen dieses Medikaments die 
eventuellen Nebenwirkungen  
übersteigen? (Auf Sie bezogen) 
a) a) Ja……………………………………………….. 
b) b) Nein …………………………………………… 
c) Ich kann es nicht beurteilen………………….. 
c) (machen Sie bitte mit der Frage 32  weiter) 
[  ]a 
[  ]b 
[  ]c 
 
31) Bei der folgenden Summe sollen Sie Ihre Einschätzung über die Gesamtwirkung 
des Medikamentes angeben. Tragen Sie bitte die Zahlen ein, die ihrer Meinung 
nach die Aufteilung in positiver Wirkung und Nebenwirkungen am besten 
darstellen:  
 
Positive Wirkungen  Nebenwirkungen    
     
  
+ 
 
  
= 
 
100 
 
32) Lesen Sie jetzt bitte aufmerksam die Packungsbeilage des Medikaments. Bitte 
heben Sie die Stellen des Textes hervor, die Sie wichtig finden und schreiben Sie 
hierunter warum: z.B. weil sie unverständlich, mehrdeutig oder unklar sind, oder auch 
weil es sich um Informationen handelt, wovon Sie vorher nicht wussten, etc. 
 
 
Bitte markieren Sie die entsprechende Nummer auf dem Beipackzettel. 
 
1)………………………………………………………………………………………………………………
………………………………………………………………………………………………………………… 
………………………………………………………………………………………………………………… 
 
2)………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
………………………………………………………………………………………………………………… 
 
3)………………………………………………………………………………………………………………. 
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………. 
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4)…………..……………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………. 
 
5)………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………. 
 
6)………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………. 
 
7)………………………………………………………………………………………………………………
………………………………………………………………………………………………………………… 
Nun einige Fragen über Ihr Leseerlebnis:  
Beim Lesen der Packungsbeilage war es wichtig … 
 
33) … die Information mit meiner 
Erfahrung über Medikamente zu  
vergleichen. 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt                                                                         sehr 
nicht wichtig                     so und so                             wichtig                           
34) … die Information mit anderen  
Informationen aus anderen Quellen  
(Medien, Arzt, Freunde, etc.)  
zu verbinden. 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt                                                                         sehr 
nicht wichtig                     so und so                             wichtig                           
35) … mir vorzustellen,  wie das 
Arzneimittel funktioniert. 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt                                                                        sehr 
nicht wichtig                     so und so                             wichtig                                                  
 
Beim Lesen der Packungsbeilage habe ich besonders beachtet … 
36) … die Informationen, die ich im 
Widerspruch zu meinen  
Kenntnissen fand.  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt                                                                         sehr 
nicht wichtig                     so und so                             wichtig                           
37) … die Informationen, die in der 
Packungsbeilage widersprüchlich 
zueinander waren. 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt                                                                         sehr 
nicht wichtig                     so und so                             wichtig                           
38) Sonstiges: __________________ 
_________________________________ 
_________________________________ 
_________________________________ 
 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt                                                                         sehr 
nicht wichtig                     so und so                             wichtig                           
 
 
39) Ich finde die Information dieser Packungsbeilage:  
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a) ausreichend ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt nicht               so und so                          absolut ja 
b) schon bekannt ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
c) überflüssig  ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
d) beängstigend ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
e) nützlich ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
f) sonstiges:_____________________ 
________________________________ 
________________________________ 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
 
 
Zweiter Teil 
 
Nun werden einige der obigen Fragen wiederholt. Es geht darum zu wissen, was für 
Informationen Sie von der Packungsbeilage erhalten haben. 
 
40) Sind Sie mit der Wahl des 
Medikaments zufrieden?  
 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) überhaupt nicht               so und so                  völlig zufrieden 
 
41) Ich bin unsicher, ob ich die  
Behandlung mit dem Medikament 
überhaupt anfange.  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) nicht anfangen              ich weiß nicht                       anfangen 
42) Ich werde das Medikament 
zunächst einmal einnehmen. 
 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) nicht einnehmen              ich weiß nicht                einnehmen 
43) Ich möchte noch einmal mit 
dem Arzt über das Medikament 
sprechen 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein,                              ich weiß nicht                     definitiv ja 
b) überhaupt nicht 
 
44) Wie viele Informationen  
haben Sie jetzt über das  
Medikament? 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) überhaupt                          einige                       mehr brauche 
b) keine                                                                            ich nicht 
 
45) Gibt es noch etwas, das Sie   
unsicher macht? 
a) a) Ja……………………………………… 
b) b) Nein  (machen Sie bitte mit der Frage 48 weiter) 
[  ]a 
[  ]b 
 
46) Was ist das?_________________________________________________________ 
___________________________________________________________________________ 
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___________________________________________________________________________ 
___________________________________________________________________________
___________________________________________________________________________ 
 
 
47) Könnte eine eventuelle weitere 
Aufklärung die Unsicherheit  
abschaffen? 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein                              Ich weiß nicht                                 Ja 
 
48) Erwägen Sie, auf Grund   
eventuell mangelnder Information das  
Medikament nicht einzunehmen? 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein                              Ich weiß nicht                                 Ja 
 
49) Würden Sie sich vor  
Fortsetzung der Therapie nach  
weiteren Informationen suchen?  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein                                 so und so                                    ja 
 
 
An Hand der Information, die Sie von der Packungsbeilage bekommen haben: 
(Beantworten Sie nach dem Schema der Fragen 22-28) 
 
50) Wie effektiv finden Sie das vorliegende Medikament im Verhältnis zu alternativen 
Behandlungen zur selben Krankheit? 
a) Ich kann es nicht beurteilen                   a) b) 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
b) nicht effektiv                    so und so                      sehr effektiv 
51) Wie optimal werden Sie auf die Behandlung reagieren? 
a) Ich kann es nicht beurteilen                   a) b) Meiner Meinung nach werde ich: 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
b) nicht                                so und so                              optimal 
c) auf die Behandlung reagieren. 
52) Glauben Sie, dass das vorliegende Medikament im Verhältnis zu 
alternativen Behandlungen zur selben Krankheit schwere Nebenwirkungen hat? 
a)  
Ich kann es nicht beurteilen                   
 ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) überhaupt nicht                tolerable                     sehr schwere 
b) schwere Nebenw.            Nebenw.                             Nebenw. 
53) Glauben Sie, dass das vorliegende Medikament im Verhältnis zu 
alternativen Behandlungen zur selben Krankheit viele Nebenwirkungen hat? 
a)  
Ich kann es nicht beurteilen                   
 ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) keine Nebenw.           durchschnittliche                     sehr viele 
b)                                        Zahl von Nebenw.                         Nebenw. 
54) Wie wahrscheinlich ist es, dass Sie von den Nebenwirkungen dieses  
Medikaments betroffen werden? 
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a)  
Ich kann es nicht beurteilen 
(Machen Sie bitte mit der Frage 57 weiter). 
b) 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
unmöglich                     wahrscheinlich                           sicher 
 
55) Von diesen werden ___% schwere und  ___% leichte Nebenwirkungen sein. 
 
56) Finden Sie dass die Wirkungen  
dieses Medikamentes die eventuelle  
Nebenwirkungen übersteigen? 
(Auf Sie bezogen) 
a) a) Ja……………………………………………… 
b) b) Nein …………………………………………… 
c) Ich kann es nicht beurteilen 
c) (machen Sie bitte mit der Frage 58  weiter) 
[  ]a 
[  ]b 
[  ]c 
 
57) Bei der folgenden Summe sollen Sie Ihre Einschätzung über die Gesamtwirkung 
des Medikamentes angeben. Tragen Sie bitte die Zahlen ein, die ihrer Meinung 
nach die Aufteilung in positiver Wirkung und Nebenwirkungen am besten 
darstellen:  
 
Positive Wirkung  Nebenwirkungen    
     
  
+ 
 
  
= 
 
100 
 
58) Würden Sie noch weitere  
Informationen in der Packungsbeilage  
hinzufügen lassen?  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) Nein,                              Ich weiß nicht                     Definitiv ja 
b) überhaupt keine 
 
59) Welche Wichtigkeit würden diese weiteren Informationen haben?  
a) Wie das Arzneimittel wirkt in  
meinem Körper 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt nicht               so und so                      sehr wichtig 
wichtig 
b) Erfolgswahrscheinlichkeit der  
Therapie  
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
c) Sonstiges:_____________________ 
________________________________ 
________________________________ 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
 
60) Würden Sie auf folgende Teile der Packungsbeilage verzichten? 
a) Zusammensetzung ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
nicht verzichten             ich weiß nicht                     verzichten 
b) Anwendung ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
c) Warnungen ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
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d) Dauer und Dosis ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
e) Sonstiges:_____________________ 
________________________________ 
________________________________ 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
 
61) Warum würden Sie darauf verzichten?______________________________________ 
 
______________________________________________________________________________ 
 
______________________________________________________________________________ 
 
 
Nun ein paar Fragen über Ihre Lesegewohnheiten mit Packungsbeilagen. 
62) Ich lese die Packungsbeilage: ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) nie                                    manchmal                              immer 
 
Ich lese die Packungsbeilage … 
63) …bevor ich mit der Behandlung  
überhaupt anfange: 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) nie                                    manchmal                              immer 
64) … erst dann, wenn bei der  
Behandlung unerwartete Wirkungen  
entstehen: 
├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) nie                                    manchmal                              immer 
65) Ich lese den ganzen Text. ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) nie                                    manchmal                              immer 
66) In der Packungsbeilage lese ich hauptsächlich: ____________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
 
67) Was für eine Funktion/Funktionen haben Packungsbeilage Ihrer Meinung nach? 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
Abschließend bitte ich Sie, einige allgemeine Informationen zu Ihrer Person und zu Ihrem 
Gesundheitszustand anzugeben: 
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68) Alter:_______  69) Geschlecht: 
 a)  b) a) weiblich ……………………….. [   ]a 
c) b) männlich ……………………… [   ]b 
 
70) Bildungsstand:   71) Beruf:  
a) Hauptschulabschluss [   ]a  a) Arbeiter/in [   ]a 
b) Realschulabschluss [   ]b  b) Angestellter/in [   ]b 
c) Abitur [   ]c  c) Beamter/in [   ]c 
d) Universitäts-/ 
     Fachhochschulabschluss 
[   ]d  d) Selbständig [   ]d 
e) Sonstige [   ]e  e) Hausfrau/mann [   ]e 
f) Medizinstudent  
(oder Fächer der Gesundheitswiss.) 
[   ]f  f) Student/in-Azubi [   ]f 
   g) Arbeitslos [   ]g 
   h) Gesundheitsberuf 
(Arzt/ Krankenpfleger...)  
[   ]h 
   i) Sonstige [   ]i 
 
 
72) Gesundheitszustand (Mehrfachangaben möglich): 
 
Ich leide an: 
a) einer                               c) leichten                Beschwerde(n) 
 b) mehreren              d) schweren             
  e) chronischen        
 
 
73) Ich bin insgesamt:  ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
a) schwer krank                                                         kerngesund 
 
74) Ich nehme zur Zeit andere 
Medikamente 
a) a) Nein……………………………………………… 
b) b) Ja ………………………Wie viele?............... 
[  ]a 
[  ]b 
75) Ich finde diesen Fragebogen:  
a) interessant ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
überhaupt nicht               so und so                          absolut ja 
b) schwer  ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
c) lang ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
d) beängstigend  ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
e) nützlich ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
0                                    50                                 100 
f) sonstiges:_____________________ ├──┬──┬──┬──┬──┬──┬──┬──┬──┬──┤ 
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________________________________ 
________________________________ 
0                                    50                                 100 
 
 
Wir bedanken uns sehr für Ihre Mitarbeit und freuen uns sehr darauf, Ihren Fragebogen 
entgegenzunehmen.  
 
Vergessen Sie nicht, die Packungsbeilage, die Sie dabei benutzt haben, dem Fragebogen 
beizulegen.  
 
Wenn Sie noch Fragen zu dieser Studie haben oder weitere Anmerkungen zum Fragebogen 
haben, dann wenden Sie sich an:  
 
Barbara Osimani 
Universität Bielefeld 
Fakultät für Linguistik und Literaturwissenschaft 
Raum C6-213 
barbara.osimani@uni-bielefeld.de 
Handy: 0162 – 1585563 
 
 
Falls Sie auch an der zweiten Phase der Studie teilnehmen wollen, können Sie hierunter 
Ihre  Rückrufnummer (oder Ihre E-Mail-Adresse) hinterlassen: 
 
Vielen Dank!  
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